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Abstract
Herpes simplex vims has long been implicated in the development of human genital 
cancers, especially carcinoma of the cervix. Recent epidemiological and biological 
studies suggest that a cooperative interaction between herpes simplex vims and 
human papillomavirus leads to an increased risk of developing cervical neoplasia.
A set of cell coded polypeptides has been detected in a transformed rat cell line 
(Bn5T) produced by transformation of rat embryo fibroblasts with a fragment of 
HSV-2. This group of polypeptides (200kDa, 90kDa (a doublet U90 and L90), 
40kDa and 32kDa) were immunoprecipitated specifically from transformed cells by 
sera from tumour bearing rats, and from rats immunised with non-transformed 
HSV-2 infected cells. This suggested that HSV-2 might be inducing polypeptides 
with a function in transformed cells. This thesis describes studies on the 40kDa 
polypeptide from this group. The 40kDa polypeptide is specifically induced in 
transformed cells and is upregulated by HSV-2 infection.
The 40kDa polypeptide was purified from Bn5T cells by ammonium sulphate 
fractionation and fast protein liquid chromatography in an attempt to raise an 
antiserum to this protein. A poor immune response was observed in rabbits injected 
with this immunogen, an observation previously and independently reported in our 
laboratory. However, amino acid sequence data and subsequent immunological 
studies (Lucasson, 1992) demonstrated that the 40kDa polypeptide was related to 
mitochondrial aspartate aminotransferase (mAspAT).
The steady state level of mAspAT mRNA was examined to determine whether 
HSV-2 infection increased the amount of mRNA in transformed cells, as the protein 
level and enzyme activity had previously been shown to be increased. This study 
demonstrated an increase of approximately 80% in the level of mAspAT mRNA 
following HSV-2 infection of Bn5T cells. This conclusion was obtained from 
Northern blotting and reverse transcriptase PCR experiments.
During Western blotting experiments to confirm the increased mAspAT protein level 
following HSV-1/HSV-2 infection (previously observed by slot blot 
immunoblotting), a second polypeptide was identified specifically in the HSV 
infected samples. This polypeptide was found to have a slightly greater molecular
weight in cells infected with HSV-1 than in HSV-2 infected cells. This information 
was used to map the region of the HSV genome encoding this polypeptide, by 
analysis of the polypeptide produced following infection of cells with a panel of 
intertypic recombinant herpes simplex viruses. The polypeptide was identified as the 
HSV dUTPase enzyme, although no obvious reason for the cross-reactivity could be 
found.
A plasmid was constructed with the mAspAT cDNA under the control of the HCMV 
major immediate early promotor. This plasmid expressed the mAspAT polypeptide 
in transfected cells, as determined by immunofluorescence studies. Transfection of 
this plasmid into normal rat kidney cells led to an increase in the number of cells 
which formed colonies in soft agar medium, in comparison to cells transfected with 
the parental control plasmid. This experiment demonstrated a direct biological 
transforming effect of increased mAspAT expression in normal cells in vitro. 
Transformation assays in vivo using these cells injected into nude mice were 
inconclusive, as tumours also developed in animals injected with control cells.
During RT-PCR experiments to quantify the level of mAspAT mRNA following 
HSV infection, an additional PCR product was observed in HSV-2 infected Bn5T 
cell samples. This product was slightly smaller than the normal sized product, and 
might explain the appearance of a 40kDa mAspAT polypeptide (in addition to the 
consitutive cellular 44kDa enzyme) and the increased membrane mAspAT 
immunofluorescence observed in transformed cells (J.C.M. Macnab, unpublished 
results). The smaller PCR product was cloned into pGEM-T and partial DNA 
sequence was obtained. This demonstrated that the mitochondrial targetting pre­
sequence was present in the smaller clones, and did not therefore explain the altered 
localisation of mAspAT to the cell surface observed in the transformed cell.
My results demonstrate an increase in the level of mAspAT mRNA in transformed 
cells following infection with HSV-2, and that increased expression of mAspAT can 
induce transformation in normal cells. The possible effects of increased mAspAT 
activity on tumour cell metabolism are discussed, along with the function of 
mAspAT as a plasma membrane long chain fatty acid binding protein (FABP(pm)) 
and a possible role for the dUTPase-mAspAT cross reactivity in promoting cervical 
neoplasia.
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1. INTRODUCTION.
1.1 HERPES SIMPLEX VIRUS.
1.1.1 INTRODUCTION.
Herpes simplex virus is one of approximately 100 viruses that belong to the family 
Herpesviridae (reviewed by Roizman, 1996). These viruses share similar general 
features. A linear double stranded DNA genome is packaged into an icosahedral 
capsid of approximately 125nm diameter, which is surrounded by an amorphous 
layer known as the tegument and enclosed in a lipoprotein envelope. The size of the 
herpesvirus virions ranges from 120nm to 300nm, determined largely by the shape of 
the envelope. A more detailed discussion of these common features is presented in 
Section 1.1.4.1 with respect to HSV-1, the most extensively studied herpesvirus.
Most animal species examined have yielded at least one herpesvirus. Eight human 
herpesviruses have so far been defined (see Table 1.1) and herpesviruses have been 
isolated from species ranging from non-human primates (e.g. B virus) to bony fish 
(e.g. Channel catfish herpesvirus).
In addition to their structural similarity, all herpesviruses can establish a latent 
infection in a specific subset of host cells. Herpes simplex virus latency is discussed 
in Section 1.1.8.
1.1.2 CURRENT CLASSIFICATION OF HERPESVIRUSES.
The family Herpesviridae is divided into three sub-families based upon their 
biological properties (Roizman et al., 1992). These are the alpha-, beta- and gamma- 
herpesvirinae.
Alphaherpesvirinae. The members of this sub-family have a variable host range, 
short reproductive cycle, spread rapidly in tissue culture, destroy infected cells and 
establish latent infection mostly in sensory ganglia. This sub-family includes the 
Simplexvirus (e.g. HSV-1, HSV-2 and B-virus) and Varicellovirus (e.g. VZV, PRV 
and EHV-1) genera.
Betaherpesvirinae. This sub-family are characterised by a long reproductive cycle 
and an infection in tissue culture which progresses slowly. Infection often leads to
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Chapter 1: Introduction.
the formation of enlarged cells (cytomegalia) and latent virus is maintained in non­
neuronal tissue. This sub-family contains the genera Cytomegalovirus (e.g. human 
cytomegalovirus (HCMV)).
Gammaherpesvirinae. Members of this sub-family have a narrow host range, 
restricted mainly to lymphoblastoid cells, establish latent infection in lymphoid tissue 
and can immortalise cells. The genera Lymphocryptovirus (e.g. EBV, associated 
with infectious mononucleosis, Burkitt’s lymphoma and nasopharyngeal carcinoma 
(Sugden, 1992)) and Rhadnovirus (e.g. herpesvirus ateles) make up this sub-family.
There are problems with this classification scheme. For example, two distinct strains 
of HHV-6 have been identified, but these could be classified as separate viruses on 
the basis of their biological, DNA sequence and epidemiological characteristics 
(Schriemer et al., 1991). Although the current classification system is based on 
biological characteristics, DNA sequence analysis of a number of herpesviruses has 
shown that most of the viruses would have been classified into the same sub-family 
using measures of evolutionary relatedness, such as the conservation of genes and 
gene clusters. Two exceptions are the Marek’s disease herpesviruses which are 
members of the gammaherpesvirinae on the basis of biological classification, but are 
genetically more related to the alphaherpesvirinae (Buckmaster et al., 1988), and 
HHV-6, biologically classified into the gammaherpesvirinae but more similar to the 
betaherpesvirinae in genome structure and sequence (Roizman, 1996).
1.1.3 ASPECTS OF HERPES SIMPLEX VIRUS DISEASE.
1.1.3.1 Pathology and Pathogenesis of HSV infection.
Primary and recurrent herpes simplex virus infection lead to characterisitc 
histopathological changes. Cells balloon, regions of condensed chromatin appear in 
the nucleus, and plasma membrane integrity is lost leading to the formation of 
multinucleated giant cells (Whitley, 1996). Upon cell lysis a clear vesicular fluid 
accumulates between the dermis and epidermal layers, and an intense immune 
response occurs. In skin lesions, as the lesion heals the vesicular fluid becomes 
pustular and scabs. In mucosal infection shallow ulcers rather than vesicular lesions 
are formed.
2
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Human disease is acquired following intimate, personal contact with someone 
excreting HSV. Infection occurs by contact of the virus with abraded skin or 
mucosal surfaces. Viral replication at the site of infection is followed by retrograde 
axonal flow (Cook and Stevens, 1973) of the nucleocapsid to the dorsal root ganglia, 
where latency is established. Systemic infection (usually of neonates or the 
immunocompromised) and infection of the central nervous system (CNS) are rare, 
but serious events.
Infection with HSV-1 is generally limited to the oropharynx, and latent infection 
persists in the trigeminal ganglion. HSV-2 infection is usually the result of genital 
transmission, virus replicates in the genital, perigenital or anal skin and establishes 
latency in the sacral ganglion.
1.1.3.2 Epidemiology.
Herpes simplex viruses are distributed worldwide, including remote Brazilian tribes. 
The ability of HSV to establish latent infection and the fact that HSV infection is 
rarely fatal means that over one third of the world population probably has recurrent 
HSV infection. No animal vector has yet been described. Despite reports of 
clustered outbreaks of HSV infection, there is no evidence that the viruses cause 
epidemics (Whitley, 1996).
1.1.3.2.1 Orolabial HSV infection.
Primary infection usually occurs early in childhood, and is influenced by socio­
economic class. Only five of 18 countries surveyed had HSV-1 antibody prevalence 
of less than 70%, with prevalence in excess of 95% observed in several countries, 
including Spain and Italy (Whitley and Gnann, 1993). Reactivation, assayed by the 
frequency of recurrent herpes labialis in 1800 graduate students in the U.S. occurred 
at a rate of 38% of cases. Interestingly, within a single community the rate of 
recurrence was greater in the more socially privileged (Ship et al. 1977).
Asymptomatic excretion of HSV-1 has been observed in approximately 1-5% of the 
normal adult population (Whitley, 1996).
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1.1.3.2.2 Genital HSV infections.
HSV-2 infection is usually aquired by sexual contact and antibodies to HSV-2 are 
therefore rarely detected prior to the age of onset of sexual activity (Whitley, 1996). 
In the U.S. alone, 40-60 million people are estimated to be infected with HSV-2 
(Magder et al., 1989). The prevalence of antibodies to HSV-2 is greater in the lower 
socio-economic classes, and in patients routinely attending STD clinics 
(approximately 3-7%).
Asymptomatic shedding of HSV-2 is estimated to occur in 23% of women with non­
primary HSV-2 infection (Koelle et a l , 1992). For women with established HSV-2 
infection the rate of asymptomatic shedding was estimated to be 1% (Brock et al., 
1990). Seroprevalence rates in preganant women are estimated to be between 8% 
and 28%. Maternal genital infection carries a risk of foetal or neo-natal infection 
(discussed in Section 1.1.3.3.3), and occasionally a widely disseminated disease with 
high mortality in the mother. The major risk to the foetus or neo-nate is primary or 
initial genital infection of the mother, and infection before 20 weeks of gestation is 
associated with spontaneous abortion. Recurrent infection is the most common form 
of maternal disease, with transmission usually occurring at the time of delivery. 
Most infants who develop neonatal disease are bom to mothers with asymptomatic 
HSV infection.
In the U.S. positive risk factors for acquisition of HSV-2 include the number of 
sexual partners, marital status, place of residence and race. Multiple sexual partners, 
irrespective of sexual preference correlates directly with acquisition of HSV-2 
infection (Nahmias et al., 1990).
Recurrent genital infection can be either symptomatic or asymptomatic, and usually 
has a shorter period of viral shedding than primary infection. Genital HSV-1 
infection reoccurs less frequently than HSV-2 infection.
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1.1.3.3 Clinical manifestations of Disease.
1.1.3.3.1 Primary/recurrent Oropharyngeal disease.
Primary infection with HSV-1 produces symptoms including fever, vesicular lesions, 
gingivostomatitis, anorexia and malaise. However, most primary infections are 
asymptomatic. Symptomatic disease is much more severe in children, and can last 
for 2-3 weeks.
Recurrent orolabial lesions appear approximately 24 hours after a period of itching or 
pain at the site of reactivation. Vesicles frequently appear at the vermillion border of 
the lip, and persist for about 48 hours prior to scabbing. Healing occurs in 8-10 days.
1.1.3.3.2 Primary/recurrent Genital disease.
Primary infection with HSV-2 results in the appearance of vesicles, pustules and 
ulcers which persist for about 3 weeks. Fever, dysuria and malaise are common in 
both men and women, although the severity of infection and rate of complications is 
higher in women than men. Systemic complications occur in almost 70% of cases, 
and include aseptic meningitis and extragenital lesions.
In women, lesions appear on the vulva and the cervix. The frequency of infection of 
the cervix without vulvar infection is unknown. In men, vesicular lesions are 
obvious on the penis, and extragenital lesions can occur. In both men and women, 
many primary infections are asymptomatic.
Non-primary infection of the genitals causes less severe disease and pre-existing 
antibodies to HSV-1 have been reported to have an ameliorative effect on disease 
severity (Whitley, 1996).
Recurrent HSV-2 disease is usually mild. The number of vesicles present and their 
duration is reduced, and virus is also shed for a shorter period of time. The frequency 
of recurrent infection (which varies from 2-3 per year to in excess of 8 recurrences 
per year) appears to correlate with the severity of the primary infection. Recurrent 
infection can be asymptomatic, resulting in unwitting transmission of the virus to 
sexual partners.
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1.1.3.3.3 Neonatal HSV infection.
The rate of occurrence of neonatal HSV infection averages 1 in 3000 to 1 in 5000 
births, and the likelihood of infection depends greatly upon the type of maternal 
genital infection at the time of birth. Primary or initial infection carries a ten-fold 
higher risk of transmission than recurrent infection. Infection occurs rarely in utero 
and postnatally (normally with HSV-1 when it does occur), but occurs commonly 
during birth.
Neonatal infection (reviewed by Whitley, 1996) is almost invariably symptomatic 
and often fatal, and disease generally falls into three categories. These are disease 
localised to the skin, eye or mouth; encephalitis or disseminated infection. 
Intrauterine infection results in serious disease, often involving encephalopathy. 
Disseminated disease, most frequently involving the liver and the adrenal glands has 
the worst prognosis for morbidity and mortality. Encephalitis occurs in 
approximately 60-75% of children with disseminated disease and in the absence of 
antiviral therapy 80% of babies will die and most survivors will be neurologically 
impaired.
Skin, mouth or eye infection is less severe, with limited mortality, but approximately 
30% of these children develop neurological impairment.
1.1.3.3.4 Other disease associated with herpes simplex virus infection.
Several other diseases have been associated with HSV infection (reviewed by 
Whitley, 1996). Approximately 300,000 cases of HSV-1 infection of the eye are 
reported yearly in the U.S. with primary infection generally resulting in 
conjunctivitis. Healing can take up to 1 month, even with antiviral therapy and 
recurrent infections are common, resulting in the progressive opacification of the 
cornea and blindness.
Skin infections with HSV generally manifest as eczema herpeticum. In a Swedish 
study, approximately 2% of patients attending dermatology clinics had evidence of 
herpetic skin lesions. Infection of the fingers, known as herpetic whitlow is 
increasing in incidence amongst healthcare workers.
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HSV encephalitis is the most common cause of sporadic, fatal encephalitis in the 
U.S. Mortality in untreated patients with HSV encephalitis exceeds 70% and few 
patients return to normal neurological function. The disease can be caused by either 
primary or recurrent HSV infection. Analysis of cerebrospinal fluid from patients 
with non-neonatal HSV encephalitis demonstrated that only approximately 2% (1/64) 
of cases were caused by HSV-2 infection (Dennett et al., 1997), whilst in neonates 
HSV encephalitis was caused by HSV-2 in 62% of cases, and produced more severe 
disease (Corey et al., 1988).
Patients who are immunocompromised suffer increased risk of severe HSV infection. 
Transplant patients are especially at risk of progressive disease, which may include 
infection of the gastro-intestinal tract. AIDS patients are at even greater risk of 
severe disease, and require aggressive antiviral therapy which can result in the 
emergence of resistant virus isolates.
1.1.3.4 Host immune response.
The natural history of HSV infections is influenced by specific and non-specific host 
responses (reviewed by Whitley, 1996). Host genetic background, macrophages, 
natural killer cells, specific T-cell populations, specific antibodies and lymphokine 
responses have all been implicated as important host defences against HSV infection. 
The typical response to HSV infection is a non-specific inflamation which co-incides 
with peak viral replication, followed by a cytotoxic T-cell response and the 
appearance of IgM and IgG specific antibodies. Antibody dependent cell mediated 
cytotoxicity (ADCC) correlates with improved clinical outcome.
The importance of the host immune response in disease progression is demonstrated 
by the following examples. Prior infection with HSV-1 appears to have a protective 
effect for HSV-2 infection, presumably due to antigenic cross-reactivity between the 
two viruses. In patients with recurrent infection it has been suggested that the 
cytotoxic T-cell response is decreased, while host immune responses in the newborn 
are delayed with respect to the adult population, which may explain the increased 
severity of disease in the neonate. Immunocompromised individuals also suffer more 
frequent and severe recurrent HSV infection.
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1.1.3.5 Latency.
Latency provides a reservoir of virus which can be transmitted following reactivation 
for the lifetime of the carrier. Recurrences occur in the presence of cell mediated and 
humoral immunity, and are associated with physical or emotional stress, fever, 
UV-light, tissue damage and immune suppression (Whitley, 1996).
The molecular biology of HSV latency is discussed in Section 1.1.8.
1.1.4 THE MOLECULAR BIOLOGY OF HSV-1.
1.1.4.1 Virion structure.
The HSV-1 virion is complex, with at least 39 of the 84 HSV-1 protein coding genes 
encoding proteins which are components of the virion or are involved in virion 
assembly (Roizman, 1996).
The HSV-1 virion consists of four distinct components. The core contains the viral 
DNA and is enclosed within an icosahedral protein capsid. This is surrounded by an 
amorphous protein layer known as the tegument which is in turn surrounded by a 
trilamellar lipid envelope which is derived from the host cell and contains virus 
glycoproteins. The localisation or function of the HSV-1 proteins known to be 
associated with the HSV virion or involved in HSV virion assembly are shown in 
Table 1.2.
Table 1.2. The localisation and function of HSV-1 virion proteins.
Capsid Minor Capsid DNA packaging Tegument Envelope
UL18 UL6 UL6 UL11 UL47 UL1 UL45
UL19 UL12.5 UL12 UL13 UL48 UL10 US4
UL26 UL15 UL15 UL21 UL49 UL20 US6
UL26.5 UL25 UL25 UL36 US9 UL22 US7
UL35 UL28 UL37 US11 UL27 US8
UL38 UL32 UL41 RL1 UL34
UL33 UL46 RSI UL44
Adapted from Homa and Brown, 1997.
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Three of the proteins involved in DNA packaging are minor, non structural 
components of the capsid. The function and virion localisation of the other DNA 
packaging proteins is presently unknown.
Three capsid types have been defined depending on whether the capsids contained 
DNA or were enveloped. These were designated A-, B- and C-capsids, and are 
discussed in relation to capsid assembly in Section 1.1.5.1.
The tegument contains the remainder of the virion proteins, including the a-trans- 
inducing factor (a-TIF, VP 16, Vmw65), the virion host shutoff protein (UL41) and a 
large protein (VP 1-2) which binds to the terminal ^-sequence of the viral genome, 
and may have a role in DNA packaging (Table 1.2).
The structure of the HSV-1 genome is shown diagramatically in Figure 1.1. The 
genome is approximately 152kbp linear double stranded DNA with a G+C content of 
68% (HSV-1) or 70.4% (HSV-2). It contains two covalently linked unique 
sequences (UL and Us) bracketed by inverted repeats (a,b and c in Figure 1.1). The 
number of a sequence repeats is variable at the L/S junction and at the L terminus. 
The structure of the a sequence (Figure 1.2) is highly conserved, containing a 20bp 
direct repeat (DR1), a 65bp unique region (Ub), a 12bp direct repeat (DR2) present in 
19-23 copies, a 37bp direct repeat (DR4) present in 2 or 3 copies, a unique region 
(Uc) and a final copy of DR1. The terminal DR1 repeats are truncated, with a single 
nucleotide overhang, and a complete DR1 repeat is formed upon genome 
circularisation.
The L and S components of the HSV genome can invert relative to each other by a 
process of intramolecular recombination involving the repeated sequences to yield 
four isomers (see Figure 1.1). The four isomers are present in equimolar amounts 
during natural infection. The internal repeat sequences are not essential for virus 
growth in cell culture, although these viruses are locked in one genome 
configuration.
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Figure 1.1. The structure o f the HSV-1 genome.
b’ c’ c as
TRl IRl IRS TRg
Legend. The HSV-1 genome is shown schematically, with unique sequences as solid lines 
(Us and UL). The repeats TRL, IRL, IRS and TRS are illustrated as boxes with their 
component parts a, b, c and a’, b’, c’ labelled.
Below the genome diagram, the isomerisation of the HSV-1 genome is illustrated. The four 
isomers are: P (prototype); IL (L inverted with respect to P); IS (S inverted with respect to 
P) and ISL (both L and S inverted with respect to P)
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Figure 1.2. The structure o f the HSV-1 a sequence.
The HSV virion contains the polyamines spermidine and spermine at levels of 
70,000 and 40,000 molecules per virion. These molecules are proposed to neutralise 
the charge due to DNA phosphate, a function which would normally be performed by 
histone proteins.
The lipid composition of the virion envelope is derived from the cell, and was 
initially thought to be derived from the nuclear membrane. Recent studies however, 
suggest that the composition is more similar to cytoplasmic membranes 
(vanGenderen et al., 1994).
1.1.4.2 Viral genes.
The complete sequence of HSV-1 was published by McGeoch et a l, (1988) and 72 
open reading frames were identified. Since then a further ten open reading frames 
have been identified (reviewed by Roizman and Sears, 1996), including those 
encoding the neurovirulence factor (ICP34.5) and the scaffold protein (UL26.5). The 
current knowledge concerning the protein products of the HSV-1 genes is presented 
in Table 1.3.
The HSV-1 genes are expressed in a sequentially ordered fashion divided into three 
main temporal classes. Where the information is available, the temporal class of the 
viral genes is shown in Table 1.3.
The a  (immediate early; IE) genes are the first to be expressed, and are expressed in 
the absence of viral protein synthesis. All a  genes contain at least a single copy of a 
consensus TAATGArATT sequence near the cap site, which is necessary for their 
transactivation by a-TIF (Mackem and Roizman, 1982). Trans-activation of HSV-1 
a  genes is discussed further in Section 1.1.6.1. The synthesis of a  proteins peaks at 
2-4 hours post infection, but continues until late in infection. All a  proteins except
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Table 1.3. The functions of the HSV genes presently identified.
Gene Protein/Function Dispensible in Temporal
tissue culture class
RL1 Neurovirulence factor (ICP34.5). Y Yi
ORFP 248 amino acid polypeptide-antisense to ICP34.5. Y
ORFO ORF partially antisense to ICP34.5. Y
RL2 IE protein- Vmwl 10 transcriptional regulator (ICPO). Y a
UL1 Glycoprotein L- role in virion entry. N y
UL2 Uracil DNA glycosylase. Y P
UL3 Function unknown- nuclear phosphoprotein. Y
UL4 Function unknown- found in virions and light particles. Y y2
UL5 Component of DNA helicase-primase. N P
UL6 Virion protein- involved in cleavage/packaging nascent 
DNA.
N
UL7 Function unknown. N
UL8
UL8.5
Component of DNA helicase-primase- necessary for DNA 
replication.
486 amino acid polypeptide (OBP-C)- possible role in 
HSV DNA replication.
N P
UL9 On-binding protein- essential for DNA replication. N Y?
UL10 Glycoprotein M. Y Y
UL11 Myristylated tegument protein- role in envelopment and 
egress of virions.
Y Y?
UL12 Alkaline exonuclease- role in maturation/packaging of 
nascent DNA.
Y P
UL13 Tegument protein- protein kinase. Y Y
UL14 Function unknown. N
UL15 Role in cleavage of concatameric DNA. N Y
UL16 Function unknown. Y
UL17 Function unknown. N Y
UL18 VP23- capsid protein triplex component. N Y
UL19 VP5- major capsid protein. N Yi
UL20 Integral membrane protein- role in egress of virions Y Y
UL20.5 Function unknown. Y Y2
UL21 Function unknown- nucleotidylyated phoshoprotein. Y
UL22 Glycoprotein H- role in entry, egress and cell-cell spread. N Y 2
UL23 Thymidine kinase (TK)- role in DNA replication. Y P
UL24 Function unknown- membrane associated? Y Y
UL25 Virion protein- role in capsid maturation and DNA 
packaging.
N Y
UL26 Proteinase- N-terminal portion is capsid protein VP24; C- 
terminal is VP21 (capsid assembly).
N Y
UL26.5 VP22a- scaffold protein for B capsids; processed by 
UL26 protease.
N Y
UL27 Glycoprotein B- role in virion entry; forms a dimer. N Yi
UL28 Role in capsid maturation/DNA packaging. N Y
UL29 ssDNA binding protein (ICP8)- essential for DNA 
replication.
N P
UL30 Catalytic subunit of replicative DNA polymerase. N P
UL31 Nucleotidylyated phosphoprotein- nuclear matrix 
associated.
N y 2
UL32 Role in DNA packaging. N Y2
UL33 Role in capsid maturation/DNA packaging. N
UL34 Membrane associated non-glycosylated phosphoprotein. N
UL35 VP26- capsid protein present on tips of hexons. N y 2
UL36 VP 1-2 (ICP1-2, Vmw273)- tegument phosphoprotein. N Y2
Table 1.3 continued
Gene Protein/Function Dispensible in 
tissue culture
Temporal
class
UL37 Tegument phosphoprotein- binds to ICP8, may have DNA 
binding function.
N Y
UL38 VP19C- component of triplexes. DNA anchor? N Y i
UL39 Ribonucleotide reductase large subunit (RR1). Y P
UL40 Ribonucleotide reductase small subunit (RR2). Y P
UL41 Virion Host Shutoff (vhs)- 55kDa polypeptide located in 
tegument.
Y Y
UL42 Subunit of replicative DNA polymerase- increases 
processivity
N P
UL43 Function unknown- probably membrane associated. Y
UL44 Glycoprotein C- role in virion attachment. Y Y2
UL45 18kDa polypeptide- function unknown. Y Y2
UL46 VP11/12- tegument phosphoprotein; modulates a-TIF. Y Y
UL47 VP 13/14- nucleotidylyated tegument phosphoprotein; 
modulates a-TIF (VP 16).
Y Y2
UL48 VP 16 (Vmw65, aTIF)- major tegument protein; 
transactivator of IE(a) genes
N Y
UL49 VP22- Nucleotidylyated tegument phosphoprotein. N Y
UL49.5 6.7kDa non-glycosylated membrane polypeptide- 
associated with tegument (disulphide bridge?).
N y 2
UL50 Deoxyuridine triphosphatase (dUTPase). Y P
UL51 Function unknown. Y Y
UL52 Component of DNA helicase-primase. N P
UL53 Glycoprotein K; role in cell fusion and viral exo-cytosis. N Y
UL54 ICP27 (Vmw63)- IE protein, positive regulator of late 
gene expression; negatively regulates early genes. SnRNP 
redistribution inhibits splicing.
N a
UL55 Function unknown. Y
UL56 Function unknown. Y
RSI ICP4 (Vmwl75)- IE protein, positive transcriptional 
regulator of most (3 and y genes.
N a
US1 ICP22 (Vmw68)- IE protein, required for optimal 
expression of ICP 0 and subset of y genes.
Y a
US 1.5 Function unknown- co-terminal with US1. Y a
US2 Function unknown. Y
US3 Protein kinase- main substrate is UL34. Y P
US4 Glycoprotein G; involved in entry, egress and cell-cell 
spread.
Y Y
US5 Glycoprotein J (predicted). Y
US6 Glycoprotein D; role in virion entry post-attachment. N Y.
US7 Glycoprotein I; complexed with gE has role in transport to 
plasma membrane. High affinity receptor for Fc of IgG.
Y g
US8 Glycoprotein E; complexes with gl. Basolateral spread of 
virus in polarised cells.
Y y 2
US8.5 Function unknown. Y Pory,
US9 Tegument protein. Y
US10 Tegument protein. Y
US11 Tegument protein- ribosome associated in infected cells. 
Binds UL34 mRNA- possible attenuation factor.
Y Y2
US12 ICP47- IE protein, blocks presentation of viral 
polypeptides to MHC class I restricted cells.
Y a
OrisTU RNA transcribed across Oris- probably not translated. Y Y2
LAT Family of transcripts expressed during latency, of 
unknown function and uncertain protein coding capacity
Y
A dapted  from  R oizm an  and Sears, 1996; H om a and B row n, 1997; B o eh m er and L ehm an, 1997.
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a47 (US 12) have a regulatory function and are required for the synthesis of 
subsequent temporal classes of proteins.
The p (early; E) genes require functional a  gene products for their expression. Peak 
rates of synthesis occur at 5-7 hours post infection. The p genes can be sub-divided 
into those that appear very early (e.g. UL39-RR1) and those that appear later (e.g. 
UL23-TK), but all require a4  (Vmwl75) for their expression. The appearance of the 
p genes signals the onset of DNA synthesis.
The y (late; L) genes are classified into two groups differing in the timing of their 
expression and dependence upon DNA synthesis. yl genes, (e.g. gB) are expressed 
relatively early (overlapping with P gene expression) and are minimally affected by 
inhibitors of DNA synthesis, while y2 genes (e.g. gC) are expressed later and require 
DNA synthesis for their expression. These genes encode mostly structural proteins 
(see Table 1.3).
The aO (Vmwl 10) and a4 genes are located within the inverted repeats of the L and 
S regions and are therefore diploid. The HSV-1 genome is organised such that the a  
genes form two clusters (aO, a4, a22 and a47, a4, aO) in the circularised genome, 
and each contains an origin of replication. The p and y genes are scattered 
throughout the UL and Us regions, with the exception of y34.5 and ORF P genes 
which are located in the repeat region of UL. Two functional clusters have been 
noted, although the biological relevance of this is uncertain. The DNA polymerase 
and ssDNA binding protein (both p genes) flank OriL and the genes for glycoproteins 
D, E, G, I and J (all y genes) map next to each other within Us.
1.1.4.3 Viral replication.
The events involved in the replication of HSV have been reviewed recently by 
Roizman and Sears, 1996.
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1.1.4.3.1 Initial stages of infection.
1.1.4.3.1.1 Attachment.
The study of HSV attachment to tissue culture cells is complicated by the un-natural 
distribution of potential cell surface receptors in non-polarised cells. For example, it 
has been shown that gC is necessary for attachment to an apical but not basal cell 
surface receptor (Sears et al., 1991). The deletion, in turn, of individual HSV-1 
glycoproteins failed to eliminate cell surface attachment, suggesting that HSV-1 can 
utilise several attachment pathways.
Cell surface heparan sulphate has been identified as the major factor in HSV 
attachment to the cell surface (Wudunn and Spear, 1989; Shieh et al., 1992; 
Gruenheid et al., 1993). Removal of heparan sulphate from the cell surface reduced 
attachment by 85%, but did not completely eliminate binding. This suggested that 
heparan sulphate is one of multiple receptors. gC is a heparin binding protein, and 
gC negative viruses have been shown to bind to cells with reduced efficiency (Fuller 
and Spear, 1985; Trybala et al., 1994). In the absence of gC, gB is thought to bind 
weakly to heparan sulphate to facilitate adsorption, as double mutants in both gB and 
gC bind with lower efficiency than a gC mutant alone (Herold et a l, 1994). 
Following initial attachment (by either gB or gC), a stable interaction between gD 
(Johnson and Ligas, 1988; Johnson et al., 1990) and a saturable cell surface receptor 
occurs. This receptor has recently been identified in some HSV-1 strains as a novel 
member of the NGF receptor family (Montgomery et al., 1996; Whitbeck et al., 
1997). Other potential cellular receptors for HSV include the basic fibroblast growth 
factor receptor (bFGFR) (Kaner et al., 1990) although this could not be confirmed by 
other workers, and the CR1 receptor, which is reported to be responsible for gC 
mediated attachment at the apical surface of polarised epithelial cells (Roizman and 
Sears, 1996).
Recently however, Griffiths et al. (1998), have reported that in certain strains of 
HSV-1, mutants in glycoproteins C, E, G, I and J are able to infect both apical and 
basal surfaces of cells with efficiencies comparable to wild type virus, suggesting 
that in certain virus strains gC has little or no role in adsorption. The mechanism of 
viral attachment therefore remains unclear at present.
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1.1.4.3.1.2 Penetration.
The mechanism of penetration is poorly understood, but is known to be very rapid 
and to occur via membrane fusion mediated by virus envelope glycoproteins 
(Roizman and Sears, 1996). In non-polarised cells, viruses with mutations in the gB 
and gD genes attach to but do not penetrate the cell surface and cells expressing gD 
allow attachment but not membrane fusion. Penetration is thought to involve gB and 
the gH:gL heterodimer whilst the other glycoproteins are dispensible and the 
expression of gD, gB and gH:gL in transfected cells has recently been shown to be 
sufficient to allow cell-cell fusion (Turner et al., 1998).
1.1.4.3.1.3 Release of viral DNA.
After entry into the cell the viral capsids are transported to the nuclear pores in a 
process probably mediated by the cytoskeleton (Kristensson et al., 1986). Release of 
the DNA into the nucleus occurs by a process that requires a viral function. Empty 
capsids are readily observed at the nuclear pore of infected cells.
1.1.4.3.2 Synthesis and processing of viral proteins.
Viral polypeptides are synthesised on both free and bound host polyribosomes, and 
are extensively modified following synthesis. Processing includes cleavage, 
phosphorylation, glycosylation, sulphation, myristylation, ADP-ribosylation and 
nucleotidylylation (Roizman and Sears, 1996). Except for some of the glycoproteins, 
it is unclear whether much of the processing is essential for virus growth.
HSV encodes a protease (UL26) which catalyses self cleavage and the cleavage of 
the scaffold protein to facilitate DNA packaging into capsids (see Section 1.1.5). At 
least three protein kinases have been identified, although substrates have only been 
defined for the UL13 kinase (which include the UL26 protease and its pre-VP22a 
substrate). ICP4 has been reported to be ADP-ribosylated (Preston and Notarianni, 
1983), and several viral polypeptides have been reported to be nucleotidylylated 
(including ICP4 and ICPO (Blaho et al., 1994)), although the importance of these 
modifications is unclear.
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1.1.4.3.3 HSV DNA replication.
Herpes simplex virus DNA synthesis has been recently reviewed by Boehmer and 
Lehman (1997). The HSV genome contains three origins of replication and encodes 
seven proteins that are essential for DNA replication. These are encoded by herpes 
simplex vims genes of the p temporal class. A set of enzymes involved in nucleotide 
metabolism are also encoded by the HSV genome, but these are dispensable in tissue 
culture.
Viral DNA synthesis is detectable as early as 3 hours post-infection, and continues 
up to 15 hours post-infection, with most replication occurring later in this period 
(Igarashi et al., 1993).
1.1.4.3.3.1 Proposed model of DNA replication.
Boehmer and Lehman (1997) suggest a model for replication of the HSV-1 genome, 
which is presented briefly below, before a more detailed discussion of the replication 
origins and the HSV proteins involved in DNA synthesis.
Early in infection the linear HSV genome circularises, and DNA replication initiates 
at an origin, proceeds initially via theta replication and then switches to rolling circle 
replication. Recombination events lead to the formation of extensively branched 
DNA intermediates, which are resolved to unit length genomes upon packaging into 
empty pre-formed capsids.
No direct evidence has been reported for the presence of the theta replication 
intermediate, but the presence of head to tail concatameric DNA molecules (Severini 
et a l , 1994) supports a rolling circle replicative mechanism. Furthermore, branched 
DNA intermediates indicative of rolling circle replication from several origins have 
been observed by electron microscopy and 2-D electrophoresis (Severini et al.,
1996).
1.1.4.3.3.2 HSV-1 origins of Replication.
The HSV-1 genome contains three origins of replication, one copy of OriL located 
between the UL29 and UL30 open reading frames in UL, and two copies of oris
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within the c sequence of the short repeats (Stow, 1982). Oris and OriL contain large 
palindromes of 45bp and 144bp centered respectively around an A+T region of 18bp 
and 20bp. Flanking the A+T region are inverted repeats that are binding sites for the 
origin binding protein (UL9). OriL contains two high affinity UL9 sites (Box 1), and 
oris one high affinity and one low affinity site (Box 2). The boxl sites in OriL are 
flanked by homolgous sequences with lower affinity for UL9 (Box 3), whilst Oris 
contains only a single Box 3 element. Efficient replication from Oris requires intact 
Box 1 and Box 2 elements. However neither copy of Oris is essential in tissue 
culture. These HSV-1 origins therefore appear to be redundant, and are conserved 
for an unknown reason.
1.1.4.3.3.3 HSV gene products essential for origin dependent replication.
1.1.4.3.3.3.1 Origin binding protein-UL9.
UL9 encodes an 851 amino acid polypeptide which binds to Boxes 1 and 2 of Oris, 
and contains ATP binding and helicase motifs that are essential for viral replication 
(Stow et al., 1993). The UL9 protein binds as a homodimer formed through a 
leucine zipper motif within the N-terminal region (Deb and Deb, 1991), while the 
sequence specific DNA binding activity resides in the C-terminal portion of the 
protein (Arbuckle and Stow, 1993).
The region within Box 1 of Oris recognised by the UL9 protein has been mapped to a 
lObp sequence (Hazuda et al., 1992), homologues of which are contained in inverted 
orientation in Boxes 2 and 3. Box 1 and Box 2 are seperated by three turns of the 
DNA helix, suggesting that two UL9 dimers bind in inverted orientation on the same 
side of the DNA molecule. Co-operative binding of UL9 to the lower affinity boxes 
within Oris is suggested to be mediated by protein-protein interactions between the 
N-terminal regions of UL9 (Elias et al., 1992).
UL9 also exhibits an ATP dependent helicase activity which proceeds in a 3’-5’ 
direction and is dependent upon the length of the DNA substrate. The processivity of 
the helicase is greatly increased in the presence of ICP8, the HSV-1 single stranded 
DNA binding protein (Fierer and Challberg, 1992). A model of origin specific DNA 
unwinding has been proposed (Boehmer and Lehman, 1997). Binding of UL9 at the 
origin is proposed to induce bending and looping out of an A+T rich region within
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the origin preventing processivity of the UL9 protein, and causing the DNA to be 
spooled through the protein complex as single stranded DNA. The unwound DNA is 
stabilised by SSB/UL9 which then recruits the primase complex to the origin.
1.1.4.3.3.3.2 Single stranded DNA binding protein (SSB)- ICP8.
The single stranded DNA binding protein (SSB), the 1196 amino acid protein 
product of the UL29 gene (Quinn and McGeoch, 1985) contains a consensus DNA- 
binding sequence and a zinc-finger motif (Berg, 1986). SSB binds co-operatively to 
single stranded DNA with a five-fold greater affinity than for double stranded DNA 
(Lee and Knipe, 1985), holding the DNA in an extended filamentous form (Machov 
et al., 1996). SSB has an ATP and direction independent helix destabilising activity 
(Boehmer and Lehman, 1993) which may facilitate the unwinding reaction. SSB 
also plays a key role in the assembly of the DNA replication apparatus.
1.1.4.3.3.3.3 DNA Helicase-Primase.
The helicase-primase complex consists of the products of the UL52, UL5 and UL8 
genes (Crute et a l, 1989), and unwinds DNA as it translocates along the lagging 
strand. The UL5 protein has ATP binding and DNA helicase motifs, while the UL52 
component contains the primase active site (Klinedinst and Challberg, 1994). The 
UL5 and UL52 subunits represent the core enzyme (Calder and Stow, 1990), while 
the UL8 component stimulates the rate of primer synthesis (Tenney et al., 1994), 
although there is no apparrent effect on the helicase activity.
1.1.4.3.3.3.4 DNA polymerase.
The HSV DNA polymerase is encoded by the UL30 gene, and exhibits high 
homology to other DNA polymerases. Formation of a heterodimer with the UL42 
gene product which possesses double stranded DNA binding activity is essential for 
viral replication (Reddig et al., 1994).
The UL30 subunit possesses a 3’-5’ exonuclease activity (Hall et al., 1996) which 
ensures high fidelity DNA replication (‘proof-reading’), and an RnaseH activity 
which facilitates primer degradation (Crute and Lehman, 1989).
The UL42 subunit increases the processivity of the UL30 DNA polymerase. Unlike 
processivity factors from other organisms, UL42 exhibits an intrinsic DNA binding
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activity. The UL42 protein binds at the primer-template junction and reduces the rate 
of dissociation of the UL30 subunit from the DNA substrate (Gottlieb and Challberg,
1994).
The site of interaction between the UL30 and UL42 proteins has been localised to 
amino acids 1209-1235 at the C-terminus of UL30 (Digard et a l, 1995) while the N- 
terminal 340 amino acids of UL42 are sufficient for binding UL30 and the activation 
of the polymerase activity (Tenney et al., 1993).
1.1.4.3.3.3.5 Protein-protein interactions.
The interaction between the components of the replication complex (replisome) are 
important for the efficient replication of viral DNA. Boehmer and Lehman (1997) 
suggest a model in which assembly of this complex is initiated by UL9 binding to the 
high affinity site within the origin. UL9 recruits ICP8, the single stranded DNA 
binding protein (SSB) which facilitates unwinding of the template DNA. UL9 is 
thought to recruit the helicase-primase to the origin. Following processive DNA 
unwinding the UL9 dissociates and unwound regions of DNA are coated with ICP8. 
Additional replication enzymes are then recruited to the replication fork by ICP8. 
An interaction between the UL8 subunit of the helicase-primase and ICP8 (SSB) is 
proposed to ensure concomitant DNA unwinding and priming at the replication fork. 
The alkaline endo-exonuclease (UL12) which plays a role in the processing of 
branched DNA replication intermediates also interacts with ICP8.
Punctate pre-repliction sites within the infected cell nucleus have been identified by 
immunofluorescence studies. With the onset of DNA replication the distribution of 
the HSV-1 replication proteins changes to globular nuclear domains which may also 
contain cellular components Studies of the protein interactions suggest that 
interactions between UL9 bound with ICP8 at an origin of replication and the 
helicase-primase initiates unwinding and primer synthesis at the origin. The 
UL30/UL42 polymerase is then recruited.
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1.1.4.3.3.3.6 Non-essential HSV-1 genes.
Several HSV-1 genes are dispensable for viral DNA repliction in tissue culture. 
These include the alkaline endo-exonuclease (UL12); uracil-N-glycosylase (UL2) 
responsible for removing uracil residues from DNA; dUTPase (UL50) which 
degrades dUTP to prevent its incorporation into DNA; thymidine kinase (UL23) 
which phosphorylates thymidine and deoxycytosine, and ribonucleotide reductase 
(UL39/UL40)2 which reduces ribonucleotides to form DNA precursors.
1.1.4.3.3.3.7 Cellular enzymes.
HSV-1 does not encode a DNA ligase or DNA topoisomerase, and must therefore 
use the host enzymes. The cellular DNA polymerase a-primase may also be required 
for viral DNA replication.
1.1.4.3.4 Capsid assembly and DNA packaging.
1.1.4.3.4.1 Structure of the HSV-1 Capsid.
Recent studies of capsid assembly (reviewed by Rixon, 1993; Homa and Brown,
1997) have demonstrated that HSV-1 capsid assembly resembles capsid formation in 
double stranded DNA phage such as X and T7.
Three distinct forms of HSV-1 capsid can be isolated from infected tissue culture 
cells. ‘A’ capsids are empty capsids which contain no DNA core and are thought to 
result from abortive packaging of the viral genome (Dilanni et al., 1993). ‘B’ capsids 
contain VP22a (cleaved scaffold protein) in the core and were once thought to be 
precursors of DNA containing capsids, although they are now thought to dead end 
products. Large cored ‘B’ capsids, similar to those produced by the protease 
deficient temperature sensitive mutant tsl201 are now thought to be the precursors 
capable of DNA packaging. ‘C’ capsids contain a liquid crystalline DNA core (Booy 
et al., 1991) and can mature into infectious virions (Perdue et al., 1976).
Cryo-electron microscopy and image reconstruction (Booy et al., 1991; Zhou et al.,
1995) have shown that the HSV-1 capsid is an icosahedral protein shell 
approximately 15nm thick and 125nm in diameter. The major structural components
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are 162 capsomers; 150 hexamers make up the edges and faces of the capsid, and 12 
pentamers are located at the vertices. The capsomers are made of VP5, the major 
capsid protein (Schrag et al., 1989; Newcomb et al., 1993) and are held in position 
by 320 triplexes, which contain two copies of VP23 and a single copy of VP19C 
(Newcomb et al., 1993; Desai et al., 1994). VP26 is thought to sit at the tip of the 
hexon, with one VP26 molecule bound to each VP5 subunit in the hexamer (Zhou et 
a l, 1995).
The 75kDa protein encoded by the UL6 ORF is associated with the capsid (Patel and 
Maclean, 1995). It is present in very low amounts, is maintained in the capsid after 
packaging of DNA, and possibly has a role in the packaging of viral DNA.
B-capsids contain a large amount of the scaffold protein, and smaller amounts of 
VP21 and VP24, the UL26 gene products, formed by self cleavage. The scaffold 
forms a core and interacts directly with the C-terminal portion of VP5 (Hong et al., 
1996) to facilitate capsid assembly, and is then lost prior to DNA packaging. The 
UL26 and UL26.5 open reading frames are co-incident, and as such the C-terminal 
cleavage site present in the protease (VP24) is also present in the scaffold protein 
(preVP22a). Cleavage at this site is thought to release the scaffold from the 
completed capsid, as the C-terminal VP5 binding domain releases the remainder of 
the polypeptide.
Recombinant baculovirus studies (Tatman et al., 1994; Thomsen et al., 1994) have 
shown that the minimum number of HSV-1 genes required to produce B capsids is 
four, the genes encoding the structural proteins (VP5, VP19C and VP23) and the 
UL26.5 gene (pre-VP22a scaffold). Mutant virus studies suggest that the UL26 
product VP21 can substitute for the preVP22a scaffold but the virus yields were 
significantly reduced (Gao et al., 1994). The presence of the VP24 protease function 
is essential for the transformation of large cored B capsids formed in insect cells 
infected with recombinant baculoviruses expressing the VP5, VP19C, VP23 and 
preVP22a and by infection of cells with the mutant HSV-1 virus to 1201, to small 
cored B capsids.
The transport of the capsid components to the nucleus has been studied (Rixon et a l, 
1996). PreVP22a and VP19C localise to the nucleus on their own, while VP5, VP23
19
Chapter 1: Introduction.
and VP26 require to interact with other proteins for transport to occur. VP5 can 
interact with either preVP22a or VP19C, while VP23 is brought to the nucleus by 
VP19C. The interaction of the proteins also prevents the formation of aberrant 
capsid structures in the cytoplasm.
Capsids have also been produced from cell free extracts of insect cells infected with 
the capsid protein expressing baculoviruses (Newcomb et al., 1996). Their formation 
was dependent upon the presence of VP5, VP 19, VP23, and preVP22a.
A recent study using a temperature sensitive mutant in the UL26 encoded 
maturational protease (teProt.A) allowed a synchronous wave of virus assembly to be 
followed (Church and Wilson, 1997). Blocking UL26 protease action resulted in the 
accumulation of large cored B capsids. Cleavage of preVP22a correlated with the 
formation of small cored B capsids that are able to package DNA and expel the 
protein scaffold. The mature C capsids bud into the inner nuclear membrane and 
become enveloped, although the precise mechanism of envelopment is unclear. 
Electron microscopy showed that clusters of large cored B capsids were present in 
cells at the non permissive temperature, and that these began to mature within 2 
hours of release. Capsids were observed budding through the nuclear membrane, and 
enveloped and naked capsids were observed in the cytoplasm 2 hours post-release.
A model for the assembly of HSV-1 capsids is presented in Figure 1.3, based upon 
information obtained using the cell free assembly system (Thomsen et al., 1994). 
Partial capsids consisting of a region of shell surrounding a region of scaffold core 
have been isolated. These form into closed procapsids, which are spherical, contain 
larger pores and are primarily held together by the triplexes. A conformational 
switch then occurs to change the procapsid to an icosahedral form. This is analagous 
to dsDNA bacteriophage capsid assembly (Prevelige and King, 1993).
1.1.4.3.4.2 DNA packaging.
HSV-1 DNA is packaged free of histones, and is highly condensed within the capsid. 
The DNA is considered to be mostly in a disordered state, similar to the liquid 
crystalline state of packaged bacteriophage DNA (Booy et al., 1991). Cleavage of 
concatameric DNA and packaging into capsids is tightly coupled, and involves cis- 
acting elements within the a sequence, seven essential viral gene products, and the
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Figure 1.3. Proposed model of HSV-1 Capsid assembly.
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Legend. Partial capsids consisting of a region of shell surrounding a region of scaffold core 
have been observed. Early partial capsids continue to grow by addition of scaffold (UL26.5) 
and structural capsid components (UL19, UL18 and UL38: VP5, VP23 and VP19C 
respectively) to the early partial capsids. The late partial capsids formed in this manner close 
in on themselves to form closed procapsids, held together primarily by the triplexes (VP23 and 
VP19C). A conformational switch transforms these procapsids into a mature icosahedral form, 
with a small scaffold core.
From Homa and Brown, (1997).
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UL12 encoded alkaline endo-exonuclease which may be involved in processing the 
branched DNA intermediates to facilitate packaging (Martinez et a l,  1996). The 
cleavage reaction occurs within the a sequence producing an L-terminus with 18bp 
of the DR1 repeat and a single 3’nucleotide extension, and an S terminus with lbp of 
DR1 and a single 3’ nucleotide extension. Circularisation reconstitutes the complete 
DR1 (Mocarski and Roizman, 1982). The sequences within the a sequence 
responsible for cleavage and packaging are designated p a d  and pac2 respectively 
(Figure 1.4; Deiss et a l,  1986). Concatameric DNA is proposed to be bound at the 
pac sites by a complex of proteins including a component of the capsid (Chou and 
Roizman, 1989). The DNA is inserted into the capsid until the next a sequence of 
like polarity is reached. Linear full length genomes are produced by a recombination 
event. Viral proteins essential for cleavage and packaging include the pac2 binding 
proteins (Chou and Roizman, 1989) and the virus induced DNA endonuclease, which 
cuts within the Uc region of the a sequence (Dutch et a l, 1994). Mutational studies 
implicate several non-structural proteins and capsid proteins in the cleavage- 
packaging process. The UL25 protein is thought have a role in retaining full length 
cleaved genomes within the capsid (McNab et a l, 1996).
Figure 1.4. Packaging signals within the HSV-1 a sequence.
DR1 Ub DR2n DR4m Uc DR1
p a d  pac2
1.1.4.3.4.3 Capsid envelopment and egress.
Regions of modified reduplicated and convex/concave nuclear membrane are 
observed late in infection. Virus is enveloped at these sites (Roizman and Sears, 
1996) which are expected to contain viral glycoproteins on the external surface, and 
anchorage and tegument proteins on the inner face. HSV glycoproteins are 
synthesised in essentially the same manner as cellular glycoproteins (Spear, 1985), 
and HSV glycoproteins containing high mannose N-linked, O-linked and complex
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oligosacharide chains have been identified. N-linked glycosylation is required for 
infectivity, but the requirement for O-linked glycosylation is unknown.
HSV capsids containing DNA attach to these modified areas of the inner lamella of 
the nuclear membrane and become enveloped. Envelopment of capsids containing 
less than a full length genome occurs only rarely (Vlazny et al., 1982). Although 
there is agreement that initial envelopment occurs within the nucleus, envelopment 
has been observed in the cytoplasm in thin section electron micrographs (Roizman 
and Sears, 1996), and the lipid content of the virion envelope is more similar to 
cytoplasmic than nuclear membrane (vanGenderen et a l, 1994). Stackpole (1969) 
proposed a model in which capsids enveloped in the nucleus are de-enveloped at the 
outer lamella, re-enveloped in the endoplasmic reticulum and released into the 
extracellular environment by either envelopment at the plasma membrane or fusion 
of vesicles carrying enveloped virus with the plasma membrane. However, the 
appearance of de-enveloped capsids in the cytoplasm could represent capsids arrested 
during transport, or virus reinfecting the cell from within the endoplasmic reticulum, 
which has become trapped in the cytoplasm rather than being transported to the 
nuclear pore (Roizman and Sears, 1996). Recent studies (Church and Wilson, 1997) 
following a synchronous wave of capsid assembly, suggested that pinching off of 
both nuclear membranes could result in the formation of an enveloped virion within 
an outer lipid vesicle which could deliver the virions to later stages of the secretory 
pathway. Alternatively, they suggest that the strain induced in the membrane by the 
curvature induced during budding could result in fusion of the nuclear membrane 
with the envelope and the release of naked viral capsids into the cytoplasm. The 
exact nature of viral envelopment therefore remains unclear.
Translocation across the cytoplasm to the extracellular space was proposed to occur 
through the Golgi apparatus in a manner similar to the secretion of soluble celluar 
proteins (Johnson and Spear, 1982). Several recent observations suggest that the 
process may be at least partially controlled by HSV. For example, in cells defective 
in processing glycoproteins to a mature form transport does not occur (Banfield and 
Tufaro, 1990), and gl and gE are essential for the basolateral spread of virus in 
polarised epithelial cells (Bloom et al., 1997).
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1.1.5 REGULATION OF VIRAL GENE EXPRESSION.
HSV genes contain signals that enable their transcription by cellular factors, and in 
addition contain response elements transactivated by other viral proteins. The 
HSV-1 genes and ds-acting sequences are discussed in the following section.
1.1.5.1 Trans-activation of a  genes by a-TIF.
Mackem and Roizman (1982) reported a consensus sequence present in all a  genes, 
and noted that some promoters also contained sites later identified as SP-1 sites. 
This a-TIF (VP 16; Vmw65) consensus binding sequence was identified as 
5 ’-GyATGnTAATGArATTCyTTGnGGG-3 ’. The a-TIF was localised to the UL48 
gene by Campbell et al., (1984). a-TIF forms complexes with DNA in the presence 
of the cellular protein Oct-1 (McKnight et a l, 1987). The functional domains of 
a-TIF have been mapped. Region 1 (residues 173-241) is basic and intertacts with 
DNA, while region II (residues 378-389) appears to be responsible for binding the 
Oct-1 POU domain (Stem and Herr, 1991). The activation domain has been mapped 
within the highly acidic C-terminal 80 amino acids (Sadowski et al., 1988), and 
appeared to involve specific hydrophobic interactions as well as less specific charge 
effects (Cress and Triezenberg, 1991). The identity of the protein that transduces the 
a-TIF signal is unknown, but reports have suggested that TFIID (Stringer et al., 
1990), TFIIB (Lin and Green, 1991) or an unknown adaptor protein (Kelleher et al.,
1990) may be involved.
a-TIF is also a structural component of the capsid and although its precise role is 
unclear, it has been reported to bind to the vhs protein (Smibert et al., 1994). This 
latter interaction would prevent the activation of a  genes late in infection by the large 
levels of a-TIF present in cells at this stage.
The Oct-1 protein with which a-TIF forms a complex interacts with the ‘octamer’ 
motif of the cis-regulatory element in the promoters of ubiquitously expressed 
cellular sequences, such as small nuclear RNAs (LaBella et al., 1988). Oct-1 is a 
member of a recently recognised homeobox protein family termed POU proteins. 
Each member contains a conserved POU domain approximately 150 amino acids 
long, which can be further subdivided into POU-homeo and POU-specific domains.
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The POU-homeo domain is involved in DNA binding and in complex formation with 
a-TIF, while the POU-specific domain of Oct-1 may contribute to DNA binding. 
The POU domain has been suggested to be a bi-partite DNA binding domain (Sturm 
and Herr, 1988), which can accomodate the introduction of extra amino acid residues 
within the linker between the POU-homeo and POU-specific regions.
Stable formation of a complex between a-TIF and Oct-1 requires an additional 
factor, termed Cl which binds to a-TIF. Another factor, C2 has also been reported. 
Roizman and Sears (1996) suggest that the multiprotein complex responsible for 
induction of a  genes is initiated by the binding of Oct-1 to the ‘octamer’ motif within 
the promoter. The a-TIF/Cl complex binds to the Oct-1/DNA complex and is 
stabilised by specific protein-protein and protein-DNA interactions. The C2 
interaction is thought to involve only protein-protein interactions.
1.1.5.2 Regulatory functions of the a gene products.
1.1.5.2.1 ICPO (Vmw 110; [RL2]).
ICPO is a protein of approximate molecular weight llOkDa which is dispensable in 
tissue culture. ICPO has been reported to promiscuously trans-activate target genes 
alone, or in conjunction with ICP4 (Vmw 175). Studies of mutants in a0  (Chen and 
Silverstein, 1992) led to the conclusion that a0  was not essential for viral replication 
in some cells, but that defects in this gene delay p and y gene expression.
1.1.5.2.2 ICP4 (Vmw 175; [RSI]).
ICP4 is a phosphoprotein essential for virus gene expression and replication. The 
phosphate is thought to cycle on and off ICP4. Only phosphorylated ICP4 binds to p 
and y promoters. Two molecules of ICP4 bind directly to DNA at consensus and 
non-consensus sequences (Michael and Roizman, 1990). Most of the key functions 
of ICP4 reside in the C-terminal half of the protein. Transactivation by ICP4 occurs 
by binding to constituents of the Pol II transcription machinery, for example TFIIB 
or the TATA binding protein (Smith et al., 1993).
ICP4 positively regulates p and y genes, but also negatively regulates specific a  
genes. ICP4 represses the expression of its own gene and that of a0  by binding to 
ds-acting DNA sequences at the transcription initiation site. Positive regulation of p
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and y genes requires cellular factors in addition to ICP4. It is likely that ICP4 acts by 
stabilising the assembly of TATA box dependent transcriptional factors, and possibly 
by localised effects on the DNA (e.g. ICP4 bends DNA) (Roizman and Sears, 1996). 
Interestingly, ICP4 has been reported to activate some cellular genes (e.g. p-globin) 
introduced into cells by transfection, probably by the stabilisation of transcription 
factor interactions.
1.1.5.2.3 ICP27 (Vmw 63; [UL54]).
ICP27 is an essential gene which exhibits both activator and repressor functions. In 
ICP27' mutant infections, a  genes are over-expressed while P and y genes are poorly 
expressed. This effect is mediated at the transcriptional level (McCarthy et al.,
1989). Other studies have defined a role for ICP27 in the selection of 
polyadenylation sites where more than one signal exists (McLauchlan et al., 1989) 
and in the inhibition of splicing by sequestering snRNPs (Hardy et al., 1992).
1.1.5.2.4 ICP22 (Vmw 68; [US1]) and ICP47 [US12].
As both of these proteins are dispensable in tissue culture neither has been studied in 
detail. In BHK cells ICP22 mutants exhibited delayed shut-off of p genes, and the 
expression of y genes was reduced. The ICP47 gene product is dispensable, and has 
a role in modulating the host immune response (see Section 1.1.9).
A further regulatory protein is the product of the US11 gene which binds to the 60S 
ribosomal RNA component, and also to the UL34 mRNA where it may act as an 
anti-terminator protein upregulating the expression of the UL34 gene (Roizman and 
Sears, 1996).
1.1.5.3 Regulation of a gene expression.
The trans-activation of a  genes by a-TIF has already been described (Section 
1.1.6.1). However, studies have shown the activation of a  genes in the absence of a- 
TIF (Post et al., 1981), suggesting that the promoters contain cw-acting sites for other 
transcriptional activators.
The switch off of a  proteins which occurs during the expression of the later temporal 
classes of genes in the presence of both Oct-1 and a-TIF may be explained by the 
interaction of a-TIF with the vhs protein, a y protein.
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Further modulation of the a  proteins may occur at the post-transcriptional level, for 
example the accumulation of ICPO in BHK cells is modulated by phosphorylation 
with the UL13 protein kinase.
1.1.5.4 Regulation of (3 gene expression.
p genes can be expressed readily in the context of the cellular genome, and have 
response elements for the cellular transcriptional apparatus (TFs, TATA box and a 
cap site). However, in the context of viral infection, a  gene products (especially 
ICP4) are required for p gene expression. The role of ICP4 in this transactivation is 
currently unknown.
1.1.5.5 Regulation of y gene expression.
The regulation of y genes is affected by the surrounding environment of the gene. In 
transfection studies using reporter genes fused to a y promoter, the reporter was 
expressed as a p protein (Dennis and Smiley, 1984). y gene expression is dependent 
upon DNA synthesis. ICP8, the ssDNA binding protein has been proposed to repress 
y gene expression. DNA replication may release this repression by seconding ICP8 
into the DNA replication machinery. Roizman and Sears, (1996) conclude that DNA 
synthesis is necessary, but not sufficient for y gene expression.
The roles of a  gene products are as follows. ICP4 is required but is not sufficient for 
y gene expression. ICPO enhances the capacity of ICP4 to transactivate y genes, 
while deletion of ICP27 reduced y gene expression. The requirement for ICP22 is 
cell type dependent.
The structure of y promoters remains unclear, with evidence that the presence of a 
cap site and a TATA box are sufficient for regulated expression of the US 11 gene 
(Johnson and Everett, 1986), contradicted by evidence from studies of gC and gH 
promoters which suggested that regions within the 5’ transcribed noncoding region 
(5’ ncr) are involved (Homa et a l , 1986; Steffy and Weir, 1991). Roizman and 
Sears, (1996) report experiments which show that deletion of regions of the 5’ ncr 
allow the expression of y2 genes as a  genes, and that the y2 5’ ncr could theoretically 
form stem-loop strucures which cannot be formed by the deletion mutant gene
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expressed as an a  gene. However, direct physical evidence for the presence of this 
structure is lacking.
1.1.5.6 Post-transcriptional regulation.
Post-transcriptional control of HSV gene expression is proposed to occur at the level 
of transport of mRNA from the nucleus to the cytoplasmic translation apparatus, and 
at the translational level (Roizman and Sears, 1996). Translational control is 
supported by the fact that the repression of host protein synthesis and of viral a  genes 
later in infection occurs in cells lacking nuclei. a-TIF is reported to inhibit the 
production of host and HSV a  genes at the translational level.
1.1.6 THE FATE OF THE INFECTED CELL.
1.1.6.1 Structural alterations.
Early in infection the nucleolus becomes enlarged and is displaced towards the 
nuclear membrane. At the same time host chromosomes become marginated, 
although this may not be linked with chromosome breakage (Roizman and Sears,
1996). Later in infection regions of duplicated membrane associated with viral 
material (possibly tegument proteins) are observed in the nucleus and endoplasmic 
reticulum and HSV glycoproteins become apparent in the cytoplasmic and plasma 
membranes.
Infection with wild-type virus causes cells to round up and stick together, while some 
viral mutants (syn ) cause cells to fuse into polykaryotes.
1.1.6.2 Shut-off of host macromolecular synthesis.
HSV infection of cells results in the rapid shut-off of host macromolecular 
metabolism. Host DNA and protein synthesis are shut off, and glycosylation of host 
glycoproteins ceases. Two stages of shut-off have been identified. The first involves 
the virion host shutoff (vhs, product of UL41) function carried into the cell in the 
tegument, whilst the second stage requires de-novo protein synthesis, and coincides 
with the expression of P proteins (Roizman and Sears, 1996).
The vhs function is responsible for both the destabilisation and degradation of host 
mRNA, and has also been shown to be responsible for the nondiscriminatory
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degradation of HSV a , P and y mRNAs (Kwong et a l , 1988). In vhs' mutants the 
expression of a  and p proteins is extended.
The shutoff of host macromolecular synthesis has two advantages for virus 
replication. The removal of host mRNAs allows viral messages to be efficiently 
translated, while the destabilisation of all classes of HSV genes facilitates the rapid 
transition from one temporal class to the next.
1.1.7 LATENCY.
HSV has the ability to remain latent for the lifetime of the host, a unique 
phenomenon of herpesviruses (Stevens and Cook, 1971; Stevens 1994). Following 
replication at the site of primary infection, the virus enters sensory nerves within the 
mucosal membranes, and the capsid is transported to the neuronal cell body by 
retrograde axonal flow. The viral genome exists in a circular form in latently 
infected neurons (Mellerick and Fraser, 1987). No viral gene function is required for 
the establishment or maintenance of latency (Roizman and Sears, 1996). A fraction 
of neurons periodically reactivate virus, and infectious virus is transported back to 
the periphery near the initial site of infection by axonal transport (Cook et al., 1973).
In-vivo experimental models of latency include the mouse eye, footpad or ear models 
for HSV-1 (Blyth et a l , 1976), and the guinea pig vaginal model for HSV-2 
(Stanberry et a l, 1982). Reactivation from latency occurs at a very low level in the 
mouse model, but recurrent lesions are observed in the guinea pig. In-vitro models 
of latency involve neuronal tissue culture. However, neurons in culture become 
permissive for infection and require treatment with nerve growth factor (NGF) to 
maintain virus in the latent state. Reactivation is induced by the removal of NGF 
(Wilcox and Johnson, 1987). Only the latency-associated transcripts (LATs) are 
detected in this system (Doerig et a l, 1991).
Results obtained using these model systems led Roizman and Sears, (1996) to 
propose the division of latency into three stages. The first stage involves the 
establishment of latency. After infection with wild-type virus, replication occurs at 
the site of innoculation, and contact with the sensory nerve endings takes place. The 
severity of the initial infection has an effect on the frequency of reactivation, thought
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to be a function of the number of neurons which become infected at this stage. The 
capsid is transported to the neuronal nucleus by retrograde axonal transport involving 
microtubules (Lycke et al., 1984; Kristensson et a l , 1986). In animal models a short 
period of viral replication occurs in the ganglia, but this is thought to be an artifact of 
the animal system. For example, corneal scarification induces host and viral trans- 
activating factors in neurons containing latent virus which might induce viral 
replication (Valyi-Nagy et a l , 1991).
In the second stage, which begins at most 2-4 weeks after infection, the virus is 
maintained in a latent state, and no viral replication can be detected.
The final stage is reactivation. In response to certain stimuli (stress, tissue damage or 
UV light, for example) virus multiplication is stimulated, and viral progeny are 
translocated by axonal transport to a site near the site of initial infection. The virus 
multiplication that accompanies reactivation is thought to destroy the cell.
1.1.7.1 Viral gene expression in latently infected cells.
The only transcripts detected to date are the latency associated transcripts (LATs), 
which are abundant (40-80,000 copies per neuron; Wagner et a l , 1988), accumulate 
in the nuclei of infected neurons and are not polyadenylated (Devi-Rao et a l , 1991). 
However, as many as 80% of latently infected cells do not express detectable 
concentrations of LAT (Maggioncalda et a l , 1996). The major LAT expressed 
during productive infection is a stable intron approximately 2kb long (Farrell et al.,
1991) spliced from a primary 8.3kb transcript (Mitchell et a l , 1990), while during 
latent infection the 2kb LAT and a further splice product of 1.45-1.5kb are present. 
The 1.45 and 2kb LATs exist in a stable non-linear form (Wu et al., 1996; Rodahl 
and Haar, 1997). This was shown to be a lariat structure with an unusual branch 
point which is proposed to increase the stability of the LAT structure (reviewed by 
Block and Hill, 1997).
The function of the LAT remains unclear, especially as much data demonstrates that 
LAT is not essential for establishment (Ho and Mocarsky, 1989) or reactivation (Hill 
et a l , 1990), while other studies demonstrate that viruses with mutations in the LAT 
promoter region reactivate much less efficiently than wild type virus (Fraser et a l ,
1992). The LAT has not been demonstrated to encode a protein expressed during
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latency in vivo. It has been suggested that as the LAT is colinear with part of the aO 
gene, it may prevent expression of oc0 in latently infected cells by an antisense 
interaction (Stevens et al., 1987). However, a recent in-vivo study demonstrated that 
a normal reactivation phenotype could be restored to a LAT null virus by insertion of 
the region of LAT lacking this antisense sequence (Pemg et al., 1996), and 
enthusiasm for the antisense model has therefore been reduced (Block and Hill,
1997). ORF P, which is contained within the 8.3kb LAT region has the potential to 
express a transcript which runs antisense to the neurovirulence factor, y34.5 
(Lagunoff and Roizman, 1994) but so far neither the transcript or the protein have 
been detected in latently infected neurons. The role of y34.5 in preventing apoptosis 
is discussed in Section 1.1.9.
Block and Hill (1997) have suggested possible functions for the LATs based upon 
recent advances in the study of the function of stable nuclear RNAs. They propose 
that LAT could: 1) act as a ‘sink’ for host RNA binding proteins; 2) induce nicks in 
regions of homologous DNA, or 3) induce the methylation of cytosine residues 
which has been shown to repress gene transcription.
HSV a  gene expression in latently infected neurons is repressed. The lack of a  gene 
products is most likely due to a host cell repressor protein, as both a-TIF and Oct-1 
have been demonstrated in latent neurons, and a  gene expression would therefore be 
expected to be stimulated.
1.1.7.2 Copy number of viral DNA in latently infected neurons.
Viral DNA is present in latently infected trigeminal ganglia at levels of 
approximately 0.1-1 viral genome per cell (Rock and Fraser, 1985). As only about 
10% of cells in the ganglia are neurons, each neuron must contain more than one 
copy of the viral genome (Roizman and Sears, 1987). Either more than one viral 
genome can enter the neuron at the establishment of latency, or the viral genome is 
replicated by the cellular machinery during latency, a proposal supported by the 
identification of a host dependent origin in the viral genome (Sears and Roizman,
1990).
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1.1.7.3 Maintenance of and reactivation from latency.
No gene has yet been identified as being essential for the maintenance of latency.
In humans latent virus is reactivated following local stimuli such as injury to tissues 
harbouring latently infected neurons, or by systemic stimuli such as stress. The 
molecular basis and order of viral gene expression is unknown, and conflicting 
evidence exists about the possible role of the LATs and ICPO in reactivation. Block 
and Hill (1997) have reviewed studies using viral mutants within the LAT region, 
and identified specific regions that are essential for maximal adrenergic reactivation 
which may be different from the regions required for spontaneous reactivation. 
Deletions within the cAMP response element within the LAT promoter abolish the 
adrenergic reactivation response (Bloom et al., 1997), and further regions within the 
LAT promoter have been identified as being essential for in-vivo reactivation in the 
rabbit eye model (Hill et al., 1997).
1.1.7.4 A model of latency.
Roizamn and Sears (1996) proposed the following model of the latent state.
A lack of a  gene expression is observed in latently infected neurons, and this may be 
due to the lack of host factors other than Oct-1, or the presence of a repressor protein. 
Repression could also be an effect of DNA secondary structure. Either mechanism of 
repression could be released by DNA replication.
Activation of virus multiplication is the consequence of the cumulative effect of 
stimuli on each virus containing cell, resulting in the replication of the viral genome 
by the cellular machinery. Increase in the copy number of the viral genome dilutes 
the repression effect on a  gene expression, probably in the presence of an activation 
factor such as the induction of a host transcription factor.
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1.1.8 MODULATION OF HOST DEFENCE MECHANISMS.
HSV has evolved a variety of mechanisms to avoid the host defence mechanisms. 
These are discussed briefly below.
The y34.5 gene product has been shown to affect the ability of HSV to replicate in 
the CNS (Whitley et al., 1993), as determined by the high LD50 for intracerebral 
innoculation of a y34.5 mutant virus (>107pfu). Study of mutants in this gene 
indicated that they trigger a premature total shut-off of protein synthesis, killing the 
cell but reducing viral replication dramatically in the process (Chou and Roizman, 
1992). This response is linked to viral DNA synthesis. The y34.5 protein has 
homology to cellular proteins (MyD116 and GADD34) induced by differentiation, 
growth arrest or DNA damage respectively. The carboxyl terminus of y34.5 which is 
homologous to the cellular proteins is essential to prevent this cellular shut down 
(Chou and Roizman, 1994). From the point of view of the virus, the y34.5 protein 
prevents early cell death which would prevent virus replication and spread 
throughout the body.
In addition HSV induces two types of Fc receptor (FcR) on the cell surface. One, a 
complex of gE and gl binds monomeric IgG (Johnson et al., 1988), whilst gE alone 
binds polymeric IgG (Dubin et a l , 1991). Both FcRs appear to play a role in 
protection against antibody dependent cell cytotoxicity (Dubin et a l , 1991).
A further interaction with the immune system is the interaction of complement 
component C3b with HSV gCl and gC2 (Siedel-Dugan et a l , 1988), via interactions 
which include, among others, a CR1 homologous domain within gC (Hung et a l ,
1992). The functional significance of this interaction with respect to viral protection 
from complement has yet to be elucidated. Studies of this interaction and those of 
the HSV FcRs are hindered by the multifunctionality of the HSV proteins.
A final defence mechanism involves the modulation of the CD8+ cytotoxic T-cell 
response (CD8+ CTL). The a47 gene product was shown to cause the retention of 
MHC class 1 molecules within the cytoplasm, preventing peptide presentation at the
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cell surface (York et a l, 1994) by direct interaction with the transporter involved in 
antigen presentation (TAP) (Hill et al., 1995). A further, as yet undefined viral 
function also appears to have a role in inactivation CD8+ CTLs (York and Johnson,
1993).
1.2 CELLULAR TRANSFORMATION BY VIRUSES.
Cellular transformation can be induced by both RNA and DNA tumour viruses, 
although each group utilises distinct mechanisms (recently reviewed by Nevins and 
Vogt, 1996). Table 1.4 summarises some of the viral groups involved in 
transformation and the type of tumour they induce. Tumour formation is not an 
inevitable consequence of viral infection, suggesting that oncogenesis is a multi-step 
process in which each step constitutes an independent and irreversible genetic change 
that contributes to the deregulation of cell growth. Viral infection is only one of 
these steps, and transformation only occurs if other changes also occur in the same 
cell.
All mechanisms of virus induced oncogenic transformation share important 
characteristics.
1) A single infectious virus particle is sufficient for transformation- a single hit 
process.
2) All or part of the viral genome persists in the transformed cell, but often no virus 
progeny are produced.
3) In almost all cases of viral transformation at least part of the viral genome is 
expressed.
4) Transformation results from the corruption of cellular growth signals.
5) Reversion of the transformed phenotype can be achieved by specific interference 
with the viral effector molecule.
Transformation induces changes in both cell growth (formation of foci, reduced 
growth factor requirement and loss of anchorage independence) and morphology 
(loss of actin stress fibers, redistribution of microfilaments).
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Table 1.4. Tumour viruses and their associated cancers.
Virus Group Examples Tumour types
Retroviridae
Mammalian B type. Mouse mammary tumour virus Mammary carcinoma 
T-cell lymphoma
Mammalian C type. Murine leukaemia virus Leukaemia, lymphoma,
Kirsten sarcoma virus sarcoma and other
Feline leukaemia viruses malignancies.
Avian C type. Avian leukosis and sarcoma viruses Sarcoma, B-cell lymphoma,
Rous sarcoma virus leukaemia, various 
carcinomas.
HTLV-BLV. Human T-lymphotrophic virus T cell leukaemia
Bovine leukaemia virus B-cell lymphoma
DNA viruses
Adenoviridae All types Various solid tumours
Hepadnaviridae Hepatitis B virus Hepatocellular carcinoma
Herpesviridae EBV Burkitt’s lymphoma, 
nasopharyngeal carcinoma
HHV-8 Kaposi’s sarcoma
Papovaviridae SV40, polyoma virus Various solid tumours
HPV, Shope papillomavirus Carcinomas, Papillomas
Poxviridae Shope fibroma virus Myxomas, fibromas
Data from Nevins and Vogt (1996).
Viruses and cancers highlighted in bold are human pathogens or diseases.
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Vims induced transformation has provided insights into intracellular signalling 
(RNA tumour viruses) and cell cycle regulation (DNA tumour viruses), and each of 
these transforming viral groups will be discussed in the following sections.
1.2.1 TRANSFORMATION BY RNA TUMOUR VIRUSES.
RNA tumour vimses have been shown to encode proteins involved in almost every 
stage of the signal transduction pathway (Figurel.5 and Table 1.6).
RNA tumour vimses (retroviruses) have a single stranded RNA genome bounded by 
long terminal repeats which contain promoter elements. This is reverse transcribed 
into double stranded DNA, and becomes integrated into the host cell genome, where 
expression of the provims occurs from the viral transcriptional regulatory sequences. 
Integration of the vims into the genome is the basis for the acquisition of cellular 
DNA sequences (transduction) and insertional activation (or inactivation) of cellular 
genes.
Retrovimses can transform cells by three distinct mechanisms (reviewed by Nevins 
and Vogt, 1996; see Table 1.5).
Table 1.5. Three classes of transforming retrovimses.
Virus category Tumour 
latency period
Efficiency 
of tumour 
formation
Oncogenic effector State of viral 
genome
Transforms
cultured
cells?
Transducing
retroviruses
Short-days High
(-100%)
Cellular oncogene 
carried in viral 
genome (v-onc)
Integrated.
Replication
defective
Yes
m-activating
retroviruses
Mid­
weeks/months
High/mid Cellular oncogene 
activated in situ
Intact.
Replication
competent
No
frans-activating
retroviruses
Long-
months/years
Low (5%) Vims coded 
transcription 
regulator
Intact.
Replication
competent
No
Data from Nevins and Vogt, 1996.
Two of these mechanisms involve the action of oncogenes. The ‘transducing 
retrovimses’ have picked up cellular oncogenes which have often then acquired
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Figure 1.5. A generalised multi-step signal transduction pathway.
Plasma membrane
Grb2
MAP kinase
Nuclear membrane
Transcription Factors
Epidermal growth factor (EGF) binds to the EGF receptor inducing dimerisation. 
The tyrosine kinase activity of the receptor is increased, and regulatory 
autophosphorylation of the cytoplasmic tail occurs. The adaptor protein Grb2 
(which contains src homology (SH) regions) binds to phosphotyrosines in the 
receptor. The SH3 domains of Grb2 are recognised by the Sos protein, and this 
complex binds to Ras. The Sos is a nucleotide exchange factor which moves Ras 
into the active GTP bound state. GTP-Ras binds to the cytoplasmic serine/threonine 
kinase Raf, increasing its activity and initiating a kinase cascade which includes 
MAP kinase and results in signal transduction to transcription factors in the nucleus 
(by an as yet unknown mechanism). Derived from Nevins and Vogt, 1996.
Ta
bl
e 
1.6
. 
Re
tro
vi
ra
l 
on
co
ge
ne
s 
and
 
the
ir 
ce
llu
lar
 h
om
ol
og
ue
s.
0)
ao
o
Bo
3r»*H
3o
<+Ho
Go
ttHOQ
Ph
O  C/D W O
o
&
oXI
o
s.
e
U t> co co c4 rt
o  o
aodo
■§
a• pH
C/3
a a o o 
d  d  o o
• § ■ §
00 CO
II'ed *e3a a
oo w
ao■a
a
02 «g
d d o o 
d  d
'& 'C o o
CO CO§ sd 43
o o
<u_O M 5i
Ch «
d d o o •d d
'&•& o oCO co 
§ § 
£  £
coe• rH>
&
<D
P4
■§ a
>w<
>00<
0
1
CO02 ’> <
>
00
s
d  
° >  O 00
s  s
a,ao
<D
g&QO
Oa
O
o 
c4 U-1
O»-iO
O to
£»*S I
a,mo2a>do
6 5o *£> ffi b
.a
<D
8 § §  ^  v V o  tc: ^
.ao
8*d<J o
.a
a>.3
COO
&
a
<L>Oa>
i- i■
do£
<u.3
do<u
<u
C/3
'-D ,o ^5 5
.au
-(-*o
ajdT> Cj X)
55 ^  ^^  s s Da
ta 
fro
m 
H
es
ke
th
, 
(1
99
5)
 
an
d 
Ne
vin
s 
an
d 
Vo
gt
, 
(1
99
6)
.
Chapter 1: Introduction.
mutations. These viruses have almost always lost sequences necessary for replication 
and therefore require helper virus to produce infectious progeny. The transducing 
retroviruses induce tumours and transform cells very rapidly. The cis-acting 
retroviruses act by integrating into the cellular genome in the vicinity of a cellular 
oncogene. These viruses are replication competent, produce tumours more slowly, 
and fail to induce oncogenic transformation in tissue culture cells. The third 
(currently hypothetical) group of viruses code for a viral transactivating protein 
which may interfere with host gene expression.
The cellular oncogenes acquired by the transducing retroviruses are involved in the 
control of cell growth. Table 1.6 presents examples of viral oncogenes from each 
class of protein involved in a generalised signal transduction pathway (illustrated in 
Figure 1.5). Cellular oncogenes expressed under normal conditions are not 
oncogenic. Unregulated expression of the cellular oncogene, or alterations in the 
structure of the oncoprotein are required for transformation.
All of the transduced retroviral oncogenes are non-essential for viral replication. In 
addition to carrying the oncogene into the cell, the virus also exercises transcriptional 
control over the oncogene. Thus point mutation, gene amplification or 
transcriptional upregulation can activate the intrinsic malignant potential of cellular 
oncogenes. Temperature sensitive and non-conditional mutants in transduced 
oncogenes have shown that the oncogene is required for both the initiation and 
maintenance of the transformed phenotype (Kawai and Hanafusa, 1971: Shih et a l , 
1979). Furthermore, transduced oncogenes have been excised from their parental 
virus and expressed at high levels from expression vectors where they confer 
oncogenicity on the new vector (Hughes et a l, 1987). Cellular transformation is an 
inevitable consequence of infection with a transducing retrovirus, and as this 
transformation is a single hit process, the tumours are normally polyclonal. Some 
retroviruses contain two co-operating oncogenes. For example, avian erythroblastosis 
virus R carries the transforming erbB oncogene and the erbA oncogene which 
enhances the transformation efficiency of erbB (Bister, 1986).
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1.2.1.1 The functions of some transduced retroviral oncogenes.
A brief description of the function of some of the known retroviral oncogenes from 
each of the groups identified in Table 1.6 will now be presented. The structure and 
function of these oncogenes is reviewed by Hesketh (1995) and Nevins and Vogt 
(1996).
1.2.1.1.1 Sis.' Growth factor.
Sis is the oncogene of simian sarcoma virus, and displays 88% homology to the B 
chain of human platelet derived growth factor (PDGF). V-sis is expressed as a fusion 
with the viral envelope protein which facilitates the targetting of protein into the 
endoplasmic reticulum. Processing of the v-sis product produces a p24 homodimer 
similar in structure to PDGF, which binds to the PDGF-receptor and induces receptor 
internalisation, phosphorylation, and stimulates the mitogenic response of the cell. 
Nevins and Vogt (1996) suggest that transformation results from an autocrine 
stimulation of cell growth (due to expression of v-sis from the integrated provirus), 
and this is supported by evidence that cellular PDGF is transforming if expressed at 
high levels.
1.2.1.1.2 ErbB and fm s : Altered receptors and constitutive mitotic signals.
Hesketh (1995) reports that v-erbB has close homology to the EGF receptor. EGFR 
has four functional domains- an amino terminal extracellular ligand binding domain, 
a transmembrane domain, a kinase domain and a carboxyl terminal regulatory 
domain containing phosphorylation sites. v-erbB lacks the negative regulatory 
phosphorylation site and extracellular ligand binding domain, and acts as a 
constitutively active EGF receptor, stimulating the activation of Ras and 
subsequently of cellular transcription factors.
V-fms is derived from the gene for the macrophage colony stimulating factor receptor 
(CSF-1R), which has a role in haemopoiesis and possibly during embryogenesis 
(Hesketh, 1995). The receptor has five external immunoglobulin repeats which are 
involved in ligand binding and receptor dimerisation. Point mutations within this 
dimerisation domain are essential for the oncogenic potential of v-fms. The absence 
of phosphorylation sites within the C-terminal regulatory domain prevents negative
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regulation of the intrinsic tyrosine kinase domain, resulting in a constitutively active 
receptor. This activates Src family kinases and the Ras-GTP pathway (illustrated in 
Figure 1.5).
1.2.1.1.3 Src and abl: membrane bound non-receptor tyrosine kinases.
Src encodes a 60kDa tyrosine kinase that is associated with the plasma membrane. 
C-src contains an amino terminal myristylation domain, two src homology domains 
(SH2 and SH3), a kinase domain and a C-terminal regulatory domain. The v-src 
protein has lost part of the regulatory domain including the site of negative 
regulatory phosphorylation (residue Y527), which causes the c-src protein to fold 
into an inactive conformation. Downstream targets of src include SHC, an adapter 
protein which associates with Grb2 and Sos to activate ras (see Figure 1.5), and focal 
adhesion kinase (FAK) which is maintained in an active state and causes the over­
phosphorylation of cytoskeletal proteins which is involved in anchorage independent 
growth.
The abl oncogene (derived from Abelson murine leukaemia virus (A-MuLV)) is also 
plasma membrane associated and has a weak intrinsic tyrosine kinase activity. The 
viral protein is expressed as a gag-abl fusion and interacts with the membrane via 
viral gag sequences. The gag domain also increases the half life of the fusion 
protein. V-abl contains SH2 and SH3 domains which interact with the signal 
transduction proteins, and a catalytic domain. The c-abl protein appears to be a 
negative regulator of cell growth, with the SH3 domain being a target of negative 
regulation. Deletion of this domain activates the oncogenic potential of abl. An 
activated abl gene is also found in human chronic myeloid leukaemia, where the c- 
onc is translocated to the bcr region, resulting in a single fused transcript in 
leukaemic cells.
1.2.1.1.4 Ras: Growth regulatory GTPase.
Three closely related ras genes have been identified in human cells, of which only 
N-ras encodes a functional 21kDa GTPase protein. Two of the human genes (H-ras 
and K-ras) have been found in a number of ‘transducing retroviruses’, including 
Harvey and Kirsten murine sarcoma viruses.
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Ras proteins are nodal points in the signal transduction pathway, and can be 
considered as membrane bound binary switches. When bound to GTP the ras protein 
is in an active state: hydrolysis of the GTP to GDP transforms the protein to an 
inactive form. At least three classes of protein regulate ras. Guanine nucleotide 
exchange factors (GEF) have an activating effect by stimulating exchange of GDP 
for GTP. GTPase activating proteins (GAP) attenuate ras by stimulating the 
conversion of GTP-ras to GDP-ras. Guanine nucleotide dissociation inhibitors are 
less well understood, but bind to GDP-ras and may interfere with both GEF and 
GAP functions.
Ras oncogenicity is greatly increased by point mutations which map to the region 
involved in interactions with GAP proteins and maintain ras in a GTP bound active 
state. Mutated ras genes have been found in human cancers, especially bladder, lung 
and colon cancers. Oncogenic ras activates protein kinase C and has been reported 
to activate transcription of other cellular oncogenes, including fo s , jun  and myc, and 
to repress the transcription of genes involved in differentiation (e.g. myoD).
1.2.1.1.5 Mos and Raf: Non- membrane associated serine/threonine kinases.
The mos oncogene was found in Moloney sarcoma virus, and can transform murine 
fibroblasts in culture. V-mos is expressed as an Env/mos fusion of 37kDa mostly in 
the nucleus, although c-mos is mainly cytoplasmic. C-mos can transform cells if 
overexpressed in culture, and has homology to Src and cAMP dependent protein 
kinases. The cellular protein is expressed at a very low level, except in germ cells. 
C-mos is required for meiosis and is a component of cytostatic factor (CSF), and also 
stabilises p34cdc2 during meiosis. C-mos also associates with and phosphorylates 
tubulin and may therefore have a role in meiotic spindle formation, activates MAP 
kinase, and has been proposed to transform cells by pushing interphase cells into 
mitosis.
R af is a cytoplasmic serine/threonine kinase, thought to be a second nodal point in 
the signal transduction pathway alongside ras. R af is activated by a number of 
receptors with intrinsic tyrosine kinase activity, and can transduce this signal via 
activation of MAP kinase kinase independently of ras.
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1.2.1.1.6 .Tun. Mvc and erbA: Transcription factors.
C-jun is a component of the AP-1 transcription factor, usually found in a heterodimer 
with fos, but also present as a jun-jun homodimer. The jun  protein contains a leucine 
zipper dimerisation domain, a basic region that binds DNA and a transactivation 
domain (reviewed by Curran and Vogt, 1991). Dimerisation is essential for DNA 
binding, transactivation and transformation. The v-jun protein (from ASV) contains 
two point mutations affecting negative regulatory phosphorylation sites (S243) and a 
27bp deletion in the 3’ untranslated region which seems to stabilise the mRNA. The 
precise mechanism of transformation is unclear, but may be a function of altered 
DNA sequence preference and hence altered target gene activation, or to constitutive 
activation of target genes.
Myc is a helix-loop-helix/leucine zipper sequence specific DNA binding protein 
expressed in most cells during proliferation. Abberant expression of myc is involved 
in several human tumours. Many, but not all Burkitt’s lymphomas contain the myc 
gene translocated to the Ig locus, resulting in the constitutive activation of myc. Myc 
forms a heterodimer with Max via a leucine zipper motif, and this interaction is 
essential for DNA binding, transformation and myc-induced apoptosis of 
haemopoietic cells. The expression of myc is growth factor dependent and is 
essential for cell-cycle progression, perhaps due to its activation of the cyclin A and 
E genes. High levels of myc expression accelerate growth, whilst reduced levels 
correlate with the onset of cellular differentiation. In addition, high levels of myc 
expression represses the activation of MHC-1 and N-CAM genes and correlates with 
increased metastatic potential.
A different class of transcriptional regulator is encoded by v-erbA. V-erbA is a 
homologue of the thyroid hormone receptor (THR), and has a ligand binding domain, 
a transactivation domain and a two zinc-fmger DNA binding motif. Although v-erbA 
can act as a repressor of thyroid hormone dependent transcription, its oncogenic 
potential is primarily due to an inhibitory effect on the retinoic acid receptor (RAR). 
The v-erbA protein acts as a constitutive repressor of THR and RAR and thus 
prevents the apoptosis of early erythroblasts that normally occurs in the absence of 
differentiation signals.
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1.2.1.2 Cis-activation of oncogenes.
Many retroviruses do not carry an oncogene, but cause transformation by insertion 
into the host genome (reviewed by Nevins and Vogt, 1996). These viruses induce 
monoclonal tumours with a long latent period, but cannot transform cells in culture. 
Viral coding sequences are not required for maintenance of the transformed state. 
Two mechanisms of insertional activation have been identified. The first is 
‘promoter insertion’, in which a read through product from the viral (usually 3’) LTR 
is expressed. This fusion often has regions of sequence deleted from the cellular 
homologue, and as these are often negative regulatory domains this contributes to the 
oncogenicity of the protein. ‘Enhancer insertion’ requires only that the virus 
integrates in the vicinity of the cellular oncogene, and the orientation/position is not 
important for activation.
Examples of insertional activation include Rous associated virus (RAV) induced 
tumours which show elevated myc transcription as a result of insertion of the viral 
promoter upstream of exon 2 of c-myc. In some RAV associated tumours integration 
downstream of the myc gene has been observed, an example of activation by 
enhancer insertion. Other insertional activation events include the ‘promoter 
insertion’ activation of erbA producing a truncated, constitutively active EGF 
receptor, and MMTV which integrates at several preferred sites which are close to 
three cellular genes designated inti, int2 and int3, known to be involved in 
development in Drosophila.
1.2.2 TRANSFORMATION BY DNA TUMOUR VIRUSES.
While retroviral oncogenes appear to have been transduced from the cell and have 
little or no role to play in the normal viral life-cycle, the DNA tumour virus 
oncogenes are essential viral gene products that bear no relation to cellular 
counterparts. The efficiency of DNA tumour virus transformation is low (Nevins and 
Vogt, 1996), due to inefficient integration of the virus into the host genome, and to 
the fact that viral infection of permissive cells leads to their destruction. Only in 
non-permissive cells can an oncogenic event be observed. The function of the DNA 
tumour virus oncogenes seems to be to induce quiescent or terminally differentiated
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cells to enter the cell cycle to provide an environment suitable for viral replication. 
However in non-permissive cells, or in the presence of viral mutations which prevent 
replication, this stimulation to enter S-phase can lead to cellular transformation.
The genes encoding the transforming activities of adenovirus, polyomavirus/SV40 
and papillomavirus have been identified, and share common mechanisms of 
transformation (reviewed by Nevins and Vogt, 1996). The adenovirus oncogenes 
were identified as the product of the El A gene, and the 55kDa product of the E1B 
gene. A 19kDa polypeptide also expressed from the E1B gene is involved in 
preventing apoptosis (see Section 1.2.2.2.2). These proteins have been shown to 
interact with the cellular proteins pl05Rb and p53 respectively. The functional 
significance of these interactions (and those of the viral oncoproteins described 
below) with respect to cellular transformation is discussed in Section 1.2.2.1.
In Polyoma virus and SV40 the transforming proteins are the T-antigens. Large T of 
SV40 binds to p53 and pl05Rb, whilst polyoma virus large T binds only to pl05Rb. 
The small t-antigen of both viruses has been reported to activate RNA Pol II and 
RNA Pol III dependent transcription, and to modulate the action of a cellular 
phosphatase. Thus small t-antigen has an enhancing effect on the efficiency of 
transformation. In addition to the T and t-antigens, polyoma virus encodes a middle 
T-antigen, which is a plasma membrane protein that binds to and activates src and 
PI-3 kinases.
The transforming functions of human papillomavirus (HPV) are provided by the E6 
and E7 open reading frames. Integrated HPV DNA isolated from tumours is usually 
integrated via a disruption in the E2 ORF, which normally functions to regulate the 
expression of the E6 and E7 open reading frames. HPV E6 protein binds to p53 and 
the E7 protein binds to cellular pl05Rb. The relationship between HPV and cervical 
carcinoma is discussed in Section 1.2.4.2.
1.2.2.1 Common cellular targets for DNA tumour virus oncoproteins.
All of the small DNA tumour viruses encode oncoproteins that bind to either p53 or 
pl05Rb (summarised in Table 1.7).
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Table 1.7. Cellular targets o f DNA tumour virus oncoproteins.
Virus Gene product Cellular target
Adenovirus E1A pl05Rb
E1B p53
SV40 T antigen p53, pl05Rb
Polyoma T antigen pl05Rb
Papillomavirus E6 p53
E7 pl05Rb
The regions of the viral oncoproteins involved in binding to these cellular targets 
were shown to be important for the transforming ability of the viruses, suggesting a 
role for these cellular targets in the suppression of transformation. This is further 
supported by the status of the p53 and pl05Rb genes within cervical cancer cell lines. 
Mutant p53 and pl05Rb genes were observed in HPV negative cell lines, while 
p53/pl05Rb are wild type in HPV positive cell lines (Crook et al., 1992) and are 
inactivated by interaction with the products of the HPV E6/E7 open reading frames.
1.2.2.1.1 Inactivation of p53 function.
The identification of p53 as a tumour supressor gene (reviewed by Lane, 1992) and 
its interaction with viral oncoproteins led to the proposal that these interactions may 
play a role in cellular transformation. Although each of the viral oncoproteins binds 
to different regions of the p53 protein via different mechanisms, the effect of these 
interactions is the same- inactivation of p53 function (reviewed by Hesketh, 1995). 
The HPV E6 protein triggers the ubiquitin mediated degradation of p53 via a cellular 
protein termed E6-AP (Hurbregste et al., 1992), whilst large T antigen appears to 
stabilise p53 in an inactive state. p53 oligomers act as a sequence specific 
transcription factor (Funk et a l , 1992), and cellular targets have recently been 
identified. The gene termed WAF1 is one such target (ElDiery et a l , 1993), the 
product of which (p21wa//) has previously been identified as an inhibitor of the G1 
cyclin/kinase activity (Xiong et a l , 1993). By inhibiting the function of the G1 
cyclin dependent kinases, p21H'a/y induction by p53 may be one mechanism by which
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p53 suppresses cell growth. Degradation of p53 could therefore lead to constitutive 
activation of G1 cyclin/kinase activity, and promote passage through the cell cycle 
(see Figure 1.6A). Furthermore, the product of a cellular gene termed mdm2 interacts 
with p53 in a manner similar to the adenovirus E1B protein, and has been proposed 
to block p53 growth suppression in normal cells. Amplification of the mdm2 gene 
has been implicated in oncogenesis (Fakharzadeh et al., 1991). In addition, p53 
represses the expression of cellular genes including bcl2, fos, jun, myb and pl05Rb 
(Hesketh, 1995). Interfering with this inhibitory action of p53 would allow the over­
expression of the cellular oncogenes which may then contribute to cellular 
transformation. Wild type p53 also functions to prevent mitosis occurring if DNA 
damage is detected in the cell. In the presence of mutated or inactivated p53 mitosis 
can occur in the cell before DNA damage is repaired, and this may lead to the 
production of malignant clones. This is illustrated in Figure 1.6A.
1.2.2.1.2 Inactivation of the retinoblastoma protein function.
The p l05Rb protein has been identified as a component of a cellular transcription 
factor complex, E2F (Bandara and LaThangue, 1991). In this complex pl05Rb acts to 
repress the binding of E2F to specific DNA targets, including cellular genes involved 
in DNA synthesis or nucleotide biosynthesis and the adenovirus E2 open reading 
frame (Qin et a l , 1992). The interaction between E2F and pl05Rb is dependent upon 
a conserved sequence in the retinoblastoma family proteins known as the ‘Rb 
pocket’. The viral oncoproteins of SV40/polyoma, adenovirus and papilloma viruses 
(T-antigen, El A and E7 respectively) bind to this pocket, and can disrupt the pl05Rb- 
E2F complex, facilitating activation of the E2F target genes. pl05Rb elicits a block at 
G1 of the cell cycle, which is released by the disruption of the pl05Rb-E2F complex. 
This model is presented diagramatically in Figure 1.6B. Other cellular targets have 
been proposed for the pl05Rb family of proteins, including the transcription factors 
c-myc and myoD (Rugsti et al., 1991; Gu et al., 1993).
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Figure 1.6A. The role o f p53 in cell cycle regulation.
Legend. p53 is a sequence specific transcription factor, with several targets that 
have a role in control of the cell cycle. One of these targets is WAF1, which is an 
inhibitor of G1 cyclin dependent kinases (CDC2/cyclin E in this instance), and acts to 
prevent entry into S-phase in response to elevated levels of p53. Inactivation of p53 
therefore allows passage through the cell cycle without the normal check point 
controlled by p21WAFI, This could allow replication of the damaged DNA before 
repair was completed. The inactive cyclin dependent kinase complexes are shaded 
red, and the active forms in green.
p53 induced apoptosis is the normal cellular response to DNA damage that cannot be 
repaired. Inactivation or mutation of p53 prevents the apoptotic response to DNA 
damage, and mitosis can proceed with mutations present in the genome, potentially 
leading to transformed clones of cells.
Figure 1.6B. The role of pl05Rb in cell cycle regulation.
Legend. pl05Rb is a component of the transcription factor complex E2F, where it 
acts to repress the activation of E2F bound to the target DNA sequences. pl05Rb 
elicits a block in G1 of the cell cycle, by preventing the activation of E2F responsive 
genes.
The affinity of pl05Rb for the E2F component of the complex is modulated by 
phosphorylation. The phosphorylated form of pl05Rb is unable to bind to E2F, and 
the target genes are therefore able to be activated, stimulating progression to S-phase 
(scheme A).
The hypo-phosphorylated form of pl05Rb can bind to E2F bound to its’ target 
sequence, and prevents transcription of the target genes, thereby maintaining the cell 
in G1 (scheme B).
The viral oncoproteins of human papillomavirus, adenovirus and SV40 (E7, El A and 
T-antigen respectively) can mimic the effect of phosphorylation of pl05Rb by binding 
to the protein and preventing it’s association with E2F. This allows expression of the 
target genes and passage into S-phase (scheme C).
In this figure, active proteins (and genes) are shaded green, and inactive forms are 
shaded red. For example, in scheme C, pl05Rb (red) is inactivated by the viral 
oncoproteins, leaving E2F in an active form to stimulate transcription of the target 
gene (both green).
Figure 1.6. The role of the tumour supressor genes p53 (A) and p l05Rb (B) in 
regulating cell growth.
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1.2.2.2 Other DNA tumour virus transforming activities.
1.2.2.2.1 Activation of cellular tyrosine kinase activity.
Polyoma virus middle T antigen has been shown to interact with the c-src 
proto-oncogene product at a region involved in the negative regulation of the kinase 
activity of c-src, resulting in the constitutive activation of the c-src kinase 
(Courtneidge, 1985). As previously described for retroviral activation of src kinases 
(Section 1.2.1.1.3) the activation of the src kinase leads to downstream activation of 
cellular targets (e.g. FAK) and is transforming in polyoma virus infected cells. 
Furthermore, the c-src/middle T complex recruits the phosphatidyl inositol-3 kinase 
(PI-3), and middle T can bind to and activate other cellular tyrosine kinases such as 
c-yes and c-fyn. The association between the c-src kinase and middle T antigen is 
not absolutely critical for transformation, but is sufficient to transform cells. 
However the co-operation of middle T with large T inactivation of pl05Rb may be 
important for increased transformation efficiency in certain circumstances (Nevins 
and Vogt, 1996).
1.2.2.2.2 Inhibition of cellular apoptosis.
Expression of adenovirus El A alone in cells leads not to transformation, but to 
induced cell death (apoptosis). Co-expression of E1B suppresses this apoptotic 
effect and allows the cells to become stably transformed. The induction of apoptosis 
is also dependent on the induction of the p53 protein. The mechanism of apoptotic 
induction by El A is unknown, but is prevented by both of the protein products of the 
E1B open reading frame. The 55kDa polypeptide blocks p53 function directly, while 
the 19kDa polypeptide seems to prevent a p53 dependent downstream event that 
triggers apoptosis, mimicking the action of the cellular oncogene bcl-2 (Nevins and 
Vogt, 1996).
1.2.3 OTHER DNA VIRUSES LINKED WITH HUMAN CANCERS.
1.2.3.1 Hepatitis B virus and hepatocellular carcinoma.
HBV DNA is frequently found integrated in human hepatocellular carcinoma (HCC) 
and in the woodchuck model, woodchuck hepatitis virus (WHV) integration has been 
shown to m-activate c-myc and N-myc, although there is no evidence for a similar
44
Chapter 1: Introduction.
effect in humans (reviewed by Slagle et al., 1994; Hildt et al., 1996). In human 
HCC, cellular genes are thought to be activated in trans by the HBV transactivator 
proteins, X and PreS2, while the X protein has also been shown to interact with p53 
(Truant et al., 1995), although the role of this p53 interaction is unclear. The viral 
transactivators have also been shown to trigger protein kinase C/Raf signalling 
pathways, leading to the activation of transcription factors (AP-1 and NF-kB) and 
their target genes, some of which are important in inducing cellular proliferation 
(reviewed by Hildt et al., 1996). The immune response to chronic HBV infection is 
also thought to play a role in the development of HCC.
1.2.3.2 Epstein-Barr virus related malignancies.
Epstein-Barr virus (EBV) is associated with lymphoma in the immunosuppressed, 
with Burkitt’s lymphoma in children (predominantly in equatorial Africa), and with 
naso-pharyngeal carcinoma in Southern China in particular (reviewed by Raab- 
Traub, 1996). EBV can establish latent infection in lymphoid cells, and induces 
proliferation. The virus enters the cell and circularises to form an episome that is 
then replicated to high copy number and segregates equally to daughter cells during 
mitosis. Integration into the host genome is infrequent, and is not thought to be 
important in the transformation process. In EBV transformed cells, a subset of viral 
genes are expressed. These include two integral membrane proteins (LMP1 and 
LMP2), and six nuclear antigens (EBNA1-6) and some small non-coding nuclear 
transcripts (reviewed by Kieff, 1996). The function of some of these proteins is 
discussed below.
The EBNA1 protein allows the viral genome to be replicated by the host cell DNA 
polymerase by binding to the episomal viral origin of replication, and EBNA1 
transgenic mice have been shown to have an increased incidence of lymphoma 
(Wilson et al., 1996). EBNA2 is essential for the transformation of lymphocytes, 
and is a transcriptional activator, acting on the viral LMP promoters and some B-cell 
activation markers (Kieff, 1996). LMP1 is essential for EBV induced transformation 
in vitro, and is directly transforming when expressed in rodent cells. In lymphocytes 
LMP1 activates the expression of genes including the anti-apoptotic genes Bcl-2 and 
A20 (A20 blocks both tumour necrosis factor and p53 mediated apoptosis; Fries et
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al., 1996). The LMP2 protein is expressed from a highly spliced mRNA which is 
complete only in the episomal form of the genome. It has been shown to inhibit the 
activation of B-cell replication by interfering with the mitogenic signal transduction 
pathway, and thus prevents activation of the viral replicative cycle. The most 
abundant mRNA in EBV infected cells are the non-coding transcripts, termed EBER, 
which are not essential for transformation but may be involved in the maintenance of 
EBV latency in vivo. Three levels of EBV latency have been defined, and appear to 
be associated with particular mailgnancies (Rickinson and Kieff, 1996). Table 1.8 
summarises this information.
Table 1.8. Three levels of EBV latency.
Genes expressed Cancer association.
Latency 1 EBNA1 and EBERs Burkitt’s lymphoma
Latency 2 EBNA1, LMP1, LMP2, 
EBERs and BamHI A
Naso-pharyngeal carcinoma, Hodgkin’s 
disease and post-transplant lymphoma
Latency 3 EBNAs 1-6, LMP1 and 
LMP2 and EBERs.
In vitro transformed B-cell lines
1.2.3.3 Human herpesvirus 8 and Kaposi’s sarcoma.
Since the emergence of human immunodeficiency virus (HIV), Kaposi’s sarcoma 
(KS) is no longer just a rare tumour of Mediterranean men, but is now the leading 
neoplasm of AIDS patients (reviewed by Ganem, 1996). Epidemiological evidence 
demonstrates that infection with human herpesvirus 8 (HHV-8 or KSHV) is tightly 
linked to KS risk (>95% of AIDS related KS cases harboured the HHV-8 genome). 
HHV-8 is also associated with rare ‘body cavity based lymphomas’ and Castlemans 
disease (a complex lymphoproliferative disorder) in AIDS patients. Two highly 
expressed transcripts of HHV-8 have been identified from KS tumours, termed ‘nu tl’ 
and ‘kaposin’, although no function has yet been assigned to either transcript 
(Ganem, 1996).
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1.2.4 THE VIRAL BASIS OF CERVICAL CANCER.
1.2.4.1 The incidence of cervical cancer.
Cervical cancer is the most common cancer in women in developing countries, and 
the second most common worldwide. Over 500,000 new cases and 300,000 deaths 
are reported globally each year, with three-quarters of these occurring in the 
developing world (WHO Press Release, 3/07/96; http//www.who.ch/). However, the 
disease is still a significant health problem in the developed world, as demonstrated 
by the data presented in Table 1.9.
Table 1.9. The incidence and mortality rates for cervical cancer in the United States 
and the United Kingdom.
United States United Kingdom
Mortality Incidence Mortality Incidence
Year Deaths *ASR(w) Cases *ASR(w) Deaths *ASR(w) Cases *ASR(w)
1985 4508 2.7 14455 9.9 2198 4.9 4554 12.2
1990 4627 2.7 13714 9.2 1981 4.3 4827 12.1
1994 *n/a *n/a *n/a *n/a 1561 3.1 *n/a *n/a
*ASR(w): Age Standardised Rate (World Population) per 100,000. *n/a: data not available. 
D a t a  o b t a in e d  f r o m  W H O  D a t a b a n k  a n d  ‘G l o b o c a n ’ a c c e s s i b l e  f r o m  ‘h t t p : / / w w w .w h o .c h / ’ .
The squamous (‘tile-like’) epithelium of the transformation zone of the cervix 
undergoes frequent regeneration and beneath the differentiated outer epithelial cells 
consists of 3-4 layers of parabasal cells overlying a single layer of basal cells and the 
basement membrane. The pathology of cervical neoplasia is clinically graded (in 
order of increasing severity) into cervical intraepithelial neoplasia (CIN) grades 1 to 
3, carcinoma in situ (CIS) and then invasive cervical carcinoma. With increasing 
CIN grade, more layers of parabasal cells show dysplasia, with CIS involving all of 
the epithelial cells including the basal cells. Following breakdown of the basement 
membrane, the disease is classified as invasive cervical carcinoma. Figure 1.7 
illustrates the histology of these disease states, and of cervical adenocarcinoma (a 
glandular tumour).
47
Figure 1.7. Cervical intraepithelial neoplasia and carcinoma.
C IN l
C e r v i c a l  i n t r a e p i t h e l i a l  
n e o p l a s i a  G r a d e  1 .
N uclear hyperchrom asia 
and pleiomorphism is 
present in the basal third 
o f  the epithelium: the 
nuclear atypia persists to 
the surface o f  the 
epithelium, but 
cytoplasmic m aturation 
occurs in the outer two 
thirds.
C e r v i c a l  i n t r a e p i t h e l i a l  
n e o p l a s i a  G r a d e  2 .
N uclear enlargem ent and 
mild pleiomorphism is 
present at all levels in the 
epithelium, and 
cytoplasm ic maturation 
occurs only in the outer 
half.
C e r v i c a l  i n t r a e p i t h e l i a l  
n e o p l a s i a  G r a d e  3 .
A population o f  cells with 
large, rather pleiomorphic 
nuclei and very little 
cytoplasm  occupies the 
full thickness o f  the 
epithelium.
C IN 2
C IN 3
Figure 1.7. continued.
M i c r o - i n v a s i v e  
c a r c i n o m a  o f  t h e  c e r v i x .
Early stromal invasion- an 
epithelium  with the 
features o f  CIN3 lies at the 
top o f  the image, with 
tongues o f  invading 
tum our cells arising from 
the base (these have a 
larger amount o f  pale 
cytoplasm  than the CIN 
cells from which they 
derive).
M i c r o - i n v a s i v e  a d e n o c a r c i n o m a  o f  t h e  c e r v i x .  The crypt (to 
the top right) is lined in its" lower part by an epithelium  with 
features o f  CGIN and from it (at the lower left) there arises a 
focus o f  superficially invasive adenocarcinom a.
Images derived from Buckley, 1994.
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1.2.4.2 Evidence for a role for HPV in the aetiology of cervical cancer.
1.2.4.2.1 Epidemiological evidence.
The epidemiological evidence linking infection with HPV and the risk of cervical 
neoplasia is compelling (reviewed by Woodman, 1994), such that HPV 16 and 18 
have been officially classified as ‘oncogenic’ and HPV 31 and 33 as ‘probably 
oncogenic’. Over 90% of all cervical cancers have been reported to contain HPV 
DNA (zurHausen, 1991a) whilst a study of HPV infection rates in 2627 women in 
the U.S. (Lorincz et al., 1992) determined that cervical samples from 79.3% of 
women with definite cervical disease contained HPV DNA (n=791) detected by low 
stringency Southern blotting, whilst only 23.7% (n=270) of patients with ‘borderline 
atypia’ and 6.4% (n=1566) of normal controls were HPV positive. By re-probing at 
higher stringency to determine HPV type, these workers were able to define four risk 
groups of HPV (summarised in Table 1.10 below), although other workers have 
noted slightly different disease associations (e.g. Hagmar et a l, 1995).
Table 1.10. Association of cervical disease with HPV type.
Risk Group HPV Types Disease association.
Low 6/11,42, 43,44 20.2% of low grade lesions; absent 
from all cancers.
Intermediate 31,33,35,51,52, 55,58 23.8% of high grade lesions 
10.5% of cancers.
and
High (HPV 16) 16 47.1% of high grade lesions 
cancers.
and
High (HPV 18) 18, 45, 56 26.8% of invasive cancers but only 
6.5% of high grade lesions.
D a t a  f r o m  L o r in c z  et al., 1 9 9 2 .
Interestingly, Iwasawa et al., (1996) have reported a difference in the HPV type 
associated with squamous cell carcinoma (HPV 16 =78%; HPV 18 =17%) and 
adenocarcinoma of the cervix (HPV 16 =16%; HPV 18 =56%), which correlates with 
the relationship of HPV 18 and invasive carcinoma reported in Table 1.10 
(adenocarcinoma tends to be more invasive). Non-prototype variants of HPV 16 
have recently been demonstrated to confer a six-fold greater risk of developing CIN 2
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or 3 than infection with prototype-like variants (Xi et al., 1997), suggesting that some 
of the HPV 16 variants are more oncogenic than others, possibly due to differences in 
the E6 and/or E7 oncoproteins. Low risk and high risk HPV E6 and E7 proteins have 
been shown to have different affinites for p53 and pl05Rb which correlates with their 
transformation ability (see Section 1.2.2.1 for the functions of p53 and pl05Rb).
Although the situation is complicated by the various types of epidemiological study 
which have been performed, and because different HPV detection methods (e.g. 
in-situ hybridisation/ PCR) produce different odds ratios relating HPV infection to 
cervical neoplasia within the same sample group, the overall trend suggests a causal 
link between HPV infection and cervical neoplasia (e.g. Munoz et al., 1992). This is 
not to say that HPV causes cervical cancer, but that infection with a high risk HPV 
type is a major event in a multistage process of oncogenesis (zurHausen, 1991b). In 
addition to risk factors associated with the transmission of sexually transmissible 
agents (number of sexual partners, age at first intercourse etc.), other studies have 
reported that risk is increased in smokers (increased levels of cotinine and nicotine in 
the cervical mucous; Hellberg et al., 1988) and is affected by diet (Vitamins C and E 
were reported to have a protective effect; Verreault et al., 1989). The involvement of 
HSV in the progression of cervical neoplasia is discussed in Section 1.2.4.3.
1.2.4.2.2 Biological Studies.
The role of the E6 and E7 oncoproteins in the de-regulation of cell growth by 
interacting with p53 and pl05Rb (respectively) was discussed briefly in Section 
1.2.2.1. The importance of these and other interactions of E6 and E7 in cervical 
neoplasia (reviewed by Vousden, 1994a, 1994b; Kubbutat and Vousden, 1996) will 
be discussed briefly in Sections 1.2.4.2.2.1-2 respectively.
In contrast to benign lesions, in the majority of HPV associated cancers the viral 
DNA is integrated into the host cell genome, often by a break within the E2 open 
reading frame (a transcriptional regulator), which, in combination with increased 
stability of the E6-E7 mRNA (Jeon and Lambert, 1995) leads to the deregulated 
expression of the E6 and E7 oncoproteins. Transfection of the E6 and E7 open 
reading frames from high risk (but not low risk) HPVs into human foreskin 
keratinocytes is necessary and sufficient for the immortalisation of these cells
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(Hawley-Nelson et al., 1989), but these cells did not display the characteristics of 
fully transformed cells (e.g. anchorage independent growth). As HPV infects 
epithelial cells which are destined to cease proliferation and terminally differentiate, 
it is necessary for the virus to stimulate proliferation in infected cells in order to 
replicate. Transformation following integration is an undesirable side effect of this 
need to stimulate proliferation, both for the virus and the host, as the integrated DNA 
in the transformed cell is incapable of producing progeny virus.
1.2.4.2.2.1 The role of HPV E7 in transformation.
HPV E7 from oncogenic HP Vs can transform established rodent cells alone, but also 
requires E6 to transform primary rodent cells or to immortalise human keratinocytes. 
The E7 protein contains two conserved domains at the N-terminus (CR1 and CR2) 
which have homology to adenovirus El A and SV40 T antigen, and include the 
‘LXCXE’ pl05Rb binding motif, and two casein kinase II sites which are essential for 
transformation (but not pl05Rb binding) and a C-terminal dimerisation domain. In 
addition to its role in binding pl05Rb (Figure 1.6B), the E7 oncoprotein has recently 
been demonstrated to interact with components of the AP-1 transcription factor 
family (e.g. c-jun; c-fos) to cause up-regulation of AP-1 responsive genes (Antinore 
et al., 1996), and to interact with TBP, the basal transcription factor (Massimi et al., 
1996).
1.2.4.2.2.2 The role of HPV E6 in transformation.
The E6 oncoprotein displays no homology to other cellular or viral proteins, but 
shares the ability to bind the tumour suppressor protein p53 with adenovirus E1B and 
SV40 large T (p53 was first identified by its ability to interact with SV40 T in SV40 
transformed cells (Lane and Crawford, 1979)). In contrast to the other viral proteins 
however, E6 targets p53 for ubiquitin mediated degradation (Scheffher et a l , 1990). 
E6 associates with E6-AP (Huibregste et a l , 1992), a cellular protein which becomes 
loaded with activated ubiquitin via a complex pathway to form a ubiquitin ligase that 
can bind to p53, transfer the activated ubiquitin moiety and target p53 for destruction 
by the 26S proteasome (reviewed by Ciechanover, 1994).
E6 from HPV 16 has recently been shown (Klingelhutz et a l , 1996) to activate 
telomerase in human foreskin keratinocytes and mammary epithelial cells, but not in
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cells which cannot be immortalised by E6 (e.g. primary rodent cells). Telomerase is 
a ribonucleoprotein complex that synthesises telomere repeat sequences, and has 
been implicated in immortalisation and cancer (Kim et al., 1994), as shortening of 
the telomeres normally occurs during the process of cellular aging.
1.2.4.2.3 The co-operative effect of E6 and E7 on the cell cycle.
The basic functions of p53 and pl05Rb have been outlined in Section 1.2.2.1. Recent 
work is beginning to show that p53 induced apoptosis is important in tumour 
suppression (reviewed by Wiman, 1997). One of the targets of p53 transcriptional 
activation (BAX) is implicated in priming cells for apoptosis via a direct physical 
interaction with the anti-apoptotic Bcl-2 protein (Miyashita and Reed, 1995), 
although box independent apoptosis also occurs. The abrogation of the anti-apoptotic 
effect of p53 by E6, combined with the induction of S-phase by E7 inactivation of 
pl05Rb allows the cell to overcome the normal growth control mechanisms, leading 
to immortalisation. This model is supported by the work of Pan and Griep (1994), 
who demonstrated altered cell cycle control in the lens of HPV 16 E6 or E7 
transgenic mice. Expression of E6 alone reduced the rate of apoptosis occurring 
during normal lens development, whilst E7 expression alone led to inappropriate 
proliferation and increased apoptosis. In E6/E7 double transgenic mice, the 
increased apoptosis observed with E7 alone was abolished, and there was a greater 
incidence of tumours during development.
The accumulated evidence suggests that infection with high risk HPV types may 
represent the first step towards malignant progression. As such, vaccination against 
HPV to prevent infection should reduce the risk of developing cancer, and much 
work is ongoing in this field (reviewed by Campo, 1994; Altman et al., 1994). In 
addition, direct treatment of HPV positive tumours induced in nude mice with 
several E6-E7 antisense oligonucleotides reduced the tumour weight significantly 
compared to control random oligonucleotides (Tan and Ting, 1995). This may 
provide a method of directly targetting HPV positive cervical tumours in the future.
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1.2.4.3 Herpes simplex virus as a co-factor in the induction of cervical 
neoplasia.
1.2.4.3.1 Epidemiological evidence.
The epidemiological evidence that links infection with a high risk human 
papillomavirus and the development of cervical intraepithelial neoplasia or cervical 
carcinoma (discussed in Section 1.2.4.2.1) also demonstrates that not all women who 
are infected with high risk HP Vs will progress to serious disease. Various studies 
have shown that between 11.5% (n=1000; Kjaer et a l, 1997) and 23% (n=143; 
Gradilone et al., 1996) of women with normal cervical cytology were infected with 
HPV 16, while Macnab et al., (1986) reported that in women with genital cancer 
73% (n=25) of internally paired normal tissue samples taken from within 3-5cm of 
the tumour contained HPV 16 DNA. These results, taken together, suggest that 
factors other than HPV infection are involved in disease progression.
Several epidemiological studies link HSV infection to increased risk of developing 
cervical disease. Kjaer et al., (1988) studied the incidence rates of HPV (by in situ 
hybridisation) and HSV-2 (sero-positivity) in a randomly selected group of women 
aged 20-39 years in Greenland (n=586) and Denmark (n=661). They noted that the 
age corrected incidence of HPV 16/18 infection in Greenland was only 67% of the 
level observed in Denmark, despite the level of cervical cancer being 5.7-fold greater 
in Greenland. However, the observed incidence of HSV-2 was 2.2-fold higher in 
Greenland. More recently, Hildesheim et a l, (1991) studied 766 confirmed cases of 
invasive cervical cancer and 1,532 controls in South America, and noted that a) 
women sero-positive for HSV-2 had a 60% increased risk of cervical cancer 
compared to sero-negative women; b) women sero-positive for both HSV-2 and 
HPV 16/18 had a 2-fold increased risk of developing cervical cancer compared to 
women infected with HPV 16/18 alone. However, in Panamanian women with 
invasive cervical cancer HSV-2 sero-positivity was not significantly associated with 
prognosis (DeBritton et al., 1993). Interestingly, recent studies have suggested a link 
between HSV-2 infection and other genitourinary malignancies. Hildesheim et a l, 
(1997a) reported a 2.1 fold increased risk of developing vaginal carcinoma (a rare 
disease) in women infected with HSV-2 after adjustment for infection with HPV and
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C. Trachomatis, and HSV-2 seropositivity remained an independent risk factor for 
vulvar neoplasia after correction for HPV infection (Hildesheim et al., 1997b). Jones 
(1995) has reviewed the available evidence regarding a role for HSV-2 as a co-factor 
in the development of cervical neoplasia, and concluded that HSV-2 might be a co­
factor in some but not all cases of cervical cancer, hypothesising that persistent or 
abortive HSV infection might induce permanent genetic alterations that interfere with 
the differentiation of cervical epithelium and subsequently induce abnormal 
proliferation.
1.2.4.3.2 Biological evidence relating HSV to cervical cancer.
At the biological level, HSV-2 has been shown to directly influence both the state of 
the HPV genome, and the amplification of both integrated and episomal HPV DNA 
(Hara et al., 1997). HeLa cells (a cervical cancer derived cell line containing 
integrated concatameric HPV 18 DNA) and an HPV negative cell line (A431) 
transiently transfected with a plasmid containing the EcoRI fragment of HPV 18 
DNA were infected with HSV-1 or HSV-2. The integrated DNA in HeLa cells was 
amplified almost threefold following infection with either HSV-1 or HSV-2, and the 
episomal DNA in the A431 cells was shown to be replicated following HSV 
infection. Hara et al. (1997) proposed that concatameric HPV DNA is formed by 
replication with HSV factors and that this cannot be packaged and is either degraded 
or becomes integrated into the host cell genome, suggesting a role for HSV in 
promoting the development of cervical neoplasia. These results were however 
obtained at a very low level of DNA amplification/ replication. Earlier work by Gius 
and Laimins (1993) used a plasmid based system to demonstrate enhanced 
expression of a CAT reporter gene placed downstream of the HPV 18 constitutive 
enhancer after co-transfection with plasmids containing either the HSV-1 a-TIF or 
ICPO genes into HeLa and to a lesser extent other cervical cancer cell lines. The 
activation of plasmid borne SV40 origins of replication in non-permissive cells 
(Danovich and Frenkel, 1988) and the amplification of resident SV40 sequences in 
SV40 transformed hamster cells (Schlelofer et al., 1983) by infection with HSV has 
also been reported. More recently, Kulomaa et al. (1992) showed by flow cytometric 
analysis of bromodeoxyuridine incorporation, that infection of cervical cancer cell 
lines with HSV-2 resulted in either a rapid increase in the proportion of cells
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undergoing DNA synthesis (HeLa cells) or an increase that occurred late in infection 
(C33-A, SiHa cells). Hossain et al., (1997) examined the effect of HSV-2 infection 
on cyclin dependent kinases in CV-1 cells. They reported that both CDK2 and cyclin 
A were elevated following HSV-2 infection while CDK4, CDC2 and cyclin B were 
not activated. CDK2 forms a complex with cyclin A and is associated with 
replicating DNA and progression through S-phase (see Figure 1.8). The 
CDK2/cyclin A complex induced by HSV-2 was also proposed to play a role in the 
phosphorylation of pl05Rb, with the subsequent release of active E2F transcription 
factor (as previously discussed in Section 1.2.2.1.2), while the induction of 
unscheduled DNA synthesis could represent a single step in a multi-step mechanism 
of transformation. A further demonstration of the multi-step nature of carcinogenesis 
is provided by an experiment in which the transfection of HPV immortalised (but 
non-tumourogenic) cells with a sub-fragment of HSV resulted in the production of a 
locally invasive carcinoma when the cells were injected sub-cutaneously into nude 
mice (reviewed in DiPaolo et al., 1993). Direct evidence of HSV induced cervical 
carcinoma was obtained in a mouse model system by the innoculation of the cervix 
with HSV-1 or HSV-2 (Wentz et al., 1981; Anthony et al., 1989), and disease 
induction could be prevented by vaccination with HSV-1 prior to challenge.
Macnab (1987) reviewed the potential role of HSV and HCMV in cellular 
transformation, and proposed mechanisms by which HSV could contribute to the 
transformation process. HSV-1 contains a single region (mapping in Xbalf and 
Bgllli; Camacho and Spear, 1978) involved in the morphological transformation of 
cultured cells (designated MTRI) which is capable of transiently expressing gB, 
while HSV-2 contains two regions defined as MTRII and MTRIII which map to the 
Bgllln and Bglllc fragments of the genome respectively (Macnab and McDougall, 
1980; Jariwalla et al., 1983). Because HSV-2 DNA was often not retained in 
transformed cells, a ‘hit and run’ mechanism of transformation has been proposed 
(Skinner, 1976), and no evidence for an HSV coded transforming protein could be 
found (Cameron et al., 1985). Several mechanisms for HSV transformation were 
proposed (Macnab, 1987), including the presence of a small stem-loop structure in 
Bgllln of HSV-2 (Galloway et al., 1984), a possible effect of ribonucleotide 
reductase on cellular nucleotide pools, increased mutagenesis of cellular genes (Pilon
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Figure 1.8. The effect of HSV-2 infection on the cyclin dependent kinases active at 
different stages o f the cell cycle.
CDC2/cyclinA or 
cyclin B (MPF)
CDK4/cyclinD or 
v CDK6/cyclinD
progression
CDC2/cyclinA or 
cyclin B (MPF) G2
/  CDK2/cyclinE
(activates origin recognition 
factors- promotes DNA synthesis)
CDK2/cyclinA 
(associates with replicating DNA- 
promotes S-phase progression)
L e g e n d .  The cyclin dependent kinases active at various tim es during the cell cycle are 
shown diagram atically (from inform ation in the text o f  Hossain et al., (1997)- see 
Section 1.2.4.3.2). CDK2 form s a com plex with cyclin A that was found to be
associated with replicating DNA, and progression through S-phase. The effect o f  
infection with HSV-2 on the levels o f  the cyclin dependent kinases w as exam ined in 
CV-1 cells. Both CDK.2 and cyclin A were elevated by HSV-2 infection while CDK4, 
CDC2 and cyclin B were not affected. No data was available regarding the other factors 
described. It is proposed that the elevation o f  the com ponents o f  the S-phase associated 
kinase (CDK2/cyclinA) by HSV-2 could prom ote de-regulated DNA synthesis. In 
addition, this com plex may play a role in the phosphorylation o f  p l0 5 Rb (see main text 
for details).
K e y :  MPF- m aturation prom otion factor. Green text- levels elevated by HSV-2 
infection. Blue text- levels unaltered.
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et al., 1985; Clarke and Clements, 1991) or amplification of cellular sequences 
(Heilbronn et al., 1990). In addition, the activation of certain cellular genes 
following HSV infection has been reported (see Section 1.2.4.3.3).
1.2.4.3.3 Activation of cellular gene expression by HSV.
HSV has been demonstrated to activate the expression of cellular genes, by 
mechanisms that need not involve virus entry into the cell. A 56kDa cellular 
polypeptide was induced in human fibroblast cells by the specific interaction of 
HSV-1 tsl204 (a mutant which fails to penetrate the cell at the non permissive 
temperature; Addison et al., 1984) with the cell surface (Preston, 1990). Viral 
protein synthesis is not required for the induction of some cellular genes by HSV 
infection (Kemp et al., 1986), although in the case of a 40kDa polypeptide 
overexpressed in cervical cancer cells accumulation is dependent upon HSV-1 ICP27 
(Estridge et al., 1989) and HSV-1 ICP4 is essential for the increased transcription of 
the human Ubiquitin B gene (Kemp and Latchman, 1988). Cellular transcription 
factors (c-jun, c-fos and oct-1) have been induced by HSV-1 infection of the cornea 
(Valyi-Nagy et al., 1991), and by infection of tissue culture cells (BHK C l3) with 
HSV-1 (AP-1 induction, dependent on ICPO; Jang et al., 1991). In a breast cancer 
cell line (MCF-7) infected with HSV, the 2-3 fold increase in the level of oestrogen 
receptor mRNA observed was dependent upon the virion a-TIF protein (Vmw 65) 
(Offord etal., 1989).
A group of cell coded polypeptides were detected in HSV transformed rat embryo 
fibroblast cells by immunoprecipitation with a monoclonal antibody (TG7A- see 
below), a polyclonal antiserum raised against HSV-2 infected rat embryo fibroblasts 
(Macnab et al., 1985), or by the sera of tumour bearing rats (TBS). TG7A was a 
monoclonal antibody raised against the DNA binding proteins of HSV-2 infected 
BHK C l3 cells (Macnab et al., 1985; LaThangue and Latchman, 1988). These 
polypeptides had molecular weights of 200kDa, 90kDa (actually a doublet termed 
U90 and L90), 40kDa and 32kDa, and could not be immunoprecipitated from 
primary, secondary or quaternary rat embryo cells, but could be immunoprecipitated 
from adenovirus 12 and Rous sarcoma virus transformed rat/mouse cells (Macnab et
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a l, 1985). This suggested that these polypeptides were not specific just to HSV 
transformation, but might be a general feature of virus transformed cells.
The U90 polypeptide from this group has been shown to be distinct from heat shock 
proteins, to be present mostly in the plasma membrane fraction of tumour cells, and 
to be increased in Bn5T cells (transformed rat embryo cells- see Materials and 
Methods, p68) by a factor of 2.5-5 fold following HSV-2 infection (Hewitt et al., 
1991). The characteristic of U90 in tumour cells which facilitates its 
immunoprecipitation from transformed but not control cells has been shown to be an 
increased half-life in tumour cells (13 hours compared to 33 minutes; Grassie et al., 
1993).
A 40kDa polypeptide with an identical peptide map to the 40kDa polypeptide 
identified above has been shown to be recognised by the sera of patients with 
cervical cancer, and both TBS and an antiserum raised against HSV-2 infected cells 
recognised an antigen specifically in tumour cells in sections of cervical carcinoma 
(Macnab et al., 1992). The 40kDa polypeptide has been identified as a form of 
mitochondrial aspartate aminotransferase (mAspAT) (Lucasson, PhD Thesis 1992), 
and been shown to be increased at the protein (Lucasson et a l, 1994) and mRNA 
levels (Lucasson et a l, 1994; see ‘Results: Chapter 4 ' of this thesis) by infection 
with HSV-2. The induction of mAspAT in normal (RE), immortalised (BHK C l3), 
and transformed (Bn5T) cells, and a possible role in the transformation process are 
the subject of this thesis.
1.3 MITOCHONDRIAL ASPARTATE AMINOTRANSFERASE.
1.3.1 INTRODUCTION.
Mitochondrial aspartate aminotransferase (mAspAT; L-aspartate:2-oxoglutarate 
aminotransferase, EC 2.6.1.1, also called glutamic oxaloacetic transaminase 
(mGOT)) catalyses the fully reversible transfer of an amino group from aspartate to 
a-ketoglutarate within the mitochondrion to form glutamate and oxaloacetate.
L-aspartate + a-ketoglutarate  ^  ^ L-glutamate + oxaloacetate
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A closely related cytosolic aspartate aminotransferase (cAspAT) perfoms the same 
reaction in the cytosol. The details of the reaction mechanism are discussed in 
Section 1.3.3 below.
Mitochondrial aspartate aminotransferase (mAspAT) from rat liver was first purified 
by Huynh et al., (1980), and shown to be very similar to other purified Asp AT 
enzymes from, for example, pig and human heart tissue. The molecular weight of 
mAspAT was estimated by gel filtration and analytical ultracentrifugation to be 
90kDa, corresponding to a dimer of approximately 45kDa per monomer. The same 
group later reported the full amino acid sequence of mAspAT, and determined it to 
contain 401 amino acids and have a predicted molecular weight of 44.358kDa 
(Huynh et al., 1981). Comparison of this sequence with that of pig heart mAspAT 
showed the two to be 94% similar at the amino acid level. Comparisons between 
mAspAT and cAspAT within the same species show 50% homology at the 
nucleotide level, whilst a higher degree of similarity (80%) is observed when 
comparing each isoenzyme from different species (Pave-Preux et al., 1988).
The mitochondrial and cytoplasmic isozymes are transcribed from separate nuclear 
genes and synthesised on free polysomes in the cytoplasm (Sonderegger et al., 1982). 
mAspAT is synthesised as a precursor containing a mitochondrial targetting pre­
sequence and is translocated to the mitochondrion, where the signal sequence is 
cleaved (Joh et al., 1985). The complete cDNA sequence of the precursor form of rat 
liver mAspAT has been published (Mattingley et al., 1987) and the predicted amino 
acid sequence was shown to differ from the actual sequence obtained by Huynh et 
al., (1981) at 13 positions. The amino terminal presequence is predicted to be 29 
amino acids in length with a predicted molecular weight of 2.807kDa. The 
presequence contains 4 basic and no acidic residues and was thought to contain all 
the necessary information for binding to mitochondrial membranes, 
penetration/translocation across the membrane and proteolytic cleavage within the 
mitochondrial matrix (Morino et al. 1990), although additional residues are now 
thought to be involved (see Section 1.3.2, p59). The first possible translation 
initiation site in the cDNA is at nucleotide 90, and the open reading frame proceeds 
to nucleotide 2362, encoding a protein of 430 amino acids (Mattingley et al., 1987). 
The predicted transcript size has been confirmed by the detection of a 2.4kKb
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mAspAT transcript in rat cells (Pave-Preux et al., 1988). The mAspAT cDNA also 
contains a 3’ untranslated region of 946 nucleotides. Expression of the cloned 
mAspAT cDNA in bacteria (Mattingley et a l , 1987) yielded a polypeptide of 
molecular weight approximately 47kDa, consistent with the presence of a 44kDa 
mature enzyme and a 3kDa translated pre-sequence.
1.3.2 PROTEIN FOLDING AND MITOCHONDRIAL IMPORT OF 
pre-mAspAT.
mAspAT has been much studied as a model for the transport and processing of 
mitochondrial matrix proteins. The precursor form of the mAspAT enzyme (‘pre- 
mAspAT’) contains the mitochondrial targetting presequence, and has been isolated 
as a soluble, dimeric, active enzyme in the cytoplasm which is able to be processed to 
the mature form by incubation with intact mitochondria (Altieri et al., 1989). The 
folding of in-vitro translated protein demonstrated a slow conversion from a trypsin 
sensitive (unfolded) state to a trypsin resistant, fully active enzyme that was unable to 
traverse the inner mitochondrial membrane (Mattingley et al., 1993). As the 
presence of the 29 amino acid presequence did not prevent ‘bulk folding’ of the 
protein, it was suggested that a ‘mitochondrial molecular chaperone’ (reviewed by 
Stuart et al., 1994) might maintain the newly synthesised pre-mAspAT in a transport 
competent conformation. Evidence supporting this proposal has been obtained in- 
vitro. The refolding of acid denatured mAspAT is prevented by the presence of 
GroEL (hsp70 homologue), while the addition of both GroES (hsp60 homologue) 
and Mg2+ to the mixture was essential to promote correct folding (Mattingley et al., 
1993). Artigues et al., (1997) similarity reported that refolding of denatured 
mAspAT could be stopped by addition of hsp70, while cAspAT is unaffected, and 
demonstrated that mAspAT undergoes two sequential first order folding reactions. 
The overall refolding mechanism includes a fast collapse to a form with 80% of the 
secondary structure found in the active dimer, followed by a slow isomerisation to 
produce assembly competent monomers that rapidly associate to form an inactive 
dimer prior to a final structural rearrangement to form active dimers. It appears that 
only the first collapsed state of mAspAT can bind hsp70 and that the inability of 
cAspAT to bind hsp70 might explain its single phase rapid refolding. Further
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evidence of an interaction of mAspAT with hsp70 is provided by experiments in 
which the mAspAT presequence was fused to the cAspAT mature protein (Lain et 
al., 1995). pre-mAspAT interacts with hsp70 early during translation while cAspAT 
does not interact with hsp70 at any time; in the fusion protein, hsp 70 binding was 
only observed once the enzyme had achieved the mature conformation. Furthermore, 
swapping the amino terminal portion of mAspAT for the equivalent cAspAT 
sequence but leaving the presequence intact eliminated binding of hsp70. The N- 
terminal region therefore contains signals that allow association with hsp70 in 
addition to those present in the presequence. The interaction of mAspAT with 
GroEL has recently been studied at the molecular level- this work showed that the 
N-terminal half of mAspAT is more flexible and lies at the mouth of the central 
cavity of GroEL while the more compact C-terminal region (200 amino acids) which 
contains residues at the subunit interface of mAspAT appears to be hidden in the 
cavity of GroEL (Torella et al., 1998).
Further evidence that the presequence is not uniquely required for the interaction 
with molecular chaperones to promote entry into mitochondria is demonstrated in- 
vitro by the mitochondrial targetting of dihydrofolate reductase (DHFR) fusion 
proteins containing the N-terminal 10 or 191 amino acids of the mature mAspAT 
polypeptide (Giannattasio et a l, 1994). The import of a mAspAT protein containing 
a deletion within the presequence into mitochondria has also been reported (Azzariti 
et a l, 1995). Berezov et a l, (1994, 1996) have demonstrated using fluorescence 
probes that binding of pre-mAspAT to anionic phospholipid vesicles locks pre- 
mAspAT in an altered, partially unfolded conformation which may be important for 
membrane translocation and results in the loss of the catalytic activity of the enzyme. 
This interaction is thought to be mediated by the positively charged residues within 
the presequence. They also demonstrated that the interaction of each subunit of the 
dimer with lipid (via interaction with N-terminal pre-sequence) perturbs the structure 
of only that half of the molecule.
To summarise, mAspAT is synthesised as a precursor in the cytoplasm and interacts 
very early in translation with a chaperone protein, hsp70 (GroEL). This interaction is 
mediated by the presequence and some amino-terminal portions of mAspAT, and 
maintains the protein in a partially unfolded, transport competent conformation. The
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interaction of the exposed N-terminal portion of mAspAT with mitochondrial 
membrane lipids contributes to the maintenance of a partially unfolded state, 
(perhaps in the GroEL/hsp70 complex?) and facilitates membrane transport.
1.3.3 TRANSAMINATION BY mAspAT.
1.3.3.1 Reaction mechanism.
mAspAT contains a pyridoxal phosphate (PLP) co-enzyme at its active site which is 
essential for mAspAT function. The PLP co-enzyme forms an internal aldimine 
bond with the e-amino group of Lysine 258 within the active site (see figures 1.9A 
and 1.10A), and is tethered to the active site by electrostatic interactions with active 
site residues, which also regulate the electron distribution within the coenzyme- 
substrate complex (Morino et al. 1990). The aldimine bond between Lysine 258 and 
PLP undergoes a pH dependent protonation/deprotonation, with the environment 
surrounding the aldimine bond giving it a lower protolytic pK^ value than for a 
normal aldimine bond to PLP (Morino et al. 1990). The co-enzyme acts an electron 
sink that stabilises the reaction intermediates during catalysis (Seaman et al., 1991). 
The interaction of the active site residues (e.g. Arg 292 and 386) with the co-enzyme- 
substrate complex determines the conformational orientation of the complex and 
positions the complex such that stereo-electronic effects favour removal of the 
substrate a - proton (Seaman et al., 1991). Malashkevich et al., (1993) determined 
the x-ray structure of a ketimine reaction intermediate (see mechanism, Figure 1.9B). 
The a-H was orientated almost perpendicular to the plane of the pyridine ring 
suggesting that sigma-pi ( a - 7 i )  orbital overlap is involved in removal of this proton. 
This conformation confers specificity to the reaction, favouring transamination rather 
than racemisation or decarboxylation (Seaman et al., 1991).
The proposed transamination reaction mechanism is illustrated in Figure 1.9. 
Briefly, the internal aldimine bond between lysine 258 and the PLP co-enzyme is 
transferred to the amino group of the di-carboxylic amino acid substrate 
(aspartate/glutamate) (Figure 1.9A and 1.10A). Specific de-protonation at the a- 
carbon of the amino acid substrate produces a quinonoid intermediate which 
undergoes protonation of the aldimine bond (Figure 1.9B, and 1.10A which shows
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Figure 1.9. Proposed transamination reaction mechanism of mAspAT.
A )
Enzyme
Amino acid 
substrateEnzyme
(CH2)
NH
:— HC— H
OH- 0 — P— OH,C- 0 — P— 0 H , C OH
CHCH - o- o
Schiff base of PLP 
and amino acid substrate
Schiff base of PLP 
and enzyme
L e g e n d .  The pyridox! phosphate co-enzym e forms an internal aldim ine bond with 
Lysine 258 o f  the enzym e (shown in blue). On addition o f  the am ino acid substrate 
(yellGw box) the covalent link between the enzym e and co-enzym e is broken, and an 
aldimine is formed between the substrate and the co-enzyme.
B )
ar-Keto acid
A m ino acid su b s tra te
C COO
H - C — COO C— COO C COO
NH
CHCH
H.O
OHOH OH
CH CHCH
Aldimine Quinonoid
intermediate
Pyridoxamine
phosphate
(PMP)
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L e g e n d .  Deprotonation o f  the a-carbon  o f  the amino acid substrate in the aldim ine 
reaction interm ediate forms a quinonoid intermediate. This species is re-protonated (at 
the carbon atom shown in red) to form a ketim ine intermediate. H ydrolysis o f  this 
molecule releases the a-ke to  acid product, and leaves the co-enzym e in the pyridoxam ine 
form, ready to catalyse the reverse reaction. See Section 1.3.3.1 for further details.
(Diagram s from Stryer, 1988)
Figure 1.1 OA. The arrangement of active site residues of aspartate aminotransferase 
stabilises the substrate- pyridoxal phosphate co-enzyme complex in an orientation 
favouring transamination.
+ +
Arg-292 NH2 ^ - 5^  Arg'386
Lys-258
1
NH2 J  II NH
0 0 N*)
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Reference: Seam an et al., 1991.
Figure 1.10B. Molecular model of aspartate aminotransferase with bound 
pyridoxamine phosphate coenzyme.
Co-enzym e= space filling model; Sticks = active site residues. 
M odel from Brookhaven Protein Structure Databank- 9AAT.
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the spatial arrangement of active site residues that stabilise the co-enzyme-substrate 
complex in the correct orientation). Hydrolysis of this aldimine bond releases an a- 
keto acid and leaves the co-enzyme in the pyridoxamine phosphate form (PMP). 
This reaction represents half of the transamination reaction catalysed by mAspAT 
(i.e. L-glutamate conversion to a-ketoglutarate), and is fully reversible. The binding 
of a second a-keto acid to the pyridoxamine (PMP) form of the co-enzyme initiates 
the reverse reaction with the formation of an amino acid and the regeneration of the 
PLP form of the enzyme (i.e. the conversion of oxaloacetate to aspartate).
1.3.3.2 Structural studies of mAspAT enzyme mechanism.
Much work has centred on determining the three dimensional structure of aspartate 
aminotransferase enzymes alone and in complexes with various inhibitors (e.g. 
McPhalen et al., 1992a; Malashkevich et al., 1993; Miyahara et al., 1994) in order to 
confirm details of the reaction mechanism described above, and to identify important 
active site and interdomain residues. McPhalen et al., (1992b) compared the 
structure of chicken mAspAT with bound PLP co-enzyme (holo-enzyme) to the 
structure of the holo-enzyme in a complex with a strong inhibitor of mAspAT, the 
substrate analogue a-methyl-aspartate. The active enzyme is a dimer of two identical 
subunits. Each subunit consists of a small and a large domain with the active site 
positioned in a cavity between the domains and near the subunit interface (Figures
1.1 OB, and 1.11 A). Each subunit contains one active site and their activities are 
independent of each other. In the liganded form, the large and small domains close 
around the substrate (analogue) and close the active site. This involves a rotation of 
the small domain relative to the large, and is discussed further below (illustrated in 
Figure 1.1 IB).
The subunit of the chicken mAspAT enzyme consists of a small domain (consisting 
of 2 small two stranded p-sheets, and 5 a-helices), and a large domain (a central 
seven stranded p-sheet surrounded by eleven a-helices that pack around the P-sheet). 
A long a-helix forms part of both subunits. The active site is formed by residues 
from both domains of the subunit and a few residues from the other subunit. These 
features can be seen in Figure 1.1 OB. An N-terminal arm from each subunit can be 
seen to extend across the large domain of its subunit partner (Figure 1.1 IB). On
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Figure 1.11A. Space filling model of chicken mitochondrial aspartate am inotransferase homodimer.
Legend. A space filling model o f a homodimer of chicken mAspAT is shown. This has an almost 
identical 3-D structure to the mammalian and E. coli enzymes. The large and small domains o f the 
right hand monomer are labelled, as is the N-terminal arm which packs across the large domain of the 
left hand subunit (monomer). The active site is marked and sits at the interface o f the left and right 
m onom er subunits and between the large and small domains of the right hand monomer. A second, 
independent active site is formed in a sim ilar way in the other monomer.
Figure 1.11B. M odel o f domain closure on substrate binding to chicken m AspAT monomer.
Legend. The peptide backbone of a single monomer of chicken mAspAT is shown, with the large and 
small domains shown in Panel A labelled to allow orientation of the two models. The solid line 
represents the structure of the m AspAT backbone without bound substrate, and the dotted line shows 
the position of the peptide backbone following binding of the inhibitor a-m ethyl aspartate, a substrate 
analog. The m ajor alterations in the structure are a rotation of 13.6 ° around the labelled axis o f rotation 
(which lies almost perpendicular to the plane of the paper), and a shift o f 0.7A along this axis. In 
addition helix 1 undergoes further rearrangement and moves to cover the active site. For further 
discussion, see main text.
70* represents the active site residue Tyrosine 70 from the subunit shown; 292* represents the position 
of the active site residue A rginine 292 which is part o f the other subunit.
Reference: M cPhalen e t  al., (1992b).
Figure 1.11. Substrate induced domain closure in mAspAT.
A) Space filling model of chicken mAspAT homodimer.
Active site
AspAT Dimer
Small
domain
Large
domain
N-terminal
arm
B) Model o f domain closure on substrate binding in chicken mAspAT monomer.
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binding to substrate, the core of the small domain moves relative to that of the large 
domain, described as a “rotation of 13.6° and a shift of 0.7A along the axis of 
rotation” (McPhalen et a l , 1992b; see Figure 1.1 IB). In addition, there are subtle 
compensatory changes within the internal structure of the domains, and in the 
interdomain and intersubunit contacts. Two of these changes occur in the peptides 
linking the two domains (an increase in the kinking of the long interconnecting helix 
13, and smaller changes at the other link point). Helix 1 (illustrated in Figure 1.1 IB) 
moves considerably upon substrate binding, so that it makes considerable new 
contacts with the large domains of both subunits of the enzyme. This motion 
effectively closes the active site, and is accommodated by movement of the N- 
terminal linking arms (McPhalen et al., 1992b). The function of the domain closure 
in mAspAT is to restructure the active site around the substrate, with the interactions 
of the active site residues and the substrate providing the driving force for domain 
closure. The salt bridges between Arg 292* (residue from the other subunit) and the 
P-carboxylate of the substrate, and Arg 386 with the a-carboxylate play a central role 
in domain closure, and these residues undergo large conformational changes to bind 
the substrate and position it near to the co-enzyme. Domain closure also moves three 
hydrophobic residues near the mouth of the active site to form a hydrophobic plug 
over the active site, removing the active site from solvent contacts, completely 
burying the substrate and facilitating catalysis (McPhalen et al., 1992b; Miyahara et 
al., 1994). The salt bridges between the two arginine side chains and the substrate 
hold the substrate tightly in the active site and confer stereo-specificity on the 
reaction (Miyahara et a l , 1994); both carboxylate groups of the substrate have been 
demonstrated to be essential for stabilising the closed conformation of the enzyme 
(Markovichousley et a l , 1996). Studies using electron spin resonance spectroscopy 
to probe the conformation of mAspAT using a spin label attached to Cysl66 showed 
that substrate binding to the PLP form of mAspAT shifted the conformational 
equilibrium of the enzyme towards the closed conformation, an effect not seen with 
the PMP form of the enzyme (Sterk et a l , 1994). This evidence from enzyme studies 
in solution supports the induced domain closure model proposed from the 
crystallographic studies.
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1.3.4 THE METABOLIC FUNCTIONS OF ASPARTATE 
AMINOTRANSFERASES.
The AspAT isoenzymes have a central role in cellular metabolism, playing an 
important role in the synthesis and degradation of amino acids, and being involved in 
the link between the Urea and tricarboxylic acid (TCA) cycles (illustrated in Figure 
1.12). They also play an essential role in the transfer of reducing equivalents across 
the mitochondrial membrane (Pave-Preux et al., 1988). This latter role is discussed 
below. In addition, cAspAT has a role in the production of glutamate, the immediate 
precursor of the neurotransmitter y-aminobutyrate (GABA) in the cell body and 
axons of GABAergic neurons (Kaneko and Mizuno, 1994).
1.3.4.1 The malate-aspartate shuttle.
NADH is synthesised during glycolysis in the cytoplasm of cells, but the next stage 
of oxidative respiration involves the electron transport chain within the mitochondria. 
The inner mitochondrial membrane is totally impermeable to both NADH and NAD+. 
The transport of reducing equivalents across the inner mitochondrial membrane is 
therefore accomplished by means of shuttles- the ‘glycerol phosphate shuttle’ and the 
‘malate-aspartate shuttle’. The malate-aspartate shuttle is illustrated in Figure 1.13. 
The shuttle consists of both the cytoplasmic and mitochondrial forms of aspartate 
aminotransferase and malate dehydrogenase (MDH), and two membrane transporter 
proteins. Electrons are transferred from cytoplasmic NADH to oxaloacetate to form 
malate in a reaction catalysed by cMDH. Malate is then transported into the 
mitochondrial matrix, and is re-oxidised by NAD+ to form NADH and oxaloacetate 
(catalysed by mMDH). A transamination reaction is necessary to facilitate the export 
of the oxaloacetate formed by this reaction out of the mitochondria. This reaction is 
catalysed by mAspAT. This shuttle is readily reversible (unlike the glycerol 
phosphate shuttle) and can therefore only transfer NADH into the mitochondrial 
matrix if the NADH/NAD+ ratio is higher in the cytoplasm than in the matrix. The 
net effect of the malate aspartate shuttle is shown below.
NADH ^ NAD+  x NAD+ ^ NADH
cytoplasmic mitochondrial ^ cytoplasmic mitochondrial
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Figure 1.12. Aspartate aminotransferase is involved in amino acid metabolism, 
and in the link between the tricarboxylic acid and Urea cycles.
A) Amino acid metabolism.
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Figure 1.13. The malate-aspartate shuttle.
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Legend. In heart and liver tissue the malate aspartate shuttle is the major mechanism for the transfer 
o f  reducing equivalents from the glycolytic pathway in the cytoplasm to the electron transfer chain in 
the mitochondrial matrix. Two parallel coupled reactions, catalysed by cytoplasmic and mitochondrial 
aspartate aminotransferase (cAspAT/mAspAT) and cytoplasmic and mitochondrial malate 
dehydrogenase (cM DH/mM DH) are involved. Essentially, electrons are transferred from cytoplasmic 
NADH to oxaloacetate, forming malate which translocates the inner mitochondrial membrane, and is 
then reoxidised by N A D + in the matrix to form NADH (represented by the blue lines in the lower 
portion o f  this figure). The resulting oxaloacetate cannot traverse the inner mitochondrial membrane, 
and is therefore transaminated to form aspartate which can be transported to the cytosolic side (red 
lines at top part o f  this figure). As this shuttle is readily reversible it can only transport NADH into 
the mitochondria if  the N A DH /N AD 4 ratio is higher in the cytosol than in the mitochondrial matrix.
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Setoyama et al., (1990) studied the malate aspartate shuttle in mouse cells, and found 
that the levels of all four enzymes were approximately equal, suggesting that 
expression of the components of the shuttle might be co-ordinately regulated. 
However, cAspAT and c/mMDH promoters were found to contain binding sites for 
the RNA polymerase II transcription factor CTF/NF, while this site was missing 
from the mAspAT promoter. The mAspAT promoter does however have an SP1 
site, in common with other ‘house-keeping’ genes. This suggested that
cAspAT/MDH and mAspAT genes are regulated differently. Indeed, following 
glucocorticoid stimulation, the levels of cAspAT mRNA, protein and enzyme 
activity are significantly elevated, while the corresponding levels of mAspAT remain 
unchanged (Pave-Preux et a l , 1988). This effect was tissue specific, occuring in 
cells capable of gluconeogenesis (e.g. liver and kidney) but not in heart or brain cells. 
The structure of the cAspAT promoter has been further studied (Garlatti et a l, 1993) 
and found to interact with CCAAT/enhancer binding protein related proteins. The 
promoter is unusual in displaying features of both house-keeping and inducible 
genes. It lacks a TATA box, and is G+C rich (house-keeping) but has several 
CCAAT boxes and glucocorticoid response elements (inducible), and thus 
demonstrates a basal level of transcription that can be elevated by hormone signals in 
a tissue specific manner. The mAspAT promoter has also been shown to be 
inducible (e.g. Franklin et a l, 1987), and contains androgen response elements 
(Juang et a l, 1995); this and other possible effects of mAspAT up-regulation will be 
discussed in the ‘General Discussion’ section with respect to the work presented in 
this thesis.
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2. MATERIALS AND METHODS.
2.1 MATERIALS.
2.1.1 CHEMICALS AND REAGENTS.
All chemicals were AnalR grade obtained from BDH (Poole, Dorset) with the 
exception of those listed below.
3-[cyclohexylamino]-l-propane-sulphonic Aldrich Chemical Co., Gillingham, 
acid (CAPS). Dorset, UK.
ECL Western blotting reagents; ECL Amersham International Pic.,
i t  • i . i ™ Buckinghamshire, UK.molecular weight markers; Megapnme™
DNA labelling system; Rainbow molecular
weight markers.
Ampicillin sodium B.P. (Penbritin®). Beecham Research Laboratories.
Electrophoresis grade reagents: Tris; Bio-Rad Laboratories, Richmond,
acrylamide; DATD; gelatin; SDS; California, USA.
N,N,N ’ ,N ’ -tetramethylenediamine 
(TEMED); N,N’-methylenebis-acrylamide; 
ammonium persulphate; HRP colour 
development reagent (4-chloro-l-napthol);
Coomassie brilliant blue R250.
Tris; DOTAP transfection reagent.
Pansorbin (formalin fixed S. aureus type A 
cells).
Trypsin; bacto-tryptone; yeast extract; 
bacto-agar.
Formaldehyde; formamide.
Boehringer Mannheim GmbH, 
Germany.
Calbiochem, LaJolla, California, USA. 
Difco Ltd.
Fluka Biochemicals. Gillingham, UK.
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Tissue culture reagents: 7.5% sodium 
bicarbonate solution; L-glutamine solution; 
penicillin/streptomycin solution; DMEM; 
lx  and lOx BHK medium; new-born and 
foetal calf serum (NCS and FCS).
Isopropyl thiogalactoside (IPTG); 5-bromo-
4-chloro-3-indolyl P-D-galactoside (X-gal).
Glycerol; ultrapure ethanol; glacial acetic 
acid; hydrochloric acid; methanol.
Ecoscint™ scintillation fluid; Sequagel 
acrylamide solution.
Sephaglas® Bandprep kit.
Rnasin® Ribonuclease inhibitor.
Plasmid purification kit.
Tween 20; Triton X-100; agarose; 
lysozyme; guanidine thiocyanide; Ficoll 
3350; polyvinylpyrollodine 360 (PVP); 
phenylmethylsulphonyl fluoride (PMSF); 
dithiothreitol; diethyl pyrocarbonate 
(DEPC); lyophilised salmon sperm DNA; 
protein-A FITC conjugate;
DNAse free RNAse A (type IA); 
chloramphenicol; S-lauryl-sarcosine; 
Antifoam A; ultrapure phenol; ethidium 
bromide (solid); isoamylalcohol.
Gibco-BRL BRL, Paisley, UK.
Life Technologies, Gaithersburg, USA. 
May and Baker Ltd., Dagenham, UK.
National Diagnostics, Manville, NJ, 
USA.
Pharmacia, Uppsala, Sweden.
Promega Corp., Wisconsin, USA. 
QIAGEN GmbH, Germany.
Sigma Chemical Co., UK.
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2.1.2 RESTRICTION AND DNA MODIFYING ENZYMES.
Restriction enzymes (lO U pl1) supplied with appropriate reaction buffers at a 10X 
concentration were purchased from Boehringer-Mannheim GmbH, Germany. T4 
polynucleotide kinase, T4 DNA polymerase and Taq DNA polymerase (SUpl'1) were 
obtained from the same source.
MoMLV Reverse transcriptase (200Upr1 with 5x buffer) and T4 DNA ligase were 
obtained from Gibco-BRL, Paisley, UK.
2.1.3 RADIOCHEMICALS.
Radiochemicals were supplied by Amersham International Pic. (Bucks., UK.).
[35S] L-methionine. SA 800 Cimmol"1 (ISpCipl'1)
[a35S] dATP. SA 1000 Cimmol1 (lO pCipl1)
5’[a32P] dCTP and 5’[a32P] dGTP. SA 3000 Cimmol1 (lO pCipl1)
5’[y” P] ATP. SA 5000 Cimmol1 (lO pCipl1)
14.3-200kDa 14C methylated protein SA 5pCipl_1
molecular weight markers.
2.1.4 OTHER MATERIALS AND APPARATUS.
Hybond-N hybridisation membrane. Amersham International, Bucks., UK.
Tissue culture plasticware. Becton Dickinson Ltd., UK.
Mini Protean® protein gel kit; Mini Trans- Bio-Rad Laboratories, Richmond,
Blot cell. USA.
Sorvall RC5B, RT6000B centrifuges.
Hybridisation oven and glass hybridisation 
tubes.
XS-1 (x-ray film); Biomax MR x-ray film. 
PD-10 desalting (Sephadex G-25) columns.
FPLC system; MonoQ HR 5/5 column. 
Polaroid 667 film.
DuPont UK., Hitchin, Herts., UK. 
Hybaid,
Kodak, UK.
Pharmacia Fine Chemicals, Uppsala, 
Sweden.
Pharmacia LKB, Uppsala, Sweden. 
Polaroid UK.
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0.5 and 1.5 ml micro-centrifuge tubes. Sarstedt Ltd., Leicester, UK.
Stratalinker™ UV cross-linker. Stratagene, USA
2.1.5 CELLS.
The following cell lines were used in the experiments described in this thesis.
BHK 21 clone 13 cells:- A fibroblast cell line derived from baby hamster kidney cells 
(Macpherson and Stoker, 1962), and maintained within the Institute of Virology, 
Glasgow.
RE cells:- Rat embryo fibroblasts prepared from 16-17 day old sibling embryos of 
inbred Hooded Lister rats, as described in Section 22.2.2 below.
BnST cells:- Derived from the in vitro culture of a tumour induced by injection of Bn5 
cells, which were RE cells transformed by the cloned BglHN fragment of HSV-2 strain 
HG52 (Cameron et al., 1985; Macnab et al., 1985).
NRK 536 cells:- Normal rat kidney fibroblast cell line used for colony formation 
assays, and obtained from B. Matz (University of Freiberg, Germany).
2.1.6 VIRUS STRAINS.
Virus stocks were provided by Mrs. Mary Murphy (Institute of Virology, Glasgow), 
except where stated below.
Herpes simplex virus type-1 (HSV-1) strain 17+ (Brown et al., 1973) and HSV-2 strain 
HG52 (Timbury, 1971) were used as wild type virus in all experiments.
The intertypic recombinant viruses Bxl, Fx9 and R12-5 were obtained from Mrs. Mary 
Murphy.
HSV-1 strain F was provided by Dr. A. Maclean, and HSV-2 strain MS was provided 
by Dr. J.C.M. Macnab, both of the Institute of Virology, Glasgow.
HSV-1 1217, a spontaneous mutant which fails to induce dUTPase activity, and HSV-1 
1218, an insertional dUTPase mutant (Fisher and Preston, 1986) were kindly provided 
by Dr. V. Preston, Institute of Virology, Glasgow.
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2.2 METHODS.
2.2.1 GENERAL PROCEDURES.
2.2.1.1 pH measurement.
The pH of aqueous solutions was measured using a Whatman PHA300T hand held pH 
meter fitted with a HI 1295 amplified electrode.
2.2.1.2 Autoclaving and Glassware sterilisation.
Equipment and solutions were sterilised at 15psi for 20 minutes by staff in the 
washroom, Institute of Virology, Glasgow. Glassware was sterilised by baking in an 
oven at 180 ° C for at least 12 hours.
2.2.1.3 Filter sterilisation.
Heat-labile solutions were sterilised by filtration through a Whatman syringe filter (pore 
diameter 0.2 pm) into a sterile tube.
2.2.2 TISSUE CULTURE.
2.2.2.1 General Solutions.
The following solutions were prepared by staff in the Media Department, Institute of 
Virology, Glasgow.
Sterile Deionised Water. De-ionised water obtained from a ‘Milli-Ro 60 plus’ 
de-ioniser (Millipore, USA) and sterilised by autoclaving.
Phosphate Buffered Saline (PBS-A). PBS-A (170mM NaCl, 3.4mM KC1, ImM 
Na2HP04, 2mM KH2P 0 4, pH 7.2) was sterilised by autoclaving.
Trypsin. Trypsin was dissolved at a concentration of 0.25% (w/v) in Tris-saline 
containing phenol red and adjusted to pH 7.5 with NaHC03. Aliquots were stored at - 
20 °C.
Versene (ethylenediaminetetra-acetic acid, EDTA). 0.6mM EDTA dissolved in PBS- 
A containing phenol red, sterilised by autoclaving and stored at room temperature. 
Trypsin/Versene (T/V). 5ml of trypsin solution 0.25% (w/v) was added to 20ml 
versene immediately prior to use, and stored for a maximum of 3 days at 4 0 C.
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Carboxy-methyl Cellulose (MC). 3% carboxy-methyl cellulose dissolved in ddH20  and 
sterilised by autoclaving.
The solutions below were purchased from Gibco-BRL, Paisley, UK.
Dulbeccofs Modified Eagles Medium (DMEM). Stored at 4°C. Supplemented with 
lOOU/ml penicillin, lOOpgml'1 streptomycin (referred to as supplemented DMEM from 
now on) and NCS/FCS as stated for each cell type.
Glasgow modified Eagle*s medium (lx  BHK medium). Stored at 4 ° C. Supplemented 
with lOOU/ml penicillin, lOOpgml'1 streptomycin, 5% tryptose phosphate broth and 
10% NCS.
Sodium Bicarbonate (NaHCOf. A 7.5% w/v NaHC03 solution was stored at 4 0 C for 
up to 2 weeks.
Newborn Calf Serum (NCS) and Foetal Calf Serum (FCS). Mycoplasma tested and 
virus screened NCS and FCS was stored in 20ml aliquots at -200 C.
L-Glutamine. L-glutamine was supplied at a concentration of 200mM and stored in 
aliquots at -20 ° C.
Penicillin/Streptomycin (PS) solution. A solution containing concentrations of 1% w/v 
streptomycin, lO ^ m l'1 penicillin was dispensed into aliquots for storage at -20 ° C.
2.2.2.2 Preparation of primary rat embryo cells
Primary rat embryo cells were prepared from 16-17 day old embryos from an inbred 
colony of Hooded Lister rats which was maintained within the Institute of Virology, 
Glasgow by brother-sister mating for over 20 years. This colony has no history of 
susceptibility to form spontaneous tumours (Macnab, 1979). Embryos from a single 
litter were removed from the uterus of a pregnant rat, washed with versene, eviscerated 
and again washed with versene before being finely chopped. To obtain a single cell 
suspension, cells were treated with 0.25% trypsin for 30 minutes at 37 °C. The 
supernatant was removed and the remaining cell clumps were treated with fresh trypsin. 
Newborn calf serum was added to a final concentration of 5% (v/v) to inactivate the 
trypsin. The supernatant was centrifuged at lOOOrpm for 10 minutes at 4 0 C. The cell 
pellet was resuspended in supplemented DMEM containing 5% NCS.
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2xl08 cells were seeded in a 850cm2 plastic tissue culture roller bottle. Cells were 
grown at 37 °C until 80% confluent, and thereafter at 31 °C with weekly medium 
changes. Cells were viable for approximately four weeks, and were routinely used at 
second passage.
2.2.2.3 Maintenance of cell lines.
Bn5T  and R E  cells were maintained in 850cm2 plastic tissue culture roller bottles at 
37 ° C in supplemented DMEM containing 5% NCS in an atmosphere containing 5% 
C 0 2. Confluent Bn5T and RE cells were split 1:5 to 1:10 and 1:3 or 1:4 respectively, 
depending on growth rates observed.
BH K  C l3 cells were maintained in roller bottles in lx BHK medium (Gibco BRL) 
containing 10 % NCS in an atmosphere containing 5% C 02, and were split 1:10 as 
required.
N RK 536 cells were cultured in 175cm2 flasks in DMEM containing 10% FCS, at 37 ° C 
in an atmosphere containing 5% C 02 and were split 1:5 when confluent.
The medium on all cells was replaced every 3-4 days. Cells were split by washing three 
times in versene, and then briefly in trypsin/versene (1:5). Released cells were pelleted 
at lOOOrpm for 5 minutes to remove the trypsin before reseeding.
2.2.2.4 Cell harvesting.
Cells required for large scale protein purification were washed in ice cold PBS-A three 
times before being scraped into PBS-A using a rubber policeman. Cells were pelleted at 
2000rpm for 10 minutes at 4 0 C. The supernatant was removed and the cell pellet was 
either used immediately or was stored dry at -70 ° C for later use.
Cell lysates for Western blotting experiments were prepared by the addition of 1ml of 
3xBM (Section 2.2.5.6) to the cell monolayer.
2.2.2.5 Preparation and storage of cell stocks.
Actively growing cells (~2 xlO8) were trypsinised and the cells pelleted at lOOOrpm for 
10 minutes at 4°C. The cell pellet was resuspended in 1ml of supplemented DMEM 
containing 10% FCS and 10% DMSO (v/v), and frozen slowly overnight at -70 °C 
before transfer for long term storage in liquid nitrogen (-1960 C).
Aliquots of stock cells were resuscitated periodically to replace existing cultures to
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prevent the accumulation of alterations within the cell lines due to continuous passage. 
To recover frozen cells, 1ml stocks were thawed rapidly and seeded into 25cm2 flasks 
and incubated at 37 °C in the appropriate medium. The medium was changed the 
following day to remove the DMSO and non-adherent cells from the culture.
2.2.2.6 Mock infection and infection of cells with HSV.
The growth medium was removed from the cells and serum free medium containing no 
virus or the appropriate amount of HSV was added; cells were incubated at 37 ° C for 1 
hour. The innoculum was removed and replaced with normal medium, and the infection 
allowed to continue for defined periods of time, usually overnight.
2.2.2.7 Transfection with plasmid DNA.
2.2.2.7.1 Calcium Phosphate precipitation.
HEBS: 137mM NaCl, 5mM KC1, 0.2mM NaH2P 0 4, 9mM D-glucose, 21mM Hepes 
pH 7.5.
A modification of the method of Stow and Wilkie (1976) was used to transfect plasmid 
DNA into BHK C13 cells. l-5pg of plasmid DNA was added to 1ml HEBS containing 
Spgml'1 calf thymus DNA and 70pl 2M CaCl2. Following mixing, this solution was 
added to 60mm plates of sub-confluent BHK C13 monolayers from which the medium 
had been removed. Following incubation at 37 °C for 45 minutes, the cells were 
overlayed with 4ml of lx  BHK medium containing 5% NCS. 4-6 hours later, the 
medium was removed and the cells washed with serum free medium. 1ml of 20% (v/v) 
DMSO in HEBS was added to each plate and incubated at room temperature for exactly 
4 minutes. The DMSO was removed and the cells washed twice with serum free 
medium before addition of 4ml of serum containing medium and incubation at 37 ° C.
2.2.2.7.2 Lipofection with DOTAP.
HBS: 20mM Hepes, 150mM NaCl, pH 7.4.
N-[l-(2,3-Dioleoyloxy)propyl]-N,N,N-trimethyl-ammoniummethysulphate (DOTAP) as 
an aqueous dispersion (lmgml'1) was used to introduce plasmid DNA containing the 
mAspAT cDNA into NRK 536 cells. 60mm plates of sub-confluent NRK 536 cells 
were transfected with up to 5pg of plasmid following the manufacturers’ instructions 
(Boehringer Mannheim).
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30 j l x 1 of the transfection reagent was diluted to lOOpl in HBS. The DNA (5pg) was 
diluted separately to lOOpl in HBS. The solutions were mixed and incubated at room 
temperature for 10 minutes. 4ml of tissue culture medium (containing serum) was 
added to the DOTAP-DNA mixture, and mixed gently, before addition to tissue culture 
cells from which the medium had been aspirated. The cells were incubated at 37 ° C for 
periods of time ranging from 6 hours to overnight, and the medium removed and 
replaced with normal tissue culture medium. The cells were incubated at 37 °C and 
were ready for further experimentation.
2.2.3 VIRUS.
2.2.3.1 Virus stock production.
Stocks of HSV-1 strain 17 and HSV-2 HG52 were produced by the infection of 20 sub­
confluent 850cm2 roller bottles of BHK C l3 cells with virus at a multiplicity of 
infection of 1:300. The virus was added in serum free BHK medium for 30 minutes, 
before removal of the virus and addition of 20ml of normal BHK medium to each bottle. 
Cells were incubated at 31 ° C for 4-7 days, until the cells were falling off the substrate. 
To harvest HSV-1, cells were shaken from the roller bottle using sterile glass beads and 
the medium poured into 250ml sterile Falcon™ tubes. After centrifugation of the tubes 
at 2000g for 10 minutes at 4 ° C (A), the supernatant was removed to a Sorvall tube and 
centrifuged at 12,000g for 2 hours at 4°C (B). The pellet from each tube was 
resuspended in 5ml of supernatant in a universal tube and stored at -700 C. Each stock 
was checked for sterility by streaking on blood agar plates which were incubated at 
37 ° C for 5 days. The first pellet (A) contains cell associated (CA) virus which was 
released by 2 cycles of sonication, freeze-thawing and centrifugation at 2000g. The 
supernatant from each stage was stored in aliquots at -70 ° C. The virus released into the 
supernatant (B) was sonicated once and stored in aliquots at -700 C.
HSV-2 infection produces mainly cell associated virus which is harvested as described 
for cell associated HSV-1 (A) above.
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2.2.3.2 Titration of Virus stocks.
Sub confluent BHK C l3 cells were routinely used to determine the titre (pfu/ml) of 
HSV. lx  106 cells were seeded into sterile 60mm diameter tissue culture plates which 
were incubated at 37 ° C overnight in a humidified 5% C 02 incubator.
Serial ten-fold dilutions of the virus stocks were made in serum free BHK medium. The 
growth medium was aspirated from the cells and 200pl of each virus dilution was added 
to a dish. The cells were then incubated at 37 ° C for 1 hour to enable virus adsorption. 
The inoculum was removed and to prevent secondary plaque formation the plates were 
overlayed with 5ml of a 1:1 mixture (v/v) of 2xBHK medium and 3% carboxy-methyl 
cellulose solution. A plate infected with each dilution was incubated at 310 C and 
another at 3 7 0 C for 2-3 days until plaques were visible. The cells were fixed by the 
addition of 5ml Giemsa stain to each plate. After staining at room temperature for 1-2 
hours the plates were rinsed gently in cold water and allowed to dry. Visible plaques 
were counted with a low power binocular light microscope and the titre of the virus 
stock calculated.
2.2.4 ANTISERA.
2.2.4.1 Production of tumour bearing serum (TBS).
TBS was produced by Dr. Joan Macnab (Institute of Virology, Glasgow) by the 
subcutaneous injection of 8 week old Hooded Lister rats with lx  107 Bn5T cells. 
Tumours generally developed within 1-2 months. Blood was collected by cardiac 
puncture, allowed to clot overnight at 4 ° C and centrifuged at 2000rpm for 10 minutes at 
4 ° C before removal of the serum. 1ml aliquots of serum were stored at -20 ° C.
2.2.4.2 Raising an antiserum against the 40 kDa polypeptide.
The 40kDa polypeptide was purified by ammonium sulphate fractionation and FPLC 
anion exchange chromatography as described in Section 2.2.5.5. The 40kDa 
polypeptide was identified on an SDS-PAGE gel by comparison with a TBS 
immunoprecipitation, and excised from the dried gel with a sterile scalpel blade. The 
backing paper was removed from the gel slice, which was ground up in a small 
homogeniser and mixed with incomplete Freund’s adjuvant. The immunogen was 
injected into a rabbit by Dr. J.C.M. Macnab, Institute of Virology, Glasgow,
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followed by regular booster innoculations. Blood was collected by Mr David Miller, 
Institute of Virology, Glasgow, and the serum collected as described above.
2.2A3  Raising antibody to mAspAT.
Antibody to mAspAT was raised by injection of pre-mAspAT purified from E.coli (gift 
of J.R. Mattingley, University of Missourri) into a rabbit by Dr. J.C.M. Macnab. Serum 
was collected as previously described.
2.2 A A  Antibody to HSV UL49.
An antiserum against the HSV UL49 gene product, p43 was kindly provided by J. 
Leslie, Institute of Virology, Glasgow.
2.2.4.5 Antibody to HSV dUTPase.
An antiserum against the HSV dUTPase was kindly provided by Dr S. Caradonna, 
Molecular Biology Department, Medical and Dental University of New Jersey, USA.
2.2.5 PROTEIN PURIFICATION AND ANALYSIS.
2.2.5.1 Solutions.
100X Protease inhibitors: 300mgmr’ benzamidine, 340mgml'1 PMSF, lOOmgml'1 
phenanthroline in ethanol.
WF buffer: 20mM Tris-acetate, 20mM NaCl, 0.5mM EDTA, lOmM P-
mercaptoethanol, pH 7.4 (Welch and Feramisco, 1985).
RIPA: 0.1% (w/v) SDS, 1% (w/v) sodium deoxycholate, 1% (w/v) triton X-100,
150mM NaCl, lOmM Tris-HCL pH 7.4 (Docherty et a l , 1981).
2.2.5.2 Radiolabelling polypeptides with [35S] L-methionine.
Cellular polypeptides were labelled with [35S] L-methionine in vitro by growing cells in 
medium lacking methionine for at least 1 hour prior to the addition of SOpCiml'1 of [35S] 
L-methionine to the medium. Radiolabelling was carried out at 37 ° C overnight, the 
cells washed twice with PBS-A and harvested for immunoprecipitation or protein 
purification, as described in Sections 2.2.5.4 and 2.2.5.5 respectively.
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2.2.5.3 Measurement of incorporation of radiolabel into polypeptides.
A lp l aliquot of cell lysate was spotted onto a DEAE filter disk, and the proteins 
precipitated by two washes in 5% TCA. The disk was rinsed in acetone, and dried 
under a heat lamp before scintillation counting in a vial containing 4ml of Ecoscint®.
2.2.5.4 Immunoprecipitation.
Immunoprecipitation of radiolabelled polypeptides was used to identify the 40kDa 
polypeptide in protein purification experiments. Radiolabelled cells were lysed by 
sonication and incubation for 30 minutes on ice in radioimmunoprecipitation assay 
buffer (RIPA) containing protease inhibitors. The incorporation of radiolabel was 
determined and 4xl06 cpm of [35S] L-methionine labelled polypeptides were 
immunoprecipitated with 10pl of tumour bearing serum for 1 hour at 4°C in a total 
volume of lOOpl. 60pl of Pansorbin® was added and the sample incubated on ice for 1 
hour. The pansorbin was pelleted by centrifugation at 13krpm, washed twice with 1ml 
of RIP A, and once in Tris-saline. 50pl of SDS-PAGE sample buffer (Section 2.2.5.6) 
was added, and immune complexes dissociated by heating at 70 °C for 10 minutes. 
After the Pansorbin® was pelleted the supernatant was loaded onto an SDS-PAGE gel, 
or stored at -20 ° C until required.
2.2.5.5 Purification of the 40kDa polypeptide.
2.2.5.5.1 Cell lysis.
Bn5T cells (approximately 4xl09) were rinsed twice, scraped into 40ml of ice cold 
PBS-A and pelleted at 1500rpm (Sorvall RTB-6 centrifuge). The pellet was 
resuspended in 20ml of WF buffer containing protease inhibitors, sonicated for 5 
minutes in a sonibath and centrifuged at lOkrpm (Sorvall SS34 rotor). The supernatant 
was taken to a fresh tube.
2.2.5.5.2 Ammonium sulphate fractionation.
Solid ammonium sulphate was ground in a pestle and mortar and added to the cell lysate 
with continuous stirring at room temperature. When the ammonium sulphate was 
completely dissolved, the solution was stirred on ice for 1 hour. The solution was then 
centrifuged at lOkrpm (Sorvall SS34 rotor) to pellet the precipitated
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polypeptides. Ammonium sulphate was added to concentrations of 30%, 60% and 90% 
in turn. The 40kDa polypeptide was precipitated in the 90% fraction.
2.2.5.5.3 Desalting.
The polypeptides precipitated in the 90% ammonium sulphate fraction were desalted 
into 50mM Tris-HCl pH 8.0 using a PD-10 column, containing 10ml of Sephadex G25. 
The polypeptides were eluted in a volume of 3.5ml and concentrated to half this volume 
in a speedivac.
2.2.5.5.4 Anion exchange chromatography.
A MonoQ prepacked HR 5/5 FPLC column was equilibrated with 50mM Tris-HCl, pH 
8.0. The samples were centrifuged at 13krpm in a micofuge to pellet any debris, and 
loaded onto the column. A gradient of 0-1.0M NaCl in buffer followed by elution with 
2M NaCl was used to elute the polypeptides. 1ml fractions were collected and desalted 
using a FastDesalt® column into lOmM ammonium bicarbonate, and concentrated to 
1/10th volume in a speedivac for loading on an SDS-PAGE gel.
2.2.5.6 SDS-PAGE.
The SDS-PAGE system first described by Laemelli (1970) was used to analyse protein 
samples. The concentration of acrylamide in the resolving gel ranged from 9% to 15%. 
Acrylamide was crosslinked by the addition of 1:40 N-N’-methylenebisacrylamide 
(w/w), and polymerised with 0.04% (w/w) APS and 0.04% (w/w) TEMED. The gel 
was overlayed with butan-2-ol which was removed after polymerisation was complete. 
Stacking gel containing 5% acrylamide was crosslinked with 1:40 (w/w) N-N’diallyl- 
tartar-diamide (DATD) and polymerised as above.
Samples were heated at 70 °C for 10 minutes in boiling mix before loading. Large 
(15cm x 15cm) gels were run at 35mA at 4°C, and mini gels at 200V at room 
temperature.
Following electrophoresis, polypeptides were visualised by staining with Coomassie 
blue for 30 minutes, and destaining with several washes in destain at 370 C. Gels were 
dried at 80 ° C under vacuum prior to autoradiography or exposure to a phosphorimager 
screen.
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Samples for Western blotting were not stained, as this inhibited the electrophoretic 
transfer of the polypeptides to the membrane.
The solutions used are detailed below.
Solution Acrylamide DATD bis-acrylamide ddH20
Stacking gel mix (30%) 58.44g 1.56g - 200ml
Resolving gel mix (30%) 55g “ 5g 200ml
Solution Tris-HCl SDS ddH20 pH
Resolving gel buffer 181.5g 4g 1000ml 8.9
Stacking gel buffer 59g 4g 1000ml 6.7
Solution Tris Glycine SDS ddH20
Tank buffer 6.32g 4g lg 1000ml
Boiling Mix (3xBM): 30% stacking gel buffer, 30% glycerol, 12.5% SDS, 15% P- 
mercaptoethanol.
Stain: 50% methanol, 7% acetic acid, 0.2% Coomassie blue R250 in ddH20 .
De-stain: 10% methanol, 7% acetic acid in ddH20.
2.2.5.7 Western Blotting.
2.2.5.7.1 Solutions.
Transfer buffer: lOmM CAPS pH 11, containing 10% (v/v) methanol.
TBS-T: 20mM Tris-HCl, 500mM NaCl, pH 7.5 containing 0.1% (v/v) Tween 20. 
Blocking solution: 3% (w/v) gelatin in TBS-T.
Antibody diluent: TBS-T containing 1% (w/v) gelatin and 0.1% sodium azide.
Stripping solution: lOOmM P-mercaptoethanol, 2% (w/v) SDS, 62.5 mM Tris-HCl pH 
6.7.
Ponceau S stain: 2% Ponceau S (w/v), 1% acetic acid (v/v) in ddH20.
78
Chapter 2: Materials and Methods.
22.5.1.2 Protocol.
Polypeptides separated by SDS-PAGE were transferred to Hybond-N™ membrane by 
electrophoretic transfer in a BioRad mini transfer kit at 50V for 2 hours. The efficiency 
of transfer was determined by analysis of transferred Rainbow molecular weight 
markers and by reversibly staining the membrane with Ponceau S.
The membrane was blocked by gentle shaking at 37 ° C in blocking buffer, washed three 
times in TBS-T and the primary antibody added in antibody diluent. After incubation 
for 1 hour, the membrane was washed again, and a 1/1000 dilution of secondary 
antibody conjugated to horse radish peroxidase (HRP) was added and the blot incubated 
for 1 hour. Final washing of the blot was with several changes of tris buffered saline 
without detergent. When biotinylated ECL molecular weight markers were used, 
streptavidin-HRP was added to the secondary antibody solution.
Detection of polypeptides was with ECL reagents (Amersham). An equal volume of 
each reagent was added to a tube, mixed and poured over the membrane. After 1 minute 
the excess reagent was removed and the membrane placed in a polythene bag. The blot 
was exposed to X-ray film for between 5 seconds and 1 minute.
The antibody could be stripped from the membrane and the samples reprobed with a 
different antiserum by treatment of the membrane with ‘stripping solution’ for 1 hour at 
55 ° C and extensive washing in TBS-T.
2.2.6 INDIRECT IMMUNOFLUORESCENCE (FITC).
2.2.6.1 General Solutions.
Tris Buffered Saline (TBS). 0.606g Tris hydroxymethyl methylamine and 8g NaCl 
were dissolved in 600ml sterile ddH20  and 38ml 1M HC1 added. The volume was made 
up to 1L and the pH adjusted to 7.6 with 2M HC1. This produces a 5mM solution with 
respect to Tris.
Triton X100. A 0.25% v/v Triton X I00 solution was made aseptically in PBS-A and 
stored at 4 ° C.
Antibody Diluent. A 1% w/v bovine serum albumin (BSA) solution was made in sterile 
PBS-A. 20pl of a 10% w/v sodium azide solution (Sigma) was added to 100ml of the 
BSA solution and the mixture was stored at 4 ° C in 10ml aliquots.
79
Chapter 2: Materials and Methods.
Tris-HCL Tris was dissolved in deionised water to a final concentration of 2M and the 
pH adjusted as required with 2M HC1. The solution was sterilised by autoclaving and 
diluted with ddH20  to the appropriate concentration for use.
Blocking Solution. FCS was added aseptically to sterile PBS-A or TBS to a final 
concentration of 5% v/v.
2.2.6.2 Antibodies.
The primary antibody was a 1/500 dilution of a rabbit antiserum raised against the 
precursor of mAspAT.
Secondary detection was with a Protein A-FITC conjugate, used at a dilution of 1/200. 
All dilutions were made with antibody diluent.
2.2.6.3 Cells.
Glass microscope coverslips were washed in a 0.1% (w/v) SDS and rinsed thoroughly 
with de-ionised water. Coverslips were rinsed in 70% ethanol, dried at 50 ° C, polished 
and sterilised by dry heat at 180°C for 2 hours. Coverslips were placed into tissue 
culture plates prior to ceil seeding. After overnight incubation, coverslips were rinsed in 
PBS-A and then fixed in pre-cooled (-20 ° C) mixture of 3:1 methanol:acetone.
2.2.6.4 Immunofluorescence.
All procedures took place at room temperature. Fixed coverslips were placed in a 
holder and cells rehydrated in 10ml PBS-A for 2 minutes. The PBS-A was drained 
from the coverslips which were then washed 3x in 10ml PBS-A (5 minutes each). The 
coverslips were placed in a moist box and 50pl of blocking solution added to each. 
Blocking solution was drained from the slides just prior to addition of lOpl of primary 
antibody and the samples incubated for a minimum of 30 minutes. Cells were then 
placed into a slide holder, rinsed 3x in 10ml PBS-A (5 minutes each) and returned to the 
moist box. All subsequent procedures were performed in the dark whenever possible. 
lOpl of secondary antibody dilution was added to each coverslip and the samples were 
then incubated for a minimum of 30 minutes. The coverslips were again washed 3x in 
10ml PBS-A, mounted onto slides using PBS:glycerol (50:50), and the edges of the 
coverslip sealed with clear nail polish. Cells were visualised using a Nikon Microphot- 
SA fluorescent microscope.
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2.2.7 RIBONUCLEIC ACID EXTRACTION FROM EUKARYOTIC CELLS.
2.2.7.1 Solutions and equipment for RNA work.
All solutions were made from separate stocks of molecular biology grade chemicals 
used only for RNA work. Solutions were treated with 0.1% (v/v) diethyl pyrocarbonate 
(DEPC) overnight at room temperature and then autoclaved. Solutions containing Tris- 
C1 were made with distilled water pre-treated with DEPC. Glassware was treated with 
DEPC and sterilised. Sterile disposable plasticware was used whenever possible.
Ribonucleoside vanadyl complexes (RVC), RVCs were purchased as a 200mM 
solution at -20 ° C (Sigma), and used at a working concentration of 20mM in RNA 
solutions not containing SDS or EDTA to inhibit the action of RNases. They do not 
affect production of cDNA by reverse transcription of mRNA, and can be removed from 
the solution by phenol extraction.
Solution D ( ‘denaturing’). 4M guanidinium thiocyanate, 50mM Tris-HCl (pH 7.5), 
0.5% (w/v) S-lauryl-sarcosine, 2mM EDTA (pH 7.5), 0.1M P-mercaptoethanol.
100ml of solution D was made by dissolving 50g guanidinium thiocyanate, 0.5g 
sarkosyl, 0.33ml AntifoamA, 2.5ml 2M Tris-HCl pH 7.5, and 0.8ml 250mM EDTA pH
7.5 in sterile ddH20  to a final volume to 99.3ml, prior to sterilisation by autoclaving. 
Following autoclaving, 0.7 ml of p-mercaptoethanol was added and the solution stored 
at 4 ° C for up to 1 month.
Ethidium Bromide (EtBr). EtBr was dissolved in ddH20  to give a final concentration 
of lOmgml1 and stored in a foil wrapped 20ml universal in a designated lockable 
cupboard. Extreme care was taken when preparing and using EtBr solutions which are 
known to be carcinogenic.
Sodium acetate (pH4.0)(NaOAc). Solid sodium acetate was dissolved in sterile ddH20  
to a final concentration of 2M, and the pH adjusted to 4.0 with glacial acetic acid, prior 
to filter sterilisation, and storage in aliquots at 4 ° C.
Chloroform :Isoamylalcohol (CHCl/IAA). Chloroform and isoamylalcohol 
(isopentylalcohol, 95% v/v 3-methyl-l-butanol) were mixed to give solutions of 24:1 
and 49:1 as required.
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Ultrapure Phenol ((p). Solid ultrapure (UP) phenol was immersed in sterile ddH20  and 
warmed to 65 ° C prior to equilibration with sterile ddH20  or TE pH 7.5-8.0. The 
saturated phenol was allowed to settle, aliquoted into dark bottles (taking some of the 
aqueous phase) and stored at -20 ° C.
2.2.7.2 Single Step Extraction of total cellular RNA from tissue culture cells. 
Protocol. This method is adapted from that of Chomczynski and Sacchi (1987). The 
volumes given refer to purification of total RNA from 106 cells and were scaled up 
accordingly. This method uses guanidinium isothiocyanate as a protein denaturant but 
omits the ultracentrifugation step that most guanidinium RNA extraction methods 
require (Chirgwin et al., 1979), allowing rapid processing of multiple samples.
Cell pellets were harvested and stored at -700 C until required, or else cell monolayers 
were treated in situ following 2 washes in ice cold PBS-A. lOOpl of solution D was 
added to the cell pellet or monolayer and mixed. lOpl 2M NaOAC (pH 4.0), lOOpil of 
phenol (pH 7.6), and 20pl chloroform:/so-amyl alcohol (v/v, 49:1) were added with 
mixing after each addition. After incubation on ice for 15 minutes, and centrifugation at 
12,000g at 4 ° C for 15 minutes, the aqueous phase was transferred (avoiding the debris 
at the interface) to a clean tube containing 100(4.1 isopropanol. The RNA was 
precipitated at -20 °C for 1 hour, followed by centrifugation at 12,000g at 4°C. The 
RNA pellet was resuspended in 300pl solution D, and re-precipitated by addition of 
300p,l of isopropanol. The RNA pellet was resuspended in 200pl RNase free ddH20  
and 20pl 3M NaOAc. EtOH (600pl) was added and the sample stored at -70 ° C until 
required. Before use the RNA was pelleted at 12,000g for 15 minutes at 4 0 C, washed 
twice with 70% EtOH and air dried before resuspension in a suitable volume (10-200(41) 
of RNAse free ddH20 . The purity of the preparation was estimated by measuring the 
absorbance at 260nm and 280nm. A pure preparation was taken as having an A260/A280 
ratio of 1.8-2.0. All aqueous RNA preparations were stored at -70 ° C.
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2.2.7.3 Isolation of polyA+RNA.
2.2.7.3.1 01igo(dT)25 -Dynabeads®.
PolyA+ RNA isolation from total cellular RNA (section 2.2.1.2) was carried out using 
oligo(dT)-Dynabeads® (Dynal, Oslo) according to the manufacturers instructions as 
indicated briefly below. 01igo(dT)25-Dynabeads® bind approximately 2pg PolyA+ RNA 
per mg of beads. A typical mammalian cell contains about 10'5pg total RNA, of which 
1-5% is mRNA.
Solutions. 2x Binding 20mM Tris-HCl, ImM LiCl, 2mM EDTA, pH 7.5 
lx  Washing lOmM Tris-HCl, 150mM LiCl, ImM EDTA, pH 7.5
lx  Elution 2mM EDTA, pH 7.5 
Protocol. Except where stated procedures were carried out at 4 ° C to reduce the effect 
of RNases. Separation of the Dynabeads® from solution was performed by inserting the 
microfuge tube into the Magnetic Particle Concentrator (MPC®) for at least 30 seconds, 
and removing the supernatant with the tube in the MPC®.
75pg of total RNA in lOOpl of DEPC treated ddH20  was added to a microfuge tube 
containing lmg oligo(dT)25-Dynabeads® which had been equilibrated in lOOjul 2x
Binding buffer. The solutions were mixed gently, and hybridisation allowed to proceed
for 5 minutes at room temperature. The tube was placed in the MPC® and the 
supernatant removed. Two washes with 200pl washing buffer were followed by careful 
removal of all the supernatant before resuspension in 5-10pl elution buffer. Elution of 
the PolyA+ RNA was facilitated by heating the sample to 65 °C for 2 minutes and 
immediately transferring the tube to the MPC®. The polyA+ RNA solution was removed 
to a fresh tube and stored at-70 ° C.
2.2.1 A  Nucleic acid precipitation.
Nucleic acids were generally precipitated by the addition of NaOAc (pH 5.2) to a final 
concentration of 0.3M, followed by the addition of two volumes of ice-cold 100% 
EtOH. DNA precipitation was aided by storing the samples at -20 ° C for 1 hour.
In precipitations where wo-propanol was used (plasmid preps and RNA extraction), 
addition of 0.6 volumes of alcohol was sufficient to precipitate the nucleic acid. In 
these cases, samples were centrifuged immediately to recover the nucleic acid.
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Nucleic acid pellets were washed twice in 70% EtOH, centrifuged briefly, air dried and 
resuspended in an appropriate volume of ddH20  or TE pH 8.0.
2.2.7.5 Quantification of DNA and RNA.
A sample of the nucleic acid solution to be quantified was diluted 1/100 in sterile 
ddH20 . The absorbance of the solution was measured at 260nm and 280nm against a 
ddH20  blank. An absorbance at 260nm (A260) of 1 was assumed to indicate the
following nucleic acid concentrations:
Type and form o f nucleic acid Concentration (jugmt1)  o f  sample
Double stranded DNA 50
Single stranded DNA and RNA 40
Oligonucleotides 20
2.2.8 ELECTROPHORESIS OF NUCLEIC ACID.
2.2.8.1 General Solutions.
10X TAE Buffer.
Tris-HCl pH 8.0 400mM
NaOAc pH 5.2 50mM
EDTA pH 8.0 lOmM
The solution was stored at room temperature and diluted 1:10 with deionised water on
use.
10XTBE Buffer.
Tris-HCl pH 8.0 900mM
Orthoboric acid 900mM
EDTA pH 8.0 25mM
The solution was checked to ensure that the pH was 8.0, then stored at room
temperature and diluted 1:10 with deionised water on use.
10X MOPS Buffer (3-[N~morphpolino]propane sulphonic acid).
MOPS (Sigma) 200mM
EDTA 50mM
NaOAc lOmM
NaOH to pH 7.0
The solution was autoclaved stored at room temperature in dark bottles, and diluted 1:10
with sterile DEPC-treated H20  on use.
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RNA Loading Buffer. This was prepared freshly on the day of use from 300pl 
ultrapure formamide, 60pl 10X sterile MOPS, lOOpl formaldehyde and 140jil sterile 
DEPC-treated 'AnalaR' water. This buffer was used for denaturing RNA gels only and 
separate stocks of the constituents were kept exclusively for RNA work.
D F Loading Dye. DF loading dye consisted of 0.25% (w/v) bromophenol blue 0.25% 
(w/v) xylene cyanol and 25% (w/v) ficoll 400 in sterile ddH20 . This was used as 
loading dye for DNA agarose and polyacrylamide- urea gels.
2.2.S.2 Agarose gel electrophoresis.
2.2.8.2.1 Denaturing electrophoresis of RNA.
The method used for formaldehyde-agarose denaturing gels for northern hybridisation 
analysis was based on that described by Lehrach et al., (1977). An appropriate amount 
of agarose (1.0 -1.5g) was added to 10ml of lOx MOPS buffer and 73ml of DEPC 
treated ddH20 . The agarose suspension was heated in a microwave oven until the 
agarose had dissolved. The volume was adjusted to 83ml and the solution cooled to 
50 ° C. 17ml of formaldehyde (37% v/v) was added and the gel was mixed by swirling 
prior to pouring. After a period of 30 minutes to allow the gel to set the gel was covered 
with lx  MOPS running buffer. The RNA sample (10-40pg) was prepared in a solution 
of 50% (v/v) formamide, lx MOPS, and 5.92% formaldehyde (v/v) to a volume not 
exceeding 100pl. This solution was heated to 65 °C for 15 minutes, cooled on ice and 
0.1 volumes of RNA loading buffer added. The sample was immediately loaded onto 
the gel and run at SVcm'1 until the bromophenol blue had migrated approximately two 
thirds of the distance down the gel. The gel was washed in DEPC-treated ddH20  for 15 
minutes to remove the formaldehyde and then the RNA transferred to Hybond-N™ by 
capillary transfer.
A marker track containing a 0.24-9.5kb RNA ladder was cut from the gel and stained in 
lpgml'1 EtBr for 20 minutes, destained in water for 20 minutes and observed under 
UV-light. Alternatively, the marker track was transferred with the RNA samples and 
the membrane stained reversibly with methylene blue (Section 2.2.9.3.6) to determine 
the efficiency of the transfer.
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2.2.8.2.2 Electrophoresis of DNA.
The appropriate amount of agarose (0.5- 1.5% w/v low EEO or 1% low EEO + 3% w/v 
NuSieve GTG (FMC Bioproducts, USA)) was added to the required volume of IX TBE 
or IX TAE and heated in a microwave oven until all the agarose had dissolved. The 
agarose solution was then allowed to cool to around 500 C before addition of ethidium 
bromide to a final concentration of ljugml'1. The gel solution was poured into the 
electrophoresis apparatus and allowed to set for 30 minutes. Sufficient lx  TBE or lx 
TAE running buffer was added to cover the gel. The DNA samples were mixed with 
one-tenth volume of DF loading buffer and gels were run at SVcnT1 until the 
bromophenol blue had migrated two-thirds of the way down the gel. 30cm long 1.5% 
agarose gels were used to isolate closely sized DNA fragments in the 2kb size range. 
The gel was then washed in ddH20  for 15 minutes and visualised under UV light. Long 
wave UV (630nm) was used to visualise DNA fragments that were to be further 
manipulated, to reduce radiation induced DNA damage.
2.2.8.2.3 Marker DNA and RNA.
Marker DNA and RNAs were run on agarose gels (as appropriate) to estimate the size 
and quantity of the DNA/RNA that was being analysed. Most frequently used for DNA 
gels was X DNA digested with EcoRl and Hindlll or a single Hindlll digest (both 
Sigma), and occasionally a 123bp ladder (Gibco-BRL).
For the analysis of RNA gels, a synthetic 0.24 - 9.5Kb RNA ladder (Gibco-BRL) was 
run in the outer lane of the gel.
2.2.8.3 Acrylamide Gels.
Polyacrylamide gels were used to purify oligonucleotides which were synthesised on a 
Cruachem PS250 synthesiser, and removed from the matrix by treatment with ammonia 
(35% pure, specific gravity 0.88) at 55 0 C for 5 hours. The lyophilised oligonucleotide 
was resuspended in 20pl formamide and 5 pi of lOx TBE. The sample was 
electrophoresed on a denaturing polyacrylamide gel (15% polyacrylamide cross linked 
with 4% (w/v) N,N’-methylenebisacrylamide in lx TBE containing 8M urea; Sequagel 
reagents). Polymerisation was catalysed by the addition of 0.05% (w/v) APS and 0.1% 
(w/v) TEMED. The oligonucleotides were visualised by UV shadowing with short 
wave UV light, and excised from the gel. Oligonucleotides were recovered as described 
below (Section 2.2.8.4.2).
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2.2.8.4 DNA Recovery from Gels.
2.2.8.4.1 Agarose Gels.
Sephaglas Kit. DNA fragments were isolated from solution or from agarose gels 
using the Sephaglas® kit following the manufacturers’ instructions. The DNA sample 
was run on a TBE gel to separate the DNA of interest from contaminating DNA. The 
DNA band was identified by illumination of the gel with long-wave UV light (X= 
630nm) and excised with a sterile scalpel blade. The agarose slice was weighed and lp l 
gel solubiliser per mg of agarose added. The agarose was dissolved by incubation at 
60 ° C for 10 minutes. 5pi of Sephaglas® per pg of DNA was added, the contents mixed 
and allowed to stand at room temperature for 5 minutes with occasional mixing. After 
pelleting of the Sephaglas® at 10,000g for 30 seconds the supernatant was removed and 
the pellet washed three times with 40pl wash buffer. The DNA was eluted by 
resuspension of the pellet in 20 pi elution buffer and incubation at 55 ° C for 3 min. 
Elution by centrifugation. DNA fragments were excised from gels as described above, 
the gel slice cut into smaller pieces and placed in a 0.5ml microfuge tube which had a 
hole in its base covered by a siliconised glass wool plug. This tube was placed inside a 
1.5ml microfuge tube and centrifuged at 6,000rpm for 10 minutes. The DNA in 
solution passed through the small tube into the larger one, leaving the solid agarose 
behind. The eluate was extracted twice with an equal volume of cp/CHCl3 (see Section 
2.2.10.1.2) and once with CHC13, before precipitation with 0.1 volumes of 5M NH4Ac 
and 2 volumes of EtOH overnight at -20 ° C. The DNA was pelleted by centrifugation at 
13,000rpm at room temperature for 10 minutes, washed in 70% v/v EtOH then absolute 
EtOH and air-dried. The DNA was resuspended in TE pH 8.0, the concentration 
estimated and the solution stored at -20 ° C.
2.2.8.4.2 Acrylamide Gels.
Elution into TE. Gel fragments containing oligonucleotides undergoing purification 
were excised as described above (Section 2.2.8.3) and placed in 1.5ml microfuge tubes. 
They were mashed using the end of a pipette tip, covered with TE and incubated on a 
rotating wheel at 370 C overnight. The tubes were centrifuged at 6,000rpm at room 
temperature for 10 minutes to pellet the acrylamide and the supernatants transferred to 
fresh microfuge tubes. The volume of each supernatant was noted and 0.1 volumes of 
5M NH4Ac and 2 volumes of EtOH was added to the tubes and the sample mixed well.
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The tubes were incubated at -20 °C for at least 3 hours and the DNA pelleted by 
centrifugation at 13,000rpm at room temperature for 10 minutes. The DNA pellets were 
washed with 70% v/v EtOH, absolute EtOH, and were air-dried prior to resuspension in 
TE pH 8.0, spectrophotometric analysis and storage at -20 ° C.
2.2.9 HYBRIDISATION.
2.2.9.1 General Solutions.
20XSSC Buffer, 3M NaCl, 0.3M Na3Citrate dissolved in sterile ddH20  at pH 7.0. The 
solution was stirred with gentle heating to aid solvation.
lOOx Denhardt's Solution. Ficoll 400, BSA and polyvinyl pyrolidone 360 were 
dissolved in sterile ddH20  to final concentrations of 2% w/v of each constituent. The 
solution was filter sterilised through a 0.45 pm filter and stored at -20 °C in 20ml 
aliquots.
Denatured Salmon Sperm DNA. Lyophilised salmon sperm DNA was added to a 
beaker of sterile ddH20  to give a final concentration of 5mgmr’. The beaker was heated 
at 3 7 0 C for 1-2 hours with stirring. The solution was periodically pushed through a 5ml 
syringe with a 21G syringe needle attached. The solution was sonicated for 3 minutes 
and aliquoted into 1.5ml microfuge tubes for storage at -200 C.
Pre-hybridisation solution. 25ml of pre-hybridisation solution was prepared from stock 
solutions as follows: 3.13ml 20x SSC, 0.625ml lOOx Denhardts and 0.313ml 20% SDS 
were mixed with ddH20  to a volume of 12.5ml. An equal volume of formamide was 
added and mixed. The solution was sterilised by filtration through a 0.45 pm filter and 
denatured salmon sperm DNA added at a concentration of lOOpgml'1. The solution was 
made on the day of use.
2.2.9.2 Radiolabelling of DNA probes.
2.2.9.2.1 Preparation of the DNA to be labelled.
The DNA fragment to be labelled was excised from the host plasmid using the 
appropriate restriction enzyme(s) and purified using Sephaglas® as described in section 
2.2.8.4.I. The amount of insert DNA was estimated spectrophotometrically.
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2.2.9.2.2 Random priming of dsDNA.
DNA fragments to be used as probes were labelled with 5’[a-32P]dCTP with the 
Megaprime™ DNA labelling kit using random nona-nucleotides to prime synthesis on 
denatured DNA. Approximately 25ng of DNA was made up to a volume of lOpl and 
5 pi of primer solution (random nona-nucleotides) was added. The solutions were mixed 
in a 1.5 ml microfuge tube and heated to 95 ° C for 5 minutes. The tube was put on ice 
and lOpl of buffer solution (dATP, dGTP, dTTP), 50pCi 5’[a-32P]dCTP, 2pl of enzyme 
solution (2U DNA polymerase 1 'Klenow* fragment) and 18pi of ddH20  were added. 
The tube was incubated at 37 °C for 10 minutes. The reaction was stopped by the 
addition of 5 pi of 0.5M EDTA and a further 45pl of ddH20 . lOOpg of denatured 
salmon sperm DNA was added as carrier DNA, and the probe precipitated with 2 
volumes of EtOH and 0.1 volume of NH4A c. After washing with 70% EtOH, the probe 
was resuspended in 250pl ddH20 , denatured by boiling for 5 minutes and used 
immediately.
Incorporation of radiolabel into probe was determined as described in Section 2.2.9.2.5.
2.2.9.2.3 Labelling of dsDNA by nick-translation.
Nick Translation buffer (lx): 50mM Tris-HCl pH 7.8, 5mM MgCl2, ImM DTT, 
5mgmr' BSA.
DNA was labelled with 5’[a-32P]dCTP and 5’[a-32P]dGTP by nick-translation using a 
method based on that of Rigby et al., (1977). 500ng of DNA probe was denatured by 
boiling and mixed with 20pCi of each labelled nucleotide, equal amounts of unlabelled 
dATP and dTTP, lp l DNasel (104 Uml'1) and 2U E. coli DNA polymerase I in lx nick 
translation buffer. The reaction was incubated at room temperature for 1 hour, and 
stopped by addition of 5pl of 1M EDTA. Separation of radiolabelled DNA from 
unincorporated radionucleotides was achieved by ethanol precipitation in the presence 
of carrier DNA.
2.2.9.2.4 End labelling.
This method was used to attach 5’[y-32P]dATP to the 5’-end of oligonucleotides. A 
reaction mix containing 100-200ng oligonucleotide in 5pi ddH20 , 2.5pi 1M Tris-HCl 
pH 7.6, 5pl 50mM MgCl2 and 2.5pl 200mM PME was prepared. Sterile stocks of all 
these solutions were stored at -200 C. 2pl T4 polynucleotide kinase (PNK) and 5 pi 5’[y- 
32P]dATP were added and the reaction incubated at 37 °C for 1 hour. The reaction
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mixture was then diluted to 200pl with TE and the incorporation of 32P label measured. 
The probe was denatured by boiling for 2 minutes, snap-cooled on ice, and was 
immediately added to the hybridisation reaction.
2.2.9.2.5 Measurement of the incorporation of radionucleotides into DNA probes.
lp l of the DNA probe mix was spotted onto each of two 2.5cm diameter filters of 
Whatman DEAE paper and dried under a heating lamp. 1 piece of DEAE paper was put 
into a scintillation vial and covered with 500pl of EcoScint® fluid. The other was 
washed twice for 3 minutes in 5% trichloroacetic acid (TCA) and once in acetone before 
drying under a lamp. The DEAE paper was put into a scintillation vial and covered with 
500pl EcoScint® fluid. The counts per minute (cpm) were counted in a scintillation 
counter. The unwashed DEAE paper gave total 32P cpm in lp l of probe mix and the 
washed DEAE paper gave the incorporated 32P counts. The percentage of radiolabel 
incorporated and the specific activity (cpmpg'1 probe) were calculated.
2.2.9.3 RNA Hybridisation.
2.2.9.3.1 Samples and gel electrophoresis.
RNA samples were prepared as described in Section 2.2.7.2, and electrophoresed on a 
denaturing gel as described in section 2.2.8.2.1.
2.2.9.3.2 RNA Transfer.
RNA was transferred to a Hybond-N™ nylon filter by capillary transfer (Alwine et al., 
1977). A ‘bridge’ was constructed over a tray containing 20x SSC and a strip of 3MM 
paper moistened in 20x SSC was laid across it as a ‘wick’. Two further layers of 3MM 
paper were placed on top of the wick and then the denaturing gel was laid on top. A 
nylon filter (pre-wetted in 20x SSC) of exactly the same size was placed on top of the 
gel, ensuring that no air bubbles were trapped between the gel and the filter. One piece 
of 3MM paper cut to the exact size was moistened in 20x SSC and carefully placed on 
top of the filter. Five more exact sized pieces of dry 3MM paper and approximately 
10cm height of absorbent paper towels were added. A gasket of polythene was put 
around the gel to prevent ‘short-circuiting’ of the 20xSSC around the gel. A weight of 
500g was placed on top of the stack of towels and the nucleic acid transferred overnight.
90
Chapter 2: Materials and Methods.
The apparatus was dismantled and the RNA was fixed to the Hybond-N™ membrane by 
UV-irradiation in a Stratalinker™ set to ‘Auto-crosslink’. The fixed blots were either 
prehybridised immediately or wrapped in clingfilm and stored wet at -200 C.
2.2.9.3.3 Hybridisation and washing.
RNA filters were prehybridised for at least 2 hours in 12.5ml pre-hybridisation solution, 
at 42 °C in glass hybridisation tubes. Denatured probe was added and hybridised 
overnight at 42 ° C in a hybridisation oven. The filter was washed twice with 2X SSC, 
0.1% SDS at room temperature for 10 minutes; then with IX SSC, 0.1% w/v SDS at 
65 0 C for 10 minutes. Control probed blots were further washed with 0.1X SSC, 0.1% 
w/v SDS at 65 ° C for 10 minutes. The filter was monitored at each washing step with a 
Geiger-Muller counter.
2.2.9.3.4 Autoradiography.
The hybridised filter was wrapped in clingfilm and exposed to pre-flashed X-OMAT S 
x-ray film in a cassette containing an intensifying screen at -70 °C, or to a 
phosphorimager screen. The film was developed in an X-omat processor model ME3. 
All procedures involving X-ray film were carried out in a darkroom under a safe-red 
light. Phosphorimager images were generally obtained after an overnight exposure.
2.2.9.3.5 Stripping filters of bound radioactive probe.
After hybridisation and autoradiography the bound probe was removed by pouring a 
boiling solution of 0.1% (w/v) SDS over the filter. The solution was then allowed to 
cool to room temperature, and the process was repeated a further two times. The filter 
was wrapped in cling film and exposed to a phosphorimager screen overnight to confirm 
removal of the bound probe. The continued presence of RNA on the filter after 
stripping could be confirmed by methylene blue staining as described below.
2.2.9.3.6 Staining of filter-bound RNA/DNA with methylene blue.
This method was described by Herrin and Schmidt (1988). The filter containing the 
bound RNA/DNA was placed in 0.04% methylene blue (w/v), 0.5 M NaOAc (pH 5.2) 
for 5 to 10 minutes. The filter was washed in DEPC-treated ddH20  until the RNA 
bands appeared as blue bands on a white background. The stain could be removed by 
washing the filter in 20% (v/v) acetic acid until the bands were no longer visible.
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2.2.10 BACTERIOLOGY AND MANIPULATION OF PLASMID DNA.
2.2.10.1 The amplification and purification of plasmid DNA.
2.2.10.1.1 Media and supplements.
All media were provided pre-sterilised by the Media department within the Institute of 
Virology, Glasgow unless otherwise stated.
Liquid media.
L-Broth (LB): 1% bacto-tryptone (w/v), 1% NaCl (w/v), 0.5% yeast extract (w/v), pH 
7.2. LB was sterilised by autoclaving and supplemented with the appropriate antibiotic 
for the culture of E. Coli strains.
2YT-broth (2YT): 0.5% NaCl, 1.6% bacto-tryptone, 1% yeast extract pH 7.2 in ddH20. 
Used for the preparation of competent E. coli XL 1-Blue (Stratagene, Cambridge, UK), 
JM101 and NM522 strains using the TSB method.
Solid media.
‘Bottom’ Agar (LB-A): L-broth containing 1.5% (w/v) bactoagar (Difco) was used for 
plating out E. coli and as the base agar for plating M l3 phage.
To make agar plates, LB-A was melted in a microwave and cooled to 50 °C. The 
appropriate antibiotic was added prior to pouring into sterile plastic petri dishes. Air 
bubbles at the surface of the agar were removed by brief flaming with a bunsen burner. 
The plates were allowed to set, dried at 37 ° C for 30 minutes and stored inverted at 4 ° C 
until needed (maximum 2 weeks). LB-A plates containing lOOpgml'1 ampicillin were 
termed LB-A(amp) plates.
Top Agar (TA): Top agar for use in plating M l3 phage was prepared by addition of 1% 
(w/v) bacto-agar and lOmM M gS04 to L-broth.
Antibiotics and selection agents.
Ampicillin (Amp). Ampicillin was dissolved in sterile ddH20  to a concentration of 100 
mgml'1. This stock solution was dispensed into 1ml aliquots and stored at -20°C. When 
required in LB-A(amp) plates or LB/ 2YT overnight cultures, stock ampicillin was 
diluted to a final concentration of lOOpgml'1.
Isopropyl thiogalactoside (IPTG). IPTG was made as a ImM stock in ddH20  and used 
at a final concentration of O.lmM. The stock solution was stored at -20 ° C.
92
Chapter 2: Materials and Methods.
5-bromo-4-chloro-3-indolyl /3-D-galactoside (X-Gal). X-Gal was made as a 20mgmr1 
stock in dimethylformamide (DMF) and used at a final concentration of SOpgml'1. The 
stock solution was stored at -20 ° C.
2.2.10.1.2 Solutions.
All the following solutions were made with molecular biology grade chemicals.
TE Buffer (10x):- lOOmM Tris-HCl pH 8.0, lOmM EDTA pH 8.0.
The solution was sterilised by autoclaving.
STE Buffer:- lOmM Tris-HCl pH 7.8, ImM EDTA pH 8.0, lOOmM NaCl.
The solution was checked to ensure that its pH was between 7.8 and 8.0 and then 
sterilised by autoclaving.
Lysis Buffer:- 25mM Tris-HCl pH 8.0, lOmM EDTA pH 8.0, 50mM Glucose.
The solution was made up aseptically and stored at 4 0 C.
Lysozyme Solution. Lysozyme solution was prepared on the day of use by dissolving 
lysozyme in lysis buffer to a final concentration of lbmgrnl'1.
Chloramphenicol Solution. Chloramphenicol was prepared as a 34mgml'1 solution in 
EtOH and stored at -20 ° C.
Ribonuclease A (RNase A). 200pgml'1 RNase A was added to a solution of lOmM 
Tris-HCl pH 7.5 and 15mM NaCl, boiled for 20 minutes then cooled to room 
temperature and stored in lOOpl aliquots at -20 ° C.
Ammonium Persulphate (APS). This was made as a 1% w/v APS solution in ddH20  
and stored at 4 ° C for a maximum of 2 weeks.
Potassium Acetate (KOAc). 5M KOAc pH 4.8 was made by addition of 11.5ml glacial 
acetic acid and 28.5ml sterile ddH20  to 60ml of sterile filtered 5M KAc solution. The 
resulting solution was inverted sharply, incubated on ice for 10 minutes and the pH of 
4.8 checked. This produced a solution that was 3M with respect to potassium (K) and 
5M with respect to acetate (OAc).
Ammonium Acetate (NHjOAc). NH4OAc was dissolved in ddH20 , the pH adjusted to 
4.0 with glacial acetic acid, and the volume adjusted to give a final concentration of 5M 
prior to filter sterilisation.
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Sodium Acetate (NaOAc). Anhydrous NaOAc was dissolved in ddH20  to produce a 
3M solution. The pH was adjusted with glacial acetic acid and the solution sterilised by 
filtration.
SDS Solution. SDS was added to sterile ddH20  to a final concentration 20% w/v. The 
solution was warmed to 650 C until the solid dissolved and stored at room temperature. 
If necessary the 20% SDS solution was warmed slightly to redissolve any precipitated 
solid before use.
Phenol/Chloroform (q/CHClj). This was made by mixing water saturated phenol with 
an equal volume of chloroform (24:1 with amyl-alcohol) and stored at -200 C. 
NaOH/SDS Solution. 10% w/v SDS and 2M sodium hydroxide solution (NaOH) were 
diluted in ddH20  to give final concentrations of 1% w/v SDS and 0.2M NaOH. This 
solution was prepared freshly on the day of use.
2.2.10.1.3 Bacterial strains and cloning vectors.
Plasmids were maintained and amplified in E. coli JM101 or NM522 which were also 
used for subsequent amplification and plating of isolated clones.
M l3 m pl9  was used for cloning PCR fragments and subsequent DNA sequencing, and 
was propagated in E. coli XL-1 Blue.
pBSKS-mAspAT: This plasmid is pBS-KS (Stratagene) containing the cDNA for rat 
mAspAT (Mattingley et al., 1987).
pCMVIO: A pUC derived plasmid which contains the HCMV major immediate early 
promotor and SV40 polyadenylation signal, and was used to express cloned DNA in 
eukaryotic cells. Obtained from Dr. N. Stow, Institute of Virology, Glasgow. 
pSV2Neo: A plasmid containing the gene conferring resistance to the antibiotic G418 
(Southern and Berg, 1982).
p x llr lR :  A plasmid containing the cDNA for X. Laevis 28S rRNA, used as a control 
probe in Northern blotting experiments. Obtained from Professor B.E.H. Maden, 
University of Liverpool, UK.
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2.2.10.1.4 Preparation of competent bacterial cells.
2.2.10.1.4.1 Calcium Chloride method.
Preparation.
100ml of L-broth was innoculated with 1ml of an overnight culture of E. coli JM101, 
XL-1 Blue or NM522 and incubated at 37° C to an optical density (O.D.) of 0.3-0.5 at 
630nm. The bacteria were pelleted at 3000rpm at 4°C for 10 minutes in a benchtop 
centrifuge, and the cells resuspended in 50ml of ice cold lOOmM CaCl2, for 2 hours. 
The bacteria were re-pelleted and resuspended in 1ml of lOOmM CaCl2. The cells were 
used within 1 hour.
Transformation.
This procedure was based on that described by Maniatis (1989). Up to 50ng of plasmid 
DNA was added to 200pl of competent bacteria in sterile 1.5ml ‘Eppendorf tubes and 
the sample mixed very gently. The tubes were incubated on ice for 30 minutes, and the 
bacteria heat shocked at 42 ° C for 2 minutes. 500pl of LB at 37 ° C was added, mixed 
gently and the tubes incubated for 45-60 minutes at 37 eC. 200pl of bacterial 
suspension was plated onto LB-A plates containing lOOpgml'1 ampicillin, spread with a 
sterile glass rod and left to dry for approximately 10 minutes. Plates were inverted and 
incubated overnight at 37 °C. Individual colonies present on the plates next day were 
streaked onto fresh LB-A plates with sterile toothpicks. These plates were incubated 
overnight at 37 °C and individual colonies from these plates used for plasmid DNA 
extraction.
2.2.10.1.4.2 TSB Method.
Transformation and Storage Buffer (TSB; Chung and Miller, 1988) was prepared by 
addition of sterile lOmM MgS04 and lOmM MgCl2, 10%(w/v) PEG 3300 and 5%(v/v) 
DMSO to L-broth. The solution was filter sterilised and stored at 4 0 C in 20ml aliquots. 
Preparation
A single colony of E. coli strain JM101, NM522 or XL-1 Blue was inoculated into 5ml 
of 2YT (without antibiotic) and grown up overnight at 37 ° C. 100ml of fresh 2YT broth 
was inoculated with 1ml of the overnight culture and was shaken at 37 °C for 
approximately 100 minutes (O.D.630 0.4 - 0.6). 50ml of this culture was transferred to a
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sterile 50ml Falcon™ tube. The cells were pelleted by centrifugation for 10 minutes at 
3000rpm at 4 0 C and the supernatant decanted. The cell pellet was resuspended in 5ml 
of ice-cold TSB and incubated on ice for 20 min. The cells were ready for 
transformation and could be kept on ice for a maximum of 2 hours without significant 
loss of transformation efficiency. Excess competent cells could be stored at -70 ° C with 
slightly diminished transformation efficiency.
Transformation.
A maximum of lpg of plasmid DNA or ligation mix was added to lOOpl of TSB- 
competent bacteria, mixed gently and incubated on ice for 30 minutes. 900pl of TSB 
containing 20mM glucose and 5% (v/v) DMSO was added and the mixture incubated at 
37 ° C with shaking for 1 hour. IOjliI and lOOpl of this mix was plated onto LB-A plates 
and incubated overnight.
2.2.10.2 Preparation of plasmid DNA.
2.2.10.2.1 Plasmid Isolation: ‘Mini-Prep9.
The method used is based on that of Bimboim and Doly (1979) as decribed by Maniatis 
(1989).
A single bacterial colony was used to inoculate 5ml of L-broth or 2YT containing 
ampicillin in a universal tube. The cultures were incubated overnight at 37 °C with 
vigorous shaking.
The next day 1.5 ml of the culture was centrifuged at 12,000g in a microcentrifuge at 
4°C for 30 seconds. The supernatant was carefully removed and the pellet was 
resuspended in lOOpl of ice-cold lysis buffer by vortexing. 200pl of a freshly prepared 
solution of 0.2M NaOH and 1% SDS was added to the resuspended pellet and mixed by 
gentle agitation. The lysate was stored on ice before the addition of 150pl ice-cold 3M 
KOAc (pH 4.8). The sample was mixed gently and incubated on ice for 5 minutes and 
then centrifuged at 12,000g for 5 minutes at 4°C. The supernatant was removed to a 
fresh microfuge tube and extracted twice with an equal volume of (p/CHCl3, and the 
upper aqueous layer transferred to new tubes. Plasmid DNA was precipitated with an 
equal volume of isopropanol at -200 C for at least 30 minutes. The plasmid DNA was 
pelleted by centrifugation at 13krpm at room temperature for 10 minutes. The 
supernatant was aspirated from the pellet, which was washed in 1ml 70% EtOH. The
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pellet was left to air dry for 10 minutes and the DNA resuspended in 50pl of TE 
containing 20pgmr1 of DNase-free RNase. Miniprep DNA was stored at -200 C.
2.2.10.2.2 Plasmid Isolation: QIAGEN® Midi-Prep.
The QIAGEN® midi plasmid isolation kit purifies up to lOOjig of pure super-coiled 
plasmid DNA by preferential binding to a resin following an alkaline lysis procedure 
(Bimboim and Doly, 1979). The method was as described in the handbook 
accompanying the kit and is described briefly below.
A single colony was inoculated into 5ml LB-amp and grown overnight, before addition 
of 1ml to 100ml L-broth containing lOOpgml'1 ampicillin. After overnight growth the 
bacterial cells were harvested by centrifugation.
The final yield was determined spectrophometrically and by analysis on an agarose gel 
with standard markers of known concentration. Samples taken during the purification 
procedure were also run on the gel to allow trouble-shooting if the purification was 
poor.
Buffer Composition Storage
PI lOOpgml'1 RNaseA, 50mM Tris-HCl, lOmM EDTA pH 8.0. 4 0 C
P2 200mM NaOH, 1 % SDS RT
P3 3M KAc, pH 5.5 4°C
QBT 750mM NaCl, 50mM MOPS, 15% EtOH,
0.15% Triton X-100, pH 7.0 RT
QC 1.0M NaCl, 50mM MOPS, 15% EtOH, pH 7.0 RT
QF 1.25M NaCl, 50mM Tris-HCl, 15% EtOH, pH 8.5 RT
TE lOmM Tris-HCl, ImM EDTA, pH 8.0 RT
STE lOOmM NaCl, lOmM Tris-HCl, ImM EDTA, pH 8.0 RT
Protocol. The bacterial pellet from a 100ml culture was resuspended in 4ml PI buffer. 
4ml P2 buffer was added, mixed by inversion and incubated at RT for 5 minutes. 4ml 
chilled P3 buffer was added and mixed by inversion prior to incubation on ice for 15 
minutes. The lysate was centrifuged at 30,000g for 30 minutes at 4°C, and the 
supernatant removed promptly. A 250pl sample was taken.
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A QIAGEN®-tip 100 was equilibrated with 4ml QBT buffer, allowing gravity flow to 
empty the column. The cleared lysate was added and allowed to enter the resin by 
gravity flow. A 250pl sample was taken.
The column was washed with 2x 10 ml QC buffer and a 500 pi sample taken, prior to 
elution of the plasmid DNA with 5ml of buffer QF. A lOOpl sample was taken for the 
analytical gel. The DNA was precipitated by addition of 3.5ml isopropanol at room 
temperature, and centrifuged immediately at 9000rpm in a Sorvall SM24 high speed 
rotor. The glassy pellet was rinsed with 5ml 70% EtOH, air dried, and resuspended in 
500pl TE pH 8.0 to a final concentration of approximately 200pgml'1.
For the analytical gel, each sample was precipitated with 0.7 volumes of isopropanol at 
room temperature, rinsed in 70% EtOH, and resuspended in 5pl TE pH 8.0. lpl of each 
was run on a 1% agarose gel with molecular weight markers and visualised by UV- 
illumination following staining with ethidium bromide.
2.2.10.3 Restriction Enzyme Digestion of DNA.
Plasmid DNA digests were performed in 0.5ml Eppendorfs for 1-2 hours at 37 °C. 
Digestion mixes contained 2U enzyme/pg DNA, 0.1 volumes of enzyme buffer, 0.1 
volumes RNase A (miniprep DNA samples only) and ddH20  to a total volume of lOpl. 
Digests performed to check plasmid identity used 0.5-1 pg DNA and for probe 
preparation used l-4pg DNA depending on the size of the inserted fragment. When two 
different restriction enzymes were used, the digestion was conducted simultaneously if 
the reaction buffers were compatible (in a volume large enough to dilute out the glycerol 
from the enzyme stock). However, if the buffers were not compatable, the DNA was 
digested with the first enzyme, precipitated and resuspended in the required buffer 
containing the second enzyme.
2.2.10.4 Ligation.
The vector backbone was linearised with the appropriate restriction enzyme and to 
prevent recircularisation 1U of calf intestinal phosphatase (CIP) was added to the 
reaction. The DNA insert was excised from the host plasmid with the required 
restriction enzymes, and both insert and vector were purified by agarose gel 
electrophoresis and Sephaglas® purification. The DNA fragments were precipitated 
with PEG 6000, and ligations set up containing ratios of vector:insert ranging from 1:3 
to 3:1. Ligations were carried out in a final volume of 20pl containing 2U T4 DNA
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ligase in ligation buffer (50mM Tris-HCl, lOmM MgCl2, ImM DTT, ImM ATP, 25% 
(w/v) PEG 6000, pH 7.8). Incubation was performed for a minimum of 2 hours at 16 ° C 
in a 0.5ml microfuge tube in a thermo-cycler.
2.2.11 REVERSE TRANSCRIPTASE-PCR.
2.2.11.1 Buffers.
5xR T buffer: 250mM Tris-HCl pH8.3, 375mM KC1, 15mM MgCl2
lOxPCR buffer: 670mM Tris-Cl pH 8.8, 67mM MgCl2, lJm grnl'1 BSA, 166mM
(NH4)2so 4
2.2.11.2 Protocol.
Amplification of mAspAT transcripts was achieved using a single tube to carry out both 
cDNA synthesis and the subsequent amplification procedure, based on a method 
described by Steinthorsdotir and Mautner, (1991). Briefly, 3-5pg of total RNA 
extracted from tissue culture cells as described above (Section 2.2.1.2) was mixed in a 
0.5ml Eppendorf® tube with 50pmol of 3’ primer (9302), lp l of dNTP mix (lOmmol of 
each), 2pl 5xRT buffer and sufficient ddH20  to make a final volume of 9.5pl. After 
incubation at 800 C for 1 minute and cooling to 370 C, 0.5pi MoMLV-RT (200UP11) 
was added and mixed, before incubation at 37 ° C for 30 minutes. The tube was placed 
on ice, before addition of 5pl lOx PCR buffer, 50pmol of 5’ primer (9301) and 33.5pi 
ddH20 . After mixing, the reaction mixture was overlaid with light mineral oil and 
heated to 94 °C for 2 minutes before addition of 0.5pl Taq DNA polymerase (5Upl ’) 
and incubation in a thermocycler as described below.
1. 94 °C 1 minutes Denaturation
2. 60 °C 1 minutes annealing
3. 72 °C 2 minutes extension
Cycle back to step 1 for 25- 40 cycles
4. 72 °C 10 minutes final extension
5. 4°C 00
The number of cycles of PCR amplification used varied. For production of double 
stranded cDNA for cloning 40 cycles were used. To analyse the relative level of RNA
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transcripts by semi quantitative RT-PCR (Results-Section 4.3) 20 cycles of 
amplification were used to ensure that the final yield of product was proportional to the 
initial input of mAspAT mRNA (Kang et al., 1995).
Each experiment contained negative and positive controls at the PCR stage. 200 ng of 
plasmid containing the mAspAT cDNA was included as the positive control, allowing 
identification of the correct sized product after agarose gel electrophoresis. The 
negative control contained all reagents except the RNA.
2.2.12 DIDEOXY DNA SEQUENCING.
DNA was sequenced using Sequenase Version 2.0 enzyme and kit obtained from 
United States Biochemicals (Ohio, USA).
2.2.12.1 Template preparation.
Phage precipitation solution: 3.75M ammonium acetate pH 7.5, 20% PEG 8000. 
Protocol. Single-stranded template DNA was prepared from M l3 phage as follows. A 
3ml overnight culture of E. coli XL-1 blue was innoculated with a single plaque of 
recombinant M l3. After incubation with shaking at 37 ° C for 6-8 hours, the cells were 
pelleted by centrifugation at 13krpm for 15 minutes. The supernatant was removed and 
centrifuged again, before addition of 0.25 volumes of phage precipitation solution on ice 
for 30 minutes. Phage were pelleted by centrifugation at 13krpm for 15 minutes, and 
resuspended in 400pl TE. The phage were extracted with an equal volume of 
chloroform:isoamyl alcohol, and then with cp/CHCl 3 until there was no material present 
at the interface. The DNA in the upper aqueous phase was precipitated with 2 volumes 
of EtOH and 0.5 volumes 7.5M ammonium acetate at -20 ° C for 30 minutes. The DNA 
was pelleted at 13krpm for 15 minutes, rinsed in 70% EtOH and resuspended in 20pl of 
ddH20.
2.2.12.2 Annealing of template and primer.
Reaction buffer: 0.2M Tris-HCl pH 7.5, 0.1M MgCl2, 0.25M NaCl.
The single stranded M l3 template DNA (lpg) was resuspended in 7 pi H20  and 2 pi 
reaction buffer and 1 pi (2.5 ng) of sequencing primer added. Annealing was 
accomplished by heating the sample to 65 0 C for 2 minutes, then cooling it slowly to 
room temperature. The tube was briefly centrifuged to collect the sample.
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2.2.12.3 Labelling and termination reactions.
Labelling mix 1.5 \iM dGTP, 1.5 pM dCTP, 1.5 pM dTTP 
Stop solution: 50% formamide (v/v)
To the annealed template-primer was added: 1 pi 0.1 M DTT, 2pi diluted labelling mix,
0.5pl (5pCi) [a-35S]dATP (lOOOCi mmol'1) and 2pl of diluted Sequenase® 2.0. The 
contents were mixed and incubated for 2-5 minutes at room temperature. Four rows of a 
microtitre plate were labelled A, C, G and T and 2.5pi of the appropriate termination 
mix added. The plate was prewarmed for 5-10 minutes at 37 ° C. On completion of the 
labelling reaction, 3.5 pi of the reaction mix was placed into each of the termination 
mixes. Termination reactions proceeded for 3-5 minutes at 37 ° C after which time 4 pi 
of stop solution was added. The plate was stored at -200 C prior to electrophoresis. 
Samples were denatured by heating to 75-80 ° C for 2 minutes before loading on the gel.
2.2.12.4 Sequencing gel electrophoresis.
Gels of dimension 20cm x 40cm x 0.4mm were prepared using Seqagel™ reagents (6% 
(w/v)acrylamide:bisacrylamide (38:2), 7M urea, lx  TBE), to give a final gel 
concentration of 6% acrylamide. The gels were pre-run for 20 minutes at a constant 
power of 100W before the samples were loaded. Gels were run for 2-2.5 hours at a 
constant power of 100W. After electrophoresis the gel plates were removed from the 
gel kit and separated. The gel was transferred onto Whatman 3MM paper directly and 
dried on a slab gel-drier at 80 °C for 1-1.5 h. Gels were autoradiographed overnight 
without intensifying screens at room temperature using Kodak Biomax MR film, and re­
exposed for a longer period of time if neccessary.
2.2.12.5 Sequence analysis.
DNA sequence was read by eye, and entered manually into a datadase using the SEQED 
sequence editor program of the GCG Wisconsin Package, Version 9.0. Subsequent 
analysis used the sequence alignment and editing programs from this same package.
2.2.13 TRANSFORMATION ASSAYS.
2.2.13.1 Growth in soft agar.
This assay is based on a method first described by Macpherson and Montagnier, 1964.
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2.2.13.1.1 Soft agar.
Noble 3.2% (w/v) agar was melted and stored at 48 °C, and added to tissue culture 
medium (as described below) pre-warmed to 45 ° C immediately prior to addition of the 
cells.
100ml Base agar (0.6%): 35ml ddH20 , 26.3ml 3.2% (w/v) noble agar, 13.3ml FCS, 
6.7ml TP broth, 2.7ml glutamine, 1.3ml Penicillin/streptomycin, 4.7ml sodium 
bicarbonate and 10ml of lOx DMEM.
100ml top agar (0.3%): as above except 48ml ddH20,13.2m l 3.2% (w/v) noble agar.
2.2.13.1.2 Protocol.
Plates (60mm) of NRK 536 cells lipofected with mAspAT expressing plasmid or a 
control plasmid overnight (Section 2.2.2.7.2) were washed twice with PBS-A, and 1ml 
of Trypsin/Versene added. Cells were collected and pelleted at lOOOrpm for 10 minutes 
at room temperature (Heraeus variable speed microfuge). The cells were resuspended in 
2ml of tissue culture medium, and vortexed to obtain a single cell suspension. 0.2ml 
and 0.4ml of cell suspension was put into labelled tubes, and 1.5ml of top agar added at 
45 0 C. The cells were mixed by inversion (with care being taken to avoid bubbles 
forming) and quickly poured onto a base agar plate. The plates were immediately 
transferred to a 37 °C incubator containing a tray of sterile ddH20  to humidify the 
atmosphere.
2.2.13.2 Loss of contact inhibition.
Cells were transfected and prepared as described above (Section 2.2.13.1.2), and 0.2ml 
or 0.4ml of the single cell suspension added to a 60mm tissue culture plate containing 
4ml of medium. The tissue culture medium was replaced every 2 days and the plates 
observed for the formation of piles of cells.
2.2.13.3 Tumourogenicity in nude mice.
Athymic nude mice were injected sub-cutaneously at the back of the neck with lx l0 6 
NRK 536 cells lipofected with plasmid as detailed above (Section 2.2.13.1.2). All live 
animal work was performed by Dr. J.C.M. Macnab, Institute of Virology, Glasgow. 
Assessment of tumour formation was performed by examination of the size of induced 
tumours by external examination of the sacrificed mice and excision of the tumours, and 
by a search for secondary tumours and metastases.
102
Results: Chapter 3
3. PURIFICATION OF THE 40kDa POLYPEPTIDE AND
PRODUCTION OF AN ANTISERUM.
3.1 INTRODUCTION.
Macnab et al. (1985) immunoprecipitated a set of polypeptides from the transformed 
Bn5T cell line with the sera of rats with tumours induced by injection of Bn5T cells. 
These polypeptides had molecular weights of 200kDa, 90kDa (doublet of U90 and 
L90), 40kDa and 32kDa. This set of polypeptides were also immunoprecipitated by 
antisera raised in rats and mice to HSV-2 infected cells (Hewitt et a l, 1991). 
However, the polypeptides were not immunoprecipitated from control RE cells.
A monoclonal antibody (TG7A) raised against the DNA binding proteins of HSV-2 
infected BHK C13 cells (Macnab et a l, 1985) immunoprecipitated a similar set of 
polypeptides from Bn5T but not RE cells. These polypeptides were transformation 
specific, and were also immunoprecipitated from rat cells transformed with Rous 
sarcoma virus or adenovirus 12 (Macnab et a l, 1985). This demonstrated that the 
polypeptides were transformation specific and not HSV encoded. These findings 
suggested that certain cellular polypeptides induced by HSV-2 infection were related 
to polypeptides expressed at increased levels in transformed cells, and that these 
polypeptides might therefore play a role in the transformation process.
The result of a similar experiment is shown in Figure 3.1. Mock infected, HSV-1 
and HSV-2 infected Bn5T and RE cell lysates labelled with [35S]-L-methionine were 
immunoprecipitated with a rat tumour bearing serum (TBS). The precipitated 
polypeptides were electrophoresed on a 9% SDS-PAGE gel and autoradiographed. 
The 90kDa polypeptide is labelled with a diamond and the 40kDa polypeptide with a 
filled rectangle on the gel. Neither the 40kDa (‘40’) or 90kDa (‘90’) polypeptides 
were visible in the mock infected RE track, but were induced by HSV infection 
(lanes 3 and 4). Both the ‘40’ and ‘90’ were present in all the transformed Bn5T 
samples (including the mock infected sample). In this experiment the L90 band was 
only just detectable in the TBS ip and Bn5T mock infected samples (lanes 5 and 8). 
The 200kDa polypeptide was detectable in all samples except the RE mock infected 
sample. These results are not consistent with those reported by Macnab et a l (1985) 
and Hewitt et a l (1991) where the 40kDa polypeptide was shown to be specific to
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Figure 3.1. Immunoprecipitation o f a 40kDa polypeptide from infected control 
and transformed cells (Phosphorimager image).
Bn5T
Legend. RE and Bn5T cells were infected overnight with HSV-1 strain 17 or HSV-2 strain 
HG52, or mock infected in tissue culture m edium  containing [35S]-L-methionine. Cells were 
lysed in RIPA buffer and im m unoprecipitated with a rat TBS (see M aterials and Methods). 
The im m unoprecipitated polypeptides were electrophoresed on a 9% SDS-PAGE gel with l4C- 
labeled m olecular weight markers (lane 1) and a control im m unoprecipitation (lane 8) provided 
by J-F. Lucasson which was known to produce a clear 40kD a band for com parison. The dried 
gel was exposed to a phosphorim ager screen overnight.
The ‘40’ and ‘90’ (m arked ■ and ♦  respectively) are not present in the mock infected RE 
sample (lane 2), but are induced in RE cells by infection with HSV-1 and HSV-2 (lanes 3 and 
4). (A faint band representing U90 may be present in the mock infected RE sample- (Grassie et 
al, 1993) see section 3.1). Both the ‘40’ and ‘90’ are present in mock infected and HSV 
infected Bn5T cells (lanes 5-7). The L90 is only ju st detectable in the TBS ip and Bn5T HSV-1 
tracks in this experim ent (lanes 8 and 6 respectively). A clearer im m unoprecipitation showing 
the full set o f  HSV induced polypeptides described by M acnab et al, (1985) is presented in 
Figure 3.4 (labelled TBS).
Results: Chapter 3
the transformed cell, and was induced by HSV infection. This may be due to 
variation in the RE cells or to the specific TBS used in this particular experiment. 
The quality of the TBS was previously noted to be variable (see below).
Grassie, (1993) raised an antiserum that was mono-specific for the U90 polypeptide, 
and used this to study in detail the biological properties of the U90 polypeptide. The 
induction of U90 by HSV was shown not to be dependent upon functional Vmwl75 
by infection with temperature sensitive mutants (tsK, tsD and tsT) and the deletion 
mutant (Inl411) viruses. This antiserum was also used to detect a homologue of U90 
in the control RE cells and demonstrate that this is increased in RE cells by HSV 
infection (a faint band is visible in the RE m.i. track in Figure 3.1). The increased 
level of the U90 detected in transformed cells compared to control RE cells was 
shown to be the result of the greatly extended half-life of the U90 polypeptide in the 
transformed cells (Grassie et al., 1993).
The purification and raising of a mono-specific antiserum to the 40kDa polypeptide 
would facilitate the characterisation, and possibly identification of this polypeptide. 
Tumour bearing sera, the only tool available at the time to study the 40kDa 
polypeptide were of variable quality and detected many polypeptides other than the 
40kDa polypeptide (for example, see figure 3.1, lane 4). The following work 
describes the purification of the 40kDa polypeptide, and an attempt to produce a 
mono-specific antiserum.
3.2 PURIFICATION OF THE 40kDa POLYPEPTIDE FROM Bn5T 
CELLS
The 40 kDa polypeptide was purified from Bn5T cells essentially as described by 
Lucasson (1992) and in Materials and Methods. Twenty plastic roller bottles (850 
cm2) of cells were grown at 37 °C until almost confluent, washed several times with 
PBS-A to remove contaminating serum proteins, and harvested using a sterile 
scraper. Cells were collected in a total volume of ice cold PBS-A of approximately 
200ml, and pelleted by centrifugation at lOOOg. 50ml of ice cold hypotonic lysis 
buffer (WF) was added and the pellet dispersed by gentle agitation. 5x107 cells 
labelled with [35S]-L-methionine were added at this stage to facilitate the subsequent 
identification of the 40kDa polypeptide. The cell suspension was homogenised with
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a dounce homogeniser, and sonicated. The solution was incubated on ice for 5 
minutes, prior to centrifugation at lOOOg to pellet cellular debris.
The clarified extract was then subjected to ammonium sulphate precipitation of the 
polypeptides by the gradual addition of solid ammonium sulphate to final 
concentrations of 30, 60 and 90% with stirring on ice. At each stage the precipitated 
polypeptides were collected by centrifugation at 30,000g at 4°C and stored on ice. 
The polypeptides precipitated at 90% saturation were resuspended in 2ml of 50mM 
Tris-HCl pH 8.0 and desalted using a PD-10 column.
The polypeptides were purified by FPLC, using a Mono-Q anion exchange column 
equilibrated with 50mM Tris-HCl buffer pH 8.0. The proteins were eluted using a 0- 
2M NaCl gradient in 50mM Tris-HCl. Figure 3.2 shows a typical FPLC trace from 
the MonoQ column, with the elution of polypeptides detected by absorbance at 
260nm. The increasing salt gradient is illustrated below the trace. The 40kDa 
polypeptide was known to elute from the column in the ‘flow-through’ volume 
(Lucasson, 1992), indicating that it did not bind to the anion exchange resin at pH 8.0 
in the Tris-HCl buffer used.
Fractions containing the protein peak from the ‘flow-through’ were desalted using a 
FastDesalt column on the FPLC into a buffer containing lOmM ammonium 
bicarbonate. This allowed the polypeptides in the fractions to be concentrated by 
lyophilisation in a vacuum dryer without increasing the salt concentration of the 
sample. Ammonia and carbon dioxide are given off during the lyophilisation 
process. The fractions were resuspended in a small amount of buffer before 
electrophoresis on a 9% SDS-PAGE gel. The gel was dried and exposed to a 
phosphorimager screen. Figure 3.3 shows the phosphorimager image of a 
preparative gel. An immunoprecipitation reaction with a tumour bearing serum 
known to produce a good 40kDa band (J-F. Lucasson, pers. comm.) was included on 
the gel to allow the 40kDa band in the FPLC fractions to be identified. Overlaying 
the phosphorimager image on the Coomassie Blue stained gel allowed the 40kDa 
polypeptide band to be excised from the dried gel with a sterile scalpel blade. The 
40kDa polypeptide is marked on the gel with an arrow. The majority of the 40kDa 
polypeptide eluted in fractions 3-7 from the MonoQ column.
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Figure 3.2. FPLC trace from MonoQ anion exchange column: 0- 2.0 M NaCl gradient.
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Legend. Polypeptides precipitated by 90% (NH4)2S 04 fractionation of a Bn5T cell 
lysatewere seperated by anion exchange chromatography on a 1ml MonoQ FPLC 
column. Samples were loaded in 1ml of 50mM Tris-HCl buffer at pH 8.0, and eluted 
from the column with an increasing gradient of NaCl. The salt gradient is illustrated 
below the trace. The ‘40’ was known to elute in the ‘flow-through’ from the column, 
and this peak is marked on the trace. The ‘40’ is therefore purified by the removal 
from the lysate of those polypeptides that bind to the column.
Vertical lines represent 1ml intervals. Absorbance at 260nm was used to detect 
polypeptides as they eluted from the column (FSD= 0.2).
Figure 3.3. Preparative SDS-PAGE gel for purification of the 40kDa polypeptide
t m q
Actin
MW 1 2 3 4 5 6 7 8 9 10 11 12 13 TBS ip
Legend. Fractions from the ‘flow -through’ (lanes 1-13) o f  an FPLC 
purification experim ent using a M onoQ column equilibrated at pH 8.0 in 
50mM Tris-HCL buffer were desalted and lyophilised. The fractions 
were resuspended in ddH 20 and electrophoresed on a 9% SDS-PAGE 
gel. A TBS ip known to produce a good ‘40 ’ band was included to 
facilitate the identification o f  the ‘4 0 ’ in the FPLC fractions. The 
radiolabelled polypeptides were detected using a phosphorim ager. The 
sizes o f  the l4C-labelled m olecular weight m arkers are shown at the left 
o f  the gel. The ‘4 0 ’ is present in fractions 3-10, and is labelled .
Actin and the ‘4 0 ’ are labelled in the TBS ip lane used to identify the 
40kDa polypeptide. The ‘4 0 ’ was excised from the SDS-PAGE gel by 
com parison with this phosphorim ager printout.
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3.3 IMMUNISATION OF A RABBIT WITH THE 40kDa POLYPEPTIDE 
AND TESTING OF ANTISERUM
The excised protein band containing the 40 kDa polypeptide was rehydrated, the 
paper backing removed and the polyacrylamide gel slice ground up in a small 
homogeniser. This suspension was mixed with Freunds incomplete adjuvant and 
injected into a rabbit by Dr. J.C.M. Macnab, Institute of Virology, Glasgow. Booster 
injections were initially given at 2 week intervals, but the animal did not produce a 
significant antibody response. Further booster injections were given over a period of 
6 months. In western blotting experiments with whole cell lysate from HSV-2 
infected Bn5T cells, this antiserum failed to detect the 40kDa polypeptide (data not 
shown), even when enhanced chemiluminescence detection reagents were used.
The rabbit was sacrificed after 6 months, and the serum collected. This serum (92A) 
was tested in immunoprecipitation assays to determine whether antibody to the 
40kDa polypeptide had been induced. Between 10 and 95pi of serum 92A were 
included in standard immunoprecipitation assays as described in Materials and 
Methods. Pre-immune control immunoprecipitations, and a TBS 
immunoprecipitation known to produce a good 40kDa band (J-F. Lucasson, pers. 
comm.) were included on a 9% SDS-PAGE gel. Figure 3.4 shows the 
phosphorimager image of this experiment. The 40kDa polypeptide is clearly visible 
in the TBS immunoprecipitation track (labelled with a star in lane 2), as are the 
200kDa, U90 and L90 and 32kDa polypeptides previously identified in Bn5T cells 
and increased by HSV-2 infection (Macnab et a l , 1985). All are labelled as 
described in the legend to Figure 3.4. A faint, diffuse band of the same molecular 
weight as the 40kDa polypeptide is present in the 92A immunoprecipitations (lanes 
3-5, 7) but this is also present in the pre-immune serum (lanes 6 and 8). The only 
polypeptide detected in the 92A immunoprecipitations that is not present in the pre- 
immune reactions is a 67kDa polypeptide (labelled with a fat arrow in lanes 5 and 7). 
This band is also present in the TBS i.p. track (lane 2). This polypeptide remains 
unidentified, but as this was a denaturing gel it is unlikely to be a dimer of the 40kDa 
polypeptide. It appears that no specific antibody to the 40kDa polypeptide was 
induced in this animal. Indirect immunofluorescence experiments using this 
antiserum displayed diffuse fluorescence at the cell surface but this was not
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Figure 3.4. Immunoprecipitations to test the rabbit antiserum 92A raised 
against purified 40kDa polypeptide
92A PI 92A PI
MW TBS 'lOpl 20^1 30pl 30pl 95pl 95pl lysate
Legend. 4 x l0 6 cpm o f [ a 35S]-L-methionine labelled polypeptides were im m unoprecipitated 
from a Bn5T cell lysate with a TBS which produces a good ‘40’ band, the rabbit antiserum 
raised against the ‘4 0 ’ purified as described in sections 3.2 and 3.3 (92A), or pre-immune 
serum (PI). ECL m olecular weight markers are shown to the left o f  the gel. The lysate lane 
contains 1 pi o f the Bn5T lysate used in the im m unoprecipitations. The volume o f  antiserum 
used in each im m unoprecipitation with 5pl o f  lysate in a total volume o f lOOpl is indicated 
above the lanes. The ‘4 0 ’ is marked with a star in the TBS ip lane, and a diffuse faint band is 
present at this position in all o f  the samples, including the pre-im m une serum reactions. The 
only polypeptide that is detected by the 92A serum that is absent in the pre-im m une serum 
lane is o f  approxim ately 67kDa, and is labelled with a ‘fat’ arrow. In the TBS ip lane the 
group o f polypeptides identified by M acnab et al, (1985) (see section 3.1) are labelled as 
described in the key below.
•  200 L90 ■ Actin
♦ U90 unknown ★  ‘40’
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significantly different to the result obtained with the pre-immune serum (Dr. J.C.M. 
Macnab, pers. comm.).
3.4 DISCUSSION
The 40kDa polypeptide was partially purified from infected Bn5T cells by 
ammonium sulphate fractionation and anion exchange chromatography as described 
by Lucasson (1992) (Section 3.2). The purification obtained was fairly crude, but all 
polypeptides that bound to the MonoQ column were removed from the sample. 
However, the purification was sufficient to allow the separation of the 40kDa 
polypeptide from contaminating polypeptides (displayed in Figure 3.3). The 40kDa 
polypeptide was excised from the 9% SDS-PAGE gel. Lucasson (1992) included a 
further ion exchange purification step, but although the degree of purification was 
greater, the overall yield of the 40kDa polypeptide was somewhat reduced. 
Experiments to further purify the 40kDa from the ‘flow-through’ fractions were 
performed using a heparin affinity chromatography column on the FPLC. The same 
buffers used with the MonoQ column were used. The FPLC trace in Figure 3.5 
shows the elution profile of polypeptides from the heparin column eluted with a 0- 
2.0M NaCl gradient. Two peaks were observed - a ‘flow-through’ peak of proteins 
which did not bind to the column, and a second broad peak eluting at 0-0.4M NaCl. 
The 40kDa polypeptide eluted in the ‘flow-through’ peak, but the purification 
obtained was not sufficient to overcome the reduced recovery of the 40kDa 
polypeptides as a result of the extra step (data not shown).
The 40kDa polypeptide purified from the MonoQ column and excised from a SDS- 
PAGE gel was therefore used to immunise a rabbit. A similar method of producing 
an immunogen had been successfully used in this laboratory to raise a mono-specific 
antibody to the U90 polypeptide immunoprecipitated from transformed cells 
(Macnab et al., 1985; Grassie, 1993; Grassie et a l, 1993). However, as described 
above {Section 3.3), there was no significant antibody response detected by 
immunoprecipitation {Figure 3.4), Western blotting or immunofluorescence 
experiments (data not shown). The lack of reaction in immunoprecipitation 
experiments could be explained because the immunogen consisted of denatured 
polypeptide, and conformational epitopes from the native polypeptide would 
therefore not be displayed. The negative Western blotting results could not however
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Figure 3.5. FPLC trace from Heparin affinity chromatography column
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Legend. The polypeptides purified from the ‘flow-through’ of the MonoQ column 
described in Section 3.2 (Figure 3.2) were pooled and concentrated in a ‘speedivac’ prior 
to loading on a 1ml Heparin affinity chromatography column. The column was 
equilibrated in 50mM Tris-HCl pH 8.0, and polypeptides were eluted with a salt gradient 
as illustrated below the trace. The ‘40’ eluted in the flow through of the column at pH 
8.0, indicating that it did not bind to heparin under the experimental conditions used. The 
second peak represents polypeptides that bound to the column. The additional 
purification of the ‘40’ obtained from this column was minimal.
Vertical lines represent 1ml volume intervals. Absorbance at 260nm was used to detect 
the eluted polypeptides (FSD= 0.2).
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be explained in this way. Lucasson (1992) attempted to raise an antiserum in rabbit 
using 40kDa polypeptide from a second ion exchange experiment at pH 9.5. This 
also failed to elicit an immune response. Why the 40kDa polypeptide purified from a 
transformed rat cell line should fail to induce an immune response in rabbit is 
unclear. The 40kDa polypeptide could be highly conserved between species, or may 
have an intrinsically low immunogenicity. Furthermore, the amount of polypeptide 
in the immunogen was quite low, as the 40kDa polypeptide has a low abundance 
even in HSV infected Bn5T cells. Alternative adjuvant and immunisation regimes 
may have elicited an immune response, but these were not tested for reasons detailed 
in the following paragraph.
During the process of this work, the 40kDa polypeptide was identified as a form of 
mitochondrial aspartate aminotransferase by internal peptide sequence analysis and 
immunological characterisation (Lucasson, 1992). A mono-specific antiserum to 
mAspAT was available (Mattingley et al., 1987), and a polyclonal rabbit antiserum 
was produced by Dr. J.C.M. Macnab using immunogen provided by Mattingley 
(University of Missouri). This serum immunoprecipitated the 40kDa polypeptide 
(Lucasson, 1992), and therefore no further attempt was made to produce an antiserum 
to the 40kDa polypeptide purified from Bn5T cells. The ease with which a rabbit 
antiserum was raised against bacterially expressed rat mitochondrial aspartate 
aminotransferase suggests that the immunogen purified from Bn5T cells above 
(Section 3.2) was of low abundance and/or of poor quality.
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4 THE EFFECT OF HSV-2 INFECTION ON THE STEADY- 
STATE LEVEL OF mAspAT mRNA IN A TRANSFORMED CELL 
LINE.
4.1 INTRODUCTION
Lucasson et al. (1994) identified the 40kDa polypeptide which is increased in tumour 
cells by infection with HSV-2 (Macnab et a l , 1985) as a form of mitochondrial 
aspartate aminotransferase (EC 2.6.1.1). We reported a fourfold increase in the level 
of mAspAT polypeptide present in Bn5T cells following infection with HSV-2 
(Lucasson, 1992; Lucasson et al, 1994) determined by slot-blot immunoblotting 
with two different antisera raised against mAspAT (Mattingley et a l, 1987). Further 
experiments investigating the effect of HSV-2 infection of Bn5T cells on the 
mAspAT enzyme activity (for a fixed amount of total cellular protein) showed a 
mean increase in the activity of 2.5 fold compared to control Bn5T cells over 3 
determinations (Lucasson et a l , 1994).
These results could arise from altered control of protein synthesis and processing, or 
by alterations in the stability of the polypeptide molecule. Specific stabilisation of a 
polypeptide molecule has been observed in HSV transformed cells. The U90 
member of the group of polypeptides that are increased in tumour cells (Macnab et 
a l, 1985) has an increased half life in transformed cells (13 hours compared to 33 
minutes in control cells) (Grassie et a l, 1993).
An increase in the steady-state level of mAspAT mRNA following HSV-2 infection 
of the transformed Bn5T cell line could also lead to an increase in the absolute 
amount of protein present, independently of direct effects at the protein level. This 
could occur by transcriptional activation of the mAspAT gene, as has been reported 
for the HSV-2 induced TI56 protein (Patel et a l, 1986; Kemp and Latchman, 1988). 
Possible mechanisms include the activation of upstream regulatory sequences by 
HSV-2 transactivation factors, or the activation of previously hidden promotor 
elements. Alternatively, the mAspAT mRNA could be preferentially stabilised 
following HSV-2 infection. This would contrast the UL41 (vhs) mediated 
destabilisation of most host cell and viral mRNA that normally accompanies 
infection (Kwong et a l, 1987; Oroskar & Read, 1989), although it should be noted 
that the HG52 strain of HSV-2 used in the following work has an inactive vhs
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function (Everett and Fenwick, 1990). Both of these mechanisms would lead to an 
accumulation of mAspAT mRNA.
Preliminary Northern blotting experiments suggested that there was an increase in the 
steady state level of the mAspAT mRNA in transformed cells after infection with 
HSV-2. Further investigation of this possibility is described below.
4.2 SLOT-BLOT AND NORTHERN BLOT EXPERIMENTS TO ANALYSE 
THE EFFECT OF HSV-2 INFECTION ON THE STEADY STATE LEVEL 
OF mAspAT RNA IN THE Bn5T TRANSFORMED CELL LINE.
4.2.1 Northern blotting
Northern blotting experiments were performed using total cellular RNA from Bn5T 
cells infected with 10 pfu/cell HSV-2 for 17 hours at 37° C, or from mock infected 
Bn5T cells. An adaptation of the single step acid guanidinium thiocyanate-phenol- 
chloroform extraction procedure of Chomczynski and Sacchi (1987) (described in 
Materials and Methods) was used. Equal quantities of total RNA (determined 
spectrophotometrically as described in Materials and Methods ) were loaded onto a 
30cm long 1.5% agarose-formaldehyde gel and electrophoresed until the 
bromophenol blue dye was near the end of the gel. The gel was rinsed in ddH20  and 
blotted by capillary transfer as described in Materials and Methods. The transferred 
nucleic acid was fixed to the Hybond-N™ membrane by UV-irradiation in a 
Stratalinker™. lp l of a synthetic RNA ladder (Gibco BRL) was run on a track 
alongside the RNA samples to facilitate a) an estimation of the size of the mAspAT 
transcript detected and b) analysis of the integrity of the RNA following fixation to 
the membrane by methylene blue staining as described in Materials and Methods.
4.2.2 mAspAT cDNA probe labelling
The blots were initially hybridised with a 2.3kb mAspAT cDNA probe. This probe 
was purified by gel electrophoresis following excision from either pBS-KS-mAspAT 
(Mattingley et al, 1987) or pCMV-mAspATl (see Chapter 6, Section 6.2) by 
digestion with EcoRI. The probe was labelled to high specific activity (>2xl 08 
cpm/pg) by nick translation, or using the Megaprime™ random priming kit 
(Amersham International), as described in Materials and Methods. A control strip 
containing dots of denatured mAspAT cDNA insert, ranging from 60ng to 0.6pg
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fixed to Hybond-N™ membrane was included in each hybridisation experiment to 
determine the effectiveness of the hybridisation procedure.
4.2.3 Optimisation of washing protocol
The washing protocol following hybridisation with the mAspAT probes was 
optimised by checking the counts remaining on the blot with a Geiger-Muller counter 
after washes of increasing stringency. It was noted that washing at a stringency 
greater than lx  SSC, 65 °C, for 30 minutes caused the counts retained on the blot to 
fall to a level indistinguishable from background. A long exposure to the 
phosphorimager screen was required to detect any bound probe. Final washing of 
blots probed with the mAspAT probes was therefore restricted to a maximum 
stringency of lx SSC at 65 °C for 30 minutes. Blots were wrapped in cling film and 
exposed to the phosphorimager screen overnight at room temperature.
Following analysis of the overnight exposure, blots were stripped by three washes 
with 1 litre of boiling 1% SDS(w/v) solution and checked to ensure complete 
stripping by exposure to the phosphorimager screen. If stripping was complete the 
blots were re-hybridised with a control probe.
4.2.4 Probing with a control probe
The control probes used to normalise the amount of RNA loaded in each track of the 
Northern blotting experiments were either a y-actin cDNA (Leader et al., 1985), or an 
X. laevis 28S rDNA clone in plasmid pXl lrlR  (Maden et al, 1987). The level of y- 
actin had previously been shown to be unaffected by HSV-2 infection in rat 
fibroblasts (Dr. J.C.M. Macnab, pers. comm.) and MCF-7 cells (Offord et al., 1989). 
The 28S rRNA has been widely used as a control in Northern blotting experiments. 
As a major constituent of cellular RNA the 28S rRNA levels have been shown to be 
generally unaffected by cellular differentiation or proliferation (Barbu & Dautry, 
1989).
4.2.5 Calculation of the relative increase of mAspAT mRNA levels
All Northern and slot-blot experiments were analysed using a Phosphorimager 
(Molecular Dynamics Inc., running ImageQuant™ (Version 1) software). The 
number of counts detected in each RNA sample when probed with the mAspAT 
cDNA was measured and compared to the number of counts detected in each sample
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when probed with the one of the control probes. This allowed a correction to be 
made for errors which may have occurred whilst preparing and loading the RNA 
samples. The calculation is described by the following equation, and was performed 
on samples from mock infected and HSV-2 infected Bn5T cells.
counts with mAspAT probe . . ,------------------------------------ = ratio of counts fo r  RNA sample
counts with control probe
The ratio obtained from the mock infected Bn5T cell RNA samples was then 
compared to the ratio obtained from the HSV infected samples. This allowed the 
overall relative increase in the level of mAspAT mRNA following HSV-2 infection 
to be calculated.
These calculations are illustrated in the sample calculation shown in Figure 4.1 and 
described in section 4.2.6 below.
4.2.6 Representative calculation of altered mAspAT mRNA levels.
Figure 4.1 presents the raw data obtained from the phosphorimager and a 
representative calculation of the altered level of mAspAT mRNA following HSV-2 
infection. The actual image of the Northern blot used in this calculation is presented 
in Figure 4.2. Bn5T cells were infected with 10 pfu/cell of HSV-2 for 17 hours. 
40pg of total RNA from mock infected Bn5T cells and from Bn5T cells infected 
with HSV-2 was electrophoresed on a 1.5% agarose-formaldehyde gel, transferred to 
Hybond-N™ and probed sequentially with mAspAT and y-Actin probes as described 
in Sections 4.2.1-4.2.4 above.
Panel A shows the results obtained when this blot was probed with the mAspAT 
cDNA. The ratio of counts in the HSV-2 infected track compared to the mock 
infected sample is 5.85 or 4.43, depending on the method used to delineate the 
boundary of the samples. Both a grid and free-drawn rectangles were used to 
delineate the area to be examined. This reduces the errors introduced by the 
positioning of the regions to be counted for analysis with the ImageQuant™ 
software. Combination of these results gives a mean 5.14 fold relative increase in the 
counts in the HSV-2 infected sample compared to the mock infected track 
Panel B shows results for the same blot probed with the control y-Actin probe. In 
this experiment the mean result was a 2.04 fold increase in the counts in the HSV-2 
infected track compared to the control track. This result most likely represents a
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Figure 4.1. Comparison of steady-state level of mAspAT mRNA in Bn5T cells 
before and after infection with HSV-2. Analysis of data from Northern blot 
illustrated in Figure 4.2A.
Panel A
mAspAT probed blot- phosphorimager results (Rectangles)
Sample counts detected % of counts Ratio HSV /mock
Bn5T 2308 14.6 5.85 (A)
Bn5T HSV-2 13505 85.4
mAspAT probed blot- phosphorimager results (Grid)
Sample counts detected % of counts Ratio HSV /mock
Bn5T 3566 5.63 4.43 (B)
Bn5T HSV-2 15798 24.93
Mean ratio of counts in HSV-2/mock infected samples = 5.14x (Cl1
Panel B
y-Actin probed blot- phosphorimager results (Rectangles)
Sample counts detected % of counts Ratio HSV /mock
Bn5T 90565 21.93 2.03 (D)
Bn5T HSV-2 184728 44.73
y-Actin probed blot- phosphorimager results (Grid)
Sample counts detected % of counts Ratio HSV /mock
Bn5T 86523 32.7 2.05 (E)
Bn5T HSV-2 178185 67.3
Mean ratio of y-Actin counts in HSV-2/mock samples = 2.04 (FI2
Overall Result3
Increase of mAspAT mRNA relative y-Actin observed following infection of Bn5T
cells with HSV-2 = 2.52x
Calculations
1 C= ((A+B)/2)
2 F= ((D+E)/2)
3 = (C/F)
Figure 4.2. Northern blot and slot blot experiments with HSV-2 infected Bn5T cell 
RNA reprobed with a y-Actin cDNA probe after hybridisation with a mAspAT probe.
A) mAspAT cDNA probe
y-Actin cDNA probe
2.3Kb
2.1Kb
mAspAT probe y-Actin cDNA probe
B)
CH
2.5
1.25
0.625
0.312
CH
ftg
total
RNA
Legend. Panel A shows a Northern blot o f  40jig o f  total RNA from mock infected (C) and 
HSV-2 infected (H) from Bn5T cells. The top phosphorimager image was obtained when the 
blot was probed with a mAspAT probe, and the lower image following reprobing with a y- 
Actin probe. A single transcript was detected with each probe. The calculated increase in the 
relative level o f  mAspAT following HSV-2 infection was 2.52 fold. (Experiment 2 in Table 
4.1). Panel B shows a slot blot o f similar mock infected or HSV-2 infected RNA, probed with 
the same probes. The samples containing 20-1.25pg o f  total RNA were analysed with the 
phosphorimager and showed a mean relative increase over all samples o f  1.49 fold 
(Experiment 3 in Table 4.1).
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loading or sample preparation error. Approximately twice as much total RNA (as 
detected by the level of y-Actin) was present in the HSV-2 infected Bn5T cell sample 
than in the mock infected sample in this particular experiment. This is despite the 
RNA being quantitated spectrophotometrically prior to denaturation and 
electrophoresis.
By dividing the HSV-2 infected counts/mock infected counts ratio calculated in 
Panel A by the ratio obtained in Panel B, the alteration in the level of mAspAT 
mRNA was corrected for the loading variations which were detected on the y-Actin 
probed blot. The overall result (see footnotes to Figure 4.1 for a summary of the 
calculations performed) is a 2.52 fold increase in the steady state level of mAspAT 
mRNA in Bn5T cells after infection with HSV2.
4.2.7 Increased mAspAT mRNA levels - cumulative results.
A total of eight experiments were performed to confirm the increase in the steady 
state level of mAspAT mRNA previously reported in Figures 4.1 and 4.2. These 
results are presented in Table 4.1. Each experiment showed an increase in the 
mAspAT mRNA level relative to the y-actin or 28S rRNA controls following 
infection with HSV-2. However, there was a range of 1.07 to 2.69 in the increase of 
mAspAT mRNA observed. Statistical analysis of these results using the ‘descriptive 
statistics’ function of Microsoft Excel® 5.0 calculated a mean value of 1.748 for the 
increase in the mAspAT mRNA following infection of Bn5T cells with HSV-2. The 
standard error was calculated as 0.255 (14.5%). An example of an RNA slot blot 
(Figure 4.2B) reprobed with a y-Actin probe, and a Northern blot (Figure 4.3) 
reprobed with a 28S rRNA probe are shown. The results of these experiments are 
presented in Table 4.1 (experiments 3 and 7 respectively). A single 2.3kb transcript 
is detected in the mAspAT probed blot of Figure 4.3 (labelled in Panel B), which 
validates the results from the slot-blot experiments.
4.3 SEMI-QUANTITATIVE RT-PCR TO EXAMINE THE ALTERED 
LEVEL OF mAspAT mRNA IN HSV-2 INFECTED Bn5T CELLS.
Further experiments were performed to confirm the increase in the level of mAspAT
mRNA following HSV-2 infection which was observed in the Northern blotting 
experiments described in Section 4.2. A semi-quantitative reverse transcriptase 
polymerase chain reaction (RT-PCR) method was used to assess the amount of
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Table 4.1. The effect of HSV-2 infection on the relative level of mAspAT mRNA 
in Bn5T cells. Cumulative results of eight experiments.
A) Ratio of increases in mAspAT mRNA observed in eight experiments
Experiment Increase in mAspAT mRNA^ Notes
1 8/12/92 2.69 Northern
2 16/12/92 2.52 Northern
3 12/01/93 1.49 Slot-blot- mean of 5 results
4 12/01/93 1.07 Northern-mean of 2 results
5 16/01/93 1.17 Northern-mean of 2 results
6 23/02/93 1.19 Northern
7 8/03/93 1.26 Northern-mean of 2 results
8 12/05/93 2.60 Slot-blot- mean of 5 results
B) Statistical Analysis of the results from eight experiments^
Mean 1.748
Standard Error 0.254
Mean overall increase in the relative level of mAspAT mRNA following HSV-2
infection of Bn5T cells
1.748 +/- 0.25
Legend. The results o f eight separate Northern blotting and slot-blot experiments to determine the 
effect o f HSV-2 infection on the level o f mAspAT mRNA relative to an internal control mRNA are 
presented in Section A. In each experiment Bn5T cells were infected with lOpfu/cell o f HSV-2 
HG52 or were mock infected overnight. Total cellular RNA was extracted and Northern blotted as 
described in Materials and Methods. The number o f separate samples analysed in each experiment 
are displayed in the ‘Notes’ section.
In section B the results presented in Section A were subjected to statistical analysis using Microsoft 
Excel. The mean and calculated standard error o f the mean are presented.
The images o f a Northern blot (experiment 2) and slot blot (experiment 3) reprobed with a y-Actin 
probe are shown in Figures 4.2A and 4.2B. The image o f a Northern blot reprobed with the 28S 
rRNA probe (experiment 7) is shown in Figure 4.3.
(A) Results calculated relative to internal control as described in Figure 4.1
/Dl
Calculated using MS Excel ‘descriptive statistics’ package
Figure 4.3. Northern blot to show increase in the level of mAspAT RNA 
(relative to 28S rRNA) following infection of Bn5T cells with HSV-2.
A) 28S rRNA Probe B) mAspAT Probe
20pg 40 pg 20pg 40pg
C H c  h |m w C H c  h |
28S rRNA
mAspAT
Legend. Total RNA was extracted from Bn5T cells which had been mock infected (C) or infected 
with 10 pfu/cell o f  HSV-2 HG52 (H) overnight. 20pg and 40pg were electrophoresed on a 1.5% 
formaldehyde-agarose gel and transferred to Hybond-N membrane. Panel B shows the 
phosphorimager image o f  the blot probed with the mAspAT probe. A single transcript o f  2.3 kb is 
observed (co-migrating with the molecular weight marker marked to the left o f  panel A). Panel A 
shows this same blot reprobed with a 28S rRNA probe. Again a single band is detected, although the 
background is somewhat higher. The amount o f  radiolabel in both the 20pg and 40pg tracks was 
analysed with the phosphorimager software and showed a mean increase in the level o f  mAspAT 
mRNA in infected cells o f  1.26 fold Experiment 7 in Table 4.1).
The presence o f  a single transcript in the mAspAT probed blot in this gel confirms the validity o f  the 
slot blot results illustrated in Figure 4.2 and Table 4.1.
The molecular weight markers were a synthetic RNA ladder (0.24-9.5kb, Gibco BRL) which 
fortuitously reacted with both o f  these probes, allowing direct visualisation o f  the size o f  the detected 
transcripts.
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mAspAT mRNA present in samples of total RNA from HSV-2 infected and mock 
infected Bn5T cells.
Oligonucleotide primers were synthesised to the 5’ and 3’ ends of the mAspAT 
cDNA clone sequenced by Mattingley et a l (1987), and are illustrated in Figure 4.4. 
Primer 9301 (5’ end) represents nucleotides 29-51 of the published sequence, 
upstream of the ATG initiation codon. Primer 9302 (3’ end) represents nucleotides 
1431-1450, downstream of the mAspAT stop codon within the long 3’ untranslated 
region. The 9302 primer was used to prime cDNA synthesis in the RT reaction. To 
maintain the PCR reaction within the linear portion of the amplification curve (Kang 
et a l , 1995) a maximum of 20 cycles of PCR were performed following cDNA 
synthesis. The amount of total RNA added (3pg) to the reverse-transcriptase 
reaction was limited relative to the amount of primers, Taq DNA polymerase and 
deoxynucleotides included in the subsequent PCR reaction to ensure the linear phase 
of the amplification reaction was maintained (Kidd & Ruano, 1995).
The results presented in Table 4.2 were obtained from two separate RT-PCR 
experiments in which the primer 9302 was end-labelled with 5’[y2P]-dATP using T4 
polynucleotide kinase as described in Materials and Methods. This facilitated the 
quantification of the PCR product by agarose gel electrophoresis of an equal volume 
of each sample.
In the top rows of Table 4.2, the results were obtained by phosphorimager analysis of 
the 1.4kbp product on a dried 1% agarose gel. The results show an approximate two­
fold (1.967x) increase in the amount of radiolabel incorporated into the major PCR 
product in the HSV-2 infected Bn5T RNA track compared to the mock infected 
track.
The RT-PCR experiment was repeated, and equal volumes of the labelled PCR 
reaction mix from the HSV-2 infected and mock infected Bn5T RNA samples were 
electrophoresed on a 1% agarose gel. The major band (1.4kbp) was visualised by 
ethidium bromide staining and short wave UV illumination of the gel. The 1.4kbp 
product was excised from each track of the gel and added to a scintillation vial 
containing 5ml of Ecoscint™. The results from the scintillation counter are 
presented in the bottom rows of Table 4.2. These results again show a two-fold 
increase (2.01x) in the number of counts in the HSV-2 infected sample compared to
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Figure 4.4. Oligonucleotide primers used in semi-quantitative RT-PCR experiments 
to determine the relative level of mAspAT mRNA in Bn5T cell samples.
9301- 5’ primer, nucleotides 29-51
5’ TCAGCGGACGCTTCCCCTGATCT 3’ 
(23-mer)
9302- 3’ primer, nucleotides 1431-1450 
5’ TCATGAGAGTCACGTGCAGG 3’
(20-mer)
Legend. Sequence of the oligonucleotide primers used in the semi-quantitative RT-PCR experiments 
to determine the effect of HSV-2 infection on the level of mAspAT mRNA in the transformed Bn5T 
cell line. The primers were designed using the published sequence of rat mAspAT cDNA and the 
nucleotide positions within the sequence are shown (Mattingley et al., 1987). Primer 9302 is 
complementary and reversed with respect to the published sequence, and was used to prime the 
reverse transcriptase reaction.
Table 4.2. RT-PCR analysis of mAspAT mRNA levels
SAMPLE COUNTS
INCORPORATED
RATIO
HSV/CONTROL
DETECTION
METHOD
Mock Infected Bn5T RNA 
Bn5T HSV-2 RNA
5935
11676
1.967 Phosphorimager
Mock Infected Bn5T RNA 
Bn5T HSV-2 RNA
29562
59452
2.011 Scintillation
counter
Legend. The number of counts in equal volumes of RT-PCR reaction mixtures from HSV-2 and 
mock infected Bn5T cells allowed a calculation of the increase in mAspAT mRNA levels. The 
increases observed in these experiments are consistent with those presented in Table 4.1.
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the mock infected sample. These results are combined with those from the Northern 
blotting experiments in Section 4.4 below.
4.4 COMBINED RESULTS OF NORTHERN BLOTTING AND RT-PCR 
EXPERIMENTS ON THE EFFECT OF HSV-2 ON mAspAT mRNA LEVELS.
The mean of the results from the Northern blotting and RT-PCR experiments
(described in sections 4.2.7 and 4.3 respectively) is calculated as 1.865, with a 
standard error of 0.08. These results confirm that there is an approximate twofold 
increase in the level of mAspAT mRNA in Bn5T cells following infection with 
HSV-2. This increase is consistent with the increase in enzyme activity (two-fold) 
and absolute protein levels (~4 fold) observed following infection of Bn5T cells with 
HSV-2 (Lucasson et a l, 1994).
4.5 EXPERIMENTS TO CONFIRM THAT THE PHOSPHORIMAGER CAN 
RELIABLY DETECT A 2-FOLD INCREASE IN THE AMOUNT OF 
RADIOACTIVITY PRESENT IN DNA AND RNA SAMPLES.
To validate the results of the Northern and slot blot experiments which showed a
two-fold increase in the level of mAspAT RNA following infection of Bn5T cells 
with HSV-2 (Section 4.2) it was necessary to confirm that the Phosphorimager could 
reliably detect a two fold increase in the amount of radiolabelled RNA or DNA 
loaded onto an agarose gel. An estimation of the error involved in the 
phosphorimager detection of a two or three-fold increase in the amount of labelled 
nucleic acid could also be made. Two different experiments were performed.
4.5.1 Agarose gel electrophoresis of 5’[y-32P] labelled DNA molecular weight 
markers.
1 pi of X DNA Hindlll molecular weight markers (Sigma) were end labelled with 
5’[y-32P] ATP using T4 polynucleotide kinase and ethanol precipitated with 5fig of 
salmon sperm DNA as carrier. The DNA pellet was resuspended in 50pl of ddH20. 
An equal volume of sucrose gel loading buffer was added. The sample was 
denaturated by boiling and rapid cooling on ice. A 1.5% agarose gel was loaded as 
described in Table 4.3 below and electrophoresed at 100 Volts until the dye front 
reached three-quarters of the way down the gel.
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Table 4.3. Volume of 5’[y-32P] labelled DNA molecular weight markers loaded onto 
an agarose gel to test the sensitivity of Phosphorimager analysis.
DNA Loading Volume of markers loaded
lx 10
2x 20
3x 30
The results from this experiment are presented in Table 4.4 and Figures 4.5 & 4.6.
The gel was rinsed in ddH20  to remove free radioactivity, dried and exposed to the 
phosphorimager screen overnight. The results were analysed using ImageQuant 
software. Figure 4.5 shows the phosphorimager image of this gel, and includes the 
rectangles (labelled 001- 008 but excluding 002) which delineate the areas used for 
the analysis of the counts in each track of the molecular weight markers.
Table 4.4A presents the number of counts detected by the phosphorimager in each of 
the seven molecular weight marker bands for each loading level (lx, 2x, 3x referred 
to in Table 4.3). In Table 4.4B the results in the 2x and 3x tracks have been 
normalised with respect to the number of counts in the lx track for each molecular 
weight marker analysed. The mean increase across all seven samples in the 2x track 
was 2.36 fold, and for the 3x track the increase was 3.5 fold (Table 4.4C). The 
standard error of the mean for each of the data series was 3.52% and 1.94% 
respectively. The individual results for each marker band are represented graphically 
in Figure 4.6, with trendlines and standard error bars marked on the chart. The error 
in these results is probably due to a systematic pipetting error, as the required volume 
of labelled markers was loaded by repeated loading of 10pl samples. This would 
cause a cumulative error in the 2x and 3x lanes of the gel. Other potential errors arise 
from the positioning of the rectangles during phosphorimager analysis. This 
introduces variation in the number of counts detected and therefore in the final ratios 
obtained. However, as the overall result is derived from the results of seven samples 
the effect of this positioning effect is reduced.
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32Figure 4.5. Phosphorimager image of a 1.5% agarose gel o f 5’[y- ~P] 
labelled X Hindlll molecular weight markers.
9416 003
6557 004
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32Legend. X Hindi I I m olecular weight markers were labelled with 5’[y- P] using T4 polynucleotide 
kinase and 10, 20 and 30 pi o f  this was electrophoresed on a 1.5% agarose gel ( lx , 2x, 3x) as 
described in the main text. The dried gel was analysed with the phosphorim ager and the num ber o f 
counts in each m olecular w eight band (labelled at left hand side) analysed in each o f  the tracks. The 
grids used to delineate the regions analysed by the phosphorim ager are labelled to the right o f  the gel. 
The counts in each track were com pared with each other as described in Table 4.4. The results 
confirm ed that the phosphorim ager can accurately determ ine a two or three fold increase in the 
am ount o f  radiolabelled DNA on an agarose gel.
(nd). Band not analysed as this distorted the grid shape and would have invalidated the results for the 
other 3 lanes.
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Table 4.4. Confirmation of linearity in Phosphorimager detection of 5'[y-32P] 
radiolabelled nucleic acid.
A) Total counts in selected bands of X molecular weight markers
Molecular weight marker band
Loading 001 003 004 005 006 007 008
lx 184093 590486 323347 105010 6306 4395 162753
2x 433092 1406101 756892 258582 12433 11966 388347
3x 629787 2189675 1120164 387645 21075 14278 597199
B) Ratio of counts in tracks relative to lx  loading counts
Molecular weight marker band
Loading 001 003 004 005 006 700 008
lx 1.00 1.00 1.00 1.00 1.00 1.00 1.00
2x 2.35 2.38 2.34 2.46 1.97 2.72 2.38
3x 3.42 3.70 3.46 3.69 3.34 3.24 3.66
C) Mean and standard error of the mean of data from Table 3.2 B.
DNA
loading
Mean of increase for all 
bands
Standard error 
of the mean"
% error (SEM/mean x 
100)
lx 1.00 n/a n/a
2x 2.36 0.083 3.52%
3x 3.50 0.068 1.94%
a Standard error of the mean calculated as shown in the equation below:-
SEM = i
N 9L (*,-*)
N - 1
■J~n
Legend. Analysis of data obtained from an experiment to determine the validity of Phosphorimager 
detection of changes in the level of RNA by Northern blotting. S’tY^P] labelled X DNA molecular 
weight markers were loaded onto a 1% agarose gel in multiples of lOpl. The total counts obtained 
from the phosphorimager (Section A) were used to calculate a value for each loading level relative to 
the counts in the standard lx  loading for each marker (Section B). The mean increase across all seven 
molecular weight markers for each loading level is highlighted in Section C. A systematic error has 
occurred in this experiment- see main text for further discussion, 
n/a- not applicable.
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Figure 4.6. Linearity o f phosphorimager detection of radiolabelled nucleic acid
4.00 T
{3 .70 {3.69 {3.66
3.50
* 3 34 {3.243.46■3.42
3.00 -■
{2.72
2.50 -- 2.38 { > 3 8
2.34" 2.35
2.00 - - J 1.97
♦ 3x
 Linear
(3x)
 Linear
(2x)
1.50
001 003 004 005
Marker Band analysed
006 007 008
Legend. Graph of data illustrated in table 4.4. The ratio of counts in each marker band (y-axis) 
relative to those in the lx loading track are plotted for each marker band (x-axis). This experiment 
confirms that a linear increase in the amount of a radiolabelled nucleic acid can be detected by 
phosphorimager analysis. The y-axis represents the relative loading of marker DNA as determned by 
the number of counts detected in each marker band (001-008 excluding 002), labelled 1 to 7 on the x- 
axis. Although the response is relatively linear, a systematic error in the loading of the samples is 
responsible for the result not being exactly 2.00 and 3.00x respectively. See main text for discussion of 
this point.
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The errors determined in this experiment are sufficiently small (+/- 4%) to allow the 
detection of a 2-fold change in the level of RNA present in Northern and slot blot 
experiments with confidence.
4.5.2 In vitro transcription analysis.
To independently confirm that the experimental system could detect two-fold 
increases in the radiolabel content of RNA samples, and that increases in radiolabel 
in RNA were detected as effectively as increases in the amount of label in a DNA 
sample, in vitro transcription experiments were performed by Dr. Joan Macnab, 
(Institute of Virology, Glasgow.) The plasmid pBS-KS containing the mAspAT 
cDNA (Mattingley et al., 1993) under the control of the T3 promotor was in vitro 
transcribed in the presence of [a-32P]-ATP and the product electrophoresed on an 
agarose gel. The number of counts in a track loaded with one volume of sample was 
compared by phosphorimager analysis with those in a track loaded with two volumes 
of the same sample. The results were 6438 and 13002 counts respectively (Lucasson 
et a l , 1994) an approximate two-fold increase (2.02x). This experiment confirmed 
that the phosphorimager was capable of detecting a twofold increase in radiolabelled 
RNA as well as DNA.
4.6 DISCUSSION.
A series of eight Northern blotting experiments (Section 4.2.7) showed that the level 
of mAspAT mRNA was increased by a factor of 1.748 +/- 0.26 in HSV-2 infected 
Bn5T cells compared to mock infected cells. These results were standardised by 
comparison with the level of the y-Actin transcript or 28S rRNA present in the 
samples.
Offord et al. (1989) determined that the level of y-actin mRNA was unaffected by 
infection of MCF-7 cells (an estrogen responsive breast cell line) with either HSV 
tsK or HG52. The level of the y-actin transcript in the Bn5T cells which were used in 
the experiments described in this chapter has also been shown to be unaffected by 
HSV-2 infection (J.C.M. Macnab, pers. comm). However, Latchman (1988) reported 
that the level of actin mRNA was decreased both at the transcriptional and post- 
transcriptional levels following HSV-2 strain 333 infection of BHK C l3 cells. The 
probe he used hybridised to both p and y-actin mRNAs, and as dot blot rather than 
Northern blot experiments were performed, it would not be possible to determine
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whether this decrease was due to a decline in the transcription of just one class of 
actin gene. As previously noted, the HG52 strain of HSV-2 used in my experiments 
has a defective host shutoff function (Everett and Fenwick, 1990) and one might not 
therefore expect to detect a decrease in the level of y-Actin in cells infected with this 
virus. In my experiments a similar increase in mAspAT mRNA was also observed 
relative to 28S rRNA, and therefore I have confidence in the use of the y-actin probe 
as an internal control in these experiments.
There is a relatively large range and standard error observed in this data series. This 
could be due to variation in the efficiency of infection of Bn5T cells with HSV-2. 
Different vials of HSV-2 HG52 stocks were used during these experiments, although 
the infection was always performed at lOpfu/cell. A more likely reason is the 
varying passage number of the Bn5T cells used. It was previously noted that Bn5T 
cells become refractory to infection with HSV-2 after extended passage. After 
extended passage (around passage number 50), infection with HSV-2 HG52 resulted 
in a less effective infection, as determined by examination of the cytopathic effect on 
cell morphology. When the typical rounding of the cells was not exhibited in 
infected cells examined microscopically, it was noted that the level of increase in 
mAspAT mRNA was much reduced, for example down to a 1.07 fold increase (Table 
4.1, experiment 4). A similar effect has been reported on examination of the effect of 
HSV-2 infection of Bn5T cells on the enzymatic activity of mAspAT (Lucasson et 
al., 1994). Only when the cytopathic effect was visible and infection with HSV-2 
was confirmed by the immunological detection of HSV-2 coded polypeptides 
(generally the large subunit of ribonucleotide reductase, (RR1)) was an increase in 
the enzyme activity observed. Productive infection therefore appears to be necessary 
for the alterations in the levels of mAspAT mRNA, protein and enzyme activity 
observed following HSV-2 infection. (See also Section 5.9.1)
Estridge et al. (1989), have previously noted that HSV-2 gene expression is required 
for the increase in the level of a cellular protein they term p40, a DNA binding 
protein purified from transformed cells and from dyskaryotic cells from cervical 
smears. The increase they observed following HSV-2 infection was dependent upon 
HSV-2 immediate early gene expression.
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The HSV gene products required for the increase in mAspAT mRNA were not 
studied in detail in this work. Attempts were made to assess the requirement for 
specific temporal classes of HSV genes using inhibitors of viral protein and DNA 
synthesis (ara-C, PAA, ActinomycinD and cycloheximide), and by infection of cells 
with UV-inactivated HSV-2. However the RNA purified from these cells was of 
poor quality, and the Northern blots were difficult to interpret. No conclusions could 
be drawn from these experiments. Grassie (1993) has shown that functionally active 
Vmw 175 is not necessary for the induction of the U90 member of this group of 
polypeptides that are specifically induced in transformed cells (Macnab et al., 1985). 
Furthermore, U90 was not induced by virus attachment to the cell surface (UV 
inactivated HSV-2) but was increased in the presence of cellular and viral DNA 
synthesis. It is possible that these results may hold true for the 40kDa polypeptide 
from this group, now known to be a form of mitochondrial aspartate 
aminotransferase (Lucasson et al, 1994).
Reverse transcriptase PCR experiments confirmed the two-fold increase in the level 
of mAspAT mRNA present in Bn5T cells after HSV-2 infection. The experimental 
conditions were such that the reaction was maintained in the linear phase, and the 
result was for the same initial amount of total cellular RNA (3 fig) in the RT reaction 
mix. No internal controls were included in this experiment. Ideally, primers which 
would amplify an mRNA known not to be altered by HSV infection should be 
included at the reverse transcriptase stage of these experiments. Two sets of primers 
to the y-actin sequence were synthesised, but did not amplify a product in these 
experiments. As a control to ensure the amplification was linear in each reaction 
tube performed at the same time, a fixed amount of a synthetic template derived from 
the mAspAT cDNA sequence containing an internal deletion should be added to each 
PCR reaction. This template would contain the same 9301 and 9302 primer 
sequences, and amplification should result in the production of an equal amount of a 
smaller distinguishable PCR product in each reaction. This would control for effects 
such as thermocycler block temperature variations.
The results from the northern blotting and RT-PCR experiments were consistent with 
each other, and the cumulative result of a 1.865 fold increase on HSV-2 infection is
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consistent with the enzyme activity (two-fold) and protein (approximately four-fold) 
increases reported previously by Lucasson et a l (1994).
Offord et al, (1989) have reported a similar degree of increase (between 1.5 and 2 
fold (+/- 0.5)) in the level of estrogen receptor mRNA in HSV-2 infected MCF-7 
cells relative to mock infected cells. These cells are an estrogen responsive 
transformed cell line, and increased expression of the estrogen receptor at the cell 
surface may have implications for the growth regulation of these cells. mAspAT is 
known to be identical to the fatty acid binding protein (mFABP) which has a role in 
the uptake of long chain fatty acids at the cell surface (Stump et al., 1993). Increased 
expression of mAspAT at the cell surface could therefore affect cellular metabolism 
by introducing an imbalance in the metabolic pools within the cell. Alterations in 
cellular metabolism could also occur by aberrant expression of mAspAT within the 
mitochondria, affecting the malate-aspartate shuttle. These possibilities are discussed 
further in the general discussion (Chapter 8) at the end of this thesis.
4.7 CONCLUSIONS.
The level of mitochondrial aspartate aminotransferase mRNA is increased in the 
transformed rat fibroblast cell line Bn5T following infection with HSV-2.
Northern blotting experiments quantify the level of this induction as 1.748 fold, and 
RT-PCR experiments as 1.98 fold.
The overall mean increase was observed as 1.865 fold, consistent with results 
previously reported from our laboratory on the induction of mAspAT protein and 
enzyme activity following HSV-2 infection (Lucasson et al., 1994).
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5. IDENTIFICATION OF A POLYPEPTIDE IN HSV INFECTED 
CELLS WHICH CROSS-REACTS WITH AN ANTISERUM 
RAISED AGAINST mAspAT.
5.1 INTRODUCTION
Whilst working on the upregulation of mAspAT as a result of HSV-2 infection, a 
colleague in the Institute of Virology, Dr. Jean-Francois Lucasson reported a fourfold 
increase in the mAspAT protein level detected by slot-blot immunoblotting. The 
enzyme activity of mAspAT in Bn5T cells was also elevated approximately two-fold 
(Lucasson, 1992; Lucasson et a l , 1994). The experiments described below were 
performed to further investigate this increase in the level of mAspAT protein 
observed following infection with HSV-2.
5.2 INITIAL INVESTIGATION
In an initial Western blotting experiment, a 9% polyacrylamide gel was run with 
samples of Bn5T cell polypeptides following an 18 hour infection with HSV-1 or 
HSV-2 at 10 pfu/cell, or a mock infection. Samples were produced by lysis of the 
cells in hypotonic WF buffer (Welch & Feramisco, 1985), sonication and pelleting of 
the cellular debris by centrifugation, essentially as described in Materials and 
Methods and Section 3.2. Following electrophoretic transfer to Hybond-N™, the 
polypeptides were probed with a 1/50 dilution of a rabbit antiserum raised against the 
pre-mAspAT polypeptide expressed in E. coli (kindly provided by J. R. Mattingley 
(Mattingley et al., 1987)), and detected using anti-rabbit Ig-HRP conjugate. The blot 
was developed using colour reagent as described in Materials and Methods.
Although the staining of this blot was faint, it appeared that an additional lower 
molecular weight band might be present in the infected cell tracks that was absent 
from the mock infected track (data not shown). This additional lower molecular 
weight band appeared to vary in size; the additional polypeptide in the HSV-1 
infected sample appeared to have a larger molecular weight than the additional 
polypeptide in the HSV-2 infected sample.
There were several possible explanations for the results described above. HSV-1 and 
HSV-2 may be inducing different forms of mAspAT, or the lower molecular weight 
polypeptides might be HSV induced degradation products of mAspAT. Another 
possibility was that the antiserum might be detecting a cross-reacting HSV coded 
polypeptide with a slightly different molecular weight depending on the HSV type
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used to infect the cells. These possibilities are investigated in the following 
experiments.
5.3 OPTIMISATION OF EXPERIMENTAL CONDITIONS
5.3.1 Gel electrophoresis conditions
The presence of the induced lower molecular weight polypeptides and the size 
difference between the two virus types were not clearly resolved on a 9% SDS- 
PAGE gel. 15% SDS-PAGE gels were therefore used in all subsequent experiments 
to increase the separation of polypeptides in the 35-50kDa range. Rainbow 
molecular weight markers (Amersham Life Sciences) were used to follow the 
migration of the polypeptides during electrophoresis. This allowed the gels to be 
electrophoresed further after the bromophenol blue marker dye had run off the gel, 
without losing the polypeptides of interest. Increased resolution was obtained in the 
35-50kDa molecular weight region of the gel. Figure 5.1 shows an example of a 
Western blot obtained using the optimised conditions described in this section, with 
HSV-2 and mock infected samples of rat embryo and Bn5T cells.
5.3.2 Cell lysis conditions
Degradation during cell lysis was unlikely to be the cause of the presence of the 
lower molecular weight polypeptides as no lower molecular weight polypeptide was 
detected in the mock infected samples (Figure 5.1, lanes 1 & 3). However, to reduce 
protein degradation during lysis to a minimum, cells were lysed by the addition of 
500pl of SDS-PAGE sample loading buffer (3xBM) directly to the cell monolayer on 
the tissue culture plate. This lysis method produced a higher protein concentration in 
the lysate than lysis in hypotonic WF buffer (data not shown). However, the lipid 
content of these samples was also elevated, and to avoid smearing of the gel care had 
to be taken not to overload the samples.
5.3.3 Western blotting
A final optimisation step was the use of enhanced chemiluminescence (ECL, 
Amersham Life Science) reagents to develop Western blots. These reagents are at 
least lOx more sensitive than the colour reagent and produce high contrast results, 
allowing detection of minor bands using lower amounts of primary antibody. A 
1/200 dilution of the anti-mAspAT antibody was used in subsequent experiments to 
reduce the background on the blots. ECL reagents have the added advantage that 
blots can be stripped of all bound antibody and re-probed several times with different
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Figure 5.1. Optimised Western blot to show detection of an additional 
polypeptide in Bn5T and RE cells after infection with HSV-2.
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Legend. Bn5T and RE cells were infected at lOpfu/cell w ith HSV-2 HG52 or mock 
infected overnight, and lysed directly into SDS-PAGE sample loading buffer (3xBM). 
Samples were electrophoresed on a 15% SDS-PAGE minigel, transferred to Hybond- 
N m em brane and W estern blotted with 1/200 dilution o f  an antiserum  raised against rat 
mitochondrial aspartate am inotransferase (a -m A sp A T , lanes 1-4) or an antiserum 
against the large subunit o f  HSV-1 ribonucleotide reductase ( a - R R l ,  lanes 5-8). 
Enhanced chem ilum inescence reagents were used to detect bound antibody. The 
position o f  the m olecular weight markers is indicated at the sides o f  the gel.
An additional polypeptide is detected by the a-m A spA T  antiserum in the HSV-2 
infected samples (lanes 2 & 4) com pared to the mock infected samples (lanes 1 & 3). 
Infection o f  the samples with HSV-2 is confirm ed by the presence o f  ribonucleotide 
reductase (lanes 6 & 8). There is no reaction with the anti-RRl antiserum  in the mock 
infected tracks.
This gel shows that the additional polypeptide detected by a-m A spA T  antiserum  is 
specific to HSV infection, and that in addition to Bn5T cells the polypeptide is also 
induced in primary rat em bryo (RE).
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primary antibodies without significant loss of sensitivity. This allows polypeptides 
of similar molecular weight to be detected sequentially in the same sample. ECL 
molecular weight markers were added to allow direct visualisation of markers on the 
Western blot.
In all the following experiments, the blots were stripped and reprobed with a 
polyclonal antiserum raised against the large subunit of HSV-1 ribonucleotide 
reductase (RR1, 124kDa) to confirm that productive infection had occurred (Figure 
5.1, lanes 6 & 8). The mock infected samples did not display any reactivity with the 
anti-RRl antiserum (Figure 1, lanes 5 & 7).
The following experiments were performed using the optimised procedures described 
above.
5.4 THE EFFECT OF HSV INFECTION ON MASPAT LEVELS IN BHK 
C13CELLS
This experiment was performed using BHK C13 cells to determine whether the lower 
molecular weight polypeptides detected in RE and Bn5T cells following HSV 
infection were also present in HSV infected BHK C l3 extracts. BHK C l3 cells, 
which are used to propagate HSV are permissive for productive virus infection, 
whilst Bn5T cells are sometimes refractory to infection. If the lower molecular 
weight polypeptides are induced by HSV infection and were present in infected BHK 
C l3 cells these cells could be used in future experiments to provide more 
reproducible results.
BHK C l3 cells were infected at 10 pfu/cell with HSV-1 or HSV-2 overnight and 
lysed directly in 500pl 3xBM. This lysate was diluted 3:2 with lxBM but remained 
too concentrated and resulted in an overloaded gel with poor resolution of the 
polypeptides (data not shown). The lysate was further diluted 1:2 with lxBM to 
prevent overloading of the gels. 50pl and lOOpl of each sample were loaded onto a 
full size 15% SDS-PAGE gel, and electrophoresed until the 21 kDa molecular weight 
marker only just remained on the bottom of the gel. Following electrophoretic 
transfer to Hybond-N™, the blot was probed with a 1/200 dilution of anti-mAspAT 
antiserum and detected using ECL reagents.
Figure 5.2 shows the presence of an additional polypeptide band following infection 
with either HSV -1 (lanes 2 & 5), or HSV-2 (lanes 3 & 6), which is not present in the 
mock infected track (tracks 1 & 4). The additional band clearly has a different
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Figure 5.2. Induction of HSV type specific additional polypeptides 
following infection of BHK Cl 3 cells with HSV-1 and HSV-2.
Legend. BHK C13 cells were infected at 10 pfu/cell HSV-1 strain 17 or HSV-2 
strain HG52 overnight and lysed directly into 3xBM. 50pl and lOOpl sam ples were 
electrophoresed on a large 15% SDS-PAGE gel and blotted as described in M aterials 
and M ethods. The W estern blot was probed with an antiserum to mAspAT.
In the m ock infected cell sam ples (lanes 1 & 4), a single polypeptide is detected, 
representing the constitutively expressed cellular mitochondrial aspartate 
am inotransferase. There is a single additional polypeptide detected in the samples 
infected with HSV-1 (lanes 2 & 5), and a different additional polypeptide detected in 
the sam ples infected with HSV-2 (lanes 3 & 6). The bands detected in HSV infected 
cells are clearly o f  differing m olecular w eights dependent upon the HSV type .
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molecular weight in HSV-1 and HSV-2 infected BHK C l3 cell samples, with the 
HSV-1 band having a slightly greater molecular weight. The apparent molecular 
weights of the HSV-1 and HSV-2 induced lower molecular weight polypeptides on 
this gel were 37.7 kDa and 35.5kDa respectively.
In this experiment the apparent molecular weight of the cellular mAspAT on a 15% 
SDS-PAGE gel is 41.1 kDa, compared to the predicted molecular weight of 
44.358kDa for rat mAspAT (Huynh et al., 1981) which corresponds to the observed 
molecular weight on SDS-PAGE gels (Huynh et al., 1980; Mattingley et al., 1987). 
This molecular weight difference may be due to different gel electrophoresis 
conditions or to altered post-transcriptional processing of the mAspAT transcript (or 
post-translational alterations to the polypeptide) in the BHK C l3, Bn5T and RE cells 
used in these experiments. The constitutive cellular mAspAT was of similar 
molecular weight in all three cell types used in these experiments. Mattingley et a l , 
(1987) do not report their experimental conditions or the derivation of the processed 
44kDa mAspAT polypeptide used as a control in his experiments. No conclusions 
can be drawn without further information. mAspAT is highly conserved in 
eukaryotes with high sequence homology at both the DNA and amino acid level {see 
Appendix 1). The variation between prokaryotic and eukaryotic proteins is greater, 
although the homology is still extensive. If the variation is biological rather than due 
to different experimental conditions, some form of cell type dependent processing is 
the most likely cause of the variation, for example altered glycosylation.
5.5 ARE THE LOWER MOLECULAR WEIGHT POLYPEPTIDES CELL 
ASSOCIATED?
An experiment was performed to determine whether the lower molecular weight 
polypeptides detected by the antiserum to mAspAT were cell associated (either 
intracellular or membrane associated), and not serum contaminants from the tissue 
culture medium or secreted cell coded polypeptides. BHK C l3 and RE cells were 
infected with 1 Opfu/cell HSV-1 or HSV-2 or were mock infected as previously 
described. An additional plate of each cell type was infected with HSV-1, and the 
cells on this plate were washed three times with 10ml ice-cold PBS-A to remove 
secreted polypeptides or serum contaminants prior to lysis in 3xBM. The other 
plates were lysed directly into 3xBM. The polypeptides extracted from the cells on
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the washed plate were compared on a Western blot with those from the plates lysed 
directly in 3xBM.
The samples from the RE cells were included to compare the induction of the lower 
molecular weight polypeptides induced following HSV infection in a primary cell 
with that observed in immortalised cell lines.
Figure 5.3 confirms the appearance of the lower molecular weight polypeptides 
specific to each HSV type following infection of BHK C13 cells (lanes 1-4). A 
similar result is observed in RE cells (lanes 5-8). The lower molecular weight 
polypeptides are probably cell associated, as washing the plate with PBS-A did not 
visibly reduce the level of polypeptide detected (compare track 2 with 3, and 6 with 
7).
The amount of the lower molecular weight polypeptides induced in RE cells is 
reduced in comparison to the level of those induced by infection of BHK C13 with 
HSV. The level of the cellular mAspAT is comparable in both cell lines. The 
reduced level of induced polypeptides may be because RE cells are less permissive 
for HSV infection than BHK C l3 cells, and therefore lower amounts of viral 
polypeptides are produced. This would have an effect whether the detected 
polypeptides were virally coded or required a viral polypeptide for their induction. 
The result could also be due to the different nature of the cells types. BHK Cl 3 cells 
are a continuous cell line whilst RE cells are primary cells. The induction of the 
additional polypeptides is greater in the immortalised cells (Figure 5.3, lanes 1-4). 
This is in agreement with the levels of the TBS-40kDa polypeptide 
immunoprecipitated from transformed Bn5T and primary RE cells (Figure 3.1) where 
the observed increase following HSV infection is greater in the Bn5T cells.
5.6 THE LOWER MOLECULAR WEIGHT POLYPEPTIDES ARE NOT 
DEGRADATION PRODUCTS
An experiment was performed to confirm that the lower molecular weight 
polypeptides were not degradation products caused directly by the lysis procedure, or 
by cellular proteases released during lysis, and were induced specifically following 
HSV infection.
60mm plates of RE and BHK C13 cells were mock infected (as described in 
Materials and Methods) and incubated at 370 C overnight. The cell monolayers were 
washed, harvested by scraping into PBS-A and pelleted before lysis by sonication in
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Figure 5.3. Experiment to determine whether the HSV induced polypeptides are cell 
associated, secreted or serum contaminants.
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Legend. BHK C13 and RE cells were infected for 17 hours with lOpfu/cell HSV-1 strain 17 or 
HSV-2 strain HG52. 50 pi samples were electrophoresed on a large 15% SDS-PAGE gel prior to 
blotting. The blot was probed with an antiserum  to mAspAT, and visualised using ECL reagents. 
The position o f  the m olecular weight m arkers is indicated to the right o f  the gel.
Lanes 1-4 contain BHK C13 samples and lanes 5-8 the corresponding samples from  RE cells. Lanes 
1 & 5 contain samples from mock infected cells; lanes 2 & 6 contain HSV-1 infected cell samples 
lysed directly into 3xBM; lanes 3 & 7 contain HSV-1 infected samples washed with PBS-A to 
remove contam inating polypeptides prior to lysis in 3xBM ; lanes 4 & 8 contain HSV-2 infected 
samples lysed directly into 3xBM.
There is an additional polypeptide detected in HSV-1 and HSV-2 infected C l 3 and RE cells (lanes 2- 
4 and 5-8), which is absent from the mock infected cells (lanes 1 & 5). The faint band in lane 1 
(m arked with an asterisk) is due to the high background in this track. W ashing o f  the infected plates 
with PBS-A prior to lysis has no effect on the level o f lower m olecular weight polypeptide present 
(lanes 3 & 7) com pared to the directly lysed cells (lanes 2 & 6). This suggests that the additional 
polypeptide is cell associated, and is not secreted into the medium. Neither is it a serum contaminant. 
The level o f  the induced bands is som ewhat reduced in the primary rat em bryo cell samples (RE, 
lanes 6-8) com pared to the levels in the C l 3 samples. See main text for further discussion.
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lml hypotonic WF buffer. lOOpl samples of the lysate were incubated at room 
temperature for periods of time ranging from 0 to 48 hours from the time of lysis. At 
the relevant time point, 50pl of 3xBM was added to each sample, which was then 
stored at -200 C until all the samples had been collected for analysis.
Figure 5.4 shows an ECL western blot of a full size 15% SDS-PAGE gel run with 
these samples. The normal cellular mAspAT band is present at approximately 42kDa 
in all the samples (BHK C l3 samples in lanes 1-7; RE samples in lanes 8-14). No 
lower molecular weight polypeptide bands were visible in the region where the 
additional bands normally run on this type of gel following HSV infection. There 
were some much smaller molecular weight polypeptides present at the foot of the gel, 
which increased in abundance with incubation time (not visible in this figure). These 
bands may be caused by the degradation of a small proportion of the mAspAT by 
cellular proteases during the incubation period. There are no intermediate molecular 
weight bands present at earlier time-points in this experiment, suggesting that this 
degradation occurs at specific proteolytic sites within the polypeptide molecule. 
However, this degradation is not responsible for the presence of the lower molecular 
weight polypeptides which appear following HSV infection.
This experiment confirms that the lower molecular weight polypeptide bands 
described in this chapter are specifically induced by HSV infection, and are not 
degradation products caused during the lysis procedure or subsequent manipulations.
5.7 TIMECOURSE OF INDUCTION OF THE LOWER MOLECULAR 
WEIGHT POLYPEPTIDES
A timecourse experiment was carried out to examine the induction of the lower 
molecular weight polypeptides following infection with HSV.
60mm plates of BHK Cl 3 cells were infected at lOpfu/cell of HSV-1 for 4, 8, 12 and 
24 hours. A plate of mock infected cells was harvested at 24 hours. Cells were 
harvested directly by addition of 500pl of 3xBM to the plates and lOpl samples were 
loaded onto a 15% SDS-PAGE mini-gel for Western blotting with the a-mAspAT 
antiserum.
Figure 5.5A shows that the HSV-1 induced lower molecular weight polypeptide is 
just detectable using ECL reagents at 12 hours post-infection (marked with an arrow 
in lane 3), and accumulates during infection (lane 4). The normal cellular mAspAT 
level remains relatively constant. Neither of the mock infected samples (lanes 5 & 6)
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Figure 5.4. Western blot to demonstrate that the additional polypeptide 
detected by anti-mAspAT antiserum is not due to non-specific proteolytic 
degradation.
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Legend. 60mm plates o f  BHK C13 and primary rat em bryo (RE) cells were mock 
infected and incubated overnight. The plates were washed with PBS-A, and a lysate 
prepared by scraping into WF buffer and sonication (as described for large scale 
protein purification in M aterials and M ethods). lOOpl samples o f  the lysate were 
incubated at room  tem perature for 0, 2, 4, 8, 12, 24 and 48 hours (lanes 1-7 and 8-14), 
before addition o f  50pl o f  3xBM. Samples were then analysed by W estern blotting as 
described in the main text.
The constitutive m AspAT band is present at approxim ately 41 kDa in all o f  the 
samples from both BHK C l 3 (lanes 1-7) and RE cells (lanes 8-14), but the additional 
polypeptide bands previously detected following HSV infection are absent from all 
samples.
This experim ent therefore confirm s that the additional polypeptides are specific to 
HSV infected cells, and are not breakdown products caused by cellular proteases 
released during the lysis procedure.
Figure 5.5A. Timecourse of induction of HSV-1 specific band detected by an
antiserum to mAspAT.
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Legend. BHK C l 3 cells were infected with lOpfu/cell o f  HSV-1 strain 17, and sam ples w ere taken at 
4, 8, 12 and 24 hours post-infection (lanes 1-4). A mock infected C l 3 cell sample (lane 5) and mock 
infected RE cell sample (lane 6) were included. Cells were lysed in 3xBM , and W estern blotted as 
described in M aterials and M ethods. ECL m olecular weight m arkers (M W ) are labelled at the side o f 
the gels.
Panel A shows a blot probed with a rabbit antiserum  raised against bacterially expressed rat 
mitochondrial aspartate am inotransferase. The lower m olecular weight band is ju st visible at 12 hours 
post-infection (m arked with an arrow  in lane 3), and increases during the course o f  infection. The 
additional polypeptide is not present in either C13 or RE mock infected samples (lanes 5 & 6).
Panel B shows the same blot stripped and re-probed with an antiserum  against the large subunit o f 
HSV-1 ribonucleotide reductase (RR1). RR1, an early ((3) HSV-1 gene, is detectable in the 8 hour 
post-infection sample (lane 2), and increases as the infection proceeds (lanes 3 & 4). N o RR1 is 
detectable in the mock infected samples (lanes 5 & 6). The appearance o f  the additional polypeptide 
in the m AspAT probed blot parallels the expression o f  RR1.
The extra band in Panel B (m arked with an asterisk) represents the constitutive m AspAT and is due to 
incomplete stripping o f the blot prior to re-probing with the anti RR1 antiserum.
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contained detectable amounts of the lower molecular weight polypeptide at 24 hours 
post-infection.
Figure 5.5B shows a Western blot of a full size 15% SDS-PAGE gel, loaded with 
lOOpl samples from a 24 hour timecourse of infection of BHK C l3 cells with 
HSV-1, to further investigate the result shown in figure 5.5A. A mock infected 
sample was taken at each time-point. In this blot, due to the greater amount of 
sample loaded, the lower molecular weight polypeptide is more readily detectable. A 
faint band is detectable at 6 hours post-infection, and is clearly present by 8 hours 
post-infection. This polypeptide accumulates during infection, whilst only the 
constitutively expressed cellular mAspAT band is present in the corresponding mock 
infected samples.
These results suggest that the lower molecular weight polypeptide is induced early 
during HSV infection, in the early (p) stage of the viral replicative cycle.
5.8 EXPERIMENTS TO IDENTIFY THE HSV INDUCED POLYPEPTIDES.
5.8.1 Infection of cells with HSV-l/HSV-2 intertypic recombinant viruses.
As previously shown (in Figures 5.2 and 5.3), HSV-1 and HSV-2 induce slightly
differently sized lower molecular weight polypeptides in infected BHK C l3, Bn5T 
and RE cells. If the lower molecular weight polypeptides are viral polypeptides 
rather than HSV induced cellular polypeptides, this difference in the molecular 
weights of the induced polypeptides could provide a method of identifying the lower 
molecular weight polypeptides. The following experiments are similar to those of 
Wohlrab et a l ,(1982) and Williams and Parris (1987), who used HSV intertypic 
recombinants to map the region of the HSV-1 genome encoding the dUTPase (see 
Section 5.9.2 of Discussion for more details).
Three HSV-l/HSV-2 intertypic recombinants (obtained as detailed in Materials and 
Methods) were used to map the region of the HSV genome encoding these lower 
molecular weight polypeptides. Comparison of the size of the particular lower 
molecular weight polypeptide produced in cells following infection with each 
intertypic recombinant (i.e. HSV-1 or HSV-2 like), and reference to the genome 
maps of these intertypic viruses would enable the region of the HSV genome 
encoding these polypeptides to be identified.
The recombinant viruses used in this experiment were B xl, Fx9 and R12-5. 
Approximate genome maps of these viruses are shown in Figure 5.6. HSV-1 strain F
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Figure 5.5B. Timecourse o f induction of the HSV specific polypeptide detected
by an antiserum to mAspAT in infected cell extracts (large gel).
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Legend. BHK C l 3 cells were infected with lOpfu/cell o f  HSV-1 strain 17 for 
periods o f  time ranging from 0 to 24 hours as labelled above the tracks. A mock 
infected sample was collected at each time point. Cells were lysed directly into 
3xBM , and equal volum es (lOOpl) o f  lysate loaded onto a large 15% SDS-PAGE 
gel. A fter transfer to Hybond-N m em brane, the polypeptides were detected by 
imm unoblotting with an anti- m AspAT antiserum.
The HSV-1 specific band is not visible in the 4 hour post-infection track, but is 
ju st detectable at 6 hours p.i.(labelled with an arrow  in the 6 hour track). The 
HSV-1 band is clearly visible in the 8 hour p.i. HSV-1 track, but is absent from 
the mock infected lane. The intensity o f  the band increases during infection as 
the polypeptide accum ulates, but is present at no stage in the mock infected 
tracks. This suggests that the polypeptide is either an HSV coded protein, or is 
induced specifically by infection with HSV. (See main text for further 
discussion).
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and HSV-2 strain MS were used in addition to HSV-1 strain 17 and HSV-2 strain 
HG52. The latter were controls to identify the benchmark size of the HSV-1 and 
HSV-2 type lower molecular weight polypeptides.
60mm plates of BHK Cl 3 cells were infected at lOpfu/cell with one of the intertypic 
recombinants, virus subtypes or control viruses for 18 hours at 37 ° C. The cells were 
lysed directly into 3xBM, electrophoresed on a 15% SDS-PAGE mini-gel and blotted 
as described previously (section 5.7). The blot was developed with ECL reagents 
and is shown in Figure 5.7. The blot was reprobed with an antibody to RR1 to 
confirm HSV infection.
In this experiment HSV-1 strain F produced the lower molecular weight polypeptide 
typical of HSV-1 strain 17 (Figure 5.7, lanes 1 & 2), and HSV-2 strain MS induced 
the typical HSV-2 HG52 type polypeptide (lanes 3 & 4). The recombinant viruses 
Bxl and R12-5 (lanes 5 & 7) induced the lower molecular weight polypeptide 
characteristic of infection with HSV-1 strain 17 (lane 1). The recombinant Fx9 (lane 
6) induced the HSV-2 type band.
Examination of the approximate genome maps of the intertypic recombinants (Figure 
5.6) revealed that the determinant was located in the region mapping between 
approximately 0.64 and 0.83 m.u. (shaded in Figure 5.6). Examination of the 
predicted molecular weights for the unprocessed virus coded polypeptide chains from 
the 0.64-0.83 m.u region (Figure 5.8 and Table 5.1) of the HSV-1 genome (McGeoch 
et al., 1988) suggested two candidate polypeptides with molecular weights of 
approximately the correct size (30-40kDa). These were the products of the UL49 and 
UL50 open reading frames, which lie within the region defined by the recombinant 
virus studies. Both of these genes are early (P) HSV genes (Wagner, 1994), which 
correlates with the observations from the timecourse experiments described in 
Section 5.7, where the additional polypeptides are detectable at 6 hours post­
infection.
5.8.2 The UL49 gene product (p43) is not the induced polypeptide.
UL49 encodes the tegument protein p43 (VP22). It is a major structural component
of the virion (Heine et a l , 1974) and is extensively post-translationally modified. 
Indirect immunofluorescence studies demonstrated that VP22 has a perinuclear 
localisation (Elliot & Meredith, 1992), and later studies that VP22 binds stably to the 
activation domain of VP 16 (Elliot et al., 1995), suggesting a role in virus assembly.
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Figure 5.6. Genome maps o f the intertypic HSV recombinants Fx9, R12-5 and Bxl.
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Legend. Approximate genome maps of the intertypic HSV-l/HSV-2 recombinant viruses 
used in the mapping of the lower molecular weight polypeptide induced by HSV in infected 
cells. The genome map is marked in 0.1 map unit divisions. The genome of the recombinant 
is shown as a bold line. For each recombinant the top line represents HSV-1 sequences, and 
the bottom line HSV-2 sequences. Where there is uncertainty about which type of HSV 
genome is present at the region of overlap, both HSV-1 and HSV-2 sequences are shown in 
bold.
On infection of BHK C13 cells, the recombinant viruses Bxl and R12-5 induced the type 1 
lower molecular weight polypeptide, and the Fx9 recombinant vims a type 2 polypeptide 
(Figure 5.7). The region of the HSV genome delineated by these experiments is shaded grey. 
The surrounding region (between 0.64 to 0.83 map units) of the HSV-1 genome was examined 
for potential polypeptides of the correct molecular weight.
(Recombinant vims data provided by Dr. H. Marsden, Institute of Virology, Glasgow).
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Figure 5.7. Intertypic recombinant HSV viruses induce different molecular 
weight polypeptides in infected cells. Mapping of the genome region responsible 
and identification of the polypeptide as the HSV dUTPase.
A) Probed with anti mAspat anti serum
MW F 17 HG52 MS Bxl Fx9 12R5 m.i. dut 
kDa --------------------------------------------------------------------------------------
Constitutive
HSV-1
HSV-2
B) Reprobed with anti RR1 antiserum
MW F 17 HG52 MS Bxl Fx9 12R5 m.i. dut
kDa
97 
69
46
30
«
RR1
Legend. BHK C13 cells were infected with lOpfu/cell o f  HSV-1 strains 17 and F, HSV-2 
strains HG52 and MS or one o f  the intertypic recombinant viruses, B x l, Fx9 or R12-5. A 
mock infected sample was included. Samples were Western blotted as previously described. 
Both F and 17 induce the type 1 lower molecular weight polypeptide, and HG52 and MS the 
type 2 polypeptide. The recombinant viruses B xl and R12-5 induce the a type 1 polypeptide 
by comparison with F and HG52. The Fx9 recombinant induces a type 2 polypeptide 
(marked by an arrow). The blot was reprobed with an antiserum to RR1 to confirm that 
infection had occurred in the recombinant virus samples. (See Section 5.8.1 for further 
discussion).
The track labelled dut' contains a sample infected with the dUTPase deficient mutant 1218, 
and fails to induce any lower molecular weight polypeptide. (See Section 5.8.3 and Figure 
5.9).
Figure 5.8. Layout o f the genes in the region 0.6-0.83 m.u. o f the genome of HSV-1
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Legend. Layout o f the genes in the genome o f HSV-1 in the region 0.64-0.83 map units. The sizes 
and orientation o f the proposed functional ORFs are shown by arrows. Locations o f proposed 
transcriptional polyadenylation sites are indicated as short vertical bars. (Derived from McGeoch et 
a l ,  1988).
Table 5.1. Function of genes mapping within the 0.6- 0.83 m.u. region of the HSV-1 
genome.
Gene No o f residues M,* Function/properties
UL45 172 18178 Hydrophobic N-terminus
UL46 718 78239 Tegument protein VP11/12
UL47 693 73812 Tegument protein VP 13/14
UL48 490 54342 Major tegument protein. Activates IE genes
UL49 301 ♦ 32252 p43 tegument protein (VP22)
UL50 371 ♦ 39125 dUTPase
UL51 244 25468 Unknown function
UL52 1058 114416 Component o f helicase primase
UL53 338 37570 Glycoprotein K
UL54 512 55249 Vmw63- post-transcriptional regulator
UL55 186 20491 Unknown function
UL56 197 21182 role in virulence
RSI 1298 132835 Vm wl75- transcriptional regulator
* M,. for unprocessed polypeptide chain
Legend. The proposed functions and molecular weights of the gene products in this region were 
compared with the molecular weight o f the polypeptide induced by HSV-1 infection o f BHK C l3 
cells. The two polypeptides with suitable molecular weights within the genome region delineated in 
figure 6, (see section 1.8) are highlighted and marked ♦  (UL49 & UL50). gK was excluded on the 
basis o f its' classification as a (3y gene (see discussion for details). (Derived from McGeoch et al., 
1988).
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Analysis of a western blot of HSV-1 and HSV-2 infected BHK Cl 3 cell polypeptides 
probed with an anti-mAspAT antiserum and then stripped and re-probed with an 
antibody against p43 (provided by J. Leslie, MRC Virology Unit, Glasgow) showed 
that the antisera recognised different polypeptides. The anti-p43 antibody recognised 
a polypeptide with a molecular weight intermediate between the constitutive cellular 
mAspAT and the HSV induced forms (Figure 5.9). This experiment confirmed that 
the lower molecular weight band induced by HSV infection is not p43 (VP22), the 
gene product of UL49.
5.8.3 HSV mutants in the dUTPase gene fail to induce the lower molecular 
weight polypeptides in infected cells.
The HSV-1 UL50 gene encodes the viral dUTPase. Preston and Fisher (1984) have 
mapped the HSV-1 dUTPase gene within genome map coordinates 0.69-0.70. The 
enzyme catalyses the hydrolysis of dUTP to prevent incorporation of dUTP into 
newly synthesised viral DNA by DNA polymerase (Ostrander and Cheng, 1980). 
The HSV-1 dUTPase has a molecular weight of 46kDa compared to 53kDa for the 
HSV-2 encoded enzyme determined by non-denaturing PAGE (Williams, 1984). 
This contradicts the size variation observed between the induced polypeptides in my 
experiments, where the HSV-1 polypeptide is the larger with an apparent molecular 
weight of 37.7kDa compared to 35.5kDa for the HSV-2 induced polypeptide (Figures
5.2 & 5.3, Section 5.4). The predicted molecular weight of the unprocessed 
polypeptide chain of HSV-1 dUTPase is 39.1kDa (McGeoch et al., 1988).
To determine whether the viral dUTPase was the HSV induced lower molecular 
weight polypeptide, two mutant dUTPase-deficient HSV-1 viruses were used to 
infect BHK C l3 cells prior to analysis by Western blotting as previously described. 
HSV-1 1217 is a spontaneous mutant which does not induce dUTPase activity and
1218 is a dUTPase-deficient (d u f) mutant obtained by insertional mutagenesis
(kindly provided by Dr. Val Preston, Institute of Virology, Glasgow (Preston and 
Fisher, 1986)).
A sample from BHK C l3 cells infected with HSV-1 1218 was probed firstly with 
anti-mAspAT antiserum and subsequently with an antiserum to HSV RR1 (kindly 
provided by Dr. Ann Cross, Institute of Virology, Glasgow) as a marker of positive
infection. This is shown in Figure 5.7, lane 9 (labelled duf)  alongside the
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Figure 5.9. The additional polypeptides recognised by the mAspAT antiserum are 
not the product of the HSV UL49 genes.
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Legend. BHK C13 cells were infected with lOpfu/cell o f  HSV-1 or HSV-2 overnight, prior to 
Western blotting as previously described. The blot was first probed with the anti-mAspAT 
antiserum (right hand panel) and then stripped and re-probed with an antiserum to p43, the 
polypeptide product o f  the HSV UL49 gene (left hand panel). Lining up the two blots illustrates 
that the polypeptide detected by the anti-p43 serum has a molecular weight intermediate between 
the constitutive cellular mAspAT and the HSV induced cross-reacting species (marked by the 
dashed line). The cross-reacting species is therefore not the product o f  the UL49 gene.
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recombinant intertypic virus samples. There is a significant absence of a lower 
molecular weight band in the track infected with HSV-1 1218 (lane 9) compared to 
HSV-2 HG52 and HSV-1 17 controls (lanes 2 & 3 respectively), despite clear 
evidence of productive HSV infection as assayed by the presence of RR1 in the 
lysate.
A repeat of this experiment was performed using Bn5T cells, as these were the cells 
in which the appearance of the lower molecular weight polypeptides were first 
observed. Bn5T cells were infected with HSV-1 strain 17, HSV-2 strain HG52, one
of the d u f  viruses 1217 or 1218, or were mock infected overnight. Samples were
electrophoresed and immunoblotted as previously described. The Western blot is 
shown in Figure 5.10. The constitutive cellular mAspAT is present in all the 
samples, and the HSV induced lower molecular weight polypeptides are present in 
the HSV-1 and HSV-2 infected samples. However, no additional polypeptides are 
detected in either of the dUTPase deficient virus infected samples.
These results demonstrate that the lower molecular weight polypeptides detected 
following infection with HSV-1 and HSV-2 by the antiserum against mAspAT 
represent the dUTPase enzymes of HSV-1 and HSV-2.
5.8.4 Western blotting with a dUTPase antiserum.
A western blot was performed using extracts from HSV-1 strain 17 and F , HSV-2 
strains HG52 and 333 or mock infected BHK C l3 cells. Blots were performed as 
previously described, but using an antiserum raised against HSV-1 dUTPase (kindly 
donated by Dr. V. Preston). The blot is shown in Figure 5.11. The HSV-1 lanes 
contain a single polypeptide band with a molecular weight slightly larger than the 
band detected in the HSV-2 samples. This result is consistent with the results 
previously described in Sections 5.8.2 and 5.8.3, and confirms the identification of 
the cross reacting species detected by the antiserum against mAspAT as the HSV 
dUTPase.
5.9 DISCUSSION.
5.9.1 Summary of Results.
As a result of the increased resolution obtained in the 30-50kDa region of SDS- 
PAGE gels by increasing the concentration of the gels to 15% polyacrylamide, and 
increasing the time of electrophoresis, an additional polypeptide was detected by
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Figure 5.10. Infection of Bn5T cells with dUTPase deficient mutants of 
herpes simplex virus.
kDa
69
46
m.i. HSV-1 HSV-2
Cellular
HSV-1
HSV-2
Legend. Bn5T cells were infected overnight with HSV-1, HSV-2, HSV 
1217, HSV 1218 or were mock infected. HSV 1217 is a spontaneous 
mutant that fails to synthesise dUTPase, and 1218 contains an in frame 
insertion resulting in a larger protein product (Preston and Fisher, 1986). 
Samples were immunoblotted with an antiserum to mAspAT as previously 
described. The position o f the induced polypeptides is marked by arrows to 
the right o f  the gel. Neither dUTPase mutant virus induces a lower 
molecular weight polypeptide o f  the type induced by wild-type infection. 
The faint band which migrates at the same position as the HSV-2 type band 
(labelled with an asterisk in the mock infected track) is due to the relatively 
high background in this blot, and is present in all the samples. This 
experiment confirms that the lower molecular weight polypeptides which 
cross-react with the anti-mAspAT antiserum represent the HSV dUTPase 
enzymes.
Figure 5.11. A dUTPase antiserum recognises different molecular weight 
polypeptide bands in HSV-1 and HSV-2 infected BHK C l3 cells.
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Legend. BHK C13 cells were infected with HSV-1 strains 17 and F, and with HSV-2 
strains HG52 and 333, or were mock infected. Cell extracts were analysed by Western 
blotting with an antiserum to the HSV-1 dUTPase (donated by Dr S. Caradonna). The 
dUTPase antiserum detects bands o f  differing molecular weight in the HSV-1 and 
HSV-2 tracks, as previously noted for the additional polypeptide detected in HSV 
infected cells with the mAspAT antiserum. In conjunction with the recombinant 
intertypic mapping and dUTPase mutant virus studies, this result confirms that the 
cross-reacting species is the HSV dUTPase.
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Western blotting with an antiserum to mAspAT in Bn5T tumour, BHK C13 and RE 
cells infected with HSV-1 and HSV-2 {Sections 5.3 and 5.4).
The increase in the level of this polypeptide was greater in the Bn5T cells than in the 
RE cells, and was also observed in the BHK C l3 cell line. The BHK C13 cells were 
routinely used to propagate HSV within this Institute, and infect reproducibly. This 
was not the case with Bn5T cells which occasionally lose their ability to be infected 
after prolonged passage in tissue culture (J.C.M. Macnab, pers. comm). This effect 
was observed at passage numbers as low as 50, and was not predictable. Therefore 
BHK C13 cells were used for further experiments on the induction of the lower 
molecular weight polypeptides following HSV infection.
A series of experiments were performed to examine the induction of the lower 
molecular weight polypeptides. These experiments showed that the polypeptides 
were associated with the cell, as washing of the cell monolayer prior to lysis failed to 
remove the induced polypeptides {Section 5.5). The polypeptides could be either 
membrane associated or intracellular proteins. Furthermore, by prolonged incubation 
in the absence of protease inhibitors, it was demonstrated that the lower molecular 
weight polypeptides were not caused by degradation of the mature cellular mAspAT 
by proteases released during the lysis procedure {Section 5.6). This result was as 
expected, as the lower molecular weight polypeptides were present following lysis of 
the cells directly in SDS-PAGE sample loading buffer (3xBM). This solution 
contains high concentrations of both SDS and P-mercaptoethanol which would be 
expected to denature the cellular proteases released during lysis.
Analysis of the time-course of induction of the lower molecular weight polypeptides 
detected by the anti-mAspAT antiserum {Section 5.7) showed that they appeared 
approximately 6 hours post infection. If the induced polypeptides are viral encoded 
polypeptides this would place the gene(s) responsible into the early (p) temporal 
class of HSV genes (Honess and Roizman, 1974). Alternatively, if the additional 
polypeptides are cell coded and are induced following HSV infection, this induction 
may require HSV immediate early gene expression. Estridge et al. (1988) previously 
reported that HSV-2 IE gene expression was necessary for the induction of a 40kDa 
polypeptide purified from transformed cells and from dyskaryotic cells from cervical 
smears. However, Preston (1990) reported the induction of a 56kDa cellular 
polypeptide in HFL cells infected with the penetration deficient HSV tsl204. This
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cellular polypeptide was present at 3.5 hours post infection, and it was suggested that 
viral attachment to the cell surface could be responsible for the induction. This could 
be the case for the induction of the lower molecular weight polypeptide detected by 
the anti-mAspAT antiserum.
The induced polypeptides were of different molecular weight depending on the HSV 
type used for the infection of the cells. Because of this, it was likely that the 
polypeptides were the product of an HSV gene or genes. If this was the case, it 
would be possible to approximately map the position of the gene(s) encoding these 
polypeptides by analysis of the phenotype displayed following infection with a panel 
of intertypic HSV-l/HSV-2 recombinants. These viruses contain delineated regions 
of the genomes of both HSV-1 and HSV-2, and express polypeptides of the relevant 
size for the HSV gene type present in the particular recombinant virus studied. I 
have demonstrated that HSV-1 and HSV-2 induce differently sized additional 
polypeptides in BHK C l3, Bn5T and RE cells (Section 5.4).
By infection of BHK C l3 cells with intertypic recombinants and analysis of the 
phenotype of the induced lower molecular weight polypeptides, I was able to 
delineate the region of the HSV genome encoding the induced polypeptide. The 
three viruses used (Fx9, Bxl and R12-5: Section 5.8, Figure 5.6) showed that the 
gene was in the region of the HSV genome between map co-ordinates 0.64 and 
0.83m.u. The complete cDNA sequence and protein coding capacity of HSV-1 
(McGeoch et al., 1988) was examined and three potential genes which coded for 
polypeptides in the molecular weight range 30-50kDa identified. These were the 
UL49 (VP22), UL50 (dUTPase) and UL53 (gK) genes. The UL49 and UL50 are 
classified as p genes, whilst gK is a Py gene (Wagner, 1994). I provisionally 
classified the gene encoding the induced polypeptides in my experiments as a 
probable p gene, on the basis of timecourse experiments (Section 5.7). gK was 
therefore excluded from further analysis.
The product of the UL49 gene is the tegument protein VP22 (p43) (Elliot and 
Meredith, 1992), which is of similar molecular weight to the induced polypeptide. 
However, in an experiment in which a blot of infected cell polypeptides was 
reprobed with an antiserum to p43, a single polypeptide was detected in each infected 
track. This was larger than the induced polypeptides and smaller than the
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constitutive cellular mAspAT polypeptide. This excluded the UL49 gene from 
further consideration.
The remaining candidate polypeptide was the viral dUTPase, encoded by the UL50 
gene (Preston and Fisher, 1984). The induced polypeptide in HSV infected cells was 
identifed as the dUTPase by infection of cells with two mutant HSV-1 viruses that 
fail to induce dUTPase activity; 1217 a spontaneous mutant, and 1218 an insertional 
mutant virus (Fisher and Preston, 1986). Infection with these viruses failed to induce 
the lower molecular weight polypeptides detected by the anti- mAspAT antiserum in 
cells infected with wild-type virus (Section 5.8). Confirmation that infection had 
occurred was obtained by the presence in the HSV-1 1218 infected cell lysates of the 
large subunit of ribonucleotide reductase, also a p HSV gene product. The intertypic 
recombinant virus experiments are further discussed in Section 5.9.2 below.
The experiments described in this chapter have identified the cross-reacting species 
detected in HSV infected cells as the product of the HSV UL50 gene, the 
deoxyuridine triphosphatase. This result was confirmed by comparison of the 
polypeptides detected with an antiserum raised against the HSV-1 dUTPase with the 
additional bands detected by the anti- mAspAT antiserum in cells infected with 
HSV-1 or HSV-2 (Figure 5.11).
5.9.2 Mapping of the HSV induced lower molecular weight polypeptides using 
HSV-l/HSV-2 intertypic recombinants.
Wohlrab et al. (1982) used a panel of intertypic recombinant viruses to map the 
location of the HSV gene encoding the viral dUTPase to within genome co-ordinates 
0.67 and 0.68 m.u., on the basis of the differential cellular localisation of the HSV-1 
and HSV-2 enzymes (ratio of nuclear/cytoplasmic dUTPase activity of 0.66 and 0.13 
respectively). More recently, Williams and Parris (1987) have repeated this 
experiment, and in addition to cellular localisation they used the differing mobility of 
the HSV dUTPases in non-denaturing PAGE experiments to classify the phenotype 
(type 1 or type 2) of the induced dUTPase. In both experiments they reported that 
the recombinant Bxl virus exhibited a type 2 phenotype despite containing a type 1 
genome in the 0.67 to 0.68 m.u. region. This contradicted the results of Wohlrab et 
al. (1982). In the work described here (Section 5.8.1), where the dUTPase phenotype 
was assessed by denaturing SDS-PAGE electrophoresis, this recombinant exhibited a 
type 1 phenotype. This is consistent with the localisation of the type specific
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determinant of dUTPase mapping within the right hand 33% of the genome, which 
includes the region previously reported by Wohlrab et al. (1982), and Preston and 
Fisher (1984). This result contradicts that of Williams and Parris (1987) who located 
the type specific determinant of HSV dUTPase to the left hand 20% of the genome 
(between either 0.06-0.1, or 0.148-0.204). Preston and Fisher (1984) cloned the 
region of the HSV-1 genome covering map co-ordinates 0.69-0.7 and demonstrated 
that this coded for a 1.5kb mRNA. The primary product of this transcript was a 
39kDa polypeptide corresponding to the previously reported molecular weight of the 
purified HSV-1 dUTPase (Caradonna and Adamkiewicz, 1984). This polypeptide 
displayed dUTPase activity in transient assays, which was abrogated by insertional 
mutagenesis. In the light of these results, Williams and Parris (1987) suggested that 
whilst the structural gene may lie within the 0.69-0.7 m.u. region of the HSV-1 
genome, an additional determinant located at the left end of the genome may 
determine type specificity in vivo.
Williams and Parris (1987) were unable to detect any dUTPase induction in cells 
infected with the R12-5 recombinant virus. In the work described here this virus 
induces a dUTPase with a type 1 phenotype; this virus contains HSV-1 genome 
representing approximately the regions 0.1-0.27m.u. and 0.64-0.98m.u. This result 
therefore fails to resolve the confusion surrounding the localisation of the type 
specific determinant of the dUTPase. The induction of a type 2 phenotype dUTPase 
by the recombinant Fx9 in these experiments is also inconclusive in this respect, as 
this virus has type 2 genome sequences at both the left hand region defined by 
Williams and Parris (1987) and the region between 0.69 and 0.7m.u. defined by the 
studies of Preston and Fisher (1986).
In summary, the recombinant virus studies described in this thesis fail to resolve the 
question of which region of the genome is responsible for the type specificity 
demonstrated by the dUTPase enzymes of HSV.
5.9.3 Discussion of the cross reactivity between HSV dUTPase and mAspAT.
5.9.3.1 Sequence comparison
The reason for the cross-reactivity of the HSV dUTPase with an antiserum raised 
against purified rat mAspAT was unclear. It was possible that there were antigenic 
epitopes in common between the two polypeptides. Analysis of the cDNA and 
derived amino acid sequences of the two enzymes performed using programs from
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the GCG Wisconsin Package failed to detect any significant similarity. ‘Bestfit’ 
comparison, illustrated in Figure 5.12, calculated the highest degree of similarity at 
the amino acid level as 18/163 identical amino acids, with the longest continuous run 
of identical amino acids being two. At the nucleotide level, the comparison was 
13/21 nucleotides, containing 5 contiguous nucleotides. Clearly it is unlikely that 
there is a linear epitope in common between these two polypeptides. Further analysis 
using the ‘Gap’ program (which aligns the full length of the two sequences by 
inserting gaps) and FASTA confirms that the similarity at nucleotide and amino acid 
level respectively is minimal.
The cross-reactivity may therefore be due to common conformational epitopes 
present in both polypeptides, perhaps a functional domain or co-factor binding site. 
A search was performed using the GCG ‘Motifs’ program to determine whether there 
were motifs in common. This program currently analyses only DNA sequences. 
Even within the motifs which were common to both sequences (2Fe2S Ferredoxin 
for example) the individual sequences within the motifs were very divergent. This 
analysis and the ‘Gap’ and FASTA analyses are presented in Appendices 2A to 2C.
5.9.3.2 Comparison of the structure and function of dUTPase and mAspAT
Consideration of the enzymatic function and structure of the two enzymes failed to
provide an obvious explanation for the cross reactivity.
There appear to be two groups of dUTPase enzyme, classified here on the basis of 
their protein structure. The first of these contains the dUTPase enzymes from E. coli 
(Cedergren-Zeppezauer et al., 1992); humans (Climie et al., 1994); FIV (Prasad et 
a l , 1996); EIAV (Bergman et a l , 1995) and Vaccinia virus (Broyles et a l , 1993). 
The crystal structures of the E. coli (Cedergren-Zeppezauer et a l , 1992; Larsson et 
a l , 1996), human (Mol et a l , 1996) and FIV (Prasad et a l , 1996) dUTPases have 
been solved. Each is a trimer consisting of subunits ranging from 14.3 to 17.5kDa. 
Each trimer binds three substrate molecules (Larsson et a l , 1996), with the active 
sites being formed by residues from each of the subunits (Mol et a l , 1996). These 
active site residues come from four of the five conserved dUTPase motifs identified 
by McGeoch (1990) which are located at the interface between the subunits.
The second group contains the dUTPase enzymes of HSV-1 (Preston and Fisher, 
1984), HSV-2 (Williams, 1984), BHV-1 (Liang et a l , 1993), EBV (Sommer et a l , 
1996), PRV (Jons and Mettenleiter, 1996), MMTV (Koppe et a l , 1994) and that
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Figure 5.12. Comparison of the nucleotide and amino acid sequences of rat 
mitochondrial aspartate aminotransferase and HSV-1 deoxyuridine triphosphatase.
A) Nucleotide sequence comparison
M18467  x  H s v l u l 5 0 . S e q
1 3 6 3  TTCACCAGGTCACCAAGTAATC 1 3 8 4
: : |  II I I : I I I I I h  h i
2 5 5  UUCCCCGGGUCACCACGUUAUC 2 7 6
B) Amino acid sequence comparison
M 1 8 4 6 7 . P e p  x  H s v l u l 5 0
36 PVASSPGWLLPFTQALQPQPLPEPAPGGPMLKWDLQIPSWE*PKPSREIP 85
M i l  I I I  I I .  I II h i
13 6 PALTEPISLRQFPQLAPPPPTGAGIREDPWLEGALGAPSVTTALPARRRG 185  
86 TARR * TWELVPTGT 99
II I I
186  RSLVYAGELTPVQT 199
Legend. Nucleotide and amino acid sequence comparisons were made between the HSV-1 
dUTPase (encoded by gene UL50) and rat mitochondrial aspartate aminotransferase 
(M18467.Em_ro), using the ‘Bestfit' program of the Wisconsin GCG software suite.
The top row of each diagram represents the mAspAT sequence, and the lower row the dUTPase 
sequence. Limited homology is observed at both the nucleotide and amino acid level. The 
degree of homology observed in this diagram, and further analysis using other GCG programs is 
discussed in the discussion for this chapter (Section 5.9.3).
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from Leishmania major (Camacho et a l , 1997). These enzymes consist of a single 
polypeptide chain ranging in molecular weight from 30kDa to 53kDa. McGeoch 
(1990) suggested a model to account for the presence of the conserved dUTPase 
motifs within the herpesvirus enzymes which suggests that the herpesvirus enzymes 
may have resulted from an intragenic duplication, resulting in a single chain enzyme 
containing the equivalent of two chains of the E. coli enzyme. Although the E. coli 
enzyme is now known to be trimeric, an adaptation of this model could still be valid, 
as the combined subunit molecular weights of the trimeric enzymes approximates the 
molecular weight of the single chain dUTPases of the herpesviruses. Comparison of 
the 3-D crystal structure of a single chain dUTPase with the overall (quaternary) 
structure of the E. coli or human enzyme may provide evidence to support this 
model.
Bjomberg and Nyman (1996) have reported that the dUTPase enzymes of HSV-1 
and MMTV are less substrate specific than the E. coli enzyme. HSV-1 dUTPase has 
a higher reactivity with dCTP and dTTP, and MMTV with dTTP and UTP. This 
substrate promiscuity may be a result of the single chain structure of these enzymes 
compared to the potentially more mobile (and therefore discriminating) active sites of 
the trimeric enzymes.
dUTPases require the divalent cations Co2+ or Mg2+ for full activity, but have no 
cofactor requirement. They bind substrate by pseudo-Watson and Crick hydrogen 
bonding to main chain residues.
The structure and function of the mAspAT enzyme have been discussed in the 
introduction to this thesis (Chapter 1, Section 1.3), and only the salient points are 
discussed here. The enzyme has a highly conserved quaternary structure despite 
divergence at the amino acid and nucleotide sequence levels. The crystal structure of 
the E. coli enzyme has been solved in the presence of substrate (McPhalen et a l, 
1992), inhibitors (Miyahara et a l, 1994) and reaction intermediates (Malashkevich et 
a l, 1993) and a Molecular Dynamics simulation of intramolecular motion within the 
enzyme performed (Kasper et a l, 1996). The E. coli enzyme is a dimer of identical 
44kDa subunits, each of which consists of a small and a large domain. The active 
site lies in a cavity that is close to both the subunit interface, and the interface 
between the two domains. On binding substrate the domains close together and bury 
the substrate in the active site, moving two arginine residues into position to form
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salt bridges with the substrate. These hold the substrate in proximity to the pyridoxal 
5’ phosphate co-factor in the correct orientation for catalysis of the transamination 
reaction (McPhalen et a l , 1992). Unhindered domain movement is required for full 
catalytic activity (Markovichousley et al., 1996), and the presence of the a- 
carboxylate groups of both the L-glutamate and L-aspartate substrate molecules are 
required to promote domain closure (Kasper et al., 1996), ensuring that the enzyme 
remains in the open conformation until catalysis can occur.
To summarise, the overall organisation of the dUTPase and mAspAT enzymes is 
very different, they have different co-factor requirements and bind different 
substrates via different electrostatic and hydrogen bonding interactions. It is difficult 
to imagine why there should be a cross-reactivity of the dUTPase with the mAspAT 
antiserum.
5 .9 .4  P o s s ib le  c o n ta m in a t io n  o f  th e  im m u n o g e n .
The antiserum used in the majority of this work was produced by Dr. Joan Macnab 
(Institute of Virology, Glasgow) by injection of purified pre-mAspAT polypeptide 
expressed in E. coli (gift of J.R. Mattingley, University of Missouri, USA). The 
initial experiments utilised an antiserum raised by Mattingley against the same 
immunogen. It was possible therefore that this immunogen could be contaminated 
with the E. coli dUTPase enzyme, and that this might cause the cross-reactivity with 
the HSV dUTPase enzyme. The purification procedure for pre-mAspAT involved 
lysis of the bacteria in 50mM Tris, 150mM NaCl and 0.5mM EDTA at pH7.5, 
followed by ammonium sulphate precipitation and serial anion and cation exchange 
chromatography at pH 8.0 (Altieri et al., 1989). This procedure produced a single 
polypeptide band on silver stained SDS-PAGE gels, and immunoblotting with an 
antiserum to pig heart mAspAT detected the same single band.
The purification procedure for the HSV-2 dUTPase begins with lysis of infected cells 
in lOmM Tris-HCl, pH 8.0, and several rounds of chromatography at pH 6.0 and 8.0 
(Williams and Parris, 1986). This is similar to the purification procedure described 
above for mAspAT. However, the pi values of the two proteins are very different, at 
9.5-10.0 for mAspAT (Stremmel et al., 1990) and 5.9 for the HSV-2 dUTPase 
(Williams, 1984). Furthermore, the E. coli dUTPase enzyme is a trimer of 14kDa 
subunits, which although likely to remain intact during the mAspAT purification 
procedure (as the mAspAT dimer does), would dissociate and be visible on the silver
137
Results: Chapter 5
stained SDS-PAGE gel. This is not the case, and it is therefore unlikely that the 
bacterially expressed mAspAT immunogen was contaminated with the E. coli 
dUTPase.
5.10 CONCLUSIONS.
HSV-1 and HSV-2 infection of a variety of cell types induces a lower molecular 
weight polypeptide which cross-reacts with an antiserum raised against rat 
mitochondrial aspartate aminotransferase. This polypeptide has been identified as 
the HSV deoxyuridine triphosphatase. No explanation for the cross reactivity was 
obvious.
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6. CLONING OF THE mAspAT cDNA INTO A EUKARYOTIC 
EXPRESSION VECTOR AND CELLULAR TRANSFORMATION 
ASSAYS.
6.1 INTRODUCTION.
Macnab et al (1985) have reported that a set of cell coded polypeptides are present in 
increased amounts in transformed cells relative to control cells, and that these 
polypeptides were further increased following infection with HSV (Macnab et al., 
1985; Grassie et al., 1992). The 40 kDa polypeptide from this group was identified 
as mitochondrial aspartate aminotransferase by comparison of partial amino acid 
sequence (Lucasson, 1992). Both the protein level and enzyme activity of mAspAT 
were increased in the transformed cells and were further increased following HSV 
infection (Lucasson et al., 1994). Furthermore, in Chapter 4 of this thesis I have 
shown that the level of mAspAT mRNA is increased approximately two-fold in 
Bn5T cells by infection with HSV-2.
The 40kDa polypeptide was shown to be specifically induced in transformed cells, 
and as HSV-2 infection increased the level further, the following experiments were 
designed to examine whether increasing the level of the mAspAT enzyme in non­
transformed cells by transfection of a mAspAT expressing plasmid would lead to an 
altered phenotype in these cells.
6.1.1 Cells.
NRK 536 cells, a rat fibroblast cell-line, were kindly provided by Bert Matz 
(University of Freiberg, Germany) who had previously used them in experiments to 
assess cellular transformation following plasmid transfection or viral infection. 
Vossbeck et al., (1995) used these cells to assay the transforming effect of EGF and 
TGF-P treatment of cells in culture. Treatment of NRK 536 cells with TGF-p alone 
led to the formation of a small percentage of colonies in soft agar. Transformation 
could only be demonstrated by addition of TGF-P to individualised NRK 536 cells 
which were already plated into soft agar, as treatment of cell monolayers led to the 
induction of apoptosis in the newly transformed cells by neighbouring normal cells. 
Colony formation in soft agar indicates anchorage independent growth and is a 
standard assay to assess the induction of phenotypic alterations characteristic of
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partial cellular transformation (MacPherson and Montagnier, 1964; Kusuhara et al., 
1992; Schultzcherry and Murphy-Ullrich, 1993).
6.1.2 Plasmids.
A full length cDNA clone of rat mAspAT (2362nt) containing the presequence (89 
nucleotides representing a 29 amino acid signal peptide which is cleaved following 
targetting of the enzyme to the mitochondrion) inserted at the EcoRI site of the 
polylinker of pBS-KS (Figure 6.1 A) was provided by J.R. Mattingley (Mattingley et 
al., 1987).
A eukaryotic expression vector, pCMVIO, (Figure 6.1 A) containing the HCMV 
major immediate early promoter (HCMV-mIE) and the SV40 RNA processing and 
polyadenylation signals was in use within the Institute of Virology, Glasgow. This 
plasmid was constructed from pCMV19K as follows (White and Cipriani, 1989). 
The BamHI site downstream of the polyadenylation signal was destroyed by 
sequential cleavage, filling in and religation, and the EcoRI-Hindlll fragment 
encoding the HCMV 19K protein was then replaced with the polylinker cloning site 
fragment of plasmid pTZ19U (Mead et al., 1986). A stock was obtained from Dr N. 
Stow (Institute of Virology, Glasgow).
6.2 CLONING OF mAspAT cDNA INTO A EUKARYOTIC EXPRESSION 
VECTOR.
6.2.1 Directional cloning into pCMVIO.
Initial attempts were made to clone the pre-mAspAT cDNA directionally into 
pCMVIO. This should yield a high percentage (ideally 100%) of the recovered 
clones containing the mAspAT cDNA in the correct orientation to facilitate 
expression from the upstream HCMV mIE promoter.
pBS-KS mAspAT and pCMVIO were digested using Kpnl, precipitated and then 
digested with BamHI. The 4kb pCMVIO vector backbone and the 2.3kb mAspAT 
cDNA insert were excised from a 1% agarose gel. The DNA fragments were purified 
using a Sephaglas kit (Pharmacia), ethanol precipitated and the concentration of each 
determined spectrophotometrically. Ligation mixes containing vector:insert ratios of 
1:1, 1:2, 1:3, 2:1, 3:1 and positive and negative controls were incubated overnight at 
16 °C, as described in Materials and Methods. Competent JM101 bacteria were 
prepared using CaCl2 and transformed with lpl, 2pl or 5pl of the ligation mixes.
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Legend. M aps of the plasmids used to clone the mAspAT cDNA into a vector for 
expression in eukaryotic cells are shown.
Figure 6.1 (facing page) shows the production of pCM V-mAspATl as described in 
Section 6.2.3. Plasmid pBS-KS containing the mAspAT cDNA inserted at the EcoRI site 
was kindly donated by J.R. M attingley (Mattingley et al., 1987) and is denoted pBS-KS- 
mAspAT. The mAspAT cDNA was excised from pBS-KS-m AspAT using E coR I , and 
inserted into the EcoRI site o f pCMVIO (provided by Dr. N. Stow, Institute of Virology, 
Glasgow) to produce pCM V-m AspATl . The orientation of the cDNA insert was 
determined by restriction of pCM V-mAspATl with SstI which cuts within the HCMV 
mIE promoter, and N col which cuts 89bp from the 5 ’ end of the cDNA (see Figure 6.4).
Figure 6.1. Plasmids used in the construction of a eukaryotic vector expressing mAspAT.
SspI 2.85. Nael 0.13 ,T7 promoter 0.62
EcoRI
SacI 
BstXI 
SacII 
EagI 
Notl 
Xbal 
Spel 
BamHI 
Smal 
PstI 
EcoRI 
EcoRV 
HindlH 
Clal
Sail (H indi) 
AccI 
Xhol 
Drall 
Apal 
Kpnl
XmnI 2.64
Seal 2.53
EcoRI
p B lu e S
m AspAT 
cDNA
T3 promoter 0.71
F1 ort
E c o R  0 .6 4
p B S K S m A s p A T
5 .3 2  Kb
m A sp A T
E c o R  3 .0 2
C lal 0 .51  
S s tl  0 .6 3
HCMV mlE prom oter
EcoRI
S ac I
Kpnl
S m al
BamHI
Xbal
S ail
P s tI
Sphl
H indlll
p CMVI O
4 .0 0  Kb
HCMV ml [prom oter
S V 4 0  polyA
pCMV-mAspATl
6 .1 0  Kb
S V 4 0  polyA
EcoRI
BamHI
H indlll
EcoRI
m A s p A T
Results: Chapter 6
Colonies resistant to ampicillin were picked and minipreps made from overnight 
cultures of these bacteria. These DNA samples were digested with Kpnl and BamHI 
to determine the size of the cDNA insert each contained. The efficiency of the 
ligation reaction was poor in many repeats of this experiment, and of the few 
colonies present on the ampicillin plates, none contained an insert of 2.3kb, 
representing the mAspAT cDNA. The positive transformation control produced 
many colonies indicating that this step was working efficiently.
In an attempt to determine the reason for the lack of recovery of recombinant plasmid 
in these experiments, various parameters were altered in turn. Firstly, fresh 
preparations of pCMVIO and pBS-KS mAspAT and restriction enzyme stocks were 
obtained, and used to produce the ligation precursors. The digested DNA was 
recovered from agarose gels by both Sephaglas extraction and by centrifugation of 
the excised DNA band through siliconised glass wool. Ligation conditions were 
varied and different sources of T4 DNA ligase used. Ligation for 72 hours at 16 ° C 
failed to produce colonies when transformed into competent JM101 bacteria (CaCl2). 
A more efficient method (A. Maclean, pers. comm.) for making and transforming 
competent cells was used in later experiments (TSB, as described in Materials and 
Methods). No combination of these altered conditions resulted in correctly ligated 
pCMVlO-mAspAT cDNA using the Kpnl and BamHI sites.
6.2.2 Cloning non-directionally into pCMVIO.
6.2.2.1 Introduction.
Because of the difficulties encountered trying to clone the mAspAT cDNA 
directionally into pCMVIO described above (Sections 6.2.1), it was decided to clone 
the mAspAT cDNA non-directionally into the EcoRI site of pCMVIO. This reduced 
the number of manipulations required in the preparation of ligation precursors, for 
example by removing an ethanol precipitation or linker ligation step. This reduced 
the chance of damage to the cDNA ends which appeared to be the most likely cause 
of the failed ligation experiments. However, non-directional cloning necessitated 
further selection for clones which contained the mAspAT cDNA insert in the correct 
orientation to facilitate expression from the HCMV-mIE promoter. Following 
confirmation of the insert size obtained from the recovered plasmids, the orientation
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of the insert was determined. A restriction digest was designed to determine the 
orientation of the insert in the plasmid. This protocol is illustrated diagramatically in 
Figure 6.5, and discussed further in section 6.2.3.3
6.2.2.2 Ligation and bacterial transformation
pCMVIO and pBSKS-mAspAT were digested with 10U/fig of EcoRI. 1U of CIP 
was added to the pCMVIO restriction digest. The DNA fragments were separated by 
electrophoresis on a 1% agarose gel, and compared to the relevant uncut plasmid and 
X Hindlll molecular weight markers to allow identification of the required fragments. 
The 4kb pCMVIO vector backbone (linearised and phosphatased) and the 2.3kb 
mAspAT cDNA fragment were excised from the gel and purified using Sephaglas® 
as described in Materials and Methods. Figures 6.2A and 6.2B show 1% agarose 
gels of the purified fragments and subsequent ligations (see below), stained with 
ethidium bromide and visualised with UV light. Lanes 4 and 5 of each gel contain 
the Sephaglas® purified EcoRI digested pCMVIO plasmid and mAspAT cDNA 
insert respectively. Each DNA fragment has approximately the expected molecular 
weight.
Ligations were set up using the DNA fragments isolated as illustrated in Figure 6.2A 
and 6.2B above, as described in Materials and Methods. The fragments were 
extracted with phenol/chloroform and precipitated with PEG 3000. A negative 
vector only control and a positive transformation control (uncut pCMVIO) were 
included. Figure 6.2A shows the results of a ligation analysed on a 1% agarose gel 
prior to the transformation of competent bacteria using the TSB transformation 
protocol. Additional DNA bands are visible in the tracks containing 1:2 and 1:1 
ratios of pCMVIO vector: mAspAT insert (lanes 2 and 3 respectively). These bands 
are not present in the pCMVIO re-ligation control (lane 1). Figure 6.2B shows a 
different ligation reaction in which only two additional bands are present in the 
ligated samples (marked with arrows in lane 1). These bands are absent from both of 
the pCMVIO control tracks (lanes 3 and 4). Following linearisation of the ligated 
plasmids in lane 1 with BamHI a single larger band (labelled with a white arrow in 
lane 2) remains in addition to the pCMVIO backbone. Comparison with the 
molecular weight markers estimates the size of this DNA species as approximately 
6.6KB. Comparison of the intensity of the higher molecular weight bands with the
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Legend. Panel A shows the results of an experiment to ligate the mAspAT cDNA 
excised from pBS-KS-m AspAT with EcoRI (lane 5) into EcoRI digested pCM VIO (lane 
4). Additional DNA bands are observed in the ligation mixtures containing a 1:1 ratio 
(lane 3) and 1:2 ratio (lane 2) o f pCM V10:mAspAT cDNA insert. Lane 1 contains a 
pCM VIO re-ligation control to demonstrate that the extra DNA bands are not due to the 
intram olecular re-ligation of the pCM VIO backbone.
Panel B shows a separate experiment to ligate the mAspAT cDNA into pCMVIO using 
the EcoRI sites. Lanes 4 and 5 contain the pCMVIO and pBS-KS mAspAT cDNA 
ligation precursors respectively. The pCMVIO re-ligation control is shown in lane 3. 
The ligation reaction produced two extra DNA bands (labelled with arrows) in addition to 
the band o f unligated pCM VIO plasmid. Following linearisation of the ligation products 
by restriction at the unique BamHI site within the polylinker, a single extra DNA band 
remains (marked with a white arrow in lane 2). This band has a molecular weight of 
approxim ately 6.6kbp determined by comparison with the molecular weight markers. 
The predicted molecular weight of pCM V-m AspATl is = 6.3kbp (4 + 2.3).
Figure 6.2. Agarose gel analysis of ligation precursors and products for 
cloning mAspAT cDNA into pCMVIO expression vector.
A) MW 1 2 3 4 5
4361bp
2322bp 
2027bp
1:2 1:1 mAspAT
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intensity of the pCMVIO remaining unligated backbone (Figure 6.2A, lanes 2 & 3; 
Figure 6.2B, lanes 1 & 2) shows that the overall efficiency of the intermolecular 
ligation reaction was low. However there was the potential to obtain positive clones 
from this ligation reaction, which was therefore transformed into TSB competent E. 
coli JmlOl. Ampicillin resistant bacterial colonies were picked from antibiotic 
containing plates.
6.2.2.3 Restriction digest analysis of ligated plasmids
Minipreps were made from each of the potential positive colonies recovered from the 
transformation plates as described in Materials and Methods. The extracted plasmid 
DNA was digested with 1U EcoRI to determine which colonies contained the 2.3kb 
mAspAT insert cDNA. Figure 6.3 shows a 1% agarose gel of the miniprep digests. 
Only one of the ten clones analysed on this gel contains a 2.3kb insert (marked with 
an arrow in lane 1). This plasmid was subjected to further restriction analysis. The 
remaining colonies were false positives, perhaps due to incomplete 
dephosphorylation and subsequent re-ligation of the vector backbone.
To determine if this miniprep contained the mAspAT cDNA insert in the correct 
orientation to allow expression of the mAspAT cDNA from the HCMV mIE 
promoter, a restriction digest was performed using SstI and NcoL The SstI site lies 
within the HCMV immediate early promoter and the Ncol site lies 89bp within the 
mAspAT cDNA. Figure 6.4 shows the digest schematically, and the fragments 
expected from the digestion with SstI and Ncol of:- a) plasmid with the mAspAT 
cDNA inserted in the correct orientation and of b) plasmid with the insert in the 
wrong orientation. These enzymes cut the plasmid in such a way as to determine the 
orientation of the cDNA insert with respect to the HCMV mIE promoter by analysis 
of the size of the fragments produced. A plasmid containing the cDNA insert in the 
correct orientation would produce fragments of approximately 6.2 and 0.15kb, whilst 
the opposite orientation would produce fragments of 3.8 and 2.4kb.
The number of bacterial colonies recovered which contained the mAspAT cDNA 
insert in the correct orientation to facilitate expression was low. One would expect a 
1:1 ratio of each insert orientation to be obtained from this experiment, and the 
reason for the heavy bias towards the opposite orientation in this case is unclear. 
Statistically however, the number of colonies tested is small and the ratio might
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Figure 6.3. Restriction digest analysis of pCMV-mAspAT plasmid clones.
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Legend. Plasmid DNA was extracted from colonies recovered from 
transfections o f  ligated pC M V 10-m AspAT and digested with EcoRI. 
D igested DNA was electrophoresed on a 1% agarose gel to analyse the size 
o f  the cDNA insert contained. Only 1 o f  the 10 clones isolated in this 
experim ent contained the correct insert (lane 1) marked with an arrow. The 
rem aining clones appear to have no insert, and are probably re-ligated 
pCM VIO, due to incomplete dephosphorylation o f the vector backbone.
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Figure 6.4. Restriction digest analysis of pCMV-mAspAT plasmid.
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Legend. Schem atic representation o f a restriction enzym e digest designed to determ ine the 
orientation o f  the m AspAT cDNA insert within recovered pCM V-m AspAT clones. 
m AspAT cDNA was excised from pBS-KS using EcoRI and ligated into the EcoRI site o f 
pCMVIO. Positive clones were recovered from transform ed bacteria and plasm id DNA 
extracted. The plasmid DNA was digested with SstI which cuts within the HCMV 
imm ediate early promoter, and Ncol which cuts at position 89 o f  the m AspAT cD N A  (the 
cleavage point for removal o f  the presequence). The digest allows clones containing the 
correct orientation o f  the m AspAT insert (to allow expression from the CM V im m ediate 
early prom oter) to be selected by analysis o f the digest on an agarose gel.
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improve if  more colonies were available for analysis. The plasmid recovered from 
this experiment was designated pCMV-AspATl.
To confirm that this plasmid actually expressed mAspAT in transfected cells, 
immunofluorescence experiments were performed (Section 6.3 below).
6.3 CONFIRMATION OF mAspAT EXPRESSION FROM pCMV-mAspATl.
6.3.1 Large scale preparation of pCMV-AspATl
A 10ml overnight culture of a bacterial stock of pCMV-mAspAT 1 was diluted into 
100ml 2YT and grown overnight with shaking at 37 ° C. Plasmid DNA was extracted 
by following the protocol provided with the Qiagen tip 100® purification kit. Yields 
ranged from 70-90 pg of plasmid DNA. The plasmid DNA was stored at -20 ° C for 
use in subsequent experiments, and a bacterial stock containing the plasmid stored at 
-70 °C.
6.3.2 Immunofluorescence experiments to confirm expression of mAspAT in 
transfected cells.
To confirm that mAspAT was being expressed from the HCMV mIE promoter on the 
pCMV-mAspAT 1 plasmid, immunofluorescence experiments were performed with 
NRK 536 cells transfected with varying amounts of pCMV-mAspAT 1. 60mm plates 
of 70% confluent cells were transfected with lpg, 5jug or lOpg of pCMV-mAspATl 
and allowed to recover overnight at 37 ° C prior to trypsinisation and re-seeding of a 
small proportion into plates containing glass coverslips. After overnight incubation 
the coverslips were removed, washed three times in PBS-A and fixed for 15 minutes 
in 3:1 MeOH/Acetone. Coverslips were probed with a 1/200 dilution of a rabbit 
antiserum to mAspAT and a 1/85 dilution of FITC-anti rabbit conjugate. Coverslips 
were examined using a Nikon epi-fluorescence microscope, and micrographs are 
shown in Figure 6.5. Panels A, B and C show images at increasing magnification 
from cells on a single coverslip transfected with lpg  of pCMV-mAspAT 1. The 
fluorescence is mainly cytoplasmic, with the nucleii appearing dark. However, 
within the cytoplasm the fluorescence is not homogeneous, and areas of stronger 
fluorescence are visible (see cells at the top of Panel C, Figure 6.5). Panels D, E and 
F show images from a coverslip from a plate of cells transfected with lOpg of the 
mAspAT expressing plasmid. A similar fluorescence pattern is observed, although 
there are many more rounded cells visible on this plate.
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Legend. Immunofluorescence experiments were performed to confirm that the pCMV- 
m A spA T l plasmid (Section 6.2.3) expressed mAspAT polypeptide in transfected cells. 
60mm plates o f NRK 536 cells were transfected with l(ig o f pCM V-m AspATl or 
pCM VIO by calcium phosphate precipitation. After overnight incubation to recover from 
the transfection procedure, the cells were trypsinised and 1/10 were re-seeded in plates 
containing glass coverslips. After overnight incubation the cells were fixed in 3:1 
M eOH:Acetone, probed with a 1/200 dilution of an anti-mAspAT antiserum and detected 
with an FITC-anti rabbit conjugate (1/85).
Panels A-C show increasing magnification of cells from one pCM V-m AspATl 
transfected plate. The fluorescence is mostly cytoplasmic, and the nuclei appear as dark 
ovals within the cell. Examination of the cell marked in Panel C with a white arrow 
suggests that the distribution of mAspAT throughout the cytoplasm is not homogeneous, 
although at this resolution it is not possible to determine what (if any) structures the 
m AspAT is associated with.
Panels D and E (overleaf) show lOx and 20x magnifications of cells from a different plate 
of cells, again transfected with the mAspAT expression plasmid (pCM V -m AspATl). 
The fluorescence pattern is similar to that observed in Panels A-C.
Panels F and G (overleaf) show cells transfected with the parental control plasmid 
(pCMVIO). Although there is a low background of fluorescence in these cells due to the 
normal cellular mAspAT enzyme, the level of fluorescence is much reduced in 
com parison to the cells transfected with pCM V-mAspAT 1 (Panels A-E).
These experiments confirm that pCM V-mAspATl expresses mAspAT polypeptide in 
transfected cells.
Figure 6.5. Immunofluorescence in NRK 536 cells transfected with a mAspAT 
expressing plasmid.
lfig pCMVmAspAT
B)
lOx
20x
lpg pCMVmAspAT
C )
40x
lpg pCMVmAspAT
Figure 6.5. Continued.
D)
E )
lOx
lOpg pCMVmAspAT
e
% 0
A *
tK
20x
10|ig pCMVmAspAT
F )
40x
10pg pCMVmAspAT
Figure 6.5. Continued.
G )
lOx
l(ig pCMVIO control
H)
20x
1 pig pCMVIO control
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Panels G and H show cells transfected with the parental pCMVIO plasmid as a 
control. There is some background fluorescence in these cells, probably due to the 
presence of the constitutive cellular mAspAT enzmye. However, the number of cells 
displaying fluorescence is much reduced in comparison to the cells which contain the 
mAspAT expressing plasmid (Panels A-F). This experiment confirms that the 
pCMV-mAspAT plasmid expresses mAspAT in transfected NRK 536 cells.
6.4 LIPOFECTION OF CELLS WITH pCMV-AspATl AND 
TRANSFORMATION ASSAYS.
6.4.1 Lipofection.
NRK 536 cells were grown as monolayers in 60mm tissue culture plates as described 
in Materials and Methods. Cells were lipofected with varying amounts of pCMV- 
mAspATl, pCMVIO or with the lipofection agent (DOTAP, Boehringer Mannheim) 
alone. In initial experiments, cells were co-transfected with a plasmid (pSV2Neo) 
expressing a neomycin resistance gene. 400pgml1 of G418 was used to select 
transfected cells, whilst this was reduced to lOOpgml'1 for maintenance of stably 
transfected cell lines. However, over extended passage (several weeks) even the 
initially selected cells appeared to be adversely affected by the G418 antibiotic and 
the viability of the mAspAT/pSV2Neo co-transfected cells was poor. Therefore in 
subsequent experiments, when cells were to be used in transformation assays, no 
selection procedure was used.
6.4.2 Colony formation in soft agar.
After overnight incubation at 37 ° C to allow the cells to recover from the lipofection 
procedure, cells were removed from the monolayer by trypsinisation. The cells were 
resuspended to make a single cell suspension and a proportion were replated on a 
60mm tissue culture plate, or were suspended in soft agar for the colony formation 
assay, as described in Materials and Methods. The soft agar plates were examined 
next day to confirm that single cells had been seeded. Plates were incubated at 37 ° C 
in a humid atmosphere and were monitored to ensure that the agarose did not dry out. 
After 5 days at 37 ° C to allow the cells to recover, the plates were observed daily 
under the microscope to identify the formation of colonies in soft agar, or of foci of 
cells on the 60mm plates.
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After approximately 14 days incubation, colonies of cells were visible in the soft agar 
plates. A colony was defined as a cluster of cells with a diameter greater than 100pm 
originating from a single progenitor cell. The plates were divided into eight sectors, 
and the number of colonies were counted in both the control and mAspAT 
transfected cell plates. The results are shown in table 6.1 A.
Table 6. IB presents the data as the total number of colonies in each lipofected plate. 
The cells lipofected with all concentrations of pCMV-mAspATl produced more 
colonies than the control pCMVIO treated cells (mean 152 compared to 63 in the 
control for 4xl05 cells plated). There is however, a background level of colony 
formation with the NRK 536 cells used in these experiments. Treatment with 
DOTAP alone results in the formation of approximately 60 colonies per 2xl05 cells 
plated. In these experiments a control using NRK 536 cells that had received no 
treatment at all was not included. This would have provided a measure of the true 
basal level of colony formation of NRK 536 cells. Furthermore, there is a reduction 
in the number of colonies formed by transfection of cells with lOpg of pCMV- 
mAspATl compared to transfection with 4pg or 6pg. This may be an effect of the 
overexpression of mAspAT in these cells, perhaps due to disruption of normal 
cellular metabolism. This is discussed later in Section 6.6.
Figure 6.6 shows representative micrographs (bar = 100pm) of colonies formed in 
soft agar by cells lipofected with A) pCMV-mAspATl and B) pCMVIO. There are 
more colonies present in the pCMV-mAspATl lipofected plate (A) than in the 
control plate (B). Some clumps of cells are visible in these pictures. These are due 
to the incomplete resuspension of the cells during trypsinisation and plating in the 
soft agar. They appear as fuzzy dead looking clumps (marked with an empty arrow 
in each image) and are obviously distinct from the growing colonies present in these 
pictures (marked with filled arrows in Figure 6.6A).
The appearance of colonies in soft agar following transfection with a mAspAT 
expressing plasmid reflects the loss of anchorage dependence and contact inhibition 
of these cells and is a measure of transformation. It is normal to calculate a 
transformation efficiency relative to the number of viable cells plated. However, as 
no determination of cell viability was made in these experiments, my results are 
calculated relative to the total number of cells plated. Table 6.2 shows the %
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Legend. lxlO 6 NRK 536 cells were lipofected with 2pg, 4jig,,6)Ltg or lOpg of pCMV- 
m AspATl, 10|ig of the pCMVIO control plasmid, or with no plasmid DNA (DOTAP 
reagent alone). A proportion of the cells (0.2 or 0.4) were plated in soft agar and 
incubated at 37 °C. Colonies which had a diameter greater than lOOfim were counted 
after approximately 14 days.
In Table 6.1A the number of colonies counted in each of the eight sectors into which the 
plates were divided are presented for each plate. The total number of colonies in each 
plate is also presented. The plate labelling (e.g. 1.02) is as follows- the prefix refers to 
the treatment the cells received, as detailed in Table 6.1B, and the suffix refers to the 
number o f cells plated. 0 .2=0 .2xl05 cells.
The dotted line across the tables seperates the control treatments from the cells lipofected 
with various amounts of pCM V-m AspATl.
The data from this experiment is summarised in Table 6.1B. The number of colonies for 
each cell treatment for both numbers of cells plated is given. A calculation of the 
percentage transformation efficiency is presented in Table 6.2, and micrographs from 
pCM V-mAspATl and pCMVIO lipofected cells are shown in Figure 6.6.
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Table 6.1A. Colony formation in soft agar. Transformation assay following 
lipofection of NRK 536 cells with a mAspAT expressing plasmid.
Number of colonies of diameter >100|Lim in each sector
Plate 1 2 3 4 5 6 7 8 Total
1.02 7 14 12 8 5 8 0a oa 72*
1.04 18 13 14 13 21 12 12 1 110
2.04 6 12 10 5 6 8 8 0 a 63*
3.02 11 11 6 9 9 11 9 10 76
3.04 16 13 17 20 19 17 16 oa 135*
4.04 17 16 18 28 19 16 24 21 159
5.02 6 5 12 8 8 oa oa oa 61*
5.04 32 24 18 20 27 15 oa oa 181*
6.02 19 11 9 15 10 16 oa 0a 93*
6.04 30 15 12 12 10 15 15 22 131
a; S ectors had fu n ga l contam ination obscuring any co lon ies present, an d  w ere not counted, 
b; Totals ca lcu la ted  by averaging results fro m  sectors counted an d  m ultiplying by  8.
Table 6.1B. Total number of colonies obtained by transfection of various amounts 
of mAspAT expressing plasmids.
Number of NRK 536 cells plated
2x 105 4x 105
Plate prefix Cell treatment p,g plasmid Corrected total number of 
colonies on plate
1 DOTAPc n/a 72 110
2 pCMVIO d 63
3 pCMV-mAspAT 2 76 135
4 pCM V-mAspAT 4 d 159
5 pCMV-mAspAT 6 61 181
6 pCMV-mAspAT 10 93 131
c; lipofection  con trol
d; These p la tes  w ere fu n ga lly  con tam inated an d  w ere not ab le  to be analysed..
Figure 6.6. Colony formation in soft agar following transfection o f NRK536 cells 
with a plasmid expressing mAspAT.
A )
o
1 0 0 p m
B )
L e g e n d .  NRK 536 cells w ere transfected with a plasm id construct expressing 
m AspAT under the control o f  the HCM V mIE prom otor (Panel A) or w ith the 
parental plasmid (Panel B).
Single cells were seeded into soft agar and incubated at 37C for 2-3 w eeks 
while colonies formed. Colonies over the arbritary cut o ff  size o f  100pm 
were counted (labelled with filled arrows in Panel A) and the num ber o f 
colonies in each sample com pared-see Table 6 .IB.
Some clum ps o f  dead cells are apparent in both samples (labelled with an 
empty arrow), but these have an appearance distinct from colonies o f  viable 
cells.
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Results: Chapter 6
transformation efficiencies for each plate. The mean transformation efficiency for all 
mAspAT transfected NRK 536 cells was 0.38%, compared to 0.24% for the control 
lipofected and DOTAP treated cells. This level of colony formation represents a 1.58 
fold increase, but is not statistically relevant without further repetition of this 
experiment.
The parallel experiment involving the transfected cells plated out for analysis of foci 
formation became contaminated prior to quantitative analysis, and no data was 
obtained from this experiment.
6.5 TUMOUROGENICITY IN NUDE MICE.
It had been planned to inject cells derived from the colonies which formed in soft 
agar into nude (athymic) mice to examine the tumourogenicity of these cells in vivo. 
Colonies were transferred from the soft agar plates to a tissue culture plate and 
dispersed using a sterile pasteur pipette. However, during the subsequent incubation 
period, fungal contamination became apparent. This necessitated the destruction of 
the cells obtained from the growth in soft agar experiments described above.
Nude mice had been purchased in order to assess the tumourogenicity of the cells 
which subsequently became contaminated. These animals have a limited life-span 
dependent to a large extent upon their exposure to pathogens, and within the Institute 
of Virology, these animals usually live for 3-5 months (Joan Macnab, personal 
communication). There is therefore a ‘window of opportunity’ in which to inject the 
mice, whilst allowing sufficient time for tumours to develop during the lifespan of 
the mouse. This period is up to about 10 weeks from the birth of the mouse. Due to 
the nature of these experiments, it was not possible to repeat the transfection and 
colony formation experiments and to grow up the transformed cells within this time 
period. It was therefore decided to repeat the lipofections of NRK 536 cells with the 
mAspAT expressing and control plasmids, and inject the lipofected cells, omitting 
the colony formation step.
NRK 536 cells were lipofected with pCMV-mAspATl, pCMVIO and DOTAP as 
detailed in Table 6.3. Following an overnight incubation to recover from the 
lipofection procedure, the cells were harvested for sub-cutaneous injection into the 
nude mice. Approximately 106 cells (lx  confluent 60mm plate) were injected sub­
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cutaneously into the back of the neck of the nude mice by Dr Joan Macnab, Institute 
of Virology, Glasgow.
After 3-4 weeks tumours were observed in the mice. The mice were sacrificed prior 
to external examination of the morphology and size of the tumours present. This 
examination was performed ‘blind’- at the time of the examination I was unaware 
which mouse had been injected with which of the lipofected cells. The results are 
presented in Table 6.3.
These results were inconclusive with respect to the effect of mAspAT expression on 
the tumourogenesis of NRK 536 cells. Tumours were present in animals injected 
with the pCMVIO lipofected control cells or cells treated with DOTAP alone. 
Analysis of the amount of tumour tissue present in the mice revealed that there was 
no correlation between the amount of pCMV-mAspATl transfected into NRK 536 
cells and the tumourogenicity of the transfected cells in vivo. It was decided not to 
explant the tumours for tissue culture and further phenotypic analysis because these 
results were inconclusive. Time constraints unfortunately prevented the repetition of 
this series of experiments.
6.6 DISCUSSION.
Attempts were made to clone the mAspAT cDNA insert into a eukaryotic expression 
vector to facilitate analysis of the effects of over-expression of mAspAT in cells. 
Cloning directionally into pCMVIO {Section 6.2.1) failed. The reason for the failure 
with pCMVIO remains unclear.
The mAspAT cDNA was finally cloned non-directionally into pCMVIO at the 
unique EcoRI site. This protocol required fewer manipulations, and was in effect a 
direct sub-cloning of the mAspAT cDNA insert cloned into pBS-KS by Mattingley et 
al. (1987). The efficiency of the ligation reaction was still low, and in the 
experiment shown {Section 6.2.3.3) only one of the ten clones analysed contained the 
mAspAT cDNA insert. A restriction digest was designed to differentiate between the 
two possible orientations of the cDNA insert with respect to the HCMV mIE 
promoter. By analysis of the fragments recovered, a single clone was picked which 
had the mAspAT cDNA in the correct orientation. To confirm that this plasmid was 
at least transiently expressing mAspAT in transfected cells, the plasmid was 
transfected (calcium phosphate) into NRK 536 cells, and these were compared with
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control cells by immunofluorescence using an antiserum to mAspAT. These 
experiments showed a greater fluorescence in the transfected cells than in the control 
cells (Section 6.3.2) indicative of expression from the plasmid. There is a 
background level of fluorescence in the control cells due to the constitutive cellular 
mAspAT. By cloning the mAspAT cDNA into an expression vector that expressed 
an epitope tag (for example the HCMV UL83 epitope used by Leslie (1996)) at the 
end of the inserted mAspAT cDNA the expression of the protein could have been 
detected without these background problems.
Lipofection of the mAspAT expressing plasmid into NRK 536 cells resulted in the 
formation of colonies in soft agar. However the increase in the number of colonies 
formed, and in tumour formation in nude mice was not significantly elevated in cells 
lipofected with the mAspAT expressing plasmid compared to controls. Ideally, the 
NRK 536 cells transfected with mAspAT should have been selected, to ensure that 
only cells expressing mAspAT were used in the soft agar assays. Cells were initially 
co-transfected with a plasmid conferring neomycin resistance, and resistant clones 
were selected. However, these cells failed to grow properly, and could not be grown 
up in large amounts. It appears that either the cells were adversely affected by the 
G418 antibiotic, or that the cells were not growing for another unrelated reason. 
Previous experiments using these cells to show the transformation of cells by 
treatment with TGF-p (Vossbeck et al., 1995) showed that stably transformed cells 
could only be obtained by treatment of individualised cells. Treatment of the cells 
whilst in contact with neighbouring cells (i.e. as monolayers) before plating into soft 
agar led to induced apoptosis of the transformed cells. A similar apoptotic effect 
could be occurring in the experiments described in this chapter, but as the 
experiments required lipofection of a plasmid into the cells it would be impossible to 
treat individual cells in soft agar. Apoptosis of lipofected cells might explain the 
reduced number of colonies formed in the cells lipofected with lOpg of pCMV- 
mAspATl compared to those lipofected with 2pg, 4pg or 6pg of plasmid. However, 
a cellular DNA fragmentation ELISA kit (Boehringer Mannheim) which detects the 
fragmented DNA characteristic of apoptosis, failed to demonstrate apoptosis in any 
of the lipofected cells. The reduced number of colonies could also be a result of the 
overexpression of mAspAT in the cell. This could cause disruption of cellular
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metabolism by disturbing the equilibrium of the malate-aspartate shuttle, which 
functions to transfer reducing equivalents (from NADH) into the mitochondria. 
Alternatively, the uptake of long chain fatty acids into the cell could be increased, as 
mAspAT has been shown to be identical to the fatty acid binding protein (Stump et 
a l , 1993). This is discussed further in the General Discussion at the end of this 
thesis.
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7. AMPLIFICATION, CLONING AND DNA SEQUENCING OF A 
SMALLER mAspAT cDNA FROM HSV-2 INFECTED Bn5T 
CELLS.
7.1 INTRODUCTION.
During both the Northern blotting and RT-PCR experiments to examine the change 
in the level of the mAspAT mRNA in cells following infection with HSV, I noticed 
that an additional minor transcript or cDNA product was present in the samples from 
HSV infected cells. This minor species had a slightly lower molecular weight than 
the major transcript or cDNA product.
The presence of a smaller mAspAT transcript in HSV infected cells could explain the 
appearance of the 40kDa polypeptide (identified as a form of mAspAT by Lucasson, 
1992) in transformed and HSV infected cells, in addition to the constitutive mAspAT 
polypeptide. To study the difference between this smaller transcript and the 
constitutive mAspAT mRNA, the minor transcript was amplifed to produce a cDNA 
by RT-PCR, cloned into M l3 phage and subjected to DNA sequence analysis.
The mAspAT gene is highly spliced. The mouse mAspAT gene contains ten exons 
ranging in size from 20 to 59 amino acids, and spanning approximately 25kb of the 
genome (Morino and Shimada, 1990). The smaller transcript observed in HSV-2 
infected Bn5T cells could be due to alternative splicing. Splicing out of one exon 
could result in the production of a truncated cDNA approximately 60bp to 180bp 
shorter. This would represent a polypeptide some 2 to 6kDa shorter. If the first exon 
(29 amino acids) containing the presequence (which encodes the mitochondrial 
targetting signal) was absent, this would cause aberrant expression of mAspAT 
within HSV infected cells. J.C.M. Macnab (personal communication) has previously 
noted the altered localisation of mAspAT in transformed cells observed by 
immunofluoresence. mAspAT fluorescence was visible at the cell surface in 
transformed, but not control cells.
The following work was designed to investigate the difference between the major 
and minor transcripts from HSV-2 infected cells by cloning and sequencing the 
minor transcript and comparing this with the published sequence of rat mAspAT 
(Mattingley et al., 1987).
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7.2 RT-PCR AMPLIFICATION USING PCR PRIMERS 9301 AND 9302 AND 
CLONING OF THE MINOR mAspAT TRANSCRIPT INTO M13.
An adaptation of the RT-PCR protocol used to analyse the amount of mRNA present
in HSV infected and mock infected cells («Section 4.3) was used to produce cDNAs
for subsequent cloning into the M13mpl9 sequencing vector. Following reverse
transcription of 3pg of total cellular RNA, 40 cycles of PCR amplification were
performed using the primers 9301 and 9302 (Figure 4.4). Following amplification,
samples of the PCR products from mock infected and HSV-2 infected Bn5T cell
RNA were electrophoresed on a 30cm long 1.5% agarose gel at 100V overnight, to
facilitate good separation of the closely related mAspAT cDNA products. To reduce
damage to the cDNAs prior to cloning, the DNA bands were visualised by ethidium
bromide staining and long wave ultraviolet irradiation of the gel for as brief a period
of time as possible.
Figure 7.1 shows a representative gel from this experiment. A positive PCR control 
containing mAspAT plasmid as template, and a negative control (no template) were 
included (lanes 2 and 3). A single PCR product is present in the mock infected 
sample (lane 4), migrating just above the 1375bp molecular weight marker (lane 6). 
In the HSV-2 infected sample (lane 5) this product is more abundant, and an extra 
PCR product is visible. This has a molecular weight less than 1375bp, and is less 
abundant than the larger molecular weight band. Both PCR products from the 
HSV-2 infected sample are marked with arrows at the right of the gel.
The minor cDNA product and the larger constitutive cDNA were excised from the 
gel and the DNA was purified using Sephaglas®.
In initial experiments the ends of these purified cDNAs were filled in, and blunt end 
ligated directly into M13mpl9 digested with Smal as described in as described in 
Materials and Methods. However, this procedure proved to be very inefficient. The 
following alterations to the protocol were made.
7.3 RT-PCR AMPLIFICATION USING PRIMERS 9301ECORI AND 
9302XBAI, AND CLONING INTO pGEM-T.
The RT-PCR experiment was repeated using the PCR primers 9301-EcoRI and 
9302-XbaI (Figure 7.2) which were the same primers as previously described but 
with the relevant restriction enzyme site and 3 random nucleotides added to the end. 
Following amplification, the cDNA products were purified directly from the
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Figure 7.1. Different sized mAspAT PCR products from HSV-2 and mock 
infected Bn5T RNA.
A  Hindi 11/ 
EcoRI 
2 1 2 2 6 “
A  EcoRI
1 2 3 4  5 6 7  8 9  10 11
Legend. Agarose gel electrophoresis o f  RT-PCR products from Bn5T cell RNA. 
RNA from Bn5T cells m ock infected or infected with 10 pfu/ml o f  HSV-2 HG52 
was reverse transcribed and am plified by PCR as described in M aterials and 
M ethods. Lane 1 contains A Hindlll DNA markers. Lanes 2 and 3 contain positive 
and negative controls respectively. Lane 4 contains PCR products from mock 
infected Bn5T cell RNA, and shows a single product o f approxim ately 1.4kbp. 
Lane 5 contains PCR products from  HSV-2 infected Bn5T cell RNA, containing 
larger am ounts o f  the product present in the mock infected sample, and an 
additional slightly sm aller product (about 1.3kbp). These two products are marked 
with arrows to the right o f  the gel. The expected size o f  the PCR product is 
1421 bp. Lane 6 contains A HindW/EcoRI DNA markers. The samples in lanes 7- 
10 are as for lanes 2-5.
Figure 7.2. PCR primers containing restriction enzyme sites.
5’ PCR Primer 9301 EcoRI
5’ CCTGAATTCTCAGCGGACGCCTTCCCCTGATCT 3’ 
32-mer, nucleotides 29-51
PCR Primer 9302XbaI
5 ’TCATGAGAGTCACGTGCAGGTCTAGACTT 3’ 
29-mer, nucleotides 1431-1450
Legend. PCR primers were synthesised from the cDNA sequence of 
mAspAT (Mattingley et al., 1987), containing a restriction enzyme recognition 
site, and 3 extra nucleotides at the end of the primer. This was to ensure any 
errors introduced at the end of the PCR products did not abolish the enzyme 
sites. The primers are essentially the same as those presented in Figure 4.4.
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RT-PCR reaction mixture using the Sephaglas® kit. The PCR products were digested 
with EcoRI and Xbal to remove the excess nucleotides from the cDNA ends and 
provide ‘sticky ends’ for ligation into PGEM-T, which was restricted with these 
same enzymes. E. coli JM101 competent bacteria were transformed with the ligation 
mixture and plated onto agar plates containing ampicillin and X-gal. Positive (white) 
clones were picked for further analysis. DNA minipreps were made from these 
colonies, and the DNA was digested with EcoRI and Xbal. Analysis on a 1.5% 
agarose gel (Figures 7.3A and 7.3B) allowed the isolation of clones containing 
smaller PCR products. In Figure 7.3A, the PGEM-T backbone migrates at about 
3kbp as expected. Clones 1-5 and 9-17 contain an insert of approximately 1.4kbp. 
The insert in clone 3 is slightly larger. The full length PCR product is expected to 
have a length of 1421bp. The clones marked with a star above the lanes were 
selected for sequence analysis.
In Figure 7.3B clones 41-61 contain an insert of about 800bp, and clones 11-31, 71, 
72 and 74 an insert of about 2kb. The clones marked with a star were selected for 
analysis. A clone (57) from a different gel with a 1.4kbp insert was also selected for 
sequencing.
Single stranded DNA was produced directly from the PGEM-T clones and sequenced 
as described in Materials and Methods. However, the quality of the sequencing 
reactions was poor, and little information could be obtained from these sequencing 
gels. The cDNA inserts from the selected clones were therefore ligated into 
EcoRl-Xbal digested M13mpl9. Single strand DNA preparation and sequencing 
using the Sequenase® kit (United States Biochemical) were performed as described in 
Materials and Methods. Sequencing from the M l3 clones was successful. Synthetic 
oligonucleotide sequencing primers were made using the rat mAspAT cDNA 
sequence published by Mattingley et al. (1987), and were provided by Mr D. McNab 
in our laboratory. The M l3 -40 primer and the primers used for the RT-PCR 
reaction were also used.
The DNA sequence obtained from each clone was analysed using the Wisconsin 
GCG package (version 9). Sequence was entered manually and aligned with the 
published cDNA sequence of rat mAspAT (Mattingley et al., 1987).
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Figure 7.3. Restriction analysis of PGEM-T clones recovered from RT-PCR of
HSV-2 infected Bn5T cell RNA.
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- 9 4 7
“ 831
- 5 6 4
Legend. RT-PCR products from mock infected or HSV-2 infected Bn5T cell RNA were 
cloned into PGEM -T at the EcoRI and Xbal sites. The insert was excised from recovered 
clones with these same enzym es and electrophoresed on a 1% agarose gel. In Figure 7.3A, 
clones 1-5 and 9-17 contain cDNA inserts o f  approxim ately 1.4kbp, although clone 3 has a 
slightly larger insert than the others. In Figure 7.3B, clones 41-61 contain an insert o f 
approxim ately 800bp, and 11-31, 71, 71 and 73 contain inserts greater than 2kbp in length. 
The clones marked with stars above the lane were selected for DNA sequencing.
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Figure 7.4 shows the alignment of of the DNA sequence obtained from the 5’ end of 
the PCR clones. The 5’ untranslated region is shown in red, the initiation codon in 
green, and the pre-sequence is shown underlined in blue. The pre-sequence is 
encoded by a separate exon of 89nt, and codes for a 29 amino acid segment 
containing the mitochondrial targetting signal which is cleaved to release the mature 
protein. Differences from the consensus sequence are shown in black. No 
corrections have been made to the sequences shown. The homology between the 
sequence of the clones and mAspAT within the 5’UTR is good. There are a few 
differences, but these are likely to be gel reading errors, as the differences are not 
present in all clones which have the same size on agarose gels (see for example the 
‘a’ at position 76 sequence 53p-40 and compare it to 51p-40 above). Within the first 
40nt of the presequence, there are few differences between the obtained sequence and 
the consensus sequence. The sequence alignment for the remainder of the 
presequence contains a large number of gaps. This is due to problems reading the 
sequence from the top of the gels. The calculated consensus from this region is 
however identical to the mAspAT sequence. Few conclusions can be drawn from the 
limited data available, but it is interesting to note that the pre-sequence is likely to be 
present in both the 800bp (clones 51 and 53) and 1.4kbp (clonesl-5, and 57) PCR 
products.
Table 7.1 shows a summary of all the sequence data available for all the clones 
analysed. No clone was sequenced completely, or from the opposite strand to 
confirm the data. An interesting observation concerning clone 53 can however be 
made. This clone has a size of around 800bp on an agarose gel (Figure 7.3B), yet 
contains sequence aligning with nucleotides 32-164 and 1051-1219 of the mAspAT 
sequence. There must therefore be an internal deletion within this clone, perhaps 
representing a splicing event. Completion of the sequencing of this clone would 
allow this possibility to be examined.
7.4 DISCUSSION.
RT-PCR experiments identified an additional product in Bn5T cells infected with 
HSV-2 compared to mock infected cells (Section 7.2). Clones were obtained in 
PGEM-T which contained differently sized PCR products {Section 7.3) from HSV-2 
infected RNA. Two classes of PCR product were obtained- approximately 800bp
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Figure 7.4. DNA sequence of PGEM-T clones of the smaller RT-PCR
products from HSV-2 infected Bn5T cells.
57p-40 > tcccctgatctccgttcta 19
51p-40 > gcggacgcttcccctgatctccgttcta 28
53p-40 > agcggacgcttcccctgatctccgttcta 29
4p-40 > agcggac.cttcccctgatctccgttcta 29
3pl0 < agcggacgcttcccctgatctccgttcta 29
lp-40 < ttctcagcggacgcttcccctgatctccgttcta 34
Aspat > TTTTTTTTTAGGAGCCCGCGCCTCGGTTTCAGCGGACGCTTCCCCTGATCTCCGTTCTA 60
CONSENSUS > TTTTTTTTTAGGAGCCCGCGCCTCGGTTTCAGCGGACGCTTCCCCTGATCTCCGTTCTA 60
53p9301 > ccgtcttaccacccacc.atggccctcctgcactccggtcgcgtcct 47
51p9301 > ccgtcttaccacccacc.atggccctcctgcactccggtcgcgtcct 47
57p-40 > ccaccatccactgccgtcttaccacccacc.atggccctcctgcactccggtcgcgtcct 79
51p-40 > ccaccatccactgccgtcttaccacccacc.atggccctcctgcactccggtcgcgt 85
53p-40 > ccaccatccactgccatcttaccacccacc.atggccctcctgcactccggta.catcct 89
4p-40 > ccaccatccactgccgtcttaccacccacc.atggccctcctgcactccggtcgcgtcct 89
3pl0 < ccaccatccactgccg....accacccacctatggccctcctgcactccggtcgcgtcct 89
lp-40 < ccaccatccactgccgtcttaccacccacc.atggccctcctgcactccggtcgcgtcct 94
Aspat > CCACCATCCACTGCCGTCTTACCACCCACC.ATGGCCCTCCTGCACTCCGGTCGCGTCCT 120
CONSENSUS > CCACCATCCACTGCCGTCTTACCACCCACC.ATGGCCCTCCTGCACTCCGGTCGCGTCCT 120
......... + ......... + ......... + ......... + ......... + ......... +
3p-40 > ctct.... 9
4p3 > tggctgctatgcctttcacccatggccttgc...agccgcagcctctgccag 52
53p9301 > ctccgggatggctgctgt.cctttcaccca.gg..ttgatgaagag 93
51p9301 > ctccgggatggctgct.... tttcaccca.ggccttgc...agccgcag 97
57p-40 > ctccgggctggctgctg.,cctttcaccca.ggccttgc...agccgcagcccctg.cag 139
53p-40 > ctccgggatggctgctg....tttcacc.a .ggcattg....ag 133
4p-40 > ctccgggatggctgctg..cctttcaccca.ggccttgc...agccgcagcctctcggag 149
3pl0 < ctccgggat.... ccgt.cgt...... ca.gcatttg. . . .ag. .gga.ccattccgac 149
lp-40 < ctccgggatggctgctg..cctttcaccca.ggaattgag..agattga 143
Aspat > CTCCGGGATGGCTGCTG..CCTTTCACCCA.GGCCTTGC...AGCCGCAGCCTCTGCCAG 180
CONSENSUS > CTCCGGGATGGCTGCTG..CCTTTCACCCA.GGCCTTGC...AGCCGCAGCCTCTGCCAG 180
......... + ......... + ......... + ......... + ......... + ......... +
3p-40 > ....caactc.tgct..gcaatcctgggtgaaat.cagcaa..ccatcccggagaggagc 69
4p3 > acgccagctcctggtcggacctcatcgttgatatatagggatctcctcc...agatgatc 112
57p-40 > a.gccagctcgtggt.ggacc.cat.gttgaaat...ggga...cctcc...a...gate 199
4p-40 > a .gccagctcctggt.ggtcc.cat.gttcaaat...ggga...cctcc.......gaat 209
3pl0 < g .acacgttc 159
Aspat > A.G< AGCTCCTGGT. GGACC. CAT. GTTGAAAT. . .GGGA. . . CCTCC.. .A . . . GATC 240
CONSENSUS > A.GO AGCTCCTGGT.GGACC.CAT.GTTGAAAT. . .GGGA. . .CCTCC. . .A .  . .GATC 240
3p-40 > gc.a.cc....ggagtgcaggagggccatggtgggtggta.agacggctagtggatg... 129
4p3 > cctatcctcgtggagtgaccga.agccttc.gg 145
57p-40 > c c .atcct..gggagtgaccga.agccttcaagagagataccaacagca 248
4p-40 > c c .atcct...gga.tagee 229
Aspat > CC . ATCCT . . GGGAGTGACCGA. AGCCTTCAAGAGAGATACCAACAGCAAGAAGATGAAC 300
CONSENSUS > C C.ATCCT. .GGGAGTGACCGA.AGCCTTCAAGAGAGATACCAACAGCAAGwrGATGAAC 300
.........+ ......... + ......... + ......... + ......... + ......... +
Legend. DNA sequence data obtained from the PGEM -T clones which contained shorter PCR 
products (see Figures 7.3A and B) was aligned with the cDNA sequence o f m AspAT 
(M attingley et al., 1987) using program s from the GCG package. The 5 ’ untranslated region is 
shown in red, and the ATG initiation codon in green. The pre-sequence o f  m A spA T is 
underlined and coloured blue. This region contains the mitochondrial targetting sequence and 
is cleaved to produce the mature protein. The consensus sequence is identical to the m AspAT 
sequence throughout this region. D ifferences from the consensus sequence in individual clones 
are coloured black. The sequence is labelled as follows- the num ber before the ‘p ’ represents 
the clone and the num ber following the ‘p ’ >s the prim er used.
Ta
bl
e 
7.1
. 
Su
m
m
ar
y 
of 
se
qu
en
ce
 
da
ta 
ob
tai
ne
d 
from
 
RT
-P
CR
 
clo
ne
s 
fro
m 
HS
V-
2 
inf
ec
ted
 
Bn
5T
 
ce
lls
.
uoCN
vo(N
CN
co(N
00 r->O vo
rH r- vo
CO ,_L) 00r- r-
tj-
CO
o
noi/~>co
i - Hi<N
CNCN
VO
00r-
cnr-~
o
COCN
00
O s
CN
l-H CN
O n
O n00 vr>t"- o
O nvr>iCO
O n
r"~ t^ - (Nm voN- VO VO
CN vo N-vn C-" OCO CO CO
CO vor- COCN o
o 00CN Tfr-
o voi—1 VOoco 1 io CO cor- r-
O
O n
CNCO
O nVO
VOCN
00
coiCM
CO
o r- ovo <—i VO ooCN l-H s—1 CN
CO CO CN CNCO CO CO N"
lo uo co r-vo CO
wa .55*• H  rT
00 (2
.9
th
er
efo
re
 
re
pr
es
en
t 
an 
in
ter
na
l 
de
let
ion
 
wi
th
in 
thi
s 
cD
N
A
, 
pr
es
um
ab
ly 
re
pr
es
en
tin
g 
di
ffe
re
nt
 R
NA
 
sp
lic
in
g.
Pr
im
er
s 
us
ed
 
in 
se
qu
en
cin
g 
re
pr
es
en
ted
 
the
 
nu
cle
ot
id
es
 o
f 
the
 
pu
bl
ish
ed
 
se
qu
en
ce
 
of 
m
As
pA
T 
as 
de
ta
ile
d 
be
lo
w
. 
-40
= 
M
13
 
-40
 
pr
im
er
; 
93
01
= 
nt
39
-5
1; 
3= 
nt
75
- 
89
; 
41
= 
nt
28
1-
29
9;
 
31
= 
nt
37
8-
39
6;
 
23
= 
nt
42
3-
44
4;
 
21
=n
t7
17
-7
38
; 
26
=n
t9
90
9-
10
14
; 
25
= 
nt
l 
12
8-
11
49
.
Results: Chapter 7
long and a group containing inserts around 1.4kb. DNA sequence analysis from 
these clones showed that all clones contained the mAspAT presequence, and as such 
would be expected to locate to the mitochondria. One clone (53) appears to have an 
internal deletion(s) of about 400bp, and would be unlikely to code for a functional 
protein. This would be unlikely to be targetted to the mitochondria, as it has been 
shown that import into mitochondria is dependent upon the correct folding of the 
polypeptide chain, and interaction with specific chaperone proteins (Mattingley et al., 
1993).
Unfortunately no further conclusions can be drawn from this work without 
completing the sequencing of the smaller clones.
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8. SUMMARY OF RESULTS AND GENERAL DISCUSSION.
8.1 SUMMARY OF RESULTS.
In this thesis I have demonstrated that:
1) The steady state level of mAspAT mRNA is increased approximately 1.8-2 fold 
in the Bn5T (transformed) cell line by infection with HSV-2 strain HG52 compared 
to HSV-2 infected control cells (Chapter 4). This value is consistent with the 
previously reported increases in the levels of mAspAT protein and enzyme activity 
(Lucasson , 1992; Lucasson et al., 1994).
2) The HSV encoded dUTPase enzyme cross reacts with antisera raised against 
mAspAT, and that there were no obvious structural or sequence similarities between 
the two proteins to explain this cross-reactivity (Chapter 5). However, a link 
between chronic inflammation of the cervix or vagina and the development of 
cervical/vaginal cancer has been reported in pessary users (Schraub et al., 1992), and 
Woodworth et al., (1995) have reported that pro-inflammatory cytokines (IL -la and 
TNF-a) specifically promoted the growth of HPV positive cervical cancer cell lines 
while inhibiting proliferation in normal cells. It is possible that the cross-reactivity 
between the HSV-2 dUTPase and cellular mAspAT (which is also expressed at the 
cell surface as FABP(pm)- see Section 8.2.1) might also lead to inflammation of the 
cervix and promote cervical disease.
3) The transient expression of mAspAT in NRK 536 cells led to an almost 1.6 fold 
increase in the number of cell colonies that formed in soft agar compared to NRK 
536 cells transfected with a control plasmid (Chapter 6). Assays of tumour 
formation in athymic mice were inconclusive, although tumours did appear more 
rapidly in the mice injected with NRK 536 cells transfected with the mAspAT 
expression plasmid (J.C.M. Macnab, pers. comm.) than in those injected with control 
cells.
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4) An additional smaller sized PCR product was obtained from RT-PCR 
experiments with HSV-2 infected Bn5T cell (transformed) RNA compared to mock 
infected Bn5T cell RNA. This product was not apparent in RE cells infected with 
HSV-2 (Chapter 7). The available sequence data demonstrated that all of the clones 
obtained from this smaller RT-PCR product contained the mitochondrial targetting 
pre-sequence, although little other information could be derived.
8.2 GENERAL DISCUSSION.
Mitochondrial aspartate aminotransferase has an important role in cellular 
metabolism, and increasing the level of the enzyme within the cell might therefore 
have an advantageous effect on the growth potential of the cell. In addition, 
mAspAT has been shown to be similar to a long chain fatty acid binding protein 
(FABP(pm)). The possible role of an elevated level of mAspAT is discussed with 
respect to these functions below.
8.2.1 PLASMA MEMBRANE FATTY ACID BINDING PROTEIN 
(FABP(pm)).
Evidence is accumulating that long chain fatty acid uptake into cells is at least 
partially mediated by a 40-43kDa plasma membrane fatty acid binding protein 
(FABP(pm); e.g. Turcotte et al., 1997), while a 15kDa cytoplasmic FABP binds to 
long chain free fatty acids within the cell (e.g. Keler and Sorof, 1993). The level of 
FABP(pm) has been shown to be elevated in the red skeletal muscle of fasting rats, 
where free fatty acids provide the major source of energy for the cell (Turcotte et 
al., 1997), and increased fatty acid utilisation has been reported in tumour cells 
(Paradies et al., 1983). In agreement with this observation, Keler and Sorof (1993) 
have demonstrated that increased expression of the cytoplasmic 15kDa FABP 
correlates with growth promotion of hepatoma cells.
Berk et al., (1990) showed that FABP(pm) from rat liver cells was similar in amino 
acid sequence, purification characteristics and immunological cross-reactivity to 
mAspAT. Zhou et al., (1995) demonstrated that FABP(pm) and mAspAT were 
related by physico-chemical properties, and also that uptake of long chain fatty acids 
into the cell could be abolished by treating the cells with antibodies to mAspAT. The 
transfection of mAspAT cDNA under the control of an inducible promotor into 3T3 
cells resulted in an increase in the saturable uptake of long chain fatty acids into the
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cell (> 10-fold), and plasma membrane mAspAT fluorescence was observed in the 
transfected, but not control cells (Isola et a l , 1995). This evidence appears to show 
that mAspAT and FABP(pm) are closely related, if not identical (although Stremmel 
et a l , (1990) reported that the two proteins were not identical).
In our laboratory, increased immunofluorescence was observed at the plasma 
membrane in transformed (Bn5T) cells compared to controls (J.C.M. Macnab, 
unpublished results). This was thought to be due to aberrant localisation of 
mAspAT, perhaps due to the deletion of the mitochondrial targetting presequence. It 
is possible however, that this immunofluorescence may have been due to the 
expression of FABP(pm)/mAspAT in these cells, and that a subsequent elevated rate 
of uptake of long chain fatty acids might be important for transformed cell growth. 
How mAspAT can perform two very different functions at different localisations 
within the cell remains unclear, as mAspAT is generally targetted to the 
mitochondria by interaction with molecular chaperone proteins (see Introduction, 
Section 1.3.2), and it would be interesting to examine the cDNA of the FABP(pm) to 
discover if regions important for targetting mAspAT to the mitochondria were 
altered, or whether there were additional plasma membrane targetting signals present.
8.2.2 HORMONAL REGULATION OF mAspAT AND CITRATE 
SYNTHESIS.
Citrate production and accumulation is a characteristic function of the prostate gland, 
and has been shown to be upregulated by hormonal stimulation (Franklin et al., 
1987; 1997). Tissue specific stimulation of mAspAT activity in the rat ventral 
prostate by testosterone has been demonstrated (Franklin et a l, 1987); this effect is 
due to a rapid and direct increase in the transcription rate of the mAspAT gene and an 
increase in the half life of the mAspAT mRNA from 2 to 16 hours in both rat ventral 
prostate and pig prostate cells (Quian et a l, 1993). Prolactin and phorbol esters have 
also been shown to increase the transcription rate of mAspAT mRNA by a factor of 
2.5 to 3-fold in pig prostate cells (Franklin et al., 1992). The promotor of mAspAT 
lacks both TATA and CCAAT boxes, but is GC rich and contains regions with high 
homology to glucocorticoid/androgen response elements (GRE/ARE), and a 
divergent ARE sequence (Juang et al., 1995). The modulation of mAspAT by 
testosterone was shown to depend on the presence of the two ARE sequences, and to 
be specific to the prostate, with testosterone having no effect on the level of
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transcription of mAspAT in liver cells. Franklin and Costello (1985) proposed the 
existence of a ‘glutamate-aspartate-citrate’ pathway in the prostate to account for the 
high levels of citrate production in this tissue. The stimulation of mAspAT by 
testosterone (or prolactin) is proposed to increase the transamination of aspartate to 
oxaloacetate, which then condenses with acetyl CoA to form citrate within the 
prostate. In support of this model, Costello et al., (1995) have demonstrated that 
pyruvate dehydrogenase El a  (which produces acetyl CoA) and mAspAT are 
coordinately upregulated in the rat lateral prostate by prolactin and in the ventral 
prostate by testosterone. The effect of testosterone treatment of two prostate cancer 
cell lines (LNCap and PC-3) has recently been studied (Franklin et a l , 1997). Both 
LNCaP and PC-3 cells responded with an increased intracellular citrate concentration 
(which accumulated in the tissue culture medium), increased mAspAT activity, 
increased steady state levels of mAspAT mRNA (consistent with the operation of the 
proposed ‘glutamate-aspartate-citrate’ pathway) and an increased rate of citrate 
oxidation in these cells. Interestingly, the more aggressive PC-3 carcinoma cell line 
has a higher rate of citrate oxidation than the LNCaP cell line, and as citrate 
metabolism is regulated by the levels of oxaloacetate and acetyl CoA, increased 
transamination of aspartate by mAspAT may correlate with more rapid cell growth 
and a more malignant phenotype.
8.2.3 INCREASED FLUX THROUGH THE MALATE-ASPARTATE 
SHUTTLE
Fahien et al., (1989) have described the quaternary complex formed by mAspAT, 
a-ketoglutarate dehydrogenase, mitochondrial malate dehydogenase (mMDH) and 
glutamate dehydrogenase (GDH), and the kinetic advantages conferred by 
channelling of common ligands between members of such complexes. More 
mAspAT and mMDH are present in this quaternary complex than in the binary 
complexes formed between GDH and mAspAT or GDH and mMDH, facilitating 
enhanced glutamate-malate oxidation. The direct transfer of a-ketoglutarate from 
mAspAT to a-ketoglutarate dehydrogenase is especially important for the 
functioning of the malate-aspartate shuttle, as a-ketoglutarate is a potent inhibitor of 
aspartate production by mAspAT. The flux through the shuttle is increased in 
response to Ca2+ mobilising hormones, an effect which is thought to be mediated by
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the activation of a-ketoglutarate dehydrogenase. High concentrations of citrate have 
been shown to dissociate mMDH and GDH from these complexes, (which would be 
expected to reduce the flux through the malate-aspartate shuttle), and so in fast 
growing tumour cells which have a lower mitochondrial citrate level these complexes 
will be more stable and flux through the shuttle maintained. Fahien et al., (1989) 
suggest that the compartmentalised metabolism of glutamate and malate within these 
complexes may allow glutamate to be utilised as the major fuel source in these cells. 
As mentioned above, Ca2+ mobilising gluconeogenic hormones (e.g. glucagon) 
increase the flux through the malate-aspartate shuttle by increasing the action of 
a-ketoglutarate dehydrogenase (Strzelecki et a l , 1988). Aspartate transport from the 
mitochondria is electrophoretically driven, and is far from equilibrium, favouring 
export to the cytoplasm. During gluconeogenesis, aspartate formed in the 
mitochondria from lactate, glutamate and glutamine enters the cytoplasm and is 
converted to phosphoenolpyruvate before entering the gluconeogenic pathway. The 
malate-aspartate shuttle is therefore essential for gluconeogensis. The aspartate- 
glutamate translocator protein interacts directly with mAspAT to channel aspartate 
directly to the cytoplasm. Lowering the level of oxaloacetate (OAA) in the cell 
increases the transamination of a-ketoglutarate to aspartate and therefore favours 
efflux. OAA levels are low when ADP levels within the cell are elevated, thus 
gluconeogenic flux through the shuttle is stimulated when energy levels are low. 
However, only if OAA is being produced in the cell can the transamination to 
aspartate occur, and therefore the level of pyruvate carboxylase must also increase- as 
this enzyme is inhibited by glutamate, and glutamate levels are reduced in response 
to gluconeogenic hormones, this activation of pyruvate carboxylase can occur.
The malate-aspartate shuttle is the major shuttle operating in a variety of tumour cells 
(Greenhouse and Lehninger, 1977), with approximately one third of the respiratory 
ATP generated through the electron flow originating from cytosolic NADH via the 
shuttle. Thomasset et al., (1992) have used L-glutamic acid monohydroxamate 
(GAH) to inhibit flux through the malate-aspartate shuttle in L1210 leukaemia cells, 
resulting in cell death. They demonstrated an 8-fold increase in the cytoplasmic 
NADH/NAD+ ratio following treatment of cells with lmM GAH, and also 
demonstrated inhibition of mAspAT in vitro. Addition of 2-oxocarboxylic acids to
160
Chapter 8: 
Summary and Discussion
the cells protected them from this rise in the NADH/NAD+ ratios, but only if they 
were substrates for the tumour lactate dehydrogenase, which uses up NADH, 
returning the NADH/NAD+ ratio to near normal and preventing cell death. An 
increased NADH/NAD+ ratio has also been induced by GAH treatment of a Burkitt 
lymphoma cell line and a Friend leukamia cell line. Thomasset et a l , (1992) propose 
a model in which increased levels of cytoplasmic NAD+ initiate a chain of events 
leading to DNA synthesis, and that inhibition of the malate-aspartate shuttle reduces 
the NAD+ level in the cytoplasm, prevents DNA synthesis and promotes cell death. 
The continuing function of the shuttle is therefore essential for tumour cell growth, 
especially as these cells often rely much more heavily on this shuttle than normal 
cells.
8.2.4 ENHANCED GLUTAMINE OXIDATION IN TUMOUR CELLS.
Bagetto (1992) has reviewed the metabolic pathways active in cancer cells. The
main pathways operating in these cells are illustrated in Figure 8.1, and discussed 
briefly below. The majority of pyruvate produced by glycolysis in cancer cells is 
oxidised to form lactate, and only a small fraction enters the TCA cycle. Glutamine 
is the major source of energy in tumour cell lines (including HeLa cells), and enters a 
truncated TCA cycle following conversion to glutamate and a subsequent 
transamination to form a-ketoglutarate, a reaction catalysed by mAspAT. The TCA 
cycle is truncated because of the export of citrate to the cytoplasm to feed the 
cholesterol and fatty acid synthetic pathways, which are much more active in tumour 
cells than in normal tissue. Increased cholesterol concentration in the inner 
mitochondrial membrane is thought to increase the ability of the cell to synthesise 
ATP by decreasing the intrinsic permeability of the membrane to protons. In order to 
complete the truncated TCA cycle and fully oxidise glutamine, a source of acetyl 
CoA is required. This is provided by the presence in tumour cells of NAD(P)+-malic 
enzyme, which converts extracellular malate into pyruvate, which is then 
decarboxylated to form acetyl CoA. It is possible that increasing the level of 
mAspAT in the cell could increase flux through the truncated TCA cycle, and 
provide more energy for the rapidly growing tumour cell. This assumes, of course 
that the mAspAT reaction is rate limiting for the overall functioning of this truncated 
TCA cycle.
161
Fi
gu
re
 
8.1
. 
A
lte
re
d 
m
et
ab
ol
ic
 
pa
th
w
ay
s 
op
er
at
e 
in 
gl
yc
ol
yt
ic
 
tu
m
ou
r 
ce
lls
.
Xfl
O
U
P
P
o
c3 ■
►  bn %
2  a
2  3 HH
HH
c
H  5  <  *
H IaCJv
u
p
L
eg
en
d.
 
In 
tu
m
ou
r 
ce
lls
 
>9
0%
 
of 
gl
yc
ol
yt
ic
 
py
ru
va
te
 
is 
m
et
ab
ol
ise
d 
to 
la
ct
at
e 
in 
the
 
cy
to
pl
as
m
. 
Th
e 
re
m
ai
ni
ng
 
py
ru
va
te
 
en
te
rs
 
a 
tr
un
ca
te
d 
K
re
bs
 
C
yc
le
, 
fro
m 
wh
ich
 
ci
tr
at
e 
is 
ex
po
rt
ed
 
to 
fu
el 
de
re
gu
la
te
d 
ch
ol
es
te
ro
l 
an
d 
fat
ty 
ac
id 
sy
nt
he
si
s. 
G
lu
ta
m
in
e 
is 
the
 
m
aj
or
 
su
bs
tr
at
e 
for
 
the
 
‘tu
m
ou
r 
ce
ll 
K
re
bs
 
C
yc
le
’, 
en
te
rin
g 
via
 
gl
ut
am
at
e 
tr
an
sa
m
in
at
io
n 
by 
m
A
sp
A
T 
to 
for
m 
a-
ke
to
gl
ut
ar
at
e.
 
In
tr
ac
el
lu
la
r 
m
al
at
e 
is 
ox
id
ise
d 
to 
ox
al
oa
ce
ta
te
, 
wh
ile
 
im
po
rt
ed
 
m
al
at
e 
is 
pr
ef
en
tia
lly
 
ox
id
ise
d 
to 
py
ru
va
te
, 
pr
ov
id
in
g 
a 
so
ur
ce
 
of 
ac
et
yl
 
Co
A 
to 
all
ow
 
the
 
co
m
pl
et
e 
ox
id
at
io
n 
of 
gl
ut
am
in
e.
 (
R
ef
er
en
ce
: 
B
ag
et
to
, 
19
92
).
Chapter 8: 
Summary and Discussion
A recent report has confirmed the importance of the truncated TCA cycle in HeLa 
cells (a cervical cancer derived cell line). Piva and McEvoy-Bowe, (1998) noted that 
a significant proportion of glutamate oxidation in these cells proceeded through 
mAspAT mediated transamination, and that if  isolated mitochondria from HeLa cells 
were incubated in medium containing glutamine, glutamate or (glutamate+malate), 
aspartate was the major metabolite that accumulated. Furthermore, amino-oxyacetate 
(which inhibits mAspAT) inhibited respiration and aspartate efflux in these isolated 
mitochondria. This report demonstrates the importance of mAspAT in the 
metabolism of tumour cells.
8.3 CONCLUSIONS.
Mitochondrial aspartate aminotransferase is increased in a tumour cell line by 
infection with HSV-2, and transfection of a plasmid expressing mAspAT into NRK 
536 cells resulted in an increased transformation efficiency, as assayed by colony 
formation in soft agar. This suggests that the HSV-2 induced increase in mAspAT 
levels may play a role in the transformation process.
mAspAT is involved in many of the metabolic pathways of the normal, and 
especially the transformed/cancerous cell. In normal cells mAspAT is involved in 
amino acid metabolism, the malate-aspartate shuttle, in linking the TCA and Urea 
cycles, and is also involved in prostate citrate synthesis and acts as a long chain fatty 
acid binding protein at the plasma membrane. In the transformed cell, in addition to 
these functions, mAspAT is involved in the ‘glutaminolysis pathway’-truncated TCA 
cycle {Figure 8.1) which provides much of the energy for the transformed cell, and 
flux through the malate-aspartate shuttle is elevated.
The elevation of mAspAT levels by HSV-2 could affect one or all of these pathways 
to promote increased cell growth, and may therefore have a role in the progression of 
cervical cancer by promoting the growth of already abnormal cells (e.g. HPV 
infected cells). Further work will be required to determine the precise effect of the 
HSV-2 stimulated increase in mAspAT expression on the metabolism of tumour 
cells.
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Appendix 1: Asp AT homology
Appendix 1. Homology within the Aspartate aminotransferase family- 
FASTA search results.
Em-ro:Mmaspatm
ID MMASPATM standard; RNA; ROD; 2346 BP.
DT 16-JUN-1993 (Rel. 36, Last updated, Version 3)
DE Mouse mitochondrial aspartate aminotransferase isoenzyme mRNA, . . . 
SCORES In itl: 6661 Initn: 8528 Opt: 8109 z-score: 7971.2 E(): 0
93.4% identity in 1860 bp overlap
Em_New:Mmu82470
ID M M U82470 standard; RNA; ROD; 1408 BP.
DT 19-DEC-1997 (Rel. 54, Last updated, Version 2)
DE Mus musculus mitochondrial aspartate aminotransferase precursor . . .
SCORES Initl: 6358 Initn: 6358 Opt: 6374 z-score: 6 2 6 6 .2 E(): 0
94.7 % identity in 1408 bp overlap
Em_Huml: Hsaspat
ID HSASPAT standard; RNA; HUM; 2339 BP.
DT 23-N O V -1994 (Rel .4 1 , Last updated, Version 2)
DE Human mitochondrial aspartate aminotransferase mRNA, complete cds. . . . 
SCORES Initl: 5147 Initn: 6243 Opt: 5729 z-score: 5628.0 E(): 0
81.0% identity in 1813 bp overlap
Em_Om:Ssaspat
ID SSASPAT standard; RNA; MAM; 2533 BP.
DT 24-N O V -1994 (Rel .4 1 , Last updated, Version 2)
DE Pig mitochondrial aspartate aminotransferase mRNA, complete cds. . . . 
SCORES Initl: 5156 Initn: 6067 Opt: 5518 z-score: 5419.7 E(): 0
86.2% identity in 1478 bp overlap
Em_Om:Btaspamta
ID BTASPAMTA standard; RNA; MAM; 2347 BP.
DT 08-NO V-l 995 (Rel. 45, Last updated, Version 13)
DE B.taurus mitochondrial aspartate aminotransferase mRNA, complete CDS. . . . 
SCORES Initl: 5100 Initn: 5557 Opt: 5419 z-score: 5322.7 E(): 0
85.6% identity in 1481 bp overlap
Em_Ov:Ggaspatm
ID GGASPATM standard; RNA; VRT; 1350 BP.
DT 22-N O V -1994 (Rel. 41, Last updated, Version 2)
DE Chicken mitochondrial isoenzyme of aspartate aminotransferase mRNA, . . . 
SCORES Initl: 3813 Initn: 3813 Opt: 3860 z-score: 3791.2 E(): 0
79.3% identity in 1231 bp overlap
Em_New:Ac003997
ID AC003997 standard; DNA; ROD; 122176 BP.
DT 17-JAN-1998 (Rel. 54, Last updated, Version 1)
DE Mouse BAC mbac20 from 14D1-D2 (T-Cell Receptor Alpha Locus),
SCORES Initl: 1942 Initn: 3599 Opt: 1954 z-score: 1886.4 E(): 0
88.1% identity in 497 bp overlap
Em_Pl:Pmaatl
ID PM A ATI standard; RNA; PLN; 1677 BP.
DT 20-M A R -1992 (Rel. 31, Last updated, Version 3)
DE P.miliaceum mRNA for aspartate aminotransferase (p m A A T l). . .
SCORES Initl: 784 Initn: 951 Opt: 1465 z-score: 1431.8 E(): 0
59.2% identity in 1313 bp overlap
Appendix 7: Asp AT homology
Em_Pl:D67043
ID D67043 standard; RNA; PLN; 1578 BP.
DT 11-DEC-1997 (Rel. 53, Last updated, Version 1)
DE Oryza sativa mRNA for aspartate aminotransferase, complete cds. . . .
SCORES Initl: 315 Initn: 566 Opt: 1397 z-score: 1365.2 E(): 0
59.6% identity in 1216 bp overlap
Em_Pl:Pmaa
ID PMAA standard; RNA; PLN; 1681 BP.
DT 16-AUG-1996 (Rel. 49, Last updated, Version 5)
DE Panicum miliaceum mRNA for plastidic aspartate aminotransferase , . . . 
SCORES Initl: 601 Initn: 829 Opt: 1298 z-score: 1267.4 E(): 0
57.4% identity in 1168 bp overlap
Em_Pl:Osd14673
ID OSD14673 standard; RNA; PLN; 1514 BP.
DT 11 -DEC -1997 (Rel. 53, Last updated, Version 3)
DE Rice mRNA for aspartate aminotransferase, complete cds. . . .
SCORES Initl: 249 Initn: 604 Opt: 1241 z-score: 1211.9 E(): 0
58.5% identity in 1129 bp overlap
Em_Pl:Atl5034
ID ATI 5034 standard; RNA; PLN; 1548 BP.
DT 18-OCT-1995 (Rel. 45, Last updated, Version 2)
DE Arabidopsis thaliana aspartate aminotransferase (Asp3) mRNA, . . . 
SCORES Initl: 266 Initn: 532 Opt: 1220 z-score: 1191.1 E(): 0
57.9% identity in 1189 bp overlap
Em_Pl:Laaspat
ID LAASPAT standard; RNA; PLN; 1645 BP.
DT 05-M A Y -1995 (Rel. 43, Last updated, Version 11)
DE L.angustifolius mRNA for aspartate aminotransferase . . .
SCORES Initl: 356 Initn: 655 Opt: 1193 z-score: 1 164.1 E(): 0
57.2% identity in 1177 bp overlap
Em_Pl:Clu89494
ID CLU89494 standard; RNA; PLN; 1737 BP.
DT 09-SE P-1997 (Rel. 52, Last updated, Version 4)
DE Canavalia lineata aspartate aminotransferase 2 precursor (A A T 2). . . 
SCORES Initl: 208 Initn: 360 Opt: 1146 z-score: 1117.5 E(): 0
57.7% identity in 1182 bp overlap
Legend. A nucleotide FASTA search (GCG, Wisconsin Package) for 
DNA sequences with homology to the rat mitochondrial aspartate 
aminotransferase (Em-ro:Ml 8467) was performed. The top scoring 
sequences are shown. Due to space limitations only the summary data is 
provided.
Appendix 2A. FASTA comparison of the derived peptide sequences of rat 
mAspAT and HSV-1 dUTPase
27.9% identity in 68 aa overlap
10 20 30 40 50 60
Aspat.Pep RLGFSGRFPXSPFYHHPLPSYHPPWPSCTPVASSPGWLLPFTQALQPQPLPEPAPGG---
• I • h I • • l l l l h
Hsvlul50 GTVMAVWAPKRTREFAPGTLRVDVTFLDILATPPALTEPISLRQFPQLAPPPPTGAGIR
110 120 130 140 150 160
70 80 90 100
170 180 190 2 0 0
110 120
Aspat.Pep — PMLKWDLQIPSWEXPKPSREIPTARRXTWELVPTGTITESLTCS PVFGRQRPRLLGKI
I |: I II : I • I • : : 11 = 1= I
Hsvlul50 EDPWLEGALGAPSVTTALPARRRGRSLVYAGELTPVQTEHGDGVREAIAFLPKREEDAGF
210 220
130 140 150 160
230 240 250 260
170 180
Aspat.Pep WTKNTYPSGDWLIFVRLLQNWPWARTAKCXKAAGLXLCRPFPGLEPXGSEPAFCKDFLSS
Hsvlul 50 DIWRRPVTVPANGTTWQPSLRMLHADAGPAACYVLGRSSLNARGLLWPTRWLPGHVC
270 280
Legend. All the manipulations were performed using GCG Wisconsin package 
version 9. The cDNA sequence of rat mitochondrial aspartate aminotransferase (Em- 
ro:M 18467) was translated, and the derived amino acid sequence compared to the 
derived amino acid sequence of the HSV-1 UL50 ORF. FASTA comparison shows 
that there is limited similarity between the derived amino acid sequences.
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Appendix 2B. Gap alignment of HSV-1 UL50 ORF DNA sequence and rat 
mAspAT cDNA sequence.
G a p  W e i g h t :  5 0
L e n g t h  W e i g h t : 3
Q u a l i t y :
R a t i o :
P e r c e n t  S i m i l a r i t y :
Match display thresholds for the alignment(s ):
| = I D E N T I T Y  
: = 5
. = 1
H s v l u l 5 0 . S e q  x  A s p a t . S e q
1 ........................................ AUGUCCCAGUG. .
1 -11111 1
11
651
1 'Mill 1
GGCTTTGACTTCTCTGGAGCCTTAGAAGACATATCAAAAATCCCAGAGCA 700
12 ..GGGUUCCGGUGCUAUCCUGGUUCAGCCGGACUCCCUGGGUCGUGGUUA 
1 1 • • 1 - 1 - I - 1 1 1 III 1 1 1 1 • 1 1
59
701
I 1 • ■ 1 - 1 ■ I -1 1 1 III llll-ll
GAGTGTTCTCCTTCTGCACGCCTGCGCTCACAACCCCACGGGCGTGGACC 750
60 CGACGGUGACUGGCACACCGCUGUUGCUACCCGUGGUGGUGGUGUUGUUC 
II 1 -1 1 1 • 1 1 • 1 1 1
109
751
II 1 • 1 1 1 • II • 1 1 1
CGCGTCCAGAGCAGTGGAAGGAAATGGCGGCGGTGGTGAAGAAAAAGAAT 800
110 AGCUGAACCUGGUUAACCGUCGUGCUGUUGCUUUCAUGCCGAAAGUUUCC 
1 • 1 • 1 • II 1 - 1 1 1
159
801
1 • 1 • • • 1 II 1 • 1 1 1
CTCTTCGCATTCTTTGACAT..GGCCTACCAAGGCTTTGCCAGCGGCGAT 848
160 GGUGACUCCGGUUGGGCUGUUGGUCGUGUUUCCCUGGACCUGCGUAUGGC 209
849 GGTGATAAGGACGCCTGGGCCGTGCGGCACTTCATCGAGCAGGGCATCAA 898
210 UAUGCCGGCUGACUUCUGCGCUAUCAUCCACGCUCCGGCUCUGGCUUCCC 259
899 TGTCTGCCTCTGCCAATCCTATGCCAAGAAC.ATGGGCCTGTACGGTGAG 947
260 CGGGUCACCACGUUAUCCUGGGUCUGAUCGACUCCGGUUACCGUGGUACC 309
948
III' 1 ‘ ' 1 1 1 ' 1 ‘ 1 ' I I  1 1
CGTGTGGGAGCCTTCACTGTGGTCTGCAAAGATGCAGAAGAAGCCAAAAG 997
310 GUUAUGGCUGUUGUUGUUGCUCCGAAACGUACCCGUGAAUUCGCUCCGGG 
1 • 1 1 • 1 1 - 1 1 II 1 II • 1 1 - • 1 III
359
998
1 • 1 1 • 1 I'll II II 1 • 1 1 • • 1 II 1 
GGTGGAGTCACAGCTGAAGATCCTGATCCGCCCCTTGTATTCCAACCCG. 1046
360 UACCCUGCGUGUUGACGUUACCUUCCUGGACAUCCUGGCUACCCCGCCGG 
II- -1 II II 1 1 1 • 1 1 • 1 1 • 1 1 1
409
1047
1 1 • - 1 II II 1 1 1 • II • 1 1 • 1 1 1
.CCTCTCAATGGAGCCCGGATCGCCGCAACCATCCTGACTTCTCCAGACT 1095
410 CUCUGACCGAACCGAUCUCCCUG.... CGUCAGUUCCCGCAGCUGGCUC 454
1096 TGCGGAAGCAATGGTTGCAGGAGGTGAAAGGCATGGCTGACCGCATCATC 1145
455 CGCCGCCGCCGACCGGUGCUGGUAUCCGUGAAGACCCGUGGCUGGAAGGU 
II 1 | | . 1 . | . | | | | | | | | . |
504
1146
II 1 1 1 • 1 1 • II II 1 II 1 • 1
AGCATGAGGACCCAGTTGGTCTCCAACCTGAAGAAAGAGGGCTCGTCCCA 1195
Average Match: 10.000 
Average Mismatch: 0.000
3636 Length: 2330
3.267 Gaps: 10
38.628 Percent Identitv: 28
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505 GCUCUGGGUGC......UCCGUCCGUUACCACCGCUCUGCCGGCUCGUCG 548
h i !  II I I I : I : | : | |  II I
1196 CAACTGGCAGCACATCACCGACCAGATCGGCATGTTCTGCTTCACCGGCC 1245 
549 UCGUGGUCGUUCCCUGGUUUACGCUGGUGAACUGACCCCGGUUCAGACCG 59 8
: I I I  I I I : I II I :|  I
12 46 TAAAGCCTGAGCAGGTGGAGCGGCTGACCAAGGAGTTCTCAGTCTACATG 12 95 
599 AACACGGUGACGGUGUUCGUGAAGCUAUCGCUUUCCUGCCGAAACGUGAA 648
I I II ’ I I I  ^ l h  I II h i
12 96 ACAAAGGATGGTCGAATCTCTGTGGCCGGGGTCACCTCTGGCAATGTGGG 13 45 
649 GAAGACGCUGGUUUCGACAUCGUUGUUCGUCGUCCGGUUACCGUUCCGGC 69 8
I I  I I  I = 1  I  :  I I I
13 46 CTACCTGGCCCACGCCATTCACCAGGTCACCAAGTAATCACCAGGTGCAA 13 95
6 99 UAACGGUACCACCGUUGUUCAGCCGUCCCUGCGUAUGCUGCACG..CUGA 746 
13 9 6 GGAAACAGAGATCACTTTCCCTTCAGCCTTTGCTCTCATGAGAGTCACGT 1445
747 CGCUGGUCCGGCUGCUUGCUACGUUCUGGGUCGUUCCUCCCUGAACGCUC 7 9 6 
1446 GCAGGGTGAGGGAGGGTGGATGGTGTTGAGTAGATCCTGTTTTCAACCAC 14 95
7 97 GUGG....... UCUGCUGGUUGUUCCGACCCGUUGGCUGCCGGGUCACGU 83 9
149 6 GGTGCATAACTCCTGTCGATTGAACGCGTTCCTCGGAAAAGAGGTAGGGC 1545
840 UUGCGCUUUCGUUGUUUACAACCUGACCGGUGUUCCGGUUACCCUGGAAG 88 9
l h  I I : I I I II I h  = I I I
1546 AGAGGCTCCCACGGCTGATATCTGGAACTTCGTCGGCTCTAAACCAAACT 15 95
8 90 CUGGUGCUAAAGUUGCUCAGCUGCUGGUUGCUGGUGCUGACGCUCUGCCG 93 9 
1596 CTCCCTCATCCTTTTGTCTCCAGCTTTTCTGAAAGTTTACACATGCAAAA 1645
940 UGGAUCCCGCCGGACAACUU................ CCACGGUACCAAAGC 97 4
1646 AAATCACAGCACCAAAACCTGTCAGCATGGCATAGGCACAGGTCAGAAGC 16 95 
97 5 UCUGCGUAACUACCCGCGUGGUGUUCCGGACUCCACCGCUGAACCGCGUA 1024
: : I : I I I  h l h h  II h i  I I  II II h i
16 96 TTTACCTGAAGCCTCAGGTGGTGTCAGGGGTTCCCCTGTGGACCCCGGTA 1745 
102 5 ACCCGCCGC....UGCUGGUUUUCACCAACGAAUUCGACGCUGAAGCUCC 1070 
1746 GAGCCTCTCATATTAGAGGCTGTAAGAGAAGAATAACTAGTTCTGTCATT 17 95 
1071 GC C GUC C GAAC GUGGUAC CGGUGGUUU C GGUU C C AC C GGUAUC....... 1113
17 9 6 AACAGTTGTCGAGTGTGTCCTCGTGGTGTGGAGCAACTGTGTCAGCAGAC 1845
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Appendix 2C. Common motifs within the HSV-1 UL50 ORF DNA sequence 
and the cDNA sequence of rat mitochondrial aspartate aminotransferase.
Motifs within the HSV-1 UL5Q ORF DNA sequence.
MOTIFS from: hsvlul50.seq
Hsvlul50.Seq Check: 3178 Length: 1,113 !
2fe2s_Ferredoxin C~(C)~(C)(G,A)~(C)C(G/A,S/T)~(C,P,D,E,K,R,H<F,Y(W)C
C-C-C(A)~CC(G)~(C,P,D,E,K,R,H,F,Y,W)C
2 83: UGGGU CUGAUCGAC UCCGG
C~C~C(G)~CC(A)~(C,P,D,E,K,R,H,F,Y,W)C
3 85: CCUUC CUGGACAUC CUGGC
★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ■ A :
* 2Fe-2S ferredoxins, iron-sulfur binding region signature *
Ferredoxins are a group of iron-sulfur proteins which mediate electron 
transfer in a wide variety of metabolic reactions. Ferredoxins can be divided 
into several subgroups depending upon the physiological nature of the iron 
sulfur cluster(s) and according to sequence similarities. One of these 
subgroups are the 2Fe-2g ferredoxins, which are proteins or domains of around 
one hundred amino acid residues that bind a single 2Fe-2S iron-sulfur cluster.
4fe4s_Ferredoxin Cx2Cx2Cx3C(P,E,G)
Cx{2}Cx{2}Cx{3}C (G )
454: UGGCU CCGCCGCCGCCG ACCGG
Cx{2}Cx{2}Cx{3}C(G)
45 8: UCCGC CGCCGCCGACCG GUGCU
Cx { 2}Cx {2}Cx{3}C (G )
1,0 67: UGAAG CUCCGCCGUCCG AACGU
★ ★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★
* 4Fe-4S ferredoxins, iron-sulfur binding region signature *
Ferredoxins are a group of iron-sulfur proteins which mediate electron 
transfer in a wide variety of metabolic reactions. Ferredoxins can be 
divided into several subgroups depending upon the physiological nature of the 
iron-sulfur cluster(s). One of these subgroups are the 4Fe-4S ferredoxins, 
which are found in bacteria and which are thus often referred as 
1 bacterial-type1 ferredoxins. The structure of these proteins consists of 
the duplication of a domain of twenty six amino acid residues; each of these 
domains contains four cysteine residues that bind to a 4Fe-4S center.
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Egf CxCx5Gx2C
CxCx{5}Gx{2}C 
165: GGUGA CUCCGGUUGGGC UGUUG
CxCx{5}Gx{2}C 
351: GAAUU CGCUCCGGGUAC. CCUGC
CxCx{5}Gx{2}C 
401: GGCUA CCCCGCCGGCUC UGACC
CxCx{5}Gx{2}C 
410: GCCGG CUCUGACCGAAC CGAUC
CxCx{5}Gx{2}C 
443: GUUCC CGCAGCUGGCUC CGCCG
CxCx{5}Gx{2}C 
5 0 6: AGGUG CUCUGGGUGCUC CGUCC
CxCx{5}Gx{2}C 
53 3: CACCG CUCUGCCGGCUC GUCGU
CxCx{5}Gx{2}C 
7 85: UUCCU CCCUGAACGCUC GUGGU
CxCx{5}Gx{2}C 
989: CUACC CGCGUGGUGUUC CGGAC
CxCx{5}Gx{2}C 
1,070: AGCUC CGCCGUCCGAAC GUGGU
* EGF-like domain cysteine pattern signature *
A sequence of about thirty to forty amino-acid residues long found in the 
sequence of epidermal growth factor (EGF) has been shown to be present, in 
a more or less conserved form, in a large number of other proteins.
Prokar_Lipoprotein ~(D,E,R,K)6(L,I,V,M,F,W,S,T,A,G)2(L,I,V,M,F,Y,S,T,A,G,C,Q) 
(A,G,S)C
65: CGACG
~ (D , E , R , K) {6} (G) {2} (C) (A) C 
GUGACUGGCAC
ACCGC
327: GUUGU 
GUACC
~(D,E,R,K){6}(A,G){2}(A)(A)C 
UGCUCCGAAAC
47 9: UGGUA 
CCGUG
~ (D ,E ,R ,K){6}(A){2}(G)(A)C 
UCCGUGAAGAC
593: GGUUC 
GGUGA
— (D, E , R, K) {6} (A) {2} (C) (A) C 
AGACCGAACAC
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613: ACGGU 
UAUCG
(D, E , R, K){6}(A,G){2}(A)(G)C 
GUUCGUGAAGC
633: GCUUU 
GUGAA
[D , E , R, K ){6}(A,G){2}(A)(A)C 
CCUGCCGAAAC
644: GAAAC 
GCUGG
~ (D ,E ,R ,K){6}(A){2}(G)(A)C 
GUGAAGAAGAC
646: AACGU
(D, E, R, K) {6} (A, G) {2} (C) (G)C 
GAAGAAGACGC
739: UGCUG 
UGGUC
CACGCUGACGC
7 84: GUUCC 
UCGUG
~ (D ,E ,R ,K){6}(A){2}(C)(G)C 
UCCCUGAACGC
8 80: CGGUU 
UGGUG
(D ,E ,R ,K) {6} (A,G) {2} (A) (G)C 
AC CCU GGAAGC
92 2: UUGCU 
UCUGC
[D , E , R , K) {6} (A,G) {2} (C) (G)C 
GGUGCUGACGC
964: UCCAC 
UCUGC
~ (D, E, R, K) {6} (A) {2} (A) (G)C 
GGUAC CAAAGC
1,051: CCAAC
UGAAG
UGGUU
(D , E , R , K ) {6} (A, G) {2} (C] 
GAAUUCGACGC
(G)C
~(D,E,R,K){6}(A,G){2}(A)(G)C 
1,057: AAUUC GACGCUGAAGC
UCCGC
* Prokaryotic membrane lipoprotein lipid attachment site * 
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
In prokaryotes, membrane lipoproteins are synthesized with a precursor signal 
peptide, which is cleaved by a specific lipoprotein signal peptidase (signal 
peptidase II). The peptidase recognizes a conserved sequence and cuts upstream 
of a cysteine residue to which a glyceride-fatty acid lipid is attached.
Appendix 2C
mAspAT motifs
Motifs within the mAspAT cDNA sequence.
MOTIFS from: em_ro:rsaspata
Rsaspata Check: 7270 Length: 2,32 5 ! Ml8467 Rattus norvegicus 
mitochondrial aspartate aminotransferase mRNA.
2fe2s_Ferredoxin C~(C)~(C)(G,A)~(C)C(G,A,S,T)~(C,P,D,E,K,R,H,F,Y,W)C
C~C~C(G)~CC(A)~(C,P,D,E,K,R,H,F,Y,W)C 
888: TCGAG CAGGGCATC AATGT
C-C-C(A)~CC(G)~(C,P,D,E,K,R,H,F,Y,W)C 
1,218: CCGAC CAGATCGGC ATGTT
C~C~C(G)~CC(G)~(C,P,D,E,K,R,H,F,Y,W)C 
2,12 7: CCCAG CTGGACGTC CTCAT
* 2Fe-2S ferredoxins, iron-sulfur binding region signature *
Ferredoxins are a group of iron-sulfur proteins which mediate electron 
transfer in a wide variety of metabolic reactions. Ferredoxins can be divided 
into several subgroups depending upon the physiological nature of the iron 
sulfur cluster(s) and according to sequence similarities. One of these 
subgroups are the 2Fe-2S ferredoxins, which are proteins or domains of around 
one hundred amino acid residues that bind a single 2Fe-2S iron-sulfur cluster.
4fe4s_Ferredoxin Cx2Cx2Cx3C(P,E,G)
Cx{2}Cx{2}Cx{3}C(G)
64: ACCAC CATCCACTGCCG TCTTA
* 4Fe-4S ferredoxins, iron-sulfur binding region signature *
Ferredoxins are a group of iron-sulfur proteins which mediate electron 
transfer in a wide variety of metabolic reactions. Ferredoxins can be 
divided into several subgroups depending upon the physiological nature of the 
iron-sulfur cluster(s). One of these subgroups are the 4Fe-4S ferredoxins, 
which are found in bacteria and which are thus often referred as 
'bacterial-type' ferredoxins. The structure of these proteins consists of 
the duplication of a domain of twenty six amino acid residues; each of these 
domains contains four cysteine residues that bind to a 4Fe-4S center.
A number of proteins have been found that include one or more 4Fe-4S 
binding domains similar to those of bacterial-type ferredoxins.
Egf CxCx5Gx2C 
CxCx{5}Gx{2}C 
84: TACCA CCCACCATGGCC CTCCT
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CxCx{5}Gx{2}C 
164: GCAGC CTCTGCCAGAGC CAGCT
CxCx{5}Gx{2}C 
17 9: GCCAG CTCCTGGTGGAC CCATG
CxCx{5}Gx{2}C 
708: GTGTT CTCCTTCTGCAC GCCTG
CxCx{5}Gx{2}C 
7 51: GGACC CGCGTCCAGAGC AGTGG
CxCx{5}Gx{2}C 
1,728: GGGTT CCCCTGTGGACC CCGGT
CxCx{5}Gx{2}C 
1,73 8: GTGGA CCCCGGTAGAGC CTCTC
CxCx{5}Gx{2}C
2,2 60: ATAAC CACCATCTGCTC TAACC
* EGF-like domain cysteine pattern signature *
A sequence of about thirty to forty amino-acid residues long found in the 
sequence of epidermal growth factor (EGF) has been shown to be present, in 
a more or less conserved form, in a large number of other proteins.
Prokar_Lipoprotein ~(D,E,R,K)6(L,I,V,M,F,W,S,T,A,G)2(L,I,V,M,F,Y,S,T,A,G,C,Q) 
(A , G , S ) C
5: TTTT
~ (D ,E ,R ,K){6}(G)(2)(A)(G)C 
TTTTTAGGAGC
CCGCG
2 9: CGGTT
(D,E,R,K){6}(A,G){2}(C)(G)C 
TCAGCGGACGC
TTCCC
84: TACCA
~(D,E,R,K){6}(T,A){2}(G)(G)C 
CCCACCATGGC
CCTCC
9 4 : CATGG
~ (D, E , R , K) {6} (T,G) {2} (C) (A)C 
CCCTCCTGCAC
TCCGG
103: CCTGC 
GTCCT
~ (D ,E ,R,K){6}(T,G){2}(C)(G)C 
ACTCCGGTCGC
12 0: TCCTC 
TGCTG
~(D,E,R,K){6}(T,A){2}(G)(G)C 
TCCGGGATGGC
13 3: GGCTG 
CCAGG
~ (D ,E ,R ,K){6}(T){2}(C)(A)C 
CTGCCTTTCAC
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2,210: TCTGG GGTTTGTATGC
TACCA
J
~(D,E,R,K){6}(T,A)(2)(A)(A)C 
2,249: CCTTG GGAAAGATAAC
CACCA
~ (D,E,R,K){6}(T,A){2}(G)(A)C 
2,274: CTCTA ACCGTGTAGAC
GTACC
~(D,E,R,K){6}(T,G){2}(T)(A)C
2,2 95: TGGTT TTCTCTGTTAC
AATAA
~(D,E,R,K){6}(T,A){2}(T)(A)C 
2,306: GTTAC AATAAAATTAC
TACAG
★ ★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★
* Prokaryotic membrane lipoprotein lipid attachment site *
In prokaryotes, membrane lipoproteins are synthesized with a precursor signal 
peptide, which is cleaved by a specific lipoprotein signal peptidase (signal 
peptidase II). The peptidase recognizes a conserved sequence and cuts upstream 
of a cysteine residue to which a glyceride-fatty acid lipid is attached.
Note that many more examples of the ‘prokaryotic membrane lipoprotein 
attachment site’ motif were present within the mAspAT cDNA sequence, but 
that only those at either end are shown here due to space limitations.
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